<SEC-DOCUMENT>0001213900-15-004303.txt : 20150605
<SEC-HEADER>0001213900-15-004303.hdr.sgml : 20150605
<ACCEPTANCE-DATETIME>20150605125528
ACCESSION NUMBER:		0001213900-15-004303
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20150605
DATE AS OF CHANGE:		20150605

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-194768
		FILM NUMBER:		15915208

	BUSINESS ADDRESS:	
		STREET 1:		546 5TH AVENUE, 14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
		BUSINESS PHONE:		212-300-2131

	MAIL ADDRESS:	
		STREET 1:		546 5TH AVENUE, 14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>f424b5052815_actinium.htm
<DESCRIPTION>PRELIMINARY PROSPECTUS SUPPLEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Filed Pursuant to Rule 424(b)(5)</B><BR>
<B>Registration No. 333-194768</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B>Prospectus Supplement</B><BR>
<B>(to Prospectus dated April 18, 2014)</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20">&nbsp;</P>



<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">1,923,078 Shares of Common Stock&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 79.25pt 0 70.1pt; text-align: center; color: #231F20"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 79.25pt 0 70.1pt; text-align: center; color: #231F20"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are offering 1,923,078 shares of
our common stock in this offering to a limited number of accredited investors <FONT STYLE="color: #231F20">pursuant to this prospectus
supplement and the accompanying prospectus. &nbsp;The shares of common stock are being sold at a price of $2.60 per share.</FONT></P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Our common stock is
traded on the NYSE MKT under the symbol &ldquo;ATNM.&rdquo; On June 3, 2015, the closing price of our common stock on the NYSE
MKT was $2.99 per share.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><B>Investing in our
common stock involves a high degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page S-7 of this prospectus supplement
and in the documents we incorporate by reference into this prospectus supplement and the accompanying prospectus.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><B>Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the
adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal
offense.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have retained Laidlaw &amp; Company
(UK) Ltd. to act as our placement agent in connection with the shares of common stock offered by this prospectus supplement. The
placement agent has agreed to use its &quot;reasonable best efforts&quot; to arrange for the sale of the common stock offered
by this prospectus supplement. We have agreed to pay the placement agent the placement agent fees set forth in the table below
and as set forth under &ldquo;Plan of Distribution&rdquo;, which assumes that we sell all of the common stock we are offering.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Per Share</B> </FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Total </B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font: 10pt Times New Roman, Times, Serif">Public Offering Price</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">2.600</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">5,000,002.80</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Placement Agent Fees (1)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.208</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">400,000.22</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Proceeds to Actinium Pharmaceuticals, Inc. before expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.392</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,600,002.57</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">(1) &nbsp;&nbsp;&nbsp;Includes <FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif; background-color: white">a
non-accountable expense allowance  payable to the placement agent. </FONT><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">See
&ldquo;Plan of Distribution&rdquo; for additional information regarding the placement agent&rsquo;s compensation.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We expect the total offering expenses,
excluding placement agent fees, to be approximately $140,000 for all sales pursuant to the prospectus supplement. Because there
is no minimum offering amount required as a condition to the closing of this offering, the actual total offering amount, placement
agent fees, and proceeds before expenses, to us are not presently determinable and may be substantially less than the maximum
amounts set forth above.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: #231F20">Delivery
of the shares is expected to be made on or about June 9, 2015.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white"><FONT STYLE="font-size: 16pt"><B>Laidlaw
&amp; Company (UK) Ltd.</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">The date of this
prospectus supplement is June 4, 2015</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0; color: #231F20"><A NAME="toc"></A><B>TABLE
OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6.25pt 0 0; text-align: right">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%; padding: 0 0 1.5pt; text-indent: 0">&nbsp;</td>
    <TD STYLE="width: 10%; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20"><B>Page</B></FONT></td></tr>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</td></tr>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; font-weight: bold; text-indent: 0"><FONT STYLE="color: #231F20">Prospectus Supplement</FONT></td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="#a-01">About This Prospectus Supplement</A></td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">S-ii</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="#a-02">Prospectus Supplement Summary</A></td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">S-1</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="#a-03">The Offering</A></td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">S-6</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="#a-04">Risk Factors</A></td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">S-7</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="#a-05">Special Note Regarding Forward-Looking Statements</A></td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">S-27</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="#a-06">Market Price Data And Dividend Information</A></td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">S-28</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="#a-07">Use Of Proceeds</A></td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">S-29</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="#a-08">Capitalization</A></td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">S-29</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="#a-09">Dilution</A></td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">S-30</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; text-align: left; vertical-align: bottom"><A HREF="#DescriptionofSecurities">Description
    of Securities We Are Offering</A></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">S-31</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; text-align: left; vertical-align: bottom"><P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 0pt"><A HREF="#divi">Dividend
                                         Policy</A></P>


</TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">S-32</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><P STYLE="margin: 0"><A HREF="#plam">Plan of Distribution</A></P>


<P STYLE="margin: 0"></P>


</td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">S-32</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="#a-11">Legal Matters</A></td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">S-35</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="#a-12">Experts</A></td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">S-35</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="#a-13">Where You Can Find More Information</A></td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">S-36</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="#a-14">Incorporation Of Certain Information By Reference</A></td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">S-36</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><B>Prospectus</B></td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="#a-15">About This Prospectus</A></td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">1</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="#a-16">Prospectus Summary</A></td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">2</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="#a-17">Risk Factors</A></td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">6</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="#a-18">Special Note Regarding Forward-Looking Statements</A></td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">6</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="#a-19">Use Of Proceeds</A></td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">8</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="#a-20">Description Of Capital Stock</A></td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">9</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="#a-21">Description Of Debt Securities</A></td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">17</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="#a-22">Description Of Warrants</A></td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">24</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="#a-23">Description Of Rights</A></td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">26</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="#a-25">Description Of Units</A></td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">28</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="#a-26">Plan Of Distribution</A></td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">29</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="#a-27">Legal Matters</A></td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">31</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="#a-28">Experts</A></td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">31</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="#a-29">Where You Can Find More Information</A></td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">31</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="#a-30">Incorporation Of Certain Information By Reference</A></td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">32</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0; color: #231F20"><A NAME="a-01"></A>ABOUT
THIS PROSPECTUS SUPPLEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 210.05pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="color: #231F20">This
document is in two parts. The first part is the prospectus supplement, which describes the specific terms of this offering and
also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into
this prospectus supplement and the accompanying prospectus. The second part, the accompanying prospectus, provides more general
information about the securities we may offer from time to time, some of which may not apply to the common stock offered by this
prospectus supplement. Generally, when we refer to this prospectus, we are referring to both parts of this document combined.
Before you invest, you should carefully read this prospectus supplement, the accompanying prospectus, all information incorporated
by reference herein and therein, and the additional information described under &ldquo;Where You Can Find More Information&rdquo;
on page S-39 of this prospectus supplement. These documents contain information you should consider when making your investment
decision. </FONT>You should assume that the information in this prospectus supplement and the accompanying prospectus is accurate
only as of the date on the front of the applicable document and that any information we have incorporated by reference is accurate
only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus supplement
or the accompanying prospectus, or any sale of a security. Our business, financial condition, results of operations and prospects
may have changed since those dates. <FONT STYLE="color: #231F20">To the extent that any statement that we make in this prospectus
supplement is inconsistent with statements made in the accompanying prospectus or any documents incorporated by reference therein,
the statements made in this prospectus supplement will be deemed to modify or supersede those made in the accompanying prospectus
and such documents incorporated by reference therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="color: #231F20">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="color: #231F20">Neither
we nor the placement agent has authorized any other person to provide you with any information that is different. You should rely
only on the information contained or incorporated herein by reference in this prospectus supplement and contained or incorporated
therein by reference in the accompanying prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">We are offering to sell, and
seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The distribution
of this prospectus supplement and/or the accompanying prospectus and the offering of the common stock in certain jurisdictions
may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement and/or the
accompanying prospectus must inform themselves about, and observe any restrictions relating to, the offering of the common stock
and the distribution of this prospectus supplement and/or the accompanying prospectus outside the United States. This prospectus
supplement and/or the accompanying prospectus do not constitute, and may not be used in connection with, an offer to sell, or
a solicitation of an offer to buy, any securities offered by this prospectus supplement and/or the accompanying prospectus by
any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Unless the context otherwise
requires, references in this prospectus supplement to &ldquo;we&rdquo;, &ldquo;us&rdquo; and &ldquo;our&rdquo; refer to Actinium
Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<DIV STYLE="padding: 12pt 5; border: Black 1.5pt solid; width: 100%"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-align: center; text-indent: 0"><A NAME="a-02"></A>PROSPECTUS
SUPPLEMENT SUMMARY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><I>This summary highlights
selected information about us, this offering and information appearing elsewhere in this prospectus supplement, in the accompanying
prospectus, in the documents we incorporate by reference and in any free writing prospectus that we have authorized for use in
connection with this offering. This summary is not complete and does not contain all the information that you should consider
before investing in our common stock. You should read this entire prospectus supplement and the accompanying prospectus carefully,
including the &ldquo;Risk Factors&rdquo; contained in this prospectus supplement, the accompanying prospectus and the financial
documents and notes incorporated by reference in this prospectus supplement and the accompanying prospectus and any free writing
prospectus that we have authorized for use in connection with this offering, before making an investment decision. This prospectus
supplement may add to, update or change information in the accompanying prospectus.</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0">The Company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><B>&nbsp;</B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0">Business Overview</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 0 0 68.8pt"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in; color: #231F20">We are a
biopharmaceutical company focused on the $57.1 billion market for cancer drugs, based on &ldquo;The Global Use of Medicines: Outlook
Through 2015 Report by the IMS Institute for Healthcare Informatics, May 2011&rdquo;. Our most advanced products are Actimab&trade;-A,
an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia (AML)
and Iomab&trade;-B, an antibody-drug construct containing iodine 131 (I-131), used in myeloconditioning for hematopoietic stem
cells transplantation (HSCT) in various indications. We are currently preparing for a Phase 3 trial of Iomab&trade;-B for bone
marrow conditioning for HSCT in relapsed and refractory AML patients age of 55 and older, which upon successful completion of
our clinical trials we intend to submit for marketing approval. We are currently also considering filing an application with the
U.S. Food and Drug Administration (FDA) for breakthrough therapy designation for Actimab&trade;-A and/or Iomab&trade;-B. We are
developing our cancer drugs using our expertise in radioimmunotherapy. In addition, our Ac-225 based drug development relies on
the patented Alpha Particle Immunotherapy Technology (APIT) platform technology co-developed with Memorial Sloan Kettering Cancer
Center (MSKCC), whose indirect subsidiary, Actinium Holdings Ltd., is a significant stockholder in our company. The APIT technology
couples monoclonal antibodies (mAb) with extremely potent but comparatively safe alpha particle emitting radioactive isotopes,
in particular actinium 225 and bismuth 213. The final drug construct is designed to specifically target and kill cancer cells
while minimizing side effects. We intend to develop a number of products for different types of cancer and derive revenue from
partnering relationships with large pharmaceutical companies and/or direct sales of its products in specialty markets in the United
States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0"><B>Business Strategy</B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in; color: #231F20">We intend
to potentially develop our most advanced clinical stage product candidates through approval in the case of Iomab&trade;-B, and
up to and including a Phase 2 proof of concept human clinical trial (a trial designed to provide data on the drug&rsquo;s efficacy)
in the case of Actimab&trade;-A. If these efforts are successful, we may elect to commercialize Iomab&trade;-B on our own or with
a partner in the United States and/or outside of the United States to out-license the rights to develop and commercialize the
product to a strategic partner. In the case of Actimab&trade;-A, we will most likely seek to enter into strategic partnerships
whereby the strategic partner(s) co-fund(s) further human clinical trials of the drug that are needed to obtain regulatory approvals
for commercial sale within and outside of the United States. In parallel, we intend to identify and begin initial human trials
with additional actinium-225 product candidates in other cancer indications. We intend to retain marketing rights for our products
in the United States whenever possible and out-license marketing rights to our partners for the rest of the world. We may also
seek to in license other applicable opportunities should such technology become available.</p>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
</Div>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<DIV STYLE="padding: 12pt 5; border: Black 1.5pt solid; width: 100%"><P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0">Market Opportunity</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 0 0 68.8pt"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">We are competing in the marketplace
for cancer treatments estimated to reach over $83-88 billion in 2016 sales, according to &ldquo;The Global Use of Medicines: Outlook
Through 2016 Report by the IMS Institute for Healthcare Informatics, July 2012&rdquo;. While surgery, radiation and chemotherapy
remain staple treatments for cancer, their use is limited by the fact that they often cause substantial damage to normal cells.
On the other hand, targeted monoclonal antibody therapies exert most or all of their effect directly on cancer cells, but often
lack sufficient killing power to eradicate all cancer cells with just the antibody. A new approach for treating cancer is to combine
the precision of antibody-based targeting agents with the killing power of radiation or chemotherapy by attaching powerful killing
agents to precise molecular carriers called monoclonal antibodies (mAb). We use mAbs labeled with radioisotopes to deliver potent
doses of radiation directly to cancer cells while sparing healthy tissues. The radioisotopes we use are the alpha emitter Ac-225
and the beta emitter I-131. I-131 is among the best known and well characterized radioisotopes. It is used very successfully in
treatment of papillary and follicular thyroid cancer as well as other thyroid conditions. It is also attached to a monoclonal
antibody in treatment of Non-Hodgkin&rsquo;s Lymphoma (NHL). It is also used experimentally with different carriers in other cancers.
Ac-225 has many unique properties and we are a leader in developing this alpha emitter for clinical applications using our proprietary
Alpha particle Immunotherapy (APIT) technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Our most advanced products
are Actimab&trade;-A, Ac-225 labeled mAb for treatment of newly diagnosed AML, a cancer of the blood, in patients ineligible for
currently approved therapies; and Iomab&trade;-B, I-131 labeled mAb for preparation of relapsed and refractory AML patients for
HSCT. Iomab&trade;-B offers a potentially curative treatment for these patients, most of whom do not survive beyond a year after
being diagnosed with this condition. Iomab&trade;-B has also demonstrated efficacy in HSCT preparation for other blood cancer
indications, including myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL), Hodgkin&rsquo;s Lymphoma, and Non-Hodgkin&rsquo;s
Lymphoma (NHL). These are all follow-on indications for which Iomab&trade;-B can be developed and it is our intention to explore
these opportunities if and when financing becomes available. We believe the aggregate worldwide market potential for the treatment
of AML, MDS, ALL, Hodgkin&rsquo;s Lymphoma, multiple myloma and NHL is approximately $4.1 billion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Other potential product opportunities
in which a significant amount of preclinical work is being undertaken include metastatic colorectal cancer, metastatic prostate
cancer and antiangiogenesis which reduces the blood supply to solid tumors. We believe the worldwide market potential for the
treatment of metastatic colorectal cancer is approximately $4.8 billion, and we believe the worldwide market potential for the
treatment of metastatic prostate cancer is approximately $6.0 billion. We also believe the worldwide market potential for the
treatment of Glioblastoma Multiforme, a potential indication based on antiangiogenesis approach, is approximately $1.1 billion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20; text-align: left">We believe
that our biggest market opportunity lies in the applicability of our APIT platform technology to a wide variety of cancers. A
broad range of solid and blood borne cancers can be potentially targeted by mAbs to enable treatment with the APIT technology.
The APIT technology could potentially be applied to mAbs that are already approved by the FDA to create more efficacious and/or
safer drugs (&ldquo;biobetters&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in; color: #231F20">In November
2014, the FDA granted orphan-drug designation for Actimab&trade;-A. The FDA, through its Office of Orphan Products Development,
grants orphan status to drugs and biologic products that are intended for the safe and effective treatment, diagnosis, or prevention
of rare diseases or disorders that affect fewer than 200,000 people in the United States. Orphan drug designation provides a drug
developer with certain benefits and incentives, including a period of marketing exclusivity if regulatory approval is ultimately
received for the designated indication; potential tax credits on United States clinical trials; eligibility for orphan drug grants;
and waiver of certain administrative fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0">Clinical Trials</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0">Actimab&trade;-A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 68.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Actimab&trade;-A is currently
in multicenter Phase 1/2 clinical trial in AML. It consists of the monoclonal antibody Lintuzumab and alpha emitting radioisotope
actinium 225 (Ac-225). The indication in the ongoing trial is newly diagnosed AML patients over the age of 60.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 32.3pt 0 68.8pt; text-align: justify; text-indent: 19.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Previous clinical trials leading
to this trial included:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 88.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 88.8pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Phase 1 clinical trial with Bismab-A,
    the first generation product consisting of the same monoclonal antibody Lintuzumab and Bi-213 alpha emitter, a daughter of
    Ac-225;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Phase 1/2 clinical trial with Bismab-A,
    the first generation product consisting of the same monoclonal antibody Lintuzumab and Bi-213 alpha emitter, a daughter of
    Ac-225; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dose escalating pilot Phase 1 clinical
    trial with Actimab&trade;-A, the current product consisting of the Lintuzumab monoclonal antibody and Ac-225 alpha emitter.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 88.8pt">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<DIV STYLE="padding: 12pt 5; border: Black 1.5pt solid; width: 100%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Completed Actimab&trade;-A
related clinical trials outcomes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 88.8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; width: 48px"></TD>
    <TD STYLE="padding-right: 5.4pt; width: 24px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt">The Phase 2 arm of the Bismab-A drug study has shown signs of the drug&rsquo;s efficacy and
    safety, including reduction in peripheral blast counts and complete responses in some patients. Bi-213 is a daughter, i.e.,
    product of the degradation of Ac-225, with cancer cell killing properties similar to Ac-225 but is less potent. The Phase
    1 Actimab&trade;-A trial at MSKCC with a single-dose administration of Actimab&trade;-A showed elimination of leukemia cells
    from blood in 67% of all evaluable patients who received a full dose and in 83% of those treated at dose levels above 0.5
    microcuries per kilogram (&micro;Ci/kg), and eradication of leukemia cells in both blood and bone marrow in 20% of all evaluable
    patients and 25% of those treated at dose levels above 0.5 &micro;Ci/kg. Maximum tolerated single dose in this trial was established
    at 3 &micro;Ci/kg.</TD></TR>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">High potency means that a relatively
low amount of drug is needed to produce a given effect. In preclinical and Phase 1 clinical studies, Actimab-A (<SUP>225</SUP>Ac-lintuzumab)
has demonstrated at least 500-1000 times higher potency than the first-generation predecessor (<SUP>213</SUP>Bi-lintuzumab) upon
which it is based. This difference is due to intrinsic physicochemical properties of Actimab-A that were first established <I>in
vitro</I>, in which Actimab-A killed multiple cell lines at doses at least 1000 times lower (based on LD50 values) than Bismab-A
analogs. Key factors in Actimab-A&rsquo;s higher potency are the yield of 4 alpha-emitting isotopes per <SUP>225</SUP>Ac (compared
to 1 alpha decay for bismuth 213) and much longer half-life (10 day for <SUP>225</SUP>Ac vs 46 minutes for <SUP>213</SUP>Bi).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 30.25pt 0 68.8pt; text-indent: 19.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">In preclinical animal models,
doses in the nanocurie range prolonged survival. In humans, Actimab-A was previously studied in a Phase I monotherapy trial of
relapsed or refractory AML patients at MSKCC. Dose levels in that study re-confirmed the substantially higher potency of Actimab-A,
as compared to equivalent dosing of the first-generation Bismab-A (<SUP>213</SUP>Bi-lintuzumab) construct, which had nevertheless
established safety and efficacy in a Phase 1/2 trial in high-risk AML with cytoreduction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Sources: Jurcic JG. Targeted
Alpha-Particle Immunotherapy with Bismuth-213 and Actinium-225 for Acute Myeloid Leukemia. J. Postgrad Med Edu Res 2013, 47(1):14-17;
; JG Jurcic et al, Phase 1 Trial of the Targeted Alpha- Particle Nano-Generator Actinium-225 (225Ac)-Lintuzumab in Acute Myeloid
Leukemia (AML) J Clin Oncol 29:2011 (suppl, abstr 6516); McDevitt MR et al, &ldquo;Tumor Therapy with Targeted Atomic Nanogenerators&rdquo;
Science 2001, 294:1537&mdash;1540; Rosenblat TL et al, &ldquo;Sequential cytarabine and alpha-particle immunotherapy with bismuth-
213-lintuzumab (HuM195) for acute myeloid leukemia&rdquo; Clin Cancer Res. 2010, 16(21):5303-5311; Jurcic JG et al. &ldquo;Phase
I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-Lintuzumab in Acute Myeloid Leukemia (AML)&rdquo; Blood
(ASH Meeting Abstracts) 2012.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; color: #231F20">Ongoing Actimab&trade;-A trial:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 68.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">We have commenced our first
company sponsored Phase 1/2 multi-center trial with fractionated (two) doses of Actimab&trade;-A, our lead product candidate for
treatment of elderly AML that consists of an AML specific monoclonal antibody (HuM195, also known as Lintuzumab&trade;) and the
actinium 225 radioactive isotope attached to it. We are conducting this trial at world-class cancer institutions such as MSKCC,
Johns Hopkins Medicine, University of Pennsylvania Health System, Fred Hutchinson Cancer Center and MD Anderson Cancer Center.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 20.2pt 0 68.8pt; text-indent: 19.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20; text-align: left">Bismab<FONT STYLE="font-family: Times New Roman, Times, Serif">t</FONT>-A
trials and the Phase 1 Actimab&trade;-A trial were focused on relapsed, refractory and other difficult to treat acute myeloid
leukemia patients. The current multicenter Phase 1/2 trial is focused on newly diagnosed AML patients who have historically had
better outcomes. In addition, the new trial includes low doses of chemotherapy with the goal of further improving patient outcomes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; color: #231F20">Iomab&trade;-B</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20; text-align: left">Iomab&trade;-B
is our product currently in preparation for a pivotal Phase 3 multicenter clinical trial. It consists of the monoclonal antibody
BC8 and beta emitting radioisotope iodine 131 (I-131). The indication for that trial is bone marrow conditioning for HSCT in relapsed
and refractory AML patients over the age of 55.</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<DIV STYLE="padding: 12pt 5; border: Black 1.5pt solid; width: 100%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Previous Iomab&trade;-B clinical
trials leading to the planned Phase 3 trial currently in preparation included:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 88.8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; padding: 0; border-bottom: Black 1.5pt solid; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Indications</B></FONT></td>
    <TD STYLE="width: 2%; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 20%; padding: 0; text-align: center; border-bottom: Black 1.5pt solid; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>N</B></FONT></td>
    <TD STYLE="width: 2%; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 42%; padding: 0; text-align: center; border-bottom: Black 1.5pt solid; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Key
    Findings</B></FONT></td></tr>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">AML, MDS, ALL (adult)</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">34</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ndash;7/34 patients with median
    disease free state (DFS) of 17 years.</FONT></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ndash;18/34 patients in remission
    at day 80</FONT></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">AML &gt;1st remission (adult)</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">23</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ndash;15/23 in remission at
    day 28</FONT></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">AML 1st remission (age 16-50)</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">43</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ndash;23/43 DFS from 5-16 years</FONT></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ndash;30/43 in remission at
    day 28</FONT></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ndash;33/43 in remission at
    day 80</FONT></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">High-risk MDS, advanced AML</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">68 in dose escalation study</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ndash;CR (complete remission)
    in all patients</FONT></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(age 50+)</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">31 treated at
    MTD</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ndash;1 yr survival ~40% for
    all patients</FONT></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ndash;1 yr survival ~45% for
    pts treated at MTD maximum tolerated dose)</FONT></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">High-risk MDS, AML</FONT><BR>
    <FONT STYLE="font: 10pt Times New Roman, Times, Serif">(age 18&ndash;50)</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">14 in dose escalation</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All patients achieved full donor
    chimerism by day 28 post-transplant</FONT></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">High-risk MDS, AML</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8 in dose escalation</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ndash;6/8 treated patients
    achieved CR by day.28</FONT></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ndash;haploidentical donors
    (adult)</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ndash;8/8
                                         patients 100% donor chimerism by day28</FONT></P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0">Ongoing Iomab&trade;-B clinical
trials include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 68.8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"><B>Indications</B></td>
    <TD STYLE="width: 1%; padding: 0 0 1.5pt; text-indent: 0">&nbsp;</td>
    <TD STYLE="width: 9%; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-align: center; text-indent: 0"><B>Phase</B></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0">Relapsed and refractory Hodgkin Lymphoma and NHL (adult)</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">Phase 1</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0">Advanced AML, ALL and MDS (adult)</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">Phase 2</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0">AML 1st remission (age 16-50)</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">Phase 2</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0">High-risk MDS, advanced AML (age 16-50)</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">Phase 2</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 68.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">There are additional ongoing
clinical trials with BC8 antibody labeled with yttrium 90 (Y-90).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; color: #231F20">Phase 3 Iomab&trade;-B clinical
trial in preparation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">While we do not have a Special
Protocol Assessment from the FDA with respect to our planned Phase 3 trial of Iomab&trade;-B, we have obtained FDA&rsquo;s comment
and guidance on the Phase 3 clinical trial design, and the FDA has identified the following design features as generally acceptable,
dependent on the results of the trial:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 23.6pt 0 68.8pt; text-indent: 19.95pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 0.5in">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 0.25in">&mdash;</td>
    <TD STYLE="padding: 0; text-indent: 0">Single pivotal study, pending trial results;</td></tr>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td></tr>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&mdash;</td>
    <TD STYLE="padding: 0; text-indent: 0">Patient population: refractory AML patients age of 55 and older, where refractory is
    defined as either primary failure to achieve a complete remission after 2 cycles of induction therapy; relapsed after 6 months
    in complete remission; second or higher relapse; or relapsed disease not responding to intensive salvage therapy;</td></tr>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td></tr>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&mdash;</td>
    <TD STYLE="padding: 0; text-indent: 0">Trial arms: study arm and control arm with physician&rsquo;s choice of conventional
    care with curative intent; and</td></tr>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td></tr>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&mdash;</td>
    <TD STYLE="padding: 0; text-indent: 0">Trial size: 150 patients total (75 patients per arm).</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 108.75pt; text-indent: -19.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">For the twelve months ended
December 31, 2014, we had no revenue and our net loss was approximately $24.7 million. For the twelve months ended December 31,
2013, we had no revenue and our net loss was approximately $10.8 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<DIV STYLE="padding: 12pt 5; border: Black 1.5pt solid; width: 100%"><P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; color: rgb(35,31,32)"><B><I>Intellectual
Property</I></B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 0 0 68.8pt"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">We
                                         have developed or in-licensed numerous patents and patent applications and possess substantial
                                         know-how and trade secrets relating to the development and commercialization of our products.
                                         As of March 16, 2015, our patent portfolio includes: 39 issued and pending patents, of
                                         which 7 are issued in the United States, 30 are issued or pending internationally, and
                                         2 are pending in the United States. Many of the patents are in-licensed from third parties
                                         and some are held by us. These patents cover key areas of our business, including use
                                         of the actinium-225 and other alpha emitting isotopes attached to cancer specific carriers
                                         like monoclonal antibodies, methods for manufacturing key components of our product candidates
                                         including actinium-225 alpha emitting radioisotope and carrier antibodies, and methods
                                         for manufacturing finished product candidates for use in cancer treatment. The table
                                         below classifies these patents by related family:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 46.55pt 0 68.8pt; text-indent: 19.95pt; color: #231F20">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; width: 35%; text-indent: 0; text-align: left; vertical-align: bottom"><B>Area</B></td>
    <TD STYLE="padding: 0 0 1.5pt; width: 2%; text-indent: 0; text-align: center; vertical-align: bottom">&nbsp;</td>
    <TD STYLE="padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-align: center; width: 30%; text-indent: 0; vertical-align: bottom"><B>Description</B></td>
    <TD STYLE="padding: 0 0 1.5pt; text-align: center; width: 2%; text-indent: 0; vertical-align: bottom">&nbsp;</td>
    <TD STYLE="padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-align: center; width: 9%; vertical-align: bottom"><B>US
    Expiration</B></td>
    <TD STYLE="padding: 0 0 1.5pt; text-align: center; width: 2%; text-indent: 0; vertical-align: bottom">&nbsp;</td>
    <TD STYLE="padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-align: center; width: 9%; vertical-align: bottom"><B>US
    Status</B></td>
    <TD STYLE="padding: 0 0 1.5pt; text-align: center; width: 2%; text-indent: 0; vertical-align: bottom">&nbsp;</td>
    <TD STYLE="padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-align: center; width: 9%; vertical-align: bottom"><B>Owner/</B><br>
    <B>Licensor</B></td></tr>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0">Platform technology</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">Metastases larger than 1 mm</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">2019</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">Issued</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">MSKCC</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0">Platform technology</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">Antibody conjugates with DOTA chelators; methods of treating cancer using the same</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">2021</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">Issued</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">MSKCC</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0">Drug preparation methods</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">Actinium 225 labeling method (binding to an antibody)</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">2030</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">Pending</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">Owned</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0">Drug preparation methods</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">Bismuth 213 labeling method (binding to an antibody)</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">2019</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">Issued</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">MSKCC</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0">Isotope production methods</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">Actinium 225 manufacturing in a cyclotron</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">2026/2027</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">Issued</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">Owned</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0">Monoclonal antibody composition and production</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-indent: 0">Manufacturing of leukemia targeting antibody</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">2014</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">Issued</td>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</td>
    <TD STYLE="padding: 0; text-align: center">Abbvie</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 46.55pt 0 68.8pt; text-indent: 19.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #231F20">There are no patents
covering Iomab&trade;-B; however, we have developed a proprietary strategy based on trade secret protection and the potential
for orphan drug and data exclusivities. The BC8 antibody, cell line and related know-how has been exclusively licensed by us from
the Fred Hutchinson Cancer Research Center (FHCRC) in exchange for milestones, royalties and research support.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #231F20">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #231F20">Patents related
to the antibody component of Actimab-A have been exclusively licensed by us from AbbVie Biotherapeutics Corp. (formerly Abbott
Biotherapeutics Corp.) for use with alpha-emitting radioisotopes in exchange for future development and commercialization milestones,
a royalty on net sales for a period of 12.5 years from first commercial sale, a negotiation right to be our clinical and/or commercial
antibody supplier, a negotiation right to co-promote Actimab&trade;-A in the United States on terms to be negotiated, and the
grant-back of IP rights covering improvements to the antibody for use other than with an alpha-emitting isotope. Patents covering
actinium-225 conjugated to antibodies have been exclusively licensed by us from MSKCC in exchange for license fees, research support
payments, development milestones, 2% royalties on net sales for the term of the licensed patents or, if later, 10 years from first
commercial sale, and 15% of any sublicense income we may receive. As of December 31, 2014, we owe MSKCC approximately $0.2 million
in past fees and research support payments. We source actinium-225 under an agreement with the Oak Ridge National Laboratory (ORNL)
that expires at the end 2015. We believe, but cannot guarantee, that we will be able to renew this contract for additional annual
periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><B>Corporate and Other
Information</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">We were organized in the State
of Nevada in October 1997 and reorganized in the State of Delaware in March 2013. Our principal executive offices are located
at 546 5th Avenue, 14<SUP>th</SUP> Floor, New York, New York 10036. Our telephone number is (646) 459-4201. Our website address
is <U>www.actiniumpharma.com</U>. Information accessed through our website is not incorporated into this prospectus supplement
and is not a part of this prospectus supplement or the accompanying prospectus.</P> </DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 23.6pt 0 68.8pt">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 23.6pt 0 68.8pt">&nbsp;</P>

<DIV STYLE="padding: 12pt 5; border: Black 1.5pt solid; width: 100%"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: #231F20"><A NAME="a-03"></A>THE
OFFERING</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: #231F20">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: #231F20"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28%; padding-left: 7.5pt; text-indent: -7.5pt; line-height: 107%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">Common
    Stock Offered by Us </FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 71%; line-height: 107%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">1,923,078 shares of our
    common stock, par value $0.001 per share.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 7.5pt; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 7.5pt; text-indent: -7.5pt; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Offering
    Price</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">2.60 per
share</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 7.5pt; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 7.5pt; text-indent: -7.5pt; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Common
    Stock outstanding before this Offering</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">36,555,244 shares
    of our common stock, par value $0.001 per share.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 7.5pt; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 7.5pt; text-indent: -7.5pt; line-height: 107%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">Common
    Stock to be Outstanding Immediately After this Offering </FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">38,478,322 shares of our common stock, par value $0.001 per share.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 7.5pt; text-indent: -7.5pt; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 7.5pt; text-indent: -7.5pt; line-height: 107%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">Use
    of Proceeds </FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">We currently intend to use the net
    proceeds from the sale of securities offered by this prospectus supplement for general corporate purposes, including capital
    expenditures, the advancement of our product candidates in clinical trials, such as Iomab&trade;-B Phase 3 clinical trial
    and Actimab&trade;-A Phase 2 clinical trial, preclinical trials, to support licensing activities, and to meet working capital
    needs. See &ldquo;Use of Proceeds&rdquo; on page S-30.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 7.5pt; text-indent: -7.5pt; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 7.5pt; text-indent: -7.5pt; line-height: 107%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">Risk
    Factors </FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif; color: #231F20">See &ldquo;Risk
    Factors&rdquo; beginning on page S-8 of this prospectus supplement, page 6 of the accompanying prospectus and the &ldquo;Risk
    Factors&rdquo; sections of our Annual Report on Form 10-K for the year ended December 31, 2014 for a discussion of factors
    that you should read and consider before investing in our securities. To the extent that the risk factors contained in this
    prospectus supplement, the accompanying prospectus or our annual or quarterly reports differ, the risk factors contained in
    this prospectus supplement shall control.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 7.5pt; text-indent: -7.5pt; line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 7.5pt; text-indent: -7.5pt; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">NYSE
    MKT symbol </FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ATNM.</FONT></TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: #231F20"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #231F20">The number
of shares of our common stock that will be outstanding immediately after the offering is based on </FONT>36,555,244 <FONT STYLE="color: #231F20">shares
outstanding as of June 3, 2015. Unless we specifically state otherwise, the share information in this prospectus supplement excludes:</FONT></P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: #231F20">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="line-height: 115%; text-align: left"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">3,549,084 shares
    of common stock issuable upon the exercise of stock options outstanding as of March 31, 2015 under our equity incentive plans,
    with a weighted average exercise price of $5.62 per share;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="line-height: 115%; text-align: left">1,873,866 shares of common stock available for future grants under our equity
    incentive plans as March 31, 2015;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="line-height: 115%; text-align: left"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">238,973 shares
    of common stock issuable upon the exercise of restricted stock units outstanding as of March 31, 2015; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="line-height: 115%; text-align: left"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">9,886,547 shares
    of common stock issuable upon the exercise of warrants outstanding as of March 31, 2015, with a weighted average exercise
    price of $3.43 per share.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><A NAME="a-04"></A><B>RISK
FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 180.5pt 0 245.2pt; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">An investment in our securities
involves a high degree of risk. Before deciding whether to invest in our securities, you should carefully consider the risks and
uncertainties described in this prospectus supplement, the accompanying prospectus and in the documents incorporated by reference.
The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently
known to us or that we currently deem immaterial may also affect our operations. Past financial performance may not be a reliable
indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods. If
any of these risks actually occurs, our business, business prospects, financial condition or results of operations could be seriously
harmed. This could cause the trading price of our common stock to decline, resulting in a loss of all or part of your investment.
Please also read carefully the section below and in the accompanying prospectus entitled &ldquo;Special Note Regarding Forward-Looking
Statements.&rdquo; Please note that additional risks not presently known to us or that we currently deem immaterial may also impair
our business and operations.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20">Risks Related to Our Business</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20">We have generated no revenue from commercial
sales to date and our future profitability is uncertain.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">We have a limited operating
history and our business is subject to all of the risks inherent in the establishment of a new business enterprise. Our likelihood
of success must be considered in light of the problems, expenses, difficulties, complications and delays frequently encountered
in connection with this development and expansion. Since we began our business, we have focused on research, development and clinical
trials of product candidates, and have incurred losses since inception. As of March 31, 2015, we had an accumulated deficit of
approximately $94.3 million. If we continue to incur operating losses and fail to become a profitable company, we may be unable
to continue our operations. We expect to continue to operate at a net loss as we continue our research and development efforts,
continue to conduct clinical trials and develop manufacturing, sales, marketing and distribution capabilities. There can be no
assurance that the products under development by us will be approved for sale in the United States or elsewhere. Furthermore,
there can be no assurance that if such products are approved they will be successfully commercialized, and the extent of our future
losses and the timing of our profitability are highly uncertain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 5.4pt 0 0; color: #231F20">If we fail to obtain the
capital necessary to fund our operations, we will be unable to continue or complete our product development and you will likely
lose your entire investment.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 5.4pt 0 68.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">We do not currently have
sufficient capital for the development and commercialization of our lead product candidate and we will need to continue to
seek capital from time to time to continue development of our lead product candidates and to acquire and develop other
product candidates. Our first product candidate is not expected to be commercialized, if approved, until at least 2017 and we
do not expect that the partnering revenues it will generate will be sufficient to fund our ongoing operations. Our cash
balance as of March 31, 2015 was approximately $19.3 million. As of  March 31, 2015, we expect that we will need
approximately $7.2 million through the end of 2015 to finance research and development and to cover our ongoing working
capital needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Our business or operations
may change in a manner that would consume available funds more rapidly than anticipated and substantial additional funding may
be required to maintain operations, fund expansion, develop new or enhanced products, acquire complementary products, business
or technologies or otherwise respond to competitive pressures and opportunities, such as a change in the regulatory environment
or a change in preferred cancer treatment modalities. However, we may not be able to secure funding when we need it or on favorable
terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">To raise additional capital, we may
in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common
stock. We cannot assure you that we will be able to sell shares or other securities in any other offering at a price per share
that is equal to or greater than the price per share paid by investors in this offering, and investors purchasing shares or other
securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional
shares of our common stock or other securities convertible into or exchangeable for our common stock in future transactions may
be higher or lower than the price per share in this offering. Additionally, you may incur dilution as a result of grants of equity
awards under our equity incentive plans, or upon exercise of options or warrants currently outstanding with exercise prices at
or below the public offering price of our common stock in this offering. See the section entitled &ldquo;Dilution&rdquo; below
for a more detailed discussion of the dilution you will incur if you purchase common stock and accompanying warrants in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">If we cannot raise adequate
funds to satisfy our capital requirements, we will have to delay, scale-back or eliminate our research and development activities,
clinical studies or future operations. We may also be required to obtain funds through arrangements with collaborators, which
arrangements may require us to relinquish rights to certain technologies or products that we otherwise would not consider relinquishing,
including rights to future product candidates or certain major geographic markets. We may further have to license our technology
to others. This could result in sharing revenues which we might otherwise have retained for ourselves. Any of these actions may
harm our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 11.5pt 0 68.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 11.5pt 0 68.8pt"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 11.5pt 0 68.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">The amount of capital we may
need depends on many factors, including the progress, timing and scope of our product development programs; the progress, timing
and scope of our preclinical studies and clinical trials; the time and cost necessary to obtain regulatory approvals; the time
and cost necessary to further develop manufacturing processes and arrange for contract manufacturing; our ability to enter into
and maintain collaborative, licensing and other commercial relationships; and our partners&rsquo; commitment of time and resources
to the development and commercialization of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 5.05pt 0 0; color: #231F20">We have limited access to
the capital markets and even if we can raise additional funding, we may be required to do so on terms that are dilutive to you.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 5.05pt 0 68.8pt"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">We have limited access to the
capital markets to raise capital. The capital markets have been unpredictable in the recent past for radio-immunotherapy and other
oncology companies and unprofitable companies such as ours. In addition, it is generally difficult for development stage companies
to raise capital under current market conditions. The amount of capital that a company such as ours is able to raise often depends
on variables that are beyond our control. As a result, we may not be able to secure financing on terms attractive to us, or at
all. If we are able to consummate a financing arrangement, the amount raised may not be sufficient to meet our future needs. If
adequate funds are not available on acceptable terms, or at all, our business, including our technology licenses, results of operations,
financial condition and our continued viability will be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 5.05pt 0 0; color: #231F20">If we fail to obtain or
maintain necessary FDA approval for our radio-immunotherapy products, or if such approvals are delayed, we will be unable to commercially
distribute and market our products.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 5.05pt 0 68.8pt"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Our products are subject to
rigorous regulation by the FDA and numerous other federal, state and foreign governmental authorities. The process of seeking
regulatory approval to market a radio-immunotherapy product is expensive and time-consuming and, notwithstanding the effort and
expense incurred, approval is never guaranteed. If we are not successful in obtaining timely approval of Company products from
the FDA, we may never be able to generate significant revenue and may be forced to cease operations. In particular, the FDA permits
commercial distribution of a new radio-immunotherapy product only after a Biologics License Application (BLA) for the product
has received FDA approval. The BLA process is costly, lengthy and inherently uncertain. Any BLA filed by us will have to be supported
by extensive data, including, but not limited to, technical, preclinical, clinical trial, manufacturing and labeling data, to
demonstrate to the FDA&rsquo;s satisfaction the safety and efficacy of the product for its intended use. The lengthy approval
process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval
to market our product candidates, which would significantly harm our business, results of operations and prospects. In addition,
even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited
indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on
the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include
the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing
scenarios could materially harm the commercial prospects for our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6.75pt 0 68.8pt; text-indent: 19.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">The approval process in the
United States and in other countries could result in unexpected and significant costs for us and consume management&rsquo;s time
and other resources. The FDA and other foreign regulatory agencies could ask us to supplement our submissions, collect non-clinical
data, conduct additional clinical trials or engage in other time-consuming actions, or it could simply deny our applications.
In addition, even if we obtain approval to market our products in the United States or in other countries, the approval could
be revoked or other restrictions imposed if post-market data demonstrates safety issues or lack of effectiveness. We cannot predict
with certainty how, or when, the FDA or other regulatory authorities will act. If we are unable to obtain the necessary regulatory
approvals, our financial condition and cash flow may be materially adversely affected, and our ability to grow domestically and
internationally may be limited. Additionally, even if we obtain approval, regulatory authorities may approve any of our product
candidates for fewer or more limited indications that we request. The Company&rsquo;s products may not be approved for the specific
indications that are most necessary or desirable for successful commercialization or profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 5.05pt 0 0; color: #231F20">Our radio-immunotherapy
product candidates are in the early stages of development; and we have not demonstrated that any of our products are safe and
effective for any indication.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 5.05pt 0 68.8pt"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">We currently have only two
products in clinical development. We have commenced a Phase 1/2 multi- center AML trial with fractionated doses of Actimab&trade;-A
under its own federal Investigational New Drug Application (IND). Additionally, there are a number of physician IND trials at
the FHCRC that have been conducted or are currently ongoing at FHCRC with single doses of Iomab&trade;-B. We plan to file our
own IND prior to initiating our planned Phase 3 study of Iomab&trade;-B.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.05pt 0 68.8pt; text-indent: 19.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">We cannot predict whether we
will encounter problems with any of our ongoing or planned clinical trials that will cause us or regulatory authorities to delay,
suspend, or discontinue clinical trials or to delay the analysis of data from ongoing clinical trials. Any of the following could
delay or disrupt the clinical development of our product candidates and potentially cause our product candidates to fail to receive
regulatory approval:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 8.05pt 0 68.8pt; text-indent: 19.95pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="padding: 0; text-indent: 0">conditions
                                         imposed on us by the FDA or comparable foreign authorities regarding the scope or design
                                         of our clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 11.5pt 0 98.35pt; text-indent: -9.55pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0">&#9679;</TD><TD STYLE="padding: 0; text-indent: 0">delays
                                         in receiving, or the inability to obtain, required approvals from institutional review
                                         boards (IRBs) or other reviewing entities at clinical sites selected for participation
                                         in our clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 33.15pt 0 98.35pt; text-indent: -9.55pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0">&#9679;</TD><TD STYLE="padding: 0; text-indent: 0">delays
                                         in enrolling patients into clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 98.35pt; text-indent: -9.55pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0">&#9679;</TD><TD STYLE="padding: 0; text-indent: 0">a
                                         lower than anticipated retention rate of patients in clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 98.35pt; text-indent: -9.55pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0">&#9679;</TD><TD STYLE="padding: 0; text-indent: 0">the
                                         need to repeat or discontinue clinical trials as a result of inconclusive or negative
                                         results or unforeseen complications in testing or because the results of later trials
                                         may not confirm positive results from earlier preclinical studies or clinical trials;</TD></TR>                                                                            <TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&#9679;</TD><TD STYLE="padding: 0; text-indent: 0">inadequate
                                         supply, delays in distribution deficient quality of, or inability to purchase or manufacture
                                         drug product, comparator drugs or other materials necessary to conduct our clinical trials;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 33.15pt 0 98.35pt; text-indent: -9.55pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0">&#9679;</TD><TD STYLE="padding: 0; text-indent: 0">unfavorable
                                         FDA or other foreign regulatory inspection and review of a clinical trial site or records
                                         of any clinical or preclinical investigation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 11.5pt 0 98.35pt; text-indent: -9.55pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0">&#9679;</TD><TD STYLE="padding: 0; text-indent: 0">serious
                                         and unexpected drug-related side effects experienced by participants in our clinical
                                         trials, which may occur even if they were not observed in earlier trials or only observed
                                         in a limited number of participants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6.45pt 0 98.35pt; text-indent: -9.55pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0">&#9679;</TD><TD STYLE="padding: 0; text-indent: 0">a
                                         finding that the trial participants are being exposed to unacceptable health risks;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 98.35pt; text-indent: -9.55pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0">&#9679;</TD><TD STYLE="padding: 0; text-indent: 0">the
                                         placement by the FDA or a foreign regulatory authority of a clinical hold on a trial;
                                         or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 98.35pt; text-indent: -9.55pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0">&#9679;</TD><TD STYLE="padding: 0; text-indent: 0">delays
                                         in obtaining regulatory agency authorization for the conduct of our clinical trials.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 98.35pt; text-indent: -9.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">We may suspend, or the FDA
or other applicable regulatory authorities may require us to suspend, clinical trials of a product candidate at any time if we
or they believe the patients participating in such clinical trials, or in independent third party clinical trials for drugs based
on similar technologies, are being exposed to unacceptable health risks or for other reasons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Further, individuals involved
with our clinical trials may serve as consultants to us from time to time and receive stock options or cash compensation in connection
with such services. If these relationships and any related compensation to the clinical investigator carrying out the study result
in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected interpretation
of the study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the
clinical trial itself may be jeopardized. The delay, suspension or discontinuation of any of our clinical trials, or a delay in
the analysis of clinical data for our product candidates, for any of the foregoing reasons, could adversely affect our efforts
to obtain regulatory approval for and to commercialize our product candidates, increase our operating expenses and have a material
adverse effect on our financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Clinical trials may also be
delayed or terminated as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended or
terminated by us, the FDA, the IRBs at the sites where the IRBs are overseeing a trial, or a data safety monitoring board, or
DSMB, overseeing the clinical trial at issue, or other regulatory authorities due to a number of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.05pt 0 68.8pt; text-indent: 19.95pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>failure to conduct
                                         the clinical trial in accordance with regulatory requirements or our clinical protocols;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 98.35pt; text-indent: -9.55pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="padding-right: 36.45pt">inspection of the clinical
                                         trial operations or trial sites by the FDA or other regulatory authorities resulting
                                         in the imposition of a clinical hold;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 36.45pt 0 98.35pt; text-indent: -9.55pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>varying interpretation
                                         of data by the FDA or similar foreign regulatory authorities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 98.35pt; text-indent: -9.55pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>failure to achieve primary or secondary endpoints or other
                                         failure to demonstrate efficacy;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 98.35pt; text-indent: -9.55pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>unforeseen safety issues; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 98.35pt; text-indent: -9.55pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>lack of adequate
                                         funding to continue the clinical trial.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 98.35pt; text-indent: -9.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Additionally, changes in regulatory
requirements and guidance may occur and we may need to amend clinical trial protocols to reflect these changes. Amendments may
require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the cost, timing or successful
completion of a clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">In addition, neither we nor
any relevant collaborative partner(s) has yet undertaken any clinical assessment or investigation of Company radio-immunotherapy
product candidates for other indications, including colon cancer or prostate cancer. Significant further investment may be required
to acquire antibody rights and to undertake necessary research and continued development. Further laboratory and specific clinical
testing will be required prior to regulatory approval of any product candidates. Adverse or inconclusive results from pre-clinical
testing or clinical trials of product candidates may substantially delay, or halt entirely, any further development of one or
more of our products. The projected timetables for continued development of the technologies and related product candidates by
us may otherwise be subject to delay or suspension.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 7.35pt 0 0; color: #231F20">Modifications to our product
candidates may require federal approvals.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 7.35pt 0 68.8pt"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">The BLA application is the
vehicle through which the company may formally propose that the FDA approve a new pharmaceutical for sale and marketing in the
United States. Once a particular product candidate receives FDA approval, expanded uses or uses in new indications of our products
may require additional human clinical trials and new regulatory approvals, including additional IND and BLA submissions and premarket
approvals before we can begin clinical development, and/or prior to marketing and sales. If the FDA requires new approvals for
a particular use or indication, we may be required to conduct additional clinical studies, which would require additional expenditures
and harm our operating results. If the products are already being used for these new indications, we may also be subject to significant
enforcement actions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Conducting clinical trials
and obtaining approvals can be a time-consuming process, and delays in obtaining required future approvals could adversely affect
our ability to introduce new or enhanced products in a timely manner, which in turn would harm our future growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 8.4pt 0 0; color: #231F20">There is no guarantee that
the FDA will approve BLAs for our product candidates and failure to obtain necessary approvals for our product candidates would
adversely affect our ability to grow our business.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 8.4pt 0 68.8pt"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">We have recently commenced
a multi-center Phase 1/2 clinical trial for our lead product candidate, Actimab&trade;-A, in AML and in the future expect to submit
a BLA to the FDA for approval of this product. This product candidate is also the subject of an ongoing human safety trial being
conducted under a physician IND at MSKCC. We are in the early stages of evaluating other product candidates consisting of conjugates
of Ac-225 with human or humanized antibodies for pre-clinical and clinical development in other types of cancer. In June 2012,
we acquired rights to Iomab&trade;, a Phase 2 clinical stage monoclonal antibody with safety and efficacy data in more than 250
patients in need of HSCT. Product candidates utilizing this antibody would also require BLA approval before they can be marketed
in the United States. The FDA may not approve these products for the indications that are necessary or desirable for successful
commercialization. Indeed, the FDA may fail to approve any BLA we submit for new product candidates or for new intended uses or
indications for approved products or future product candidates. Failure to obtain FDA approval for our products in the proposed
indications would have an adverse effect on our ability to expand our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 11.5pt 0 0; color: #231F20">Clinical trials necessary
to support approval of BLAs for our product candidates will be time consuming and expensive. Delays or failures in our clinical
trials may prevent us from commercializing our product candidates and will adversely affect our business, operating results and
prospects and could cause us to cease operations.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 11.5pt 0 68.8pt"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Initiating and completing clinical
trials necessary to support FDA approval of a BLA for Actimab&trade;-A and other product candidates, is a time-consuming and expensive
process, and the outcome is inherently uncertain. Moreover, the results of early clinical trials are not necessarily predictive
of future results, and any product candidate we advance into clinical trials may not have favorable results in later clinical
trials. We have worked with the FDA to develop a clinical trial designed to test the initial safety and efficacy of Actimab&trade;-A
in newly diagnosed AML patients over the age of 60, and on October 6, 2008, and January 5, 2009, we submitted IND amendments to
the FDA for the conduct of a multi-center Phase 1/2 clinical trial for treatment of AML. The trial is now underway with the purpose
of examining the use of Actimab&trade;-A in AML patients who are not eligible for approved forms of treatment with curative intent.
The trial is not designed to support marketing approval for the product candidate, and one or more additional trials will have
to be conducted in the future before we file a BLA. In addition, there can be no assurance that the data generated during the
trial will meet our chosen safety and effectiveness endpoints or otherwise produce results that will eventually support the filing
or approval of a BLA. Even if the data from this trial are favorable, these data may not be predictive of the results of any future
clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>The issued patents, which are
licensed by us for the HuM-195 antibody, our acute myeloid leukemia targeting antibody, may expire before we have commercialized
Actimab&trade;-A.</I></B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">The humanized antibody which
we use in the conjugated Actimab&trade;-A product candidate is covered by the claims of issued patents that we license from Facet
Biotech Corporation, a wholly-owned subsidiary of AbbVie Laboratories. After these patents expire, others may be eventually able
to use an antibody with the same sequence, and we will then need to rely on additional patent protection covering alpha particle
drug products comprising actinium 225. Any competing product based on the HuM-195 antibody is likely to require several years
of development before achieving our product candidate&rsquo;s current status and may be subject to significant regulatory hurdles,
but is nevertheless a possibility that can affect the Company&rsquo;s business in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Additionally, because we expect
that certain of these patents will expire prior to commercialization of Actimab&trade;-A, we expect that in order to attract a
commercialization partner for that product candidate, we may need to reach an agreement with AbbVie to reduce the milestone payments
and royalties currently required to be paid under our license agreement for HuM-195. There can be no assurance that the parties
will be able to agree on an amendment to the terms of the license. Failure to reach such an agreement could materially adversely
affect our ability to find a commercialization partner for Actimab&trade;-A which may materially harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20">Iomab&trade;-B is not patent protected.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 0 0 68.8pt"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Neither the antibody portion
nor the composition of matter as a whole for the conjugated Iomab&trade; product candidate is covered by the claims of any issued
or pending patents. Accordingly, there are no patents that would prevent others from using an antibody with the same antibody
sequence in any drug product (e.g., those comprising iodine 131 or alpha particle emitters). Any competing product based on the
antibody used in Iomab-B&trade; is likely to require several years of development before achieving our product candidate&rsquo;s
current status and may be subject to significant regulatory hurdles, but is nevertheless a possibility that could negatively impact
the Company&rsquo;s business in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 8.85pt 0 68.8pt; text-indent: 19.95pt">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20">We may be unable to obtain a sufficient
supply of Ac-225 medical grade isotope in order to continue clinical trials and to allow for the manufacture of commercial quantities
of Actimab&trade;-A</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 11.5pt 0 68.8pt"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">There are limited quantities
of Ac-225 available today. The existing supplier of Ac-225 to us is the ORNL, which is a science and energy national laboratory
in the Department of Energy system. ORNL manufactures Ac-225 by eluting it from its supply of Thorium-229. Although this has proven
to be a very reliable source of production for a number of years, it is limited by the quantity of Thorium-229 at ORNL. We believe
that the current approximate maximum of Ac-225 production from this source is sufficient for approximately 1,000&ndash;2,000 patient
treatments per year. Since our needs are significantly below that amount at this time, and will continue to be below that for
as long as we do not have a commercial product with a potential of selling more than 2,000 patient doses per year, we believe
that this supply will be sufficient for completion of clinical trials and early commercialization. To secure supplies beyond this
amount, we have developed what we believe to be a scalable cost-effective process for manufacturing Ac-225 in a cyclotron at an
estimated cost in excess of $5 million. This work has been conducted at Technical University Munich (TUM) in Germany. We are now
in possession of detailed descriptions of all the developed manufacturing procedures and have rights to all relevant patent applications
and other intellectual property. However, we do not currently have access to a commercial cyclotron capable of producing medical
grade Ac-225. Although beam time on such cyclotrons is commercially available, we do not currently have a relationship with any
entity that owns or controls a suitable cyclotron. We have identified possible sources and estimate that we could secure the necessary
beam time when needed at a cost of approximately $2 million per year. In the meantime, our contract for supply of this isotope
from ORNL must be renewed yearly, and the current contract extends through the end of 2015. While we expect this contract will
be renewed at the end of its term, there can be no assurance that ORNL will decide to renew the contract or that the United States
Department of Energy will not change its policies that allow for the sale of isotope to us. Failure to acquire sufficient quantities
of medical grade Ac-225 would make it impossible to effectively complete clinical trials and to commercialize Actimab&trade;-A
and would materially harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 7.4pt 0 68.8pt; text-indent: 19.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 7.4pt 0 68.8pt; text-indent: 19.95pt"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 7.4pt 0 68.8pt; text-indent: 19.95pt">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20">Conducting successful clinical studies
may require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 11.5pt 0 68.8pt"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Patient enrollment in clinical
trials and completion of patient participation and follow-up depends on many factors, including the size of the patient population;
the nature of the trial protocol; the availability of approved effective treatments for the relevant disease; competition from
other clinical trial programs for similar indications; the attractiveness of, or the discomforts and risks associated with, the
treatments received by enrolled subjects; the availability of appropriate clinical trial investigators; support staff; and proximity
of patients to clinical sites and ability to comply with the eligibility and exclusion criteria for participation in the clinical
trial and patient compliance. For example, patients may be discouraged from enrolling in our clinical trials if the trial protocol
requires them to undergo extensive post-treatment procedures or follow-up to assess the safety and effectiveness of our product
candidates or if they determine that the treatments received under the trial protocols are not attractive or involve unacceptable
risks or discomforts. Patients may also not participate in our clinical trials if they choose to participate in contemporaneous
clinical trials of competitive product candidates. In addition, patients participating in refractory AML clinical trials are seriously
and often terminally ill and therefore may not complete the clinical trial due to reasons including comorbid conditions or occurrence
of adverse medical events related or unrelated to the investigational products, or death.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5pt 0 68.8pt; text-indent: 19.95pt">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20">Development of sufficient and appropriate
clinical protocols to demonstrate safety and efficacy are required and we may not adequately develop such protocols to support
approval.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 5.05pt 0 68.8pt"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">The FDA may require us to submit
data on a greater number of patients than we originally anticipated and/or for a longer follow-up period or change the data collection
requirements or data analysis applicable to our clinical trials. It may also require additional data on certain categories of
patients, should it emerge during the conduct of our clinical trials that certain categories of patients are likely to be affected
in different and/or additional manners than the rest of the patient population. In addition to FDA requirements, our clinical
trials require the approval of the IRB at each site selected. We have submitted our clinical trial protocol for our current Actimab&trade;-A
clinical trial to the IRBs at participating sites for approval and we have thus far obtained approval from seven IRBs. Our clinical
trial protocols have not been rejected by any IRB to date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20">FDA may take actions that would prolong,
delay, suspend, or terminate clinical trials of our product candidates, which may delay or prevent us from commercializing our
product candidates on a timely basis, causing us to incur additional costs and delay our receipt of any revenue from potential
product sales.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 5.05pt 0 68.8pt"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">There can be no assurance that
the data generated in our clinical trials will be acceptable to FDA or that if future modifications during the trial are necessary,
that any such modifications will be acceptable to FDA. Certain modifications to a clinical trial protocol made during the course
of the clinical trial have to be submitted to the FDA. This could result in the delay or halt of a clinical trial while the modification
is evaluated. In addition, depending on the quantity and nature of the changes made, FDA could take the position that some or
all of the data generated by the clinical trial is not usable because the same protocol was not used throughout the trial. This
might require the enrollment of additional subjects, which could result in the extension of the clinical trial and the FDA delaying
approval of a product candidate. If the FDA believes that its prior approval is required for a particular modification, it can
delay or halt a clinical trial while it evaluates additional information regarding the change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.6pt 0 68.8pt; text-indent: 19.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Serious injury or death resulting
from a failure of one of our product candidates during current or future clinical trials could also result in the FDA delaying
our clinical trials or denying or delaying approval of a product candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">The Phase 1 portion of the
ongoing Phase 1/2 clinical trial for Actimab&trade;-A&nbsp;being conducted at seven clinical centers in the United States (MSKCC,
MD Anderson Cancer Center, Fred Hutchinson Cancer Research Center, Johns Hopkins Medicine, University of Pennsylvania Health System,
Baylor Summons Cancer Center and Columbia University Medical Center) was designed to establish the maximum tolerated dose of the
product. As the Company expected, patients receiving highest dose of the drug administered in the trial so far had prolonged bone
marrow suppression which could lead to fatal infections and other severe consequences. Consequently, the dose levels of our drug
in that trial were reduced as we continue our work on establishing maximum tolerated dose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Even though an adverse event
may not be the result of our product candidate, the FDA or an IRB could delay or halt a clinical trial for an indefinite period
of time while an adverse event is reviewed, and likely would do so in the event of multiple such events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.05pt 0 68.8pt; text-indent: 19.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.05pt 0 68.8pt; text-indent: 19.95pt"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.05pt 0 68.8pt; text-indent: 19.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Any delay or termination of
our current or future clinical trials as a result of the risks summarized above, including delays in obtaining or maintaining
required approvals from IRBs, delays in patient enrollment, the failure of patients to continue to participate in a clinical trial,
and delays or termination of clinical trials as a result of protocol modifications or adverse events during the trials, may cause
an increase in costs and delays in the filing of any submissions with the FDA, delay the approval and commercialization of our
product candidates or result in the failure of the clinical trial, which could adversely affect our business, operating results
and prospects. Lengthy delays in the completion of our Actimab&trade;-A clinical trials would adversely affect our business and
prospects and could cause us to cease operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20">If the third parties on which we rely
to conduct our clinical trials and to assist us with pre-clinical development do not perform as contractually required or expected,
or fail to comply with applicable regulations and standards, we may not be able to obtain regulatory approval for or commercialize
our product candidates.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 5.05pt 0 68.8pt"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">We do not have the ability
to independently conduct our pre-clinical and clinical trials for our product candidates and we must rely on third parties, such
as contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct such trials.
Our reliance on these third parties for clinical development activities results in reduced control over these activities. Moreover,
the FDA requires us to comply with regulations and standards, commonly referred to as GCPs, for conducting, recording and reporting
the results of clinical trials to assure that data and reported results are credible and accurate and that the trial participants
are adequately protected. Our reliance on third parties does not relieve us of these responsibilities and requirements. If we
or any of our third party contractors fail to comply with applicable GCPs, the clinical data generated in our clinical trials
may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical
trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority,
such regulatory authority will determine that any of our clinical trials complies with GCP regulations. In addition, our clinical
trials must be conducted with product produced under current good manufacturing practice, or cGMP, regulations. Our failure to
comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6.45pt 0 68.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">To date, we believe our consultants,
contract research organizations and other similar entities with which we are working have performed well; however, if these third
parties do not successfully carry out their contractual duties, meet expected deadlines, or comply with applicable regulations,
we may be required to replace them. Although we believe that there are a number of other third-party contractors we could engage
to continue these activities, we may not be able to enter into arrangements with alternative third-party contractors or to do
so on commercially reasonable terms, which may result in a delay of our planned clinical trials. Accordingly, we may be delayed
in obtaining regulatory approvals for our product candidates and may be delayed in our efforts to successfully develop our product
candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.05pt 0 68.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">In addition, our third-party
contractors are not our employees, and except for remedies available to us under our agreements with such third-party contractors,
we cannot control whether or not they devote sufficient time and resources to our ongoing clinical, nonclinical and preclinical
programs. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected
deadlines, if these third parties need to be replaced, or if the quality or accuracy of the data they obtain is compromised due
to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our pre-clinical development
activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval
for, or successfully commercialize, our product candidates on a timely basis, if at all, and our business, operating results and
prospects may be adversely affected. Furthermore, our third-party clinical trial investigators may be delayed in conducting our
clinical trials for reasons outside of their control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20">The future results of our current or
future clinical trials may not support our product candidate claims or may result in the discovery of unexpected adverse side
effects.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 5.05pt 0 68.8pt"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Even if our clinical trials
are completed as planned, we cannot be certain that their results will support our product candidate claims or that the FDA or
foreign authorities will agree with our conclusions regarding them. Success in pre-clinical studies and early clinical trials
does not ensure that later clinical trials will be successful, and we cannot be sure that the later trials will replicate the
results of prior trials and pre-clinical studies. The clinical trial process may fail to demonstrate that our product candidates
are safe and effective for the proposed indicated uses. If FDA concludes that the clinical trials for Actimab&trade;-A, or any
other product candidate for which we might seek approval, have failed to demonstrate safety and effectiveness, we would not receive
FDA approval to market that product candidate in the United States for the indications sought. In addition, such an outcome could
cause us to abandon the product candidate and might delay development of others. Any delay or termination of our clinical trials
will delay or preclude the filing of any submissions with the FDA and, ultimately, our ability to commercialize our product candidates
and generate revenues. It is also possible that patients enrolled in clinical trials will experience adverse side effects that
are not currently part of a product candidate&rsquo;s profile. In addition, our clinical trials for Actimab&trade;-A involve a
relatively small patient population. Because of the small sample size, their results may not be indicative of future results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20">Our product candidates for which we
intend to seek approval as biologic products may face competition sooner than anticipated.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 5.05pt 0 68.8pt"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Our product candidates are
regulated by the FDA as biologic products and we intend to seek approval for these products pursuant to the BLA pathway. The Biologics
Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated pathway for the approval of biosimilar and interchangeable
biologic products. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar
biologics, including the possible designation of a biosimilar as &ldquo;interchangeable&rdquo; based on its similarity to an existing
brand product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the
original branded product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA.
As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes
intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future
commercial prospects for our biologic products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20">Actimab&trade;-A and future product
candidates may never achieve market acceptance.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 0 0 68.8pt"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Actimab&trade;-A and future
product candidates that we may develop may never gain market acceptance among physicians, patients and the medical community.
The degree of market acceptance of any of product will depend on a number of factors, including the actual and perceived effectiveness
and reliability of the product; the results of any long-term clinical trials relating to use of the product; the availability,
relative cost and perceived advantages and disadvantages of alternative technologies; the degree to which treatments using the
product are approved for reimbursement by public and private insurers; the strength of our marketing and distribution infrastructure;
and the level of education and awareness among physicians and hospitals concerning the product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Failure of Actimab&trade;-A
or any of our other product candidates to significantly penetrate current or new markets would negatively impact our business
financial condition and results of operations<B><I>.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20">To be commercially successful, physicians
must be persuaded that using our product candidates for treatment of AML and other cancers, if approved for those indications,
are effective alternatives to existing therapies and treatments.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 11.5pt 0 68.8pt"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">We believe that oncologists
and other physicians will not widely adopt a product candidate unless they determine, based on experience, clinical data, and
published peer-reviewed journal articles, that the use of that product candidate provides an effective alternative to other means
of treating specific cancers. Patient studies or clinical experience may indicate that treatment with our product candidates does
not provide patients with sufficient benefits in extension of life or quality of life. We believe that recommendations and support
for the use of each product candidate from influential physicians will be essential for widespread market acceptance. Our product
candidates are still in the development stage and it is premature to attempt to gain support from physicians at this time. We
can provide no assurance that such support will ever be obtained. If our product candidates do not receive such support from these
physicians and from long-term data, physicians may not use or continue to use, and hospitals may not purchase or continue to purchase,
them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20">Both before and after marketing approval,
our product candidates are subject to ongoing regulatory requirements and continued regulatory review, and if we fail to comply
with these continuing regulatory requirements, we could be subject to a variety of sanctions and the sale of any approved products
could be suspended.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 5.05pt 0 68.8pt"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Both before and after regulatory
approval to market a particular product candidate, the manufacturing, labeling, packaging, adverse event reporting, storage, advertising,
promotion, distribution and record keeping related to the product are subject to extensive, ongoing regulatory requirements enforced
by FDA and other similar regulatory bodies. Additionally, because our product candidates include radio-active isotopes, they will
be subject to additional regulation and oversight from the United States Nuclear Regulatory Commission (NRC) and similar bodies
in other jurisdictions. The FDA regulatory requirements include submissions of safety and other post-marketing information and
reports, registration, as well as continued compliance with cGMP requirements and GCP requirements for any clinical trials that
we conduct post-approval. Any regulatory approvals that we receive for our product candidates may also be subject to limitations
on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements
for potentially costly post-marketing testing, including Phase IV clinical trials, and surveillance to monitor the safety and
efficacy of the product candidate. Later discovery of previously unknown problems with a product, including adverse events of
unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with
the regulatory requirements of the FDA and other applicable U.S. and foreign regulatory authorities could subject us to administrative
or judicially imposed sanctions, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 9.65pt 0 68.8pt; text-indent: 19.95pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">restrictions
                                         on the marketing of our products or their manufacturing processes;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 98.35pt; text-indent: -9.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">warning
                                         letters;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 98.35pt; text-indent: -9.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">civil
                                         or criminal penalties;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 98.35pt; text-indent: -9.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">fines;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 98.35pt; text-indent: -9.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">injunctions;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 98.35pt; text-indent: -9.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">product
                                         seizures or detentions;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 98.35pt; text-indent: -9.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">import
                                         or export bans;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 98.35pt; text-indent: -9.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">voluntary
                                         or mandatory product recalls and related publicity requirements;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 98.35pt; text-indent: -9.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">suspension
                                         or withdrawal of regulatory approvals;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 98.35pt; text-indent: -9.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">total
                                         or partial suspension of production; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 98.35pt; text-indent: -9.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="padding-right: 29pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">refusal
                                         to approve pending applications for marketing approval of new products or supplements
                                         to approved applications.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 29pt 0 98.35pt; text-indent: -9.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">The FDA&rsquo;s policies may
change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product
candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies,
or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would
adversely affect our business, prospects and ability to achieve or sustain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Even if regulatory approval
of a product candidate is granted, such approval may be subject to limitations on the intended uses for which a product may be
marketed and reduce the potential to successfully commercialize that product and generate revenue from that product. If the FDA
determines that the product promotional materials, labeling, training or other marketing or educational activities constitute
promotion of an unapproved use, it could request that we or our commercialization partners cease or modify our training or promotional
materials or subject us to regulatory enforcement actions. It is also possible that other federal, state or foreign enforcement
authorities might take action if they consider such training or other promotional materials to constitute promotion of an unapproved
use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims
for reimbursement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20">Our revenue stream will depend upon
third party coverage and reimbursement of our product candidates, if approved.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0 13.55pt 0 68.8pt"><FONT STYLE="font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">The commercial success of our
product candidates in both domestic and international markets will be substantially dependent on whether third-party coverage
and reimbursement is available for patients that use our products. However, the availability of insurance coverage and reimbursement
for newly approved cancer therapies is uncertain, and therefore, third-party coverage may be particularly difficult to obtain
even if our products are approved by the FDA as safe and efficacious. Patients using existing approved therapies are generally
reimbursed all or part of the product cost by Medicare or other third-party payors. Medicare, Medicaid, health maintenance organizations
and other third-party payors are increasingly attempting to contain healthcare costs by limiting both coverage and the level of
reimbursement of new drugs, and, as a result, they may not cover or provide adequate payment for these products. Submission of
applications for reimbursement approval generally does not occur prior to the filing of a BLA for that product and may not be
granted until many months after BLA approval. In order to obtain coverage and reimbursement for these products, we or our commercialization
partners may have to agree to a net sales price lower than the net sales price we might charge in other sales channels. The continuing
efforts of government and third-party payors to contain or reduce the costs of healthcare may limit our revenue. Initial dependence
on the commercial success of our products may make our revenues particularly susceptible to any cost containment or reduction
efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>



<P STYLE="margin: 0"><B><I>We have no manufacturing capacity and depend on third-party manufacturers to produce our pre-clinical
and clinical trial drug supplies.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">We do not currently
operate manufacturing facilities for pre-clinical or clinical production of any of our product candidates. We lack experience
in drug manufacturing, and we lack the resources and the capabilities to manufacture any of our product candidates on a clinical
or commercial scale. As a result, we rely on a third-party manufacturer to supply, store, and distribute pre-clinical and clinical
supply of our product candidates, and plan to continue to do so for the foreseeable future. Any performance failure on the part
of our existing or future manufacturers could delay clinical development or regulatory approval of our product candidates or commercialization
of any approved products, producing additional losses and depriving us of potential product revenue.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Our product candidates
require precise, high quality manufacturing. Failure by our contract manufacturer to achieve and maintain high manufacturing standards
could result in patient injury or death, product recalls or withdrawals, delays or failures in testing or delivery, cost overruns,
or other problems that could seriously hurt our business. Contract manufacturers may encounter difficulties involving production
yields, quality control, and quality assurance. These manufacturers are subject to ongoing periodic and unannounced inspections
by the FDA and corresponding state and foreign agencies to ensure strict compliance with cGMPs and other applicable government
regulations and corresponding foreign standards; however, we do not have control over third-party manufacturers&rsquo; compliance
with these regulations and standards.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">If a contract manufacturer
cannot perform as agreed, we may be required to replace it. We may incur added costs and delays in identifying and qualifying
replacements because the FDA must approve any replacement manufacturer prior to manufacturing our product candidates. Such approval
would require new testing and compliance inspections. In addition, a new manufacturer would have to be educated in, or develop
substantially equivalent processes for, production of our product candidates after receipt of FDA approval.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>We anticipate continued reliance on
third parties for manufacturing and marketing, if we are successful in obtaining marketing approval from the FDA and other regulatory
agencies for any of our product candidates. If we are not able to secure favorable arrangements with such third parties, our business
and financial condition would be harmed, and our commercialization of any of our product candidates may be halted, delayed or
made less profitable if those third parties fail to obtain such approvals, fail to provide us with sufficient quantities of product
or fail to do so at acceptable quality levels or prices.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">To date, our product
candidates have been manufactured in small quantities for preclinical and clinical testing by third-party manufacturers. If the
FDA or other regulatory agencies approve any of our product candidates for commercial sale, we expect that we would continue to
rely, at least initially, on third-party specialized manufacturers to produce commercial quantities of approved products. These
manufacturers may not be able to successfully increase the manufacturing capacity for any approved product in a timely or economic
manner, or at all. Significant scale-up of manufacturing may require additional validation studies, which the FDA must review
and approve. If third party manufacturers are unable to successfully increase the manufacturing capacity for a product candidate,
or we are unable to establish our own manufacturing capabilities, the commercial launch of any approved products may be delayed
or there may be a shortage in supply, which in turn could have a material adverse effect on our business.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">In addition, the facilities
used by our contract manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections that
will be conducted after we submit a BLA to the FDA. We do not control the manufacturing process of, and are completely dependent
on, our contract manufacturing partners for compliance with cGMPs. If our contract manufacturers cannot successfully manufacture
material that conforms to our specifications and the strict regulatory requirements of the FDA or other regulatory authorities,
they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. If the FDA or a comparable
foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws
any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our
ability to develop, obtain regulatory approval for or market our product candidates, if approved.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">We also intend to partner
with larger pharmaceutical companies for the commercialization of any of our product candidates that are approved. In connection
with our efforts to commercialize our product candidates, we will seek to secure favorable arrangements with third parties to
distribute, promote, market and sell them. If we are not able to secure favorable commercial terms or arrangements with third
parties for distribution, marketing, promotion and sales of our product candidates, we may have to retain promotional and marketing
rights and seek to develop the commercial resources necessary to promote or co-promote or co-market certain or all of our product
candidates to the appropriate channels of distribution in order to reach the specific medical market that we are targeting. We
may not be able to enter into any partnering arrangements on this or any other basis. If we are not able to secure favorable partnering
arrangements, or are unable to develop the appropriate resources necessary for the commercialization of our product candidates,
our business and financial condition could be harmed. In addition, we will have to hire additional employees or consultants, since
our current employees have limited experience in these areas. Sufficient employees with relevant skills may not be available to
us. Any increase in the number of our employees would increase our expense level, and could have an adverse effect on our financial
position.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">In addition, we, or
our potential commercial partners, may not successfully introduce our product candidates or they may not achieve acceptance by
patients, health care providers and insurance companies. Further, it is possible that we may not be able to secure arrangements
to manufacture, market, distribute, promote and sell our product candidates at favorable commercial terms that would permit us
to make a profit. To the extent that corporate partners conduct clinical trials, we may not be able to control the design and
conduct of these clinical trials.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>We may have conflicts with our partners
that could delay or prevent the development or commercialization of our product candidates.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">We may have conflicts
with our partners, such as conflicts concerning the interpretation of preclinical or clinical data, the achievement of milestones,
the interpretation of contractual obligations, payments for services, development obligations or the ownership of intellectual
property developed during our collaboration. If any conflicts arise with any of our partners, such partner may act in a manner
that is adverse to our best interests. Any such disagreement could result in one or more of the following, each of which could
delay or prevent the development or commercialization of our product candidates, and in turn prevent us from generating revenues:
unwillingness on the part of a partner to pay us milestone payments or royalties we believe are due under a collaboration; uncertainty
regarding ownership of intellectual property rights arising from our collaborative activities, which could prevent us from entering
into additional collaborations; unwillingness by the partner to cooperate in the development or manufacture of the product, including
providing us with product data or materials; unwillingness on the part of a partner to keep us informed regarding the progress
of its development and commercialization activities or to permit public disclosure of the results of those activities; initiating
litigation or alternative dispute resolution options by either party to resolve the dispute; or attempts by either party to terminate
the agreement.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>Upon commercialization of our product
candidates, we may be dependent on third parties to market, distribute and sell them.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Our ability to generate
revenues may be dependent upon the sales and marketing efforts of any future co-marketing partners and third-party distributors.
At this time, we have not entered into an agreement with any commercialization partner and only plan to do so after the successful
completion of Phase 2 clinical trials and prior to commercialization. If we fail to reach an agreement with any commercialization
partner, or if upon reaching such an agreement that partner fails to sell a large volume of our products, it may have a negative
impact on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>Our product candidates will face significant
competition in the markets for them, and if they are unable to compete successfully, our business will suffer.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our product candidates face, and will
continue to face, intense competition from large pharmaceutical companies, as well as academic and research institutions. We compete
in an industry that is characterized by (i) rapid technological change, (ii) evolving industry standards, (iii) emerging competition
and (iv) new product introductions. Our competitors have existing products and technologies that will compete with our product
candidates and technologies and may develop and commercialize additional products and technologies that will compete with our
product candidates and technologies. Because several competing companies and institutions have greater financial resources than
us, they may be able to (i) provide broader services and product lines, (ii) make greater investments in research and development,
or R&amp;D, and (iii) carry on broader R&amp;D initiatives. Our competitors also have greater development capabilities than we
do and have substantially greater experience in undertaking preclinical and clinical testing of product candidates, obtaining
regulatory approvals, and manufacturing and marketing pharmaceutical products. They also have greater name recognition and better
access to customers than us. Our chief competitors include companies such as Bayer AG, GlaxoSmithKline Plc and Spectrum Pharmaceuticals,
Inc. and others.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>If side effects are identified during
the time our product candidates are in development or after they are approved and on the market, we may choose to or be required
to perform lengthy additional clinical trials, discontinue development of the affected product candidate, change the labeling
of any such products, or withdraw or recall any such products from the market, any of which would hinder or preclude our ability
to generate revenues.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Undesirable side effects
caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could
result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities.
The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result
in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.
Even if any of our product candidates receives marketing approval, as greater numbers of patients use a product following its
approval, an increase in the incidence of side effects or the incidence of other post-approval problems that were not seen or
anticipated during pre-approval clinical trials could result in a number of potentially significant negative consequences, including:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">regulatory
    authorities may withdraw their approval of the product;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">regulatory
    authorities may require the addition of labeling statements, such as warnings or contraindications;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">we may
    be required to change the way the product is administered, conduct additional clinical trials or change the labeling of the
    product;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">we may
    elect, or we may be required, to recall or withdraw product from the market;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">we could
    be sued and held liable for harm caused to patients; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">our
    reputation may suffer.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Any of these events
could substantially increase the costs and expenses of developing, commercializing and marketing any such product candidates or
could harm or prevent sales of any approved products.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>Our business depends upon securing
and protecting critical intellectual property.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Our commercial success
will depend in part on our obtaining and maintaining patent, trade secret, copyright and trademark protection of our technologies
in the United States and other jurisdictions, as well as successfully enforcing this intellectual property and defending this
intellectual property against third-party challenges. We will only be able to protect our technologies from unauthorized use by
third parties to the extent that valid and enforceable intellectual property protection, such as patents or trade secrets law,
cover them. In particular, we place considerable emphasis on obtaining patent and trade secret protection for significant new
technologies, products and processes. Furthermore, the degree of future protection of our proprietary rights is uncertain because
legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive
advantage. Moreover, the degree of future protection of our proprietary rights is uncertain for product candidates that are currently
in the early stages of development because we cannot predict which of these product candidates will ultimately reach the commercial
market or whether the commercial versions of these product candidates will incorporate proprietary technologies.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>Our patent position is highly uncertain
and involves complex legal and factual questions.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Accordingly, we cannot
predict the breadth of claims that may be allowed or enforced under our patents or in third-party patents. For example, we or
our licensors might not have been the first to make the inventions covered by each of our pending patent applications and issued
patents; we or our licensors might not have been the first to file patent applications for these inventions; others may independently
develop similar or alternative technologies or duplicate any of our technologies; it is possible that none of our pending patent
applications or the pending patent applications of our licensors will result in issued patents; our issued patents and issued
patents of our licensors may not provide a basis for commercially viable technologies, or may not provide us with any competitive
advantages, or may be challenged and invalidated by third parties; and, we may not develop additional proprietary technologies
that are patentable.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">As a result, our owned
and licensed patents may not be valid and we may not be able to obtain and enforce patents and to maintain trade secret protection
for the full commercial extent of our technology. The extent to which we are unable to do so could materially harm our business.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">We or our licensors
have applied for and will continue to apply for patents for certain products. Such applications may not result in the issuance
of any patents, and any patents now held or that may be issued may not provide us with adequate protection from competition. Furthermore,
it is possible that patents issued or licensed to us may be challenged successfully. In that event, if we have a preferred competitive
position because of such patents, such preferred position would be lost. If we are unable to secure or to continue to maintain
a preferred position, we could become subject to competition from the sale of generic products. Failure to receive, inability
to protect, or expiration of our patents for medical use, manufacture, conjugation and labeling of Ac-225, the antibodies that
we license from third parties, or subsequent related filings, would adversely affect our business and operations.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Patents issued or licensed
to us may be infringed by the products or processes of others. The cost of enforcing our patent rights against infringers, if
such enforcement is required, could be significant, and we do not currently have the financial resources to fund such litigation.
Further, such litigation can go on for years and the time demands could interfere with our normal operations. There has been substantial
litigation and other proceedings regarding patent and other intellectual property rights in the pharmaceutical industry. We may
become a party to patent litigation and other proceedings. The cost to us of any patent litigation, even if resolved in our favor,
could be substantial. Some of our competitors may be able to sustain the costs of such litigation more effectively than we can
because of their substantially greater financial resources. Litigation may also absorb significant management time.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Unpatented trade secrets,
improvements, confidential know-how and continuing technological innovation are important to our scientific and commercial success.
Although we attempt to and will continue to attempt to protect our proprietary information through reliance on trade secret laws
and the use of confidentiality agreements with our partners, collaborators, employees and consultants and other appropriate means,
these measures may not effectively prevent disclosure of our proprietary information, and, in any event, others may develop independently,
or obtain access to, the same or similar information.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Certain of our patent
rights are licensed to us by third parties. If we fail to comply with the terms of these license agreements, our rights to those
patents may be terminated, and we will be unable to conduct our business.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>If we are found to be infringing on
patents or trade secrets owned by others, we may be forced to cease or alter our product development efforts, obtain a license
to continue the development or sale of our products, and/or pay damages.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Our manufacturing processes
and potential products may violate proprietary rights of patents that have been or may be granted to competitors, universities
or others, or the trade secrets of those persons and entities. As the pharmaceutical industry expands and more patents are issued,
the risk increases that our processes and potential products may give rise to claims that they infringe the patents or trade secrets
of others. These other persons could bring legal actions against us claiming damages and seeking to enjoin clinical testing, manufacturing
and marketing of the affected product or process. If any of these actions are successful, in addition to any potential liability
for damages, we could be required to obtain a license in order to continue to conduct clinical tests, manufacture or market the
affected product or use the affected process. Required licenses may not be available on acceptable terms, if at all, and the results
of litigation are uncertain. If we become involved in litigation or other proceedings, it could consume a substantial portion
of our financial resources and the efforts of our personnel.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>Our ability to protect and enforce
our patents does not guarantee that we will secure the right to commercialize our patents.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">A patent is a limited
monopoly right conferred upon an inventor, and his successors in title, in return for the making and disclosing of a new and non-obvious
invention. This monopoly is of limited duration but, while in force, allows the patent holder to prevent others from making and/or
using its invention. While a patent gives the holder this right to exclude others, it is not a license to commercialize the invention
where other permissions may be required for commercialization to occur. For example, a drug cannot be marketed without the appropriate
authorization from the FDA, regardless of the existence of a patent covering the product. Further, the invention, even if patented
itself, cannot be commercialized if it infringes the valid patent rights of another party.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>We rely on confidentiality agreements
to protect our trade secrets. If these agreements are breached by our employees or other parties, our trade secrets may become
known to our competitors.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">We rely on trade secrets
that we seek to protect through confidentiality agreements with our employees and other parties. If these agreements are breached,
our competitors may obtain and use our trade secrets to gain a competitive advantage over us. We may not have any remedies against
our competitors and any remedies that may be available to us may not be adequate to protect our business or compensate us for
the damaging disclosure. In addition, we may have to expend resources to protect our interests from possible infringement by others.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>The use of hazardous materials, including
radioactive and biological materials, in our research and development efforts imposes certain compliance costs on us and may subject
us to liability for claims arising from the use or misuse of these materials.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Our research, development
and manufacturing activities involves the controlled use of hazardous materials, including chemicals, radioactive and biological
materials, such as radioactive isotopes. We are subject to federal, state, local and foreign environmental laws and regulations
governing, among other matters, the handling, storage, use and disposal of these materials and some waste products. We cannot
completely eliminate the risk of contamination or injury from these materials and we could be held liable for any damages that
result, which could exceed our financial resources. We currently maintain insurance coverage for injuries resulting from the hazardous
materials we use; however, future claims may exceed the amount of our coverage. Also, we do not have insurance coverage for pollution
cleanup and removal. Currently the costs of complying with such federal, state, local and foreign environmental regulations are
not significant, and consist primarily of waste disposal expenses. However, they could become expensive, and current or future
environmental laws or regulations may impair our research, development, production and commercialization efforts.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>We may undertake international operations,
which will subject us to risks inherent with operations outside of the United States.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Although we do not have
any foreign operations at this time, we intend to seek market clearances in foreign markets that we believe will generate significant
opportunities. However, even with the cooperating of a commercialization partner, conducting drug development in foreign countries
involves inherent risks, including, but not limited to difficulties in staffing, funding and managing foreign operations; unexpected
changes in regulatory requirements; export restrictions; tariffs and other trade barriers; difficulties in protecting, acquiring,
enforcing and litigating intellectual property rights; fluctuations in currency exchange rates; and potentially adverse tax consequences.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20">If
we were to experience any of the difficulties listed above, or any other difficulties, any international development activities
and our overall financial condition may suffer and cause us to reduce or discontinue our international development and registration
efforts.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>We may not be successful in hiring
and retaining key employees.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Our future operations
and successes depend in large part upon the continued service of key members of our senior management team whom we are highly
dependent upon to manage our business. If any member of our current senior management terminates his or her employment with us,
such a departure may have a material adverse effect on our business.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Our future success also
depends on our ability to identify, attract, hire or engage, retain and motivate other well-qualified managerial, technical, clinical
and regulatory personnel. There can be no assurance that such professionals will be available in the market, or that we will be
able to retain existing professionals or meet or continue to meet their compensation requirements. Furthermore, the cost base
in relation to such compensation, which may include equity compensation, may increase significantly, which could have a material
adverse effect on us. Failure to establish and maintain an effective management team and work force could adversely affect our
ability to operate, grow and manage our business.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>We may be subject, directly or indirectly,
to federal and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws. If
we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">If we obtain FDA approval
for any of our product candidates and begin commercializing those products in the United States, our operations may be directly,
or indirectly through our customers, subject to various federal and state fraud and abuse laws, including, without limitation,
the federal Anti-Kickback Statute, the federal False Claims Act, and physician sunshine laws and regulations. These laws may impact,
among other things, our proposed sales, marketing, and education programs. In addition, we may be subject to patient privacy regulation
by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate
include:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">the
    federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving,
    offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an
    item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">federal
    civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities
    from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors
    that are false or fraudulent;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">the
    federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created federal criminal statutes that
    prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">HIPAA,
    as amended by the Health Information Technology and Clinical Health Act, or HITECH, and its implementing regulations, which
    imposes certain requirements relating to the privacy, security, and transmission of individually identifiable health information;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">the
    federal physician sunshine requirements under PPACA, which require certain manufacturers of drugs, devices, biologics, and
    medical supplies to report annually to the U.S. Department of Health and Human Services information related to payments and
    other transfers of value to physicians, other healthcare providers, and teaching hospitals, and ownership and investment interests
    held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">state
    law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or
    services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies
    to comply with the industry&rsquo;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the
    federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources;
    state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians
    and other healthcare providers or marketing expenditures; and state laws governing the privacy and security of health information
    in certain circumstances, many of which differ from each other in significant ways, thus complicating compliance efforts.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Because of the breadth
of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business
activities could be subject to challenge under one or more of such laws. In addition, recent health care reform legislation has
strengthened these laws. For example, the PPACA, among other things, amends the intent requirement of the federal anti-kickback
and criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of this statute or specific
intent to violate it to have committed a violation. Moreover, the PPACA provides that the government may assert that a claim including
items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for
purposes of the False Claims Act.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">If our operations are
found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be
subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government health
care programs, such as Medicare and Medicaid, imprisonment, and the curtailment or restructuring of our operations, any of which
could adversely affect our ability to operate our business and our results of operations.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>Healthcare legislative reform measures
may have a material adverse effect on our business and results of operations.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">In March 2010, President
Obama signed the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively,
&ldquo;PPACA&rdquo;), which makes changes that are expected to significantly impact the pharmaceutical industries. One of the
principal aims of the PPACA as currently enacted is to expand health insurance coverage to approximately 32 million Americans
who are currently uninsured. The consequences of this significant coverage expansion on the sales of our products, once they are
developed, are unknown and speculative at this point.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">The PPACA contains a
number of provisions designed to generate the revenues necessary to fund the coverage expansions among other things. This includes
new fees and taxes on manufacturers of certain branded prescription drugs, an abbreviated pathway for approval of biosimilar products,
a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that
are inhaled, infused, instilled, implanted or injected, increases in the minimum Medicaid rebates owed by manufacturers under
the Medicaid Drug Rebate Program and an extension of the rebate program to individuals enrolled in Medicaid managed care organizations,
and a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts
off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for
the manufacturer&rsquo;s outpatient drugs to be covered under Medicare Part D.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">The PPACA provisions
on comparative clinical effectiveness research extend the initiatives of the American Recovery and Reinvestment Act of 2009, also
known as the stimulus package, which included $1.1 billion in funding to study the comparative effectiveness of health care treatments
and strategies. This stimulus funding was designated for, among other things, conducting, supporting or synthesizing research
that compares and evaluates the risks and benefits, clinical outcomes, effectiveness and appropriateness of products. The PPACA
appropriates additional funding to comparative clinical effectiveness research. Although Congress has indicated that this funding
is intended to improve the quality of health care, it remains unclear how the research will impact current Medicare coverage and
reimbursement or how new information will influence other third-party payor policies.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">In addition, other legislative
changes have been proposed and adopted since the PPACA was enacted. On August 2, 2011, President Obama signed into law the Budget
Control Act of 2011, which, among other things, creates the Joint Select Committee on Deficit Reduction to recommend proposals
in spending reductions to Congress. The Joint Select Committee did not achieve a targeted deficit reduction of at least $1.2 trillion
for the years 2013 through 2021, which threatened to trigger the legislation&rsquo;s automatic reduction to several government
programs. This includes aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in
April 2013 and will stay in effect through 2024 unless additional Congressional action is taken. On January 2, 2013, Congress
passed and President Obama signed the American Taxpayer Relief Act of 2012 which, among other things, further reduced Medicare
payments to certain providers, including physicians, hospitals and cancer treatment centers. We expect that the PPACA, as well
as other federal or state health care reform measures that may be adopted in the future, could have a material adverse effect
on our industry generally and our ability to successfully commercialize our products or could limit or eliminate our spending
on certain development projects. The taxes imposed by the PPACA and the expansion in the government&rsquo;s role in the U.S. healthcare
industry may result in decreased profits to us, lower reimbursement by payors for our products, and/or reduced medical procedure
volumes, all of which may adversely affect our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0; color: #231F20"><B><I>Managing our growth
as we expand operations may strain our resources.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">We expect to need to
grow rapidly in order to support additional, larger, and potentially international, pivotal clinical trials of our product candidates,
which will place a significant strain on our financial, managerial and operational resources. In order to achieve and manage growth
effectively, we must continue to improve and expand our operational and financial management capabilities. Moreover, we will need
to increase staffing and to train, motivate and manage our employees. All of these activities will increase our expenses and may
require us to raise additional capital sooner than expected. Failure to manage growth effectively could materially harm our business,
financial condition or results of operations.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>We may expand our business through
the acquisition of rights to new product candidates that could disrupt our business, harm our financial condition and may also
dilute current stockholders&rsquo; ownership interests in our company.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Our business strategy
includes expanding our products and capabilities, and we may seek acquisitions of product candidates, antibodies or technologies
to do so. Acquisitions involve numerous risks, including substantial cash expenditures; potentially dilutive issuance of equity
securities; incurrence of debt and contingent liabilities, some of which may be difficult or impossible to identify at the time
of acquisition; difficulties in assimilating acquired technologies or the operations of the acquired companies; diverting our
management&rsquo;s attention away from other business concerns; risks of entering markets in which we have limited or no direct
experience; and the potential loss of our key employees or key employees of the acquired companies.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">We can make no assurances
that any acquisition will result in short-term or long-term benefits to us. We may incorrectly judge the value or worth of an
acquired product, company or business. In addition, our future success would depend in part on our ability to manage the rapid
growth associated with some of these acquisitions. We cannot assure that we will be able to make the combination of our business
with that of acquired products, businesses or companies work or be successful. Furthermore, the development or expansion of our
business or any acquired products, business or companies may require a substantial capital investment by us. We may not have these
necessary funds or they might not be available to us on acceptable terms or at all. We may also seek to raise funds by selling
shares of our preferred or common stock, which could dilute each current stockholder&rsquo;s ownership interest in the Company.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>Risks Related to Ownership of Our
Common Stock</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>Because we became public by means
of a &ldquo;reverse merger,&rdquo; we may not be able to attract the attention of major brokerage firms.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Additional risks may
exist since we became public through a &ldquo;reverse merger.&rdquo; Securities analysts of major brokerage firms may not provide
coverage of us since there is little incentive to brokerage firms to recommend the purchase of our common stock. We cannot assure
you that brokerage firms will want to conduct any secondary offerings on behalf of our company in the future.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20; text-align: left"><B><I>The sale of securities
by us in any equity or debt financing could result in dilution to our existing stockholders and have a material adverse effect
on our earnings.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in; color: #231F20">As
of  March 31, 2015, we believe we need up to $7.2 million in cash to finance research and development and to cover our
ongoing working capital needs through 2015, and we have not completed efforts to establish a stable recurring source of
revenues sufficient to cover our operating costs for the next twelve months. We have financed our operations primarily
through sales of stock and the issuance of convertible promissory notes. It is likely that during the next twelve months we
will seek to raise additional capital through the sales of stock and/or issuance of convertible debentures in order to expand
our level of operations to continue our research and development efforts.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in; color: #231F20"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Any sale of common stock
by us in a future public offering or private placement offering could result in dilution to the existing stockholders as a direct
result of our issuance of additional shares of our capital stock. In addition, our business strategy may include expansion through
internal growth or by establishing strategic relationships with targeted customers and vendor. In order to do so, or to finance
the cost of our other activities, we may issue additional equity securities that could dilute our stockholders&rsquo; stock ownership.
We may also assume additional debt and incur impairment losses related to goodwill and other tangible assets if we acquire another
company and this could negatively impact our earnings and results of operations.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in; color: #231F20"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in; color: #231F20"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Future sales of a substantial
number of shares of our common stock in the public market, or the perception that such sales may occur, could adversely affect
the then prevailing market price of our common stock and could make it more difficult for us to raise funds in the future through
a public offering of our securities.  We have financed our operations primarily through
sales of stock and the issuance of convertible promissory notes. It is likely that during the next twelve months we will to continue
to finance our operations through sales of stock and/or issuance of convertible promissory notes.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in; color: #231F20"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0; color: #231F20"><B><I>Our
common stock has been considered a penny stock.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0; color: #231F20"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the fiscal
year 2013 and through the second quarter of 2015 our common stock has or had been a penny stock, therefore, when our stock is
considered a penny stock trading in our securities may be subject to penny stock considerations. Broker-dealer practices in connection
with transactions in &ldquo;penny stocks&rdquo; are regulated by certain penny stock rules adopted by the SEC.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Penny stocks generally
are equity securities with a price of less than $5.00 (other than securities registered on certain national securities exchanges
or quoted on the NASDAQ system). Penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise
exempt from the rules, to deliver a standardized risk disclosure document that provides information about penny stocks and the
risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations for the
penny stock, the compensation of the broker-dealer and its salesperson in the transaction, and monthly account statements showing
the market value of each penny stock held in the customer&rsquo;s account. The broker-dealer must also make a special written
determination that the penny stock is a suitable investment for the purchaser and receive the purchaser&rsquo;s written agreement
to the transaction. These requirements may have the effect of reducing the level of trading activity, if any, in the secondary
market for a security that becomes subject to the penny stock rules. The additional burdens imposed upon broker-dealers by such
requirements may discourage broker-dealers from effecting transactions in our securities, which could severely limit their market
price and liquidity of our securities. These requirements may restrict the ability of broker-dealers to sell our common stock
and may affect your ability to resell our common stock.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>Our common stock is extremely thinly
traded, so you may be unable to sell at or near asking prices or at all if you need to sell your shares to raise money or otherwise
desire to liquidate your shares.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-weight: normal; font-style: normal">Trading
volume in our common stock is limited. This may inhibit investment by major institutional investment funds, including mutual funds,
as well as individual investors. A higher volume trading market may never develop or be maintained. Active trading markets generally
result in lower price volatility and more efficient execution of buy and sell orders. Absence of an active trading market reduces
the liquidity of the shares traded there-in.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>Our Common Stock is subject to price
volatility unrelated to our operations.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">The trading volume of
our common stock has been and may continue to be extremely limited and sporadic. As a result of such trading activity, the quoted
price for our common stock on the NYSE MKT may not necessarily be a reliable indicator of its fair market value.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">We expect the market
price of our Common Stock to fluctuate substantially due to a variety of factors, including market perception of our ability to
achieve our planned growth, quarterly operating results of other companies in the same industry, trading volume in our common
stock, changes in general conditions in the economy and the financial markets or other developments affecting the Company&rsquo;s
competitors or the Company itself. This volatility has had a significant effect on the market price of securities issued by many
companies for reasons unrelated to their operating performance and could have the same effect on our common stock.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>Because we do not intend to pay dividends,
stockholders will benefit from an investment in our Common Stock only if it appreciates in value.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">We have never declared
or paid any cash dividends on our Preferred Stock or Common Stock. For the foreseeable future, it is expected that earnings, if
any, generated from our operations will be used to finance the growth of our business, and that no dividends will be paid to holders
of our Preferred Stock or Common Stock. As a result, the success of an investment in our Preferred Stock or Common Stock will
depend upon any future appreciation in its value. There is no guarantee that our Preferred Stock or Common Stock will appreciate
in value.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>Certain provisions of our Certificate
of Incorporation and Bylaws and Delaware law make it more difficult for a third party to acquire us and make a takeover more difficult
to complete, even if such a transaction were in the stockholders&rsquo; interest.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Our Certificate of Incorporation
and Bylaws and certain provisions of Delaware State law could have the effect of making it more difficult or more expensive for
a third party to acquire, or from discouraging a third party from attempting to acquire, control of the Company, even when these
attempts may be in the best interests of our stockholders. For example, we are governed by Section 203 of the Delaware General
Corporation Law. In general, Section 203 prohibits a public Delaware corporation from engaging in a &ldquo;business combination&rdquo;
with an &ldquo;interested stockholder&rdquo; for a period of three years after the date of the transaction in which the person
became an interested stockholder, unless the business combination is approved in a prescribed manner. A &ldquo;business combination&rdquo;
includes mergers, asset sales or other transactions resulting in a financial benefit to the stockholder. An &ldquo;interested
stockholder&rdquo; is a person who, together with affiliates and associates, owns, or within three years, did own, 15% or more
of the corporation&rsquo;s outstanding voting stock. These provisions may have the effect of delaying, deferring or preventing
a change in our control.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>Compliance with the reporting requirements
of federal securities laws can be expensive.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">We are subject to the
information and reporting requirements of the Exchange Act and other federal securities laws, and the compliance obligations of
the Sarbanes-Oxley Act. The costs of preparing and filing annual and quarterly reports and other information with the SEC and
furnishing audited reports to stockholders are substantial. In addition, we will incur substantial expenses in connection with
the preparation of registration statements and related documents with respect to the registration of resale of the Common Stock.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>Applicable regulatory requirements,
including those contained in and issued under the Sarbanes-Oxley Act, may make it difficult for us to retain or attract qualified
officers and directors, which could adversely affect the management of its business and its ability to obtain or retain listing
of our Common Stock.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
may be unable to attract and retain those qualified officers, directors and members of board committees required to provide for
effective management because of the rules and regulations that govern publicly held companies, including, but not limited to,
certifications required by principal executive officers. The enactment of the Sarbanes-Oxley Act has resulted in the issuance
of a series of related rules and regulations and the strengthening of existing rules and regulations by the SEC, as well as the
adoption of new and more stringent rules by the stock exchanges. The perceived increased personal risk associated with these changes
may deter qualified individuals from accepting roles as directors and executive officers.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Further, some of these
changes heighten the requirements for board or committee membership, particularly with respect to an individual&rsquo;s independence
from the corporation and level of experience in finance and accounting matters. We may have difficulty attracting and retaining
directors with the requisite qualifications. If we are unable to attract and retain qualified officers and directors, the management
of our business and our ability to obtain or retain listing of our shares of Common Stock on any stock exchange (assuming we elect
to seek and are successful in obtaining such listing) could be adversely affected.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>If we fail to maintain an effective
system of internal controls, we may not be able to accurately report our financial results or detect fraud. Investors could lose
confidence in our financial reporting and this may decrease the trading price of our Common Stock.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in; color: #231F20"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">We must maintain effective
internal controls to provide reliable financial reports and detect fraud. We have previously identified material weaknesses in
our internal control over financial reporting because we did not have sufficient written policies and procedures for accounting
and financial reporting and we did not have effective controls over period end financial disclosures and reporting processes.
During 2014, our management remediated these previously identified material weaknesses. In future periods, we may identify additional
deficiencies in our system of internal controls over financial reporting that may require remediation. There can be no assurances
that any such future deficiencies identified may not be material weaknesses that would be required to be reported in future periods.
Failure to maintain an effective system of internal controls could harm our operating results and cause investors to lose confidence
in our reported financial information. Any such loss of confidence would have a negative effect on the trading price of our Common
Stock.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in; color: #231F20"></P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>The price of our common stock may
become volatile, which could lead to losses by investors and costly securities litigation.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">The trading price of
our Common Stock may be highly volatile and could fluctuate in response to factors such as:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">actual
    or anticipated variations in our operating results;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">announcements
    of developments by us or our competitors;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">the
    timing of IND and/or BLA approval, the completion and/or results of our clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">regulatory
    actions regarding our products;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">announcements
    by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">adoption
    of new accounting standards affecting the our industry;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">additions
    or departures of key personnel;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">introduction
    of new products by us or our competitors;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">sales
    of the our Common Stock or other securities in the open market; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">other
    events or factors, many of which are beyond our control.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">The stock market is
subject to significant price and volume fluctuations. In the past, following periods of volatility in the market price of a company&rsquo;s
securities, securities class action litigation has often been initiated against such a company. Litigation initiated against us,
whether or not successful, could result in substantial costs and diversion of our management&rsquo;s attention and Company resources,
which could harm our business and financial condition.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B>Additional Risks Relating to this Offering</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>Our management team may invest or
spend the proceeds of this offering in ways with which you may not agree or in ways which may not yield a significant return.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Our management will
have broad discretion over the use of proceeds from this offering. We currently intend to use the net proceeds from the sale of
securities offered by this prospectus for general corporate purposes, including capital expenditures, the advancement of our product
candidates in clinical trials, such as Iomab&trade;-B and Actimab-A, preclinical trials, and to meet working capital needs. However,
our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds
in ways that do not improve our results of operations or enhance the value of our common stock. The failure by management to apply
these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the
price of our common stock to decline and delay the development of our product candidates.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>Purchasers in this offering will likely
experience immediate and substantial dilution in the book value of their investment.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Because the prices per
share at which shares of our common stock are sold in this offering may be substantially higher than the book value per share
of our common stock, you may suffer immediate and substantial dilution in the net tangible book value of the common stock you
purchase in this offering. After giving effect to the sale of 1,923,078 shares of common stock in this offering at the offering
price of $2.60 per share, and after deducting estimated offering expenses payable by us, our net tangible book value as of March
31, 2015 would have been $20.9 million, or $0.56&nbsp;per share of common stock. This represents an immediate increase in the
net tangible book value of $0.10 per share to our existing stockholders and an immediate and substantial dilution in net tangible
book value of $2.04 per share to new investors who purchase our common stock in the offering. See the section entitled &ldquo;Dilution&rdquo;
for a more detailed discussion of the dilution you will incur if you purchase common stock in this offering.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>Sales of a substantial number of shares
of our common stock, or the perception that such sales may occur, may adversely impact the price of our common stock.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Almost all of our 36,555,244 outstanding
shares of common stock as of June 3, 2015, as well as a substantial number of shares of our common stock underlying outstanding
options, restricted stock and warrants, are available for sale in the public market, either pursuant to Rule 144 under the Securities
Act of 1933, as amended, or an effective registration statement. Pursuant to our shelf registration statement on Form S-3, we
may sell up to $200,000,000 of our equity securities over the next three years. Sales of a substantial number of shares of our
common stock, or the perception that such sales may occur, may adversely impact the price of our common stock.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In order to raise additional capital,
we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our
common stock. We cannot assure you that we will be able to sell shares or other securities in any other offering at a price per
share that is equal to or greater than the price per share paid by investors in this offering, and investors purchasing shares
or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional
shares of our common stock or other securities convertible into or exchangeable for our common stock in future transactions may
be higher or lower than the price per share in this offering. See the section entitled &ldquo;Dilution&rdquo; below for a more
detailed discussion of the dilution you will incur if you purchase common stock in this offering.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>Withholding taxes may be imposed under
FATCA on dividends on, or gross proceeds from the sale or other disposition of, our common stock paid to non-U.S. financial institutions
and certain other non-U.S. entities.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Withholding taxes may
be imposed under Sections 1471 to 1474 of the U.S. Internal Revenue Code of 1986, as amended (the &ldquo;Code&rdquo;) (such Sections
commonly referred to as the Foreign Account Tax Compliance Act, or &ldquo;FATCA&rdquo;) on certain types of payments made to non-U.S.
financial institutions and certain other non-U.S. entities. Specifically, a 30% withholding tax may be imposed on dividends on,
or gross proceeds from the sale or other disposition of, our common stock paid to a &ldquo;foreign financial institution&rdquo;
or a &ldquo;non- financial foreign entity&rdquo; (each as defined in the Code), unless (1) the foreign financial institution undertakes
certain diligence and reporting obligations, (2) the non-financial foreign entity either certifies it does not have any &ldquo;substantial
United States owners&rdquo; (as defined in the Code) or furnishes identifying information regarding each substantial United States
owner, or (3) the foreign financial institution or non-financial foreign entity otherwise qualifies for an exemption from these
rules. If the payee is a foreign financial institution and is subject to the diligence and reporting requirements in (1) above,
it must enter into an agreement with the U.S. Department of the Treasury requiring, among other things, that it undertake to identify
accounts held by certain &ldquo;specified United States persons&rdquo; or &ldquo;United States-owned foreign entities&rdquo; (each
as defined in the Code), annually report certain information about such accounts, and withhold 30% on certain payments to non-compliant
foreign financial institutions and certain other account holders. Foreign financial institutions located in jurisdictions that
have an intergovernmental agreement with the United States governing FATCA may be subject to different rules.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Under the applicable
Treasury Regulations, withholding under FATCA generally applies to payments of dividends on our common stock, and, after December
31, 2016, will apply to payments of gross proceeds from the sale or other disposition of such stock. Prospective investors should
consult their tax advisors regarding the potential application of withholding under FATCA to their investment in our common stock.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B><I>We may be limited in our ability to
utilize, or may not be able to utilize, net operating loss, or NOL, carryforwards to reduce our future tax liability.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">In general, a corporation
that undergoes an &ldquo;ownership change&rdquo; is subject to limitations on its ability to utilize its pre-change NOLs, to offset
future taxable income. In general, under the Code, an ownership change occurs if the aggregate stock ownership of certain stockholders
(generally 5% stockholders, applying certain look-through and aggregation rules) increases by more than 50 percentage points over
such stockholders&rsquo; lowest percentage ownership during the testing period (generally three years). Purchases of our common
stock in amounts greater than specified levels, which will be beyond our control, could create a limitation on our ability to
utilize our NOLs for tax purposes in the future. Limitations imposed on our ability to utilize NOLs could cause U.S. federal and
state income taxes to be paid earlier than would be paid if such limitations were not in effect and could cause such NOLs to expire
unused, in each case reducing or eliminating the benefit of such NOLs. Furthermore, we may not be able to generate sufficient
taxable income to utilize our NOLs before they expire. If any of these events occur, we may not derive some or all of the expected
benefits from our NOLs. In addition, NOLs incurred in one state may not be available to offset income earned in a different state.
Furthermore, there may be periods during which the use of NOLs is suspended or otherwise limited for state tax purposes, which
could accelerate or permanently increase state taxes owed.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>A substantial number of shares of our common stock
may be sold in this offering, which could cause the price of our common stock to decline.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">In this offering we
will sell 1,923,078 shares, or approximately 5.3% of our outstanding common stock as of June&nbsp;3, 2015.&nbsp;&nbsp;This sale
and any future sales of a substantial number of shares of our common stock in the public market, or the perception that such sales
may occur, could adversely affect the price of our common stock. We cannot predict the effect, if any, that market sales of those
shares of common stock or the availability of those shares of common stock for sale will have on the market price of our common
stock.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: #231F20"><A NAME="a-05"></A><B>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">This prospectus supplement
and accompanying prospectus and the information incorporated by reference in this prospectus supplement and accompanying prospectus
contain &ldquo;forward-looking statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), which include information
relating to future events, future fi performance, strategies, expectations, competitive environment and regulation. Words such
as &ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential,&rdquo;
&ldquo;continue,&rdquo; &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;future,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo;
&ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; and similar expressions, as well as statements in future tense, identify forward-looking
statements. Forward-looking statements should not be read as a guarantee of future performance or results and will probably not
be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information
we have when those statements are made or our management&rsquo;s good faith belief as of that time with respect to future events,
and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed
in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited
to:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">our
    history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty
    regarding the adequacy of our liquidity to pursue our complete business objectives;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">our
    ability to complete clinical trials as anticipated and obtain and maintain regulatory approvals for our products;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; line-height: 115%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif; color: #231F20">our
    ability to adequately protect our intellectual property;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif; color: #231F20">disputes over ownership
    of intellectual property;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">our
    dependence on a single manufacturing facility and our ability to comply with stringent manufacturing quality standards and
    to increase production as necessary;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">the
    risk that the data collected from our current and planned clinical trials may not be sufficient to demonstrate that our products
    are an attractive alternative to other procedures and products;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">intense
    competition in our industry, with competitors having substantially greater financial, technological, research and development,
    regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do;</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">entry
    of new competitors and products and potential technological obsolescence of our products;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">loss
    of a key customer or supplier;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">adverse
    economic conditions;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">adverse
    federal, state and local government regulation, in the United States;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">price
    increases for supplies and components;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">inability
    to carry out research, development and commercialization plans; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">loss
    or retirement of key executives and research scientists.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Although we believe
that the forward-looking statements contained herein are reasonable, we can give no assurance that our expectations will be met.
All forward-looking statements contained herein are expressly qualified in their entirety by this cautionary statement and the
risk factors beginning on page S-8 of this prospectus supplement.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">You are cautioned not
to place undue reliance on these forward-looking statements, which speak only as of the date of this prospectus supplement. Except
to the extent required by applicable laws and regulations, we undertake no obligation to update these forward-looking statements
to reflect events or circumstances after the date of this prospectus or to reflect the occurrence of unanticipated events.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: #231F20"><A NAME="a-06"></A><B>MARKET
PRICE DATA AND DIVIDEND INFORMATION</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B>Market Price Data</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Our common stock is
listed for quotation on the NYSE MKT under the symbol &ldquo;ATNM&rdquo;. The following table sets forth, for the quarters indicated,
the high and low sale per share sales prices of our common stock as reported by the NYSE MKT or <U>www.otcbb.com</U>, as applicable.
On March 26, 2014 our common stock commenced trading on the NYSE MKT.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20"><B><I>Quarterly
    Common Stock Price Ranges</I></B></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20"><B>Fiscal
    Year 2015, Quarter Ended:</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20"><B>High</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; color: #231F20">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20"><B>Low</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; color: #231F20">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font: 10pt Times New Roman, Times, Serif; color: #231F20">March 31, 2015</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: #231F20">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: #231F20; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; color: #231F20; text-align: right">6.07</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">2.45</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">June 30, 2015 (though June 3, 2015)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20; text-align: right">3.94</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.38</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20; text-align: left; padding-bottom: 1.5pt; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20"><B>Fiscal
    Year 2014, Quarter Ended:</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: #231F20; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20"><B>High</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; color: #231F20; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20"><B>Low</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; color: #231F20; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">March 31, 2014</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20; text-align: right">12.49</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4.51</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">June 30, 2014</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20; text-align: right">15.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6.74</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">September 30, 2014</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20; text-align: right">7.77</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5.93</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">December 31, 2014</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20; text-align: right">8.12</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5.40</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B>Dividends</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">We have never declared
or paid a cash dividend. Any future decisions regarding dividends are made by our Board of Directors. We currently intend to retain
and use any future earnings for the development and expansion of our business and do not anticipate paying any cash dividends
in the foreseeable future. Our Board of Directors has complete discretion on whether to pay dividends. Even if our Board of Directors
decides to pay dividends, the form, frequency and amount will depend upon our future operations and earnings, capital requirements
and surplus, general financial condition, contractual restrictions and other factors that the Board of Directors may deem relevant.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: #231F20"><A NAME="a-07"></A><B>USE
OF PROCEEDS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">We estimate the net proceeds from this offering will be approximately $4,460,000, after
deducting underwriting discounts and commissions and our estimated offering expenses.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Unless otherwise indicated
in the prospectus supplement, we currently intend to use the net proceeds from the sale of securities offered by this prospectus
for general corporate purposes, including capital expenditures, the advancement of our product candidates in clinical trials,
such as Iomab&trade;-B and Actimab&trade;- A, preclinical trials, to support licensing activities, and to meet working capital
needs.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Investors are cautioned,
however, that expenditures may vary substantially from these uses. Investors will be relying on the judgment of our management,
who will have broad discretion regarding the application of the proceeds of this offering. The amounts and timing of our actual
expenditures will depend upon numerous factors, including the amount of cash generated by our operations, the amount of competition
and other operational factors. We may find it necessary or advisable to use portions of the proceeds from this offering for other
purposes.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">From time to time, we
evaluate these and other factors and we anticipate continuing to make such evaluations to determine if the existing allocation
of resources, including the proceeds of this offering, is being optimized. Circumstances that may give rise to a change in the
use of proceeds include:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">a change in development
    plan or strategy;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">the addition of new products
    or applications;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">technical delays;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">delays or difficulties
    with our clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">negative results from
    our clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">difficulty obtaining
    FDA approval;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">failure to achieve sales
    as anticipated; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">the availability of other
    sources of cash including cash flow from operations and new bank debt financing arrangements, if any.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Pending other uses,
we intend to invest the proceeds to us in investment-grade, interest-bearing securities such as money market funds, certificates
of deposit, or direct or guaranteed obligations of the U.S. government, or hold as cash. We cannot predict whether the proceeds
invested will yield a favorable, or any, return.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: #231F20"><A NAME="a-08"></A><B>CAPITALIZATION</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">The following table
sets forth our cash and cash equivalents and capitalization as of March 31, 2015 as follows:</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">on an actual basis; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; line-height: 115%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="line-height: 115%; font-size: 10pt">on an as adjusted basis to reflect our issuance and sale in this offering of
1,923,078 shares of our common stock at a public offering price of $2.60 per share, after deducting estimated offering expenses
payable by us.</TD></TR>
</TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">You should read this table together
with the section of this prospectus supplement entitled &ldquo;Use of Proceeds&rdquo; and with the financial statements and related
notes and the other information that we incorporated by reference into this prospectus supplement and the accompanying prospectus,
including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that we file from time to time.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>March 31, 2015</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Actual</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>As Adjusted</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(dollars in thousands)</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">19,285</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">23,745</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Long-term debt, including current portion</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Stockholders&rsquo; equity:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Preferred stock, $0.01 par value; 50,000,000 shares authorized; no shares issued or outstanding</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Common stock, $.001 par value; 200,000,000 shares authorized; 35,705,313 shares issued and outstanding, actual; shares issued and outstanding, as adjusted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">36</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">38</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Additional paid-in capital</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">110,688</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">115,146</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Accumulated deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(94,280</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(94,280</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total stockholders&rsquo; equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">16,444</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">20,904</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total capitalization</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">16,444</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">20,904</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">The table above excludes
the following shares issuable as of March 31, 2015:</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #231F20">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; line-height: 115%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif; color: #231F20">3,549,084
    shares of common stock issuable upon the exercise of outstanding stock options, at a weighted average exercise price of $5.62
    per share; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif; color: #231F20">238,973 shares of
    common stock issuable upon the exercise of restricted stock units; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif; color: #231F20">9,886,547 shares
    of common stock issuable upon the exercise of outstanding warrants, at a weighted average exercise price of $3.43 per share;
    and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="line-height: 115%">1,873,866 shares of common stock available for future issuance under our equity compensation
    plans.</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><A NAME="a-09"></A><B>DILUTION</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">If you invest in our
common stock, your interest will be diluted to the extent of the difference between the price per share you pay in this offering
and the net tangible book value per share of our common stock immediately after this offering.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Our net tangible book
value of our common stock as of March 31, 2015 was approximately $16.4 million, or approximately $0.46 per share of common stock,
based upon 35,705,313 shares outstanding at that time. &ldquo;Net tangible book value&rdquo; is total assets minus the sum of
liabilities and intangible assets. &ldquo;Net tangible book value per share&rdquo; is net tangible book value divided by the total
number of shares outstanding.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">After giving effect
to the sale of 1,923,078 shares of common stock in the aggregate amount of $5,000,002.80 at an assumed offering price of $2.60
per share, the last reported sale price of our common stock on the NYSE MKT on June 3, 2015, after deducting estimated offering
expenses payable by us, our net tangible book value as of March 31, 2015 would have been $20.9&nbsp;million, or $0.56 per share
of common stock. This represents an immediate increase in net tangible book value of $0.10 per share to our existing stockholders
and an immediate dilution in net tangible book value of $2.04 per share to new investors in this offering.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">The following table
illustrates this calculation on a per share basis:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 78%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Assumed offering price per share:</FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.60</FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Net tangible book value per share as of March 31, 2015</FONT></TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.46</FONT></TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Increase in net tangible book value per share after this offering</FONT></TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.10</FONT></TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Net tangible book value per share after this offering</FONT></TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.56</FONT></TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dilution per share to new investors</FONT></TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.04</FONT></TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">The number of shares
of our common stock that will be outstanding immediately after the offering is based on 35,705,313 shares outstanding as of March
31, 2015, and excludes:</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; line-height: 115%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">3,549,084
    shares of common stock issuable upon the exercise of stock options outstanding as of March&nbsp;31, 2015 under our equity
    incentive plans, with a weighted average exercise price of $5.62 per share;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="line-height: 115%">1,873,866 shares of common stock available for future grants under our equity incentive plans
    as of March 31, 2015;</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; line-height: 115%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif; color: #231F20">238,973
    </FONT><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">shares of common stock issuable upon the exercise of restricted
    stock units outstanding as of March 31, 2015; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif; color: #231F20">9,886,547 </FONT><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">shares
    of common stock issuable upon the exercise of warrants outstanding as of March 31, 2015, with a weighted average exercise
    price of $3.43 per share.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
foregoing illustration does not reflect potential dilution from the exercise of outstanding options or warrants to purchase shares
of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white; text-align: left"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><A NAME="DescriptionofSecurities"></A><B>DESCRIPTION
OF SECURITIES WE ARE OFFERING</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; color: #231F20"><B>Common Stock</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">The holders of our common
stock are entitled to one vote per share. Our certificate of incorporation does not provide for cumulative voting. Our directors
are divided into three classes. At each annual meeting of stockholders, directors elected to succeed those directors whose terms
expire are elected for a term of office to expire at the third succeeding annual meeting of stockholders after their election.
The holders of our common stock are entitled to receive ratably such dividends, if any, as may be declared by our board of directors
out of legally available funds; however, the current policy of our board of directors is to retain earnings, if any, for operations
and growth. Upon liquidation, dissolution or winding-up, the holders of our common stock are entitled to share ratably in all
assets that are legally available for distribution. The holders of our common stock have no preemptive, subscription, redemption
or conversion rights. The rights, preferences and privileges of holders of our common stock are subject to, and may be adversely
affected by, the rights of the holders of any series of preferred stock, which may be designated solely by action of our board
of directors and issued in the future.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Our common stock is
listed on the NYSE MKT under the symbol &ldquo;ATNM.&rdquo; On March 26, 2014 our common stock commenced trading on the NYSE MKT
exchange.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><A NAME="divi"></A><B>DIVIDEND
POLICY</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">We have never declared or paid a cash dividend.
Any future decisions regarding dividends are made by our Board of Directors. We currently intend to retain and use any future
earnings for the development and expansion of our business and do not anticipate paying any cash dividends in the foreseeable
future. Our Board of Directors has complete discretion on whether to pay dividends. Even if our Board of Directors decides to
pay dividends, the form, frequency and amount will depend upon our future operations and earnings, capital requirements and surplus,
general financial condition, contractual restrictions and other factors that the Board of Directors may deem relevant.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><A NAME="plam"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Laidlaw
&amp; Co. (UK) Ltd. is acting as the sole placement agent in connection with this offering. The placement agent may engage selected
dealers to assist in the placement of the shares of common stock. The placement agent is not purchasing or selling any of the
shares of common stock offered by this prospectus supplement and the accompanying prospectus, nor are they required to arrange
the purchase or sale of any specific number or dollar amount of shares of common stock. The placement agent has agreed to use
its commercially reasonable efforts to arrange for the sale of all of the shares of common stock offered hereby.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
placement agent agreement provides that the obligations of the placement agent is subject to certain conditions precedent, including,
among other things, the absence of any material adverse change in our business and the receipt of customary opinions and closing
certificates.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
placement agent proposes to arrange for the sale of the securities we are offering pursuant to this prospectus supplement to one
or more investors through securities purchase agreements directly between the purchasers and us. All of the securities will be
sold at the same price and, we expect, at a single closing. We established the price following negotiations with prospective investors
and with reference to the prevailing market price of our common stock, recent trends in such price and other factors. It is possible
that not all of the securities we are offering pursuant to this prospectus supplement will be sold at the closing, in which case
our net proceeds would be reduced.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Commissions
and Expenses</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have agreed to pay the placement agent an aggregate cash placement fee equal to seven percent (7.0%) of the gross proceeds in
this offering.&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following table shows the per share and total cash placement agent&rsquo;s fees we will pay to the placement agent in connection
with the sale of the shares of our common stock offered pursuant to this prospectus supplement and the accompanying base prospectus
assuming the purchase of all of the shares offered hereby:</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Per Share Placement Agent Fees (1)</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.208</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">Total</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">400,000.22</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0pt; text-indent: 0pt; text-align: justify">(1)&nbsp;&nbsp;&nbsp;Includes
<FONT STYLE="background-color: white">a non-accountable expense allowance in the amount of one percent (1%) of the gross proceeds
payable to the placement agent.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">We
have agreed to pay a non-accountable expense allowance to the placement agent equal to 1.0% of the gross proceeds received
in this offering. We have also agreed to pay the placement agent&rsquo;s expenses relating to the offering,
including&nbsp;(a) all filing fees relating to the registration of the&nbsp;Securities to be sold in the Offering with the
Commission; (b) all actual filing fees associated with the review of this offering by FINRA; (c) all fees and expenses
relating to the listing of our shares of common stock on the NYSE MKT; (d)&nbsp;all fees, expenses and disbursements relating
to the registration or qualification of our securities under the &ldquo;blue sky&rdquo; securities laws of such states and
other jurisdictions as the representative may reasonably designate (including, without limitation, all filing and
registration fees)); (e) all fees, expenses and disbursements relating to the registration,&nbsp;qualification or exemption
of our securities under the securities laws of such foreign jurisdictions as the placement agent may reasonably designate;
(f) the costs of all mailing and printing of the offering documents&nbsp;as the placement agent may reasonably deem
necessary; (g)&nbsp;the costs of preparing, printing and delivering certificates representing the securities sold in this
Offering; (h) fees and expenses of our transfer agent; (i) stock transfer and/or stamp taxes, if any, payable upon the
transfer of securities from the Company&nbsp;to the representative;&nbsp;(j)&nbsp;the fees and expenses of our accountants;
and (k) the fees and expenses of our legal&nbsp;counsel and other agents and representatives.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">In addition to the
placement agent fee to be paid by us as set forth above, we have agreed to reimburse the placement agent for up to $60,000 of
certain of its out-of-pocket legal expenses incurred in connection with the offering. We estimate the total offering expenses
of this offering that will be payable by us, excluding the placement agents&rsquo; fee, will be approximately $140,000, which
includes legal and printing costs, and various other fees.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We currently anticipate that the sale
of the shares of our common stock will be completed on or about June 9, 2015, subject to customary closing conditions. Because
there is no minimum offering amount required as a condition to closing in this offering, the actual total offering placement agent
fees and commission, if any, may be substantially less than the maximum amount set forth above.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
obligation to issue and sell shares of our common stock to the purchasers is subject to the conditions set forth in the securities
purchase agreements, which may be waived by us at our discretion. The purchasers&rsquo; obligation to purchase shares of our common
stock is subject to the conditions set forth in the securities purchase agreements as well, which may also be waived.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
negotiated the price for the shares of common stock offered in this offering with the purchasers. The factors considered in determining
the price included the recent market price of our common stock, the general condition of the securities market at the time of
this offering, the history of, and the prospects, for the industry in which we compete, our past and present operations, and our
prospects for future revenues.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We currently anticipate that the sale of the shares of our common stock will
be completed on or about June 9, 2015, subject to customary closing conditions.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Indemnification</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have agreed to indemnify Laidlaw against liabilities under the Securities Act of 1933, as amended. We have also agreed to contribute
to payments Laidlaw may be required to make in respect of such liabilities.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Lock-up
Agreements</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pursuant
to certain &ldquo;lock-up&rdquo; agreements, our executive officers and directors have agreed, subject to certain exceptions,
not to offer, sell, assign, transfer, pledge, contract to sell, or otherwise dispose of or announce the intention to otherwise
dispose of, or enter into any swap, hedge or similar agreement or arrangement that transfers, in whole or in part, the economic
risk of ownership of, directly or indirectly, engage in any short selling of any common stock or securities convertible into or
exchangeable or exercisable for any common stock, whether currently owned or subsequently acquired, without the prior written
consent of the underwriter, for a period of sixty (60) days from the effective date of the offering.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
lock-up period described in the preceding paragraphs will be automatically extended if: (1) during the last 17 days of the restricted
period, we issue an earnings release or announce material news or a material event; or (2) prior to the expiration of the lock-up
period, we announce that we will release earnings results during the 16-day period beginning on the last day of the lock-up period,
in which case the restrictions described in the preceding paragraph will continue to apply until the expiration of the 18-day
period beginning on the date of the earnings release, unless the representative waives this extension in writing.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Laidlaw
&amp; Company (UK) Ltd. may, in its sole discretion and at any time or from time to time before the termination of the 60-day
period release all or any portion of the securities subject to lock-up agreements. There are no existing agreements between the
underwriters and any of our stockholders who will execute a lock-up agreement, providing consent to the sale of shares prior to
the expiration of the lock-up period.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Listing</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
common stock is listed on the NYSE MKT under the symbol &ldquo;ATNM.&rdquo;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Electronic
Distribution</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
prospectus supplement and the accompanying prospectus may be made available in electronic format on websites or through other
online services maintained by either placement agent, or by an affiliate. Other than this prospectus supplement and the accompanying
prospectus in electronic format, the information on any placement agent&rsquo;s website and any information contained in any other
website maintained by any placement agent is not part of this prospectus supplement and the accompanying prospectus or the registration
statement of which this prospectus supplement and the accompanying prospectus form a part, has not been approved and/or endorsed
by us or the placement agent, and should not be relied upon by</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
foregoing does not purport to be a complete statement of the terms and conditions of the placement agency agreement and the securities
purchase agreements, copies of which are included as exhibits to our current report on Form 8-K that will be filed with the SEC
and incorporated by reference into the Registration Statement of which this prospectus supplement forms a part. See &ldquo;Where
You Can Find More Information&rdquo; on page S-__.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Regulation
M Restrictions</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
placement agent may be deemed to be an underwriter within the meaning of Section 2(a)(11) of the Securities Act, and any commissions
received by them and any profit realized on the resale of the units sold by them while acting as a principal might be deemed to
be underwriting discounts or commissions under the Securities Act. As underwriters, the placement agent would be required to comply
with the requirements of the Securities Act and the Securities Exchange Act of 1934, as amended, including, without limitation,
Rule 415(a)(4) under the Securities Act and Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations may
limit the timing of purchases and sales of units offered hereby by any placement agent acting as a principal. Under these rules
and regulations, each placement agent:</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; line-height: 107%">&#9679;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">must not engage in any stabilization
    activity in connection with our securities; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; line-height: 107%">&#9679;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">must not bid for or purchase any of our
    securities or attempt to induce any person to purchase any of our securities, other than as permitted under the Exchange Act,
    until it has completed its participation in the distribution.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Passive
Market Making</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
connection with this offering, the placement agent and any selling group members may engage in passive market making transactions
in our common stock on the NYSE MKT in accordance with Rule&nbsp;103 of Regulation&nbsp;M under the Securities Exchange Act of
1934, as amended, during a period before the commencement of offers or sales of common stock and extending through the completion
of the distribution. A passive market maker must display its bid at a price not in excess of the highest independent bid of that
security. However, if all independent bids are lowered below the passive market maker's bid, that bid must then be lowered when
specified purchase limits are exceeded.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Other</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>FROM
TIME TO TIME, THE PLACEMENT AGENT AND ITS AFFILIATES HAVE PROVIDED, AND MAY IN THE FUTURE PROVIDE, VARIOUS INVESTMENT BANKING,
FINANCIAL ADVISORY AND OTHER SERVICES TO US AND OUR AFFILIATES FOR WHICH SERVICES THEY HAVE RECEIVED, AND MAY IN THE FUTURE RECEIVE,
CUSTOMARY FEES. IN THE COURSE OF THEIR BUSINESSES, THE PLACEMENT AGENT AND ITS AFFILIATES MAY ACTIVELY TRADE OUR SECURITIES OR
LOANS FOR THEIR OWN ACCOUNT OR FOR THE ACCOUNTS OF CUSTOMERS, AND, ACCORDINGLY, THE PLACEMENT AGENT AND ITS AFFILIATES MAY AT
ANY TIME HOLD LONG OR SHORT POSITIONS IN SUCH SECURITIES OR LOANS.</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Transfer
Agent</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
transfer agent for our common stock is Action Stock Transfer Corp., 2469 E. Fort Union Blvd., Suite 214, Salt Lake City, UT 84121,
(801) 274-1088.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: #231F20"><A NAME="a-11"></A><B>LEGAL
MATTERS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in; color: #231F20"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The validity of the securities offered
by this prospectus will be passed upon for us by Barclay Damon&nbsp;LLP, Syracuse, New York. Certain legal matters related to
the offering will be passed upon for the placement agents by Sichenzia Ross Friedman Ference LLP, New York, New York.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: #231F20"><A NAME="a-12"></A><B>EXPERTS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">The financial statements
incorporated in this prospectus supplement by reference to the Annual Report on Form 10-K for the fiscal year ended December 31,
2014 have been so incorporated in reliance on the report of GBH CPAs, PC, an independent registered public accounting firm, given
on the authority of said firm as experts in auditing and accounting.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: #231F20"><A NAME="a-13"></A><B>WHERE
YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have filed with the SEC a registration
statement on Form S-3 under the Securities Act of 1933, as amended (&ldquo;Securities Act&rdquo;), with respect to the securities
covered by this prospectus. This prospectus, which is a part of the registration statement, does not contain all of the information
set forth in the registration statement or the exhibits and schedules filed therewith. For further information with respect to
us and the securities covered by this prospectus, please see the registration statement and the exhibits filed with the registration
statement. A copy of the registration statement and the exhibits filed with the registration statement may be inspected without
charge at the Public Reference Room maintained by the SEC, located at 100&nbsp;F&nbsp;Street, N.E., Washington,&nbsp;D.C. 20549.
Please call the SEC at 1-800-SEC-0330 for more information about the operation of the Public Reference Room. The SEC also maintains
an Internet website that contains reports, proxy and information statements and other information regarding registrants that file
electronically with the SEC. The address of the website is http://www.sec.gov.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">We are subject to the
information and reporting requirements of the Securities Exchange Act of 1934, as amended, and in accordance therewith file annual,
quarterly and current reports, proxy statements and other information with the Securities and Exchange Commission. Such reports,
proxy statements and other information can be read and copied at the Securities and Exchange Commission&rsquo;s public reference
facilities and website of the SEC referred to above.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We make available free of charge on
or through our website at www.actiniumpharmceuticals.com our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current
Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange
Act of 1934, as amended, as soon as reasonably practicable after we electronically file such material with or otherwise furnish
it to the Securities and Exchange Commission. Our website and the information contained on that site, or connected to that site,
are not incorporated into and are not a part of this prospectus.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">We have not incorporated
by reference into this prospectus supplement and the accompanying prospectus the information on our website, and you should not
consider it to be a part of this prospectus supplement and the accompanying prospectus.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: #231F20"><A NAME="a-14"></A><B>INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">The Securities and Exchange
Commission allows us to &ldquo;incorporate by reference&rdquo; the information we have filed with it, which means that we can
disclose important information to you by referring you to those documents. The information we incorporate by reference is an important
part of this prospectus supplement and the accompanying prospectus, and later information that we file with the Securities and
Exchange Commission will automatically update and supersede this information. We incorporate by reference the documents listed
below and any future documents (excluding information furnished pursuant to Items 2.02 and 7.01 of Form 8-K) we file with the
Securities and Exchange Commission pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended,
subsequent to the date of this prospectus supplement and prior to the termination of the offering:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; line-height: 115%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif; color: #231F20">Our
    Annual Report on Form 10-K for the fiscal year ended December 31, 2014, filed with the Securities and Exchange Commission
    on March 16, 2015;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif; color: #231F20">Our Quarterly Report
    on Form 10-Q for the three months ended March 31, 2015, filed with the Securities and Exchange Commission on May 8, 2015;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif; color: #231F20">Our Current Report
    on Form 8-K, filed with the Securities and Exchange Commission on February 5, 2015;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif; color: #231F20">Our Current Report
    on Form 8-K, filed with the Securities and Exchange Commission on February 6, 2015;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif; color: #231F20">Our Current Report
    on Form 8-K, filed with the Securities and Exchange Commission on March 4, 2015; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif; color: #231F20">&#9679;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif; color: #231F20">The description
    of our common stock, which is contained in our Form 8- A, filed with the Securities and Exchange Commission on&nbsp;January&nbsp;28,&nbsp;2013.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Additionally, all documents filed by
us with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, after the date of this prospectus and before the
termination or completion of this offering shall be deemed to be incorporated by reference into this prospectus from the respective
dates of filing of such documents. Any information that we subsequently file with the SEC that is incorporated by reference as
described above will automatically update and supersede any previous information that is part of this prospectus.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">You should rely only
on the information incorporated by reference or provided in this prospectus supplement. We have not authorized anyone else to
provide you with different information. You should not assume that the information in this prospectus supplement is accurate as
of any date other than the date of this prospectus supplement or the date of the documents incorporated by reference in this prospectus
supplement.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">We will provide without
charge to each person to whom a copy of this prospectus supplement is delivered, upon written or oral request, a copy of any or
all of the information that has been incorporated by reference in this prospectus supplement but not delivered with this prospectus
supplement (other than an exhibit to these filings, unless we have specifically incorporated that exhibit by reference in this
prospectus supplement). Any such request should be addressed to us at: 546 5th Avenue, 14th Floor, New York, New York 10036, Attention:
David Gould, SVP Finance and Corporate Development, or made by phone at (646) 459-4201.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: #231F20">$200,000,000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.35pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; color: #231F20; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt/10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0.45pt; text-align: center; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #231F20"><B>$200,000,000</B></P>

<P STYLE="font: 10pt/103% Times New Roman, Times, Serif; margin: 0; text-align: center; color: #231F20"><B>Common<FONT STYLE="letter-spacing: 0.15pt">
</FONT>Stock</B></P>

<P STYLE="font: 10pt/103% Times New Roman, Times, Serif; margin: 0; text-align: center; color: #231F20"><FONT STYLE="letter-spacing: -0.05pt"><B>Preferred
</B></FONT><B>Stock</B></P>

<P STYLE="font: 10pt/103% Times New Roman, Times, Serif; margin: 0; text-align: center; color: #231F20"><B>Debt<FONT STYLE="letter-spacing: 0.15pt">
</FONT>Securities</B></P>

<P STYLE="font: 10pt/103% Times New Roman, Times, Serif; margin: 0; text-align: center; color: #231F20"><FONT STYLE="letter-spacing: -0.1pt"><B>Warrants
</B></FONT><B>Rights</B></P>

<P STYLE="font: 10pt/103% Times New Roman, Times, Serif; margin: 0; text-align: center; color: #231F20"><FONT STYLE="letter-spacing: -0.05pt"><B>Purchase
</B></FONT><B>Contracts<FONT STYLE="letter-spacing: 1.2pt"> </FONT>Units</B></P>

<P STYLE="font: 10pt/103% Times New Roman, Times, Serif; margin: 0; text-align: center; color: #231F20"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/103% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
may offer and sell from time to time, in one or more series or issuances and on terms that we will determine at the time of the
offering, any combination of the securities described in this prospectus, up to an aggregate amount of $200,000,000.</FONT></P>

<P STYLE="font: 10pt/103% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/103% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
will provide specific terms of any offering in a supplement to this prospectus. Any prospectus supplement may also add, update,
or change information contained in this prospectus. You should carefully read this prospectus and the applicable prospectus supplement
as well as the documents incorporated or deemed to be incorporated by reference in this prospectus before you purchase any of
the securities offered hereby.</FONT></P>

<P STYLE="font: 10pt/103% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/103% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">These
securities may be offered and sold in the same offering or in separate offerings; to or through underwriters, dealers, and agents;
or directly to purchasers. The names of any underwriters, dealers, or agents involved in the sale of our securities, their compensation
and any over-allotment options held by them will be described in the applicable prospectus supplement. See &ldquo;Plan of Distribution.&rdquo;</FONT></P>

<P STYLE="font: 10pt/103% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/103% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
common stock is presently traded on the NYSE MKT under the symbol &ldquo;ATNM.&rdquo; On April 16, 2014, the last reported sale
price of our common stock was $11.69 per share. On March 26, 2014 our common stock commenced trading on the NYSE MKT exchange.
We recommend that you obtain current market quotations for our common stock prior to making an investment decision. We will provide
information in any applicable prospectus supplement regarding any listing of securities other than shares of our common stock
on any securities exchange.</FONT></P>

<P STYLE="font: 10pt/103% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/103% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>You should carefully read this prospectus, any prospectus supplement relating to any specific offering
of securities, and all information incorporated by reference herein and therein.</B></FONT></P>

<P STYLE="font: bold 10pt/103% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/103% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Investing
in our securities involves a high degree of risk. These risks are discussed in this prospectus under &ldquo;Risk Factors&rdquo;
beginning on page 6 and in the documents incorporated by reference into this prospectus.</B></FONT></P>

<P STYLE="font: 10pt/103% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/103% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt/103% Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt; color: #231F20"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #231F20">The<FONT STYLE="letter-spacing: 0.6pt">
</FONT>date<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>this<FONT STYLE="letter-spacing: 0.6pt">
</FONT>prospectus<FONT STYLE="letter-spacing: 0.6pt"> </FONT>is<FONT STYLE="letter-spacing: 0.6pt"> </FONT>April<FONT STYLE="letter-spacing: 0.6pt">
</FONT>18,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: #231F20"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.05pt 0 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0 0 1.5pt; text-indent: 0; font: 10pt Times New Roman, Times, Serif; width: 92%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-align: center; text-indent: 0; width: 8%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20"><B>Page</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#a-15"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">About
    This Prospectus</FONT></A></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#a-16"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Prospectus
    Summary</FONT></A></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#a-17"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Risk
    Factors</FONT></A></TD>
    <TD STYLE="padding: 0; text-align: center; font: 10pt Times New Roman, Times, Serif">6</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#a-18"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Special
    Note Regarding Forward-Looking Statements</FONT></A></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif">6</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#a-19"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Use
    Of Proceeds</FONT></A></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif">8</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#a-20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Description
    Of Capital Stock</FONT></A></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif">9</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#a-21"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Description
    Of Debt Securities</FONT></A></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif">17</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#a-22"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Description
    Of Warrants</FONT></A></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif">24</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#a-23"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Description
    Of Rights</FONT></A></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif">26</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#a-25"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Description
    Of Units</FONT></A></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif">28</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#a-26"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Plan
    of Distribution</FONT></A></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif">29</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#a-27"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Legal
    Matters</FONT></A></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif">31</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#a-28"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Experts</FONT></A></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif">31</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#a-29"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Where
    You Can Find More Information</FONT></A></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif">31</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#a-30"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporation
    Of Certain Information By Reference</FONT></A></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0; font: 10pt Times New Roman, Times, Serif">32</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 68.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 68.8pt"></P>

<!-- Field: Page; Sequence: 42; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 68.8pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #231F20"><A NAME="a-15"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ABOUT
THIS PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
prospectus is part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission using a &ldquo;shelf&rdquo;
registration process. Under this shelf process, we may, from time to time, sell any combination of the securities described in
this prospectus in one or more offerings up to a total amount of $200,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
prospectus provides you with a general description of the securities we may offer. Each time we sell securities, we will provide
a prospectus supplement that will contain specific information about the terms of that offering. The prospectus supplement may
also add to, update or change information contained in the prospectus and, accordingly, to the extent inconsistent, information
in this prospectus is superseded by the information in the prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
prospectus supplement to be attached to the front of this prospectus may describe, as applicable: the terms of the securities
offered; the public offering price; the price paid for the securities; net proceeds; and the other specific terms related to the
offering of the securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">You
should only rely on the information contained or incorporated by reference in this prospectus and any prospectus supplement or
issuer free writing prospectus relating to a particular offering. No person has been authorized to give any information or make
any representations in connection with this offering other than those contained or incorporated by reference in this prospectus,
any accompanying prospectus supplement and any related issuer free writing prospectus in connection with the offering described
herein and therein, and, if given or made, such information or representations must not be relied upon as having been authorized
by us. Neither this prospectus nor any prospectus supplement nor any related issuer free writing prospectus shall constitute an
offer to sell or a solicitation of an offer to buy offered securities in any jurisdiction in which it is unlawful for such person
to make such an offering or solicitation. This prospectus does not contain all of the information included in the registration
statement. For a more complete understanding of the offering of the securities, you should refer to the registration statement,
including its exhibits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">You
should read the entire prospectus and any prospectus supplement and any related issuer free writing prospectus, as well as the
documents incorporated by reference into this prospectus or any prospectus supplement or any related issuer free writing prospectus,
before making an investment decision. Neither the delivery of this prospectus or any prospectus supplement or any issuer free
writing prospectus nor any sale made hereunder shall under any circumstances imply that the information contained or incorporated
by reference herein or in any prospectus supplement or issuer free writing prospectus is correct as of any date subsequent to
the date hereof or of such prospectus supplement or issuer free writing prospectus, as applicable. You should assume that the
information appearing in this prospectus, any prospectus supplement or any document incorporated by reference is accurate only
as of the date of the applicable documents, </FONT>regardless of the time of delivery of this prospectus or any sale of securities.
Our business, financial condition, results of operations and prospects may have changed since that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 43; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<DIV STYLE="padding: 12pt 5; border: Black 1.5pt solid; width: 100%"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #231F20"><A NAME="a-16"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PROSPECTUS
SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>This
summary provides an overview of selected information contained elsewhere or incorporated by reference in this prospectus and does
not contain all of the information you should consider before investing in our securities. You should carefully read the prospectus,
the information incorporated by reference and the registration statement of which this prospectus is a part in their entirety
before investing in our securities, including the information discussed under &ldquo;Risk Factors&rdquo; in this prospectus and
the documents incorporated by reference and our financial statements and notes thereto that are incorporated by reference in this
prospectus. As used in this prospectus, unless the context otherwise indicates, the terms &ldquo;we,&rdquo; &ldquo;our,&rdquo;
&ldquo;us,&rdquo; or &ldquo;the Company&rdquo; refer to Actinium Pharmaceuticals, Inc., a Delaware corporation, and its subsidiaries
taken as a whole.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>The
Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Business
Overview</I></B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
are a biopharmaceutical company focused on the $54 billion market for cancer drugs. Our most advanced products are Actimab&trade;-A,
an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia (AML)
and Iomab&trade;-B, an antibody-drug construct containing iodine 131 (I-131), used in myeloconditioning for hematopoietic stem
cells transplantation (HSCT) in various indications. We are currently designing a trial which we intend to submit for registration
approval in HSCT in the settings of refractory and relapsed acute myeloid leukemia in older patients. We are developing our cancer
drugs using our expertise in radioimmunotherapy. In addition, the Ac-225 based drugs development relies on the patented Alpha
Particle Immunotherapy Technology (APIT) platform technology </FONT>co-developed with Memorial Sloan Kettering Cancer Center (MSKCC),
whose indirect subsidiary, Actinium Holdings Ltd., is a significant stockholder of us. The APIT technology couples monoclonal
antibodies (mAb) with extremely potent but comparatively safe alpha particle emitting radioactive isotopes, in particular actinium
225 and bismuth 213. The final drug construct is designed to specifically target and kill cancer cells while minimizing side effects.
We intend to develop a number of products for different types of cancer and derive revenue from partnering relationships with
large pharmaceutical companies and/or direct sales of its products in specialty markets in the U.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Business
Strategy</I></B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
intend to potentially develop our most advanced clinical stage drug candidates through approval in the case of Iomab&trade;-B
and up to and including a Phase 2 proof of concept human clinical trial (a trial designed to provide data on the drug&rsquo;s
efficacy) in the case of Actimab&trade;-A. If these efforts are successful, we may elect to commercialize Iomab&trade;-B on our
own or with a partner in the United States and/or outside of the United States to out-license the rights to develop and commercialize
the product to a strategic partner. In the case of Actimab&trade;-A, we will most likely seek to enter into strategic partnerships
whereby the strategic partner(s) co-fund(s) further human clinical trials of the drug that are needed to obtain regulatory approvals
for commercial sale within and outside of the United States. In parallel, we intend to identify and begin initial human trials
with additional actinium-225 drug candidates in other cancer indications. We intend to retain marketing rights for our products
in the United States whenever possible and out-license marketing rights to our partners for the rest of the world.</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt">&nbsp;</P>

<DIV STYLE="padding: 12pt 5; border: Black 1.5pt solid; width: 100%"><P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Market
Opportunity</I></B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
are competing in the marketplace for cancer treatments estimated at over $54 billion in 2011 sales pursuant to an IMS Health report
and projected to exceed $76 billion per year by 2015, according to the Global Academy for Medical Education. While surgery, radiation
and chemotherapy remain staple treatments for cancer, their use is limited by the fact that they often cause substantial damage
to normal cells. On the other hand, targeted monoclonal antibody therapies exert most or all of their effect directly on cancer
cells, but often lack sufficient killing power to eradicate all cancer cells with just the antibody. A new approach for treating
cancer is to combine the precision of antibody-based targeting agents with the killing power of radiation or chemotherapy by attaching
powerful killing agents to precise molecular carriers called monoclonal antibodies (mAb). The Company uses monoclonal antibodies
labeled with radioisotopes to deliver potent doses of radiation directly to cancer cells while sparing healthy tissues. The radioisotopes
we use are the alpha emitter Ac-225 and the beta emitter I-131. I-131 is among the best known and well characterized radioisotopes.
It is used very successfully in treatment of papillary and follicular thyroid cancer as well as other thyroid conditions. It is
also attached to a monoclonal antibody in treatment of Non-Hodgkin&rsquo;s Lymphoma (NHL). It is also used experimentally with
different carriers in other cancers. Ac-225 has many unique properties and the Company is a leader in developing this alpha emitter
for clinical applications using its proprietary APIT technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
most advanced products are Actimab&trade;-A, Ac-225 labeled mAb for treatment of newly diagnosed AML, a cancer of the blood, in
patients ineligible for currently approved therapies, and Iomab&trade;-B, I-131 labeled mAb for preparation of relapsed and refractory
AML patients for HSCT. Iomab&trade;-B offers a potentially curative treatment for these patients most of whom do not survive beyond
a year after being diagnosed with this condition. Iomab&trade;-B has also demonstrated efficacy in HSCT preparation for other
blood cancer indications, including Myelodysplastic Syndrome (MDS), acute lymphoblastic leukemia (ALL), Hodgkin&rsquo;s Lymphoma,
and NHL. These are all follow-on indications for which Iomab&trade;-B can be developed and it is our intention to explore these
opportunities when financing becomes available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">There
are currently no FDA approved treatments for either Actimab&trade;-A or Iomab&trade;-B targeted patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Other
potential product opportunities in which a significant amount of preclinical work is being undertaken include metastatic colorectal
cancer, metastatic prostate cancer and antiangiogenesis which reduces the blood supply to solid tumors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
believe that our biggest market opportunity lies in the applicability of our APIT platform technology to a wide variety of cancers.
A broad range of solid and blood borne cancers can be potentially targeted by monoclonal (mAbs) to enable treatment with its APIT
technology. The APIT technology could potentially be applied to mAbs that are alreadyFood and Drug Administration (FDA) approved
to create more efficacious and/or safer drugs (&ldquo;biobetters&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Clinical
Trials</I></B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Actimab-A</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Actimab-A
is currently in multicenter Phase 1/2 clinical trial in AML. It consists of the monoclonal antibody Lintuzumab and alpha emitting
radioisotope actinium 225 (Ac-225). The indication in the ongoing trial is newly diagnosed AML patients over the age of 60.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-align: left; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Previous
clinical trials leading to this trial included:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Phase
                                         1 clinical trial with Bismab-A, the first generation product consisting of the same monoclonal
                                         antibody Lintuzumab and Bi-213 alpha emitter, a daughter of Ac-225;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Phase
                                         1/2 clinical trial with Bismab-A, the first generation product consisting of the same
                                         monoclonal antibody Lintuzumab and Bi-213 alpha emitter, a daughter of Ac-225; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dose
                                         escalating pilot Phase 1 clinical trial with Actimab-A, the current product consisting
                                         of the Lintuzumab monoclonal antibody and Ac-225 alpha emitter.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -19.95pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Completed
Actimab-A related clinical trials outcomes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; color: #231F20"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
                                         Phase 2 arm of the Bismabt-A drug study has shown signs of the drug&rsquo;s efficacy
                                         and safety, including reduction in peripheral blast counts and complete responses in
                                         some patients. Bi-213 is a daughter, i.e., product of the degradation of Ac-225, with
                                         cancer cell killing properties similar to Ac-225 but is less potent.The Phase 1 Actimab-A
                                         trial at MSKCC with a single-dose administration of Actimab&trade;-A showed elimination
                                         of leukemia cells from blood in 67% of all evaluable patients who receive a full dose
                                         and in 83% of those treated at dose levels above 0.5 microcuries per</FONT> kilogram
                                         (&micro;Ci/kg), and eradication of leukemia cells in both blood and bone marrow in 20%
                                         of all evaluable patients and 25% of those treated at dose levels above 0.5 &micro;Ci/kg.
                                         Maximum tolerated single dose in this trial was established at 3 &micro;Ci/kg.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<DIV STYLE="padding: 12pt 5; border: Black 1.5pt solid; width: 100%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Ongoing
Actimab-A trial:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have commenced our first company sponsored Phase 1/2 multi-center trial with fractionated (two) doses of Actimab&trade;-A, Actinium&rsquo;s
lead product candidate for treatment of elderly AML that consists of an AML specific monoclonal antibody (HuM195, also known as
Lintuzumab&trade;) and the actinium 225 radioactive isotope attached to it. We are conducting this trial at world-class cancer
institutions such as MSKCC, Johns Hopkins Medicine, University of Pennsylvania Health System, Fred Hutchinson Cancer Center and
MD Anderson Cancer Center.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Bismabt-A
trials and the Phase 1 Actimab&trade;-A trial were focused on relapsed, refractory and other difficult to treat acute myeloid
leukemia patients. The current multicenter Phase 1/2 trial is focused on newly diagnosed AML patients who have historically had
better outcomes. In addition, the new trial includes low doses of chemotherapy with the goal of further improving patient outcomes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Iomab-B</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Iomab-B
is currently in preparation for a pivotal Phase 3 multicenter clinical trial. It consists of the monoclonal antibody BC8 and beta
emitting radioisotope iodine 131 (I-131). The indication for that trial is bone marrow conditioning for hematopoietic stem cell
transplant in relapsed and refractory AML patients over the age of 55.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Previous
Iomab-B clinical trials leading to the Phase 3 trial currently in preparation included:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Indications</B></FONT></TD>
    <TD STYLE="padding: 0; width: 2%; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="padding: 0; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 22%; text-align: center; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>N</B></FONT></TD>
    <TD STYLE="padding: 0; width: 2%; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="padding: 0; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Key
    Findings</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">AML,
    MDS, ALL (adult)</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">34</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ndash;7/34
    patients with median disease free state (DFS) of 17 years.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ndash;18/34
    patients in remission at day 80</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">AML
    &gt;1st remission (adult)</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">23</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ndash;15/23
    in remission at day 28</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">AML
    1st remission (age 16-50)</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">43</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ndash;23/43
    DFS from 5-16 years</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ndash;30/43
                                         in remission at day 28</FONT></P></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ndash;33/43
    in remission at day 80</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">High-risk
    MDS, advanced AML </FONT><BR>
    <FONT STYLE="font: 10pt Times New Roman, Times, Serif">(age 50+)</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">68
                                         in dose escalation study 31 treated at MTD</FONT></P></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ndash;CR
    (complete remission) in all patients</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ndash;1
                                         yr survival ~ 40% for all patients</FONT></P></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ndash;1
                                         yr survival ~ 45% for pts treated at MTD</FONT></P></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(maximum
    tolerated dose)</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif">High-risk MDS,<FONT STYLE="letter-spacing: -0.15pt">
    </FONT>AML<BR>
    (age 18&ndash;50)</TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">14
    in<FONT STYLE="letter-spacing: 0.45pt"> </FONT>dose<FONT STYLE="letter-spacing: 0.5pt"> </FONT>escalation</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;<FONT STYLE="color: #231F20">All
    patients<FONT STYLE="letter-spacing: 0.45pt"> </FONT>achieved<FONT STYLE="letter-spacing: 0.5pt"> </FONT>full<FONT STYLE="letter-spacing: 0.45pt">
    </FONT>donor<FONT STYLE="letter-spacing: 0.45pt"> </FONT>chimerism<FONT STYLE="letter-spacing: 0.5pt"> </FONT>by<FONT STYLE="letter-spacing: 0.45pt">
    </FONT>day 28<FONT STYLE="letter-spacing: 0.05pt"> </FONT>post-transplant</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">High-risk
    MDS, AML</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8
    in dose escalation</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ndash;6/8
    treated patients achieved CR by day.28</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ndash;haploidentical
    donors (adult)</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ndash;8/8
    patients 100% donor chimerism by day28</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Ongoing
Iomab-B clinical trials include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 88%; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20"><B>Indications</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 10%; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20"><B>Phase
    </B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Relapsed
    and refractory Hodgkin Lymphoma and NHL (adult) </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Phase
    1</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Advanced
    AML, ALL and MDS (adult) </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Phase
    2</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">AML
    1st remission (age 16-50)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Phase
    2</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">High-risk
    MDS, advanced AML (age 16-50) </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Phase
    2</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">There
are additional ongoing clinical trials with BC8 antibody labeled with yttrium 90 (Y-90).</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<DIV STYLE="padding: 12pt 5; border: Black 1.5pt solid; width: 100%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Phase
3 Iomab-B clinical trial in preparation:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
FDA agreed to the Phase 3 clinical trial design as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; color: #231F20"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Single
                                         pivotal study, pending trial results;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Patient
                                         population: refractory AML patients over the age of 55, where refractory includes primary
                                         and secondary refractory and relapsed after &lt;6 months in complete remission;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Trial
                                         arms: study arm and control arm with physician&rsquo;s choice of conventional care with
                                         curative intent; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Trial
                                         size: 150 patients total (75 patients per arm).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">For
the twelve months ended December 31, 2013, we had no revenue and our net loss was approximately </FONT>$10.8 million. For the
twelve months ended December 31, 2012, we had no revenue and our net loss was approximately $8.4 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Corporate
and Other Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0.5in">We were organized in the State
of Nevada on October 6, 1997 and reorganized in the State of Delaware on March 20, 2013. Our principal executive offices are located
at 501 5th Avenue, 3rd Floor, New York, New York 10017. Our telephone number is (646) 459-4201. Our website address is www.actiniumpharma.com.
Information accessed through our website is not incorporated into this prospectus and is not a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>The
Securities We May Offer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
descriptions of the securities contained in this prospectus, together with the applicable prospectus supplements, summarize the
material terms and provisions of the various types of securities that we may offer. We will describe in the applicable prospectus
supplement relating to any securities the particular terms of the securities offered by that prospectus supplement. If we so indicate
in the applicable prospectus supplement, the terms of the securities may differ from the terms we have summarized below. We will
also include information in the prospectus supplement, where applicable, about material U.S. federal income tax considerations
relating to the securities, and the securities exchange, if any, on which the securities will be listed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
may sell from time to time, in one or more primary offerings, our common stock, preferred stock, debt securities, warrants, rights,
purchase contracts or units, or any combination of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
this prospectus, we refer to the common stock, preferred stock, debt securities, warrants, rights, purchase contracts or units,
or any combination of the foregoing securities to be sold by us in a primary offering collectively as &ldquo;securities.&rdquo;
The total dollar amount of all securities that we may issue under this prospectus will not exceed $200,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
prospectus may not be used to consummate a sale of securities unless it is accompanied by a prospectus supplement.</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #231F20"><A NAME="a-17"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">An
investment in our securities involves a high degree of risk. The prospectus supplement applicable to each offering of our securities
will contain a discussion of the risks applicable to an investment in our securities. Before deciding whether to invest in our
securities, you should carefully consider the specific factors discussed under the heading &ldquo;Risk Factors&rdquo; in the applicable
prospectus supplement, together with all of the other information contained or incorporated by reference in the prospectus supplement
or appearing or incorporated by reference in this prospectus. You should also consider the risks, uncertainties and assumptions
discussed under Item 1A, &ldquo;Risk Factors,&rdquo; in our Annual Report on Form 10-K for the fiscal year ended December 31,
2013, all of which are incorporated herein by reference, as updated or superseded by the risks and uncertainties described under
similar headings in the other documents that are filed after the date hereof and incorporated by reference into this prospectus
and any prospectus supplement related to a particular offering. The risks and uncertainties we have described are not the only
ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect
our operations. Past financial performance may not be a reliable indicator of future performance, and historical trends should
not be used to anticipate results or trends in future periods. If any of these risks actually occurs, our business, business prospects,
financial condition or results of operations could be seriously harmed. This could cause the trading price of our common stock
to decline, resulting in a loss of all or part of your investment. Please also read carefully the section below entitled &ldquo;Special
Note Regarding Forward-Looking Statements.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #231F20"><A NAME="a-18"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
prospectus, each prospectus supplement and the information incorporated by reference in this prospectus and each prospectus supplement
contain &ldquo;forward-looking statements,&rdquo; which include information relating to future events, future financial performance,
strategies, expectations, competitive environment and regulation. Words such as &ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;could,&rdquo;
&ldquo;would,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential,&rdquo; &ldquo;continue,&rdquo; &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo;
&ldquo;future,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; and similar
expressions, as well as statements in future tense, identify forward-looking statements. Forward-looking statements should not
be read as a guarantee of future performance or results and will probably not be accurate indications of when such performance
or results will be achieved. Forward-looking statements are based on information we have when those statements are made or our
management&rsquo;s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties
that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking
statements. Important factors that could cause such differences include, but are not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; color: #231F20"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
                                         history of recurring losses and negative cash flows from operating activities, significant
                                         future commitments and the uncertainty regarding the adequacy of our liquidity to pursue
                                         our complete business objectives;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
                                         ability to complete clinical trials as anticipated and obtain and maintain regulatory
                                         approvals for our products;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
                                         ability to adequately protect our intellectual property;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">disputes
                                         over ownership of intellectual property;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         risk that the data collected from our current and planned clinical trials may not be
                                         sufficient to demonstrate that our products is an attractive alternative to other products;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">intense
                                         competition in our industry, with competitors having substantially greater financial,
                                         technological, research and development, regulatory and clinical, manufacturing, marketing
                                         and sales, distribution and personnel resources than we do;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">entry
                                         of new competitors and products and potential technological obsolescence of our products;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">loss
                                         of a key customer or supplier;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">technical
                                         problems with our research and products and potential product liability claims;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; color: #231F20"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">adverse
                                         economic conditions;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">adverse
                                         federal, state and local government regulation, in the United States;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">price
                                         increases for supplies;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">inability
                                         to carry out research, development and commercialization plans; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">loss
                                         or retirement of key executives and research scientists.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">You
should review carefully the section entitled &ldquo;Risk Factors&rdquo; beginning on page 6 of this prospectus for a discussion
of these and other risks that relate to our business and investing in our securities. The forward-looking statements contained
or incorporated by reference in this prospectus or any prospectus supplement are expressly qualified in their entirety by this
cautionary statement. We do not undertake any obligation to publicly update any forward-looking statement to reflect events or
circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #231F20"><A NAME="a-19"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Unless
otherwise indicated in the prospectus supplement, we currently intend to use the net proceeds from the sale of securities offered
by this prospectus for general corporate purposes, including capital expenditures, the advancement of our drug candidates in clinical
trials, such as Iomab&trade;-B and Actimab-A, preclinical trials, and to meet working capital needs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Investors
are cautioned, however, that expenditures may vary substantially from these uses. Investors will be relying on the judgment of
our management, who will have broad discretion regarding the application of the proceeds of this offering. The amounts and timing
of our actual expenditures will depend upon numerous factors, including the amount of cash generated by our operations, the amount
of competition and other operational factors. We may find it necessary or advisable to use portions of the proceeds from this
offering for other purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">From
time to time, we evaluate these and other factors and we anticipate continuing to make such evaluations to determine if the existing
allocation of resources, including the proceeds of this offering, is being optimized. Circumstances that may give rise to a change
in the use of proceeds include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; color: #231F20"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a
                                         change in development plan or strategy;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         addition of new products or applications;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">technical
                                         delays;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">delays
                                         or difficulties with our clinical trials;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">negative
                                         results from our clinical trials;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">difficulty
                                         obtaining U.S. Food and Drug Administration approval; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         availability of other sources of cash including additional offerings, if any.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0; color: #231F20"><A NAME="a-20"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>DESCRIPTION
OF CAPITAL STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following description of common stock and preferred stock summarizes the material terms and provisions of the common stock and
preferred stock that we may offer under this prospectus, but is not complete. For the complete terms of our common stock and preferred
stock, please refer to our certificate of incorporation, as amended and our bylaws, as may be amended from time to time. While
the terms we have summarized below will apply generally to any future common stock or preferred stock that we may offer, we will
describe the specific terms of any series of preferred stock in more detail in the applicable prospectus supplement. If we so
indicate in a prospectus supplement, the terms of any preferred stock we offer under that prospectus supplement may differ from
the terms we describe below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have authorized 250,000,000 shares of capital stock, par value $0.001 per share, of which 200,000,000 are shares of common stock
and 50,000,000 are shares of preferred stock. On March 13, 2014, there were 25,324,978 shares of common stock issued and outstanding
and no shares of preferred stock issued and outstanding. There are no preferred issued and outstanding. The authorized and unissued
shares of common stock and the authorized and undesignated shares of preferred stock are available for issuance without further
action by our stockholders, unless such action is required by applicable law or the rules of any stock exchange on which our securities
may be listed. Unless approval of our stockholders is so required, our board of directors does not intend to seek stockholder
approval for the issuance and sale of our common stock or preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
also have warrants that are outstanding, which are described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
holders of our common stock are entitled to one vote per share. Our certificate of incorporation does not provide for cumulative
voting. Our directors are divided into three classes. At each annual meeting of stockholders, directors elected to succeed those
directors whose terms expire are elected for a term of office to expire at the third succeeding annual meeting of stockholders
after their election. The holders of our common stock are entitled to receive ratably such dividends, if any, as may be declared
by our board of directors out of legally available funds; however, the current policy of our board of directors is to retain earnings,
if any, for operations and growth. Upon liquidation, dissolution or winding-up, the holders of our common stock are entitled to
share ratably in all assets that are legally available for distribution. The holders of our common stock have no preemptive, subscription,
redemption or conversion rights. The rights, preferences and privileges of holders of our common stock are subject to, and may
be adversely affected by, the rights of the holders of any series of preferred stock, which may be designated solely by action
of our board of directors and issued </FONT>in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
common stock is listed on the NYSE MKT under the symbol &ldquo;ATNM.&rdquo; On March 26, 2014 our common stock commenced trading
on the NYSE MKT exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
board of directors is authorized, subject to any limitations prescribed by law, without further vote or action by the stockholders,
to issue from time to time shares of preferred stock in one or more series. Each such series of preferred stock shall have such
number of shares, designations, preferences, voting powers, qualifications, and special or relative rights or privileges as shall
be determined by the board of directors, which may include, among others, dividend rights, voting rights, liquidation preferences,
conversion rights and preemptive rights. Issuance of preferred stock by our board of directors may result in such shares having
dividend and/or liquidation preferences senior to the rights of the holders of our common stock and could dilute the voting rights
of the holders of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Prior
to the issuance of shares of each series of preferred stock, the board of directors is required by the Delaware General Corporation
Law and our certificate of incorporation to adopt resolutions and file a certificate of designation with the Secretary of State
of the State of Delaware. The certificate of designation fixes for each class or series the designations, powers, preferences,
rights, qualifications, limitations and restrictions, including, but not limited to, some or all of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; color: #231F20"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         number of shares constituting that series and the distinctive designation of that series,
                                         which number may be increased or decreased (but not below the number of shares then outstanding)
                                         from time to time by action of the board of directors;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         dividend rate and the manner and frequency of payment of dividends on the shares of that
                                         series, whether dividends will be cumulative, and, if so, from which date;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">whether
                                         that series will have voting rights, in addition to any voting rights provided by law,
                                         and, if so, the terms of such voting rights;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">whether
                                         that series will have conversion privileges, and, if so, the terms and conditions of
                                         such conversion, including provision for adjustment of the conversion rate in such events
                                         as the board of directors may determine;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">whether
                                         or not the shares of that series will be redeemable, and, if so, the terms and conditions
                                         of such redemption;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">whether
                                         that series will have a sinking fund for the redemption or purchase of shares of that
                                         series, and, if so, the terms and amount of such sinking fund;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">whether
                                         or not the shares of the series will have priority over or be on a parity with or be
                                         junior to the shares of any other series or class in any respect;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         rights of the shares of that series in the event of voluntary or involuntary liquidation,
                                         dissolution or winding up of the corporation, and the relative rights or priority, if
                                         any, of payment of shares of that series; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">any
                                         other relative rights, preferences and limitations of that series.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -9.55pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Once
designated by our board of directors, each series of preferred stock may have specific financial and other terms that will be
described in a prospectus supplement. The description of the preferred stock that is set forth in any prospectus supplement is
not complete without reference to the documents that govern the preferred stock. These include our certificate of incorporation
and any certificates of designation that our board of directors may adopt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All
shares of preferred stock offered hereby will, when issued, be fully paid and non-assessable, including shares of preferred stock
issued upon the exercise of preferred stock warrants or subscription rights, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Although
our board of directors has no intention at the present time of doing so, it could authorize the issuance of a series of preferred
stock that could, depending on the terms of such series, impede the completion of a merger, tender offer or other takeover attempt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Common
Stock Warrants</I></B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
December 27, 2013 and January 10, 2014, we issued common stock warrants to certain investors in a private placement of common
stock and warrants (the &ldquo;Common Stock Warrants&rdquo;). The Common Stock Warrants have a five year term from each closing
that occurred on December 27, 2013 and January 10, 2014, and are exercisable for an aggregate of up to 276,529 shares of the Company&rsquo;s
common stock at an initial per share exercise price of $9.00, subject to adjustments as set forth below. The Company may also
call this warrant for redemption upon written notice to all warrant holders at any time the closing price of the common stock
exceeds $15.00 (as may be adjusted pursuant to warrant agreement) for 20 consecutive trading days, as reported by Bloomberg, provided
at such time there is an effective registration statement covering the resale of the shares underlying the warrants. In the 60
business days following the date the redemption notice is deemed given in accordance with the agreement, investors may choose
to exercise this warrant or a portion of the warrant by paying the then applicable exercise price per share for every share exercised.
Any shares not exercised on the last day of the exercise period will be redeemed by the Company at $0.001 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
exercise prices of the Common Stock Warrants are subject to adjustment upon certain events. If the Company at any time while the
warrants remain outstanding and unexpired shall declare a dividend or make a distribution on the outstanding Common Stock payable
in shares of its capital stock, or split, subdivide or combine the securities as to which purchase rights under this Warrant exist
into a different number of securities of the same class, the exercise price for such securities shall be proportionately decreased
in the case of a dividend, split or subdivision or proportionately increased in the case of a combination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Series
B Warrants</I></B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Series B Warrants have a five year term from January 28, 2013 and are exercisable for an aggregate of up to 1,590,484 shares of
the Company&rsquo;s common stock at an initial per share exercise price of $2.48, subject to adjustment as set forth below. As
of March 13, 2014, there were 1,557,925 warrants outstanding. These warrants have a cashless exercise provision. The Company also
has a right of first refusal on the holder&rsquo;s sale of the warrant shares. The Company may also call this warrant for redemption
upon written notice to all warrant holders at any time the closing price of the common stock exceeds $1.50 (as may be adjusted
pursuant to warrant agreement) for 20 consecutive trading days, as reported by Bloomberg, provided at such time there is an effective
registration statement covering the resale of the shares underlying the warrants. In the 60 business days following the date the
redemption notice is deemed given in accordance with the agreement, investors may choose to exercise this warrant or a portion
of the warrant by paying the then applicable exercise price per share for every share exercised. Any shares not exercised on the
last day of the exercise period will be redeemed by the Company at $0.001 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
exercise price of the Series B Warrants is subject to adjustment upon certain events. If the Company at any time while the warrants
remain outstanding and unexpired shall declare a dividend or make a distribution on the outstanding Common Stock payable in shares
of its capital stock, or split, subdivide or combine the securities as to which purchase rights under this Warrant exist into
a different number of securities of the same class, the exercise price for such securities shall be proportionately decreased
in the case of a dividend, split or subdivision or proportionately increased in the case of a combination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
addition, for so long as there are any warrants outstanding, if and whenever at any time and from time to time after the warrant
issue date, as applicable, the Company shall issue any shares of common stock for no consideration or a consideration per share
less than the exercise price, as applicable, then, forthwith upon such issue or sale, the warrants shall be subject to a proportional
adjustment determined by multiplying such warrant exercise price by the following fraction:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>N(0)
+ N(1)</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">N(0)
+ N(2)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">N(0)
= the number of shares of common stock outstanding (calculated on a Fully Diluted Basis) immediately prior to the issuance of
such additional shares of common stock or common stock Equivalents;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">N(1)
= the number of shares of common stock which the aggregate consideration, if any (including the aggregate Net Consideration Per
Share with respect to the issuance of common stock equivalents), received or receivable by the Company for the total number of
such additional shares of common stock so issued or deemed to be issued would purchase at the warrant exercise price, as applicable,
in effect immediately prior to such issuance; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">N(2)
= the number of such additional shares of common stock so issued or deemed to be issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Stock
Offering Warrants</I></B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Stock Offering Warrants have a term ending on January 31, 2019 and are exercisable for an aggregate of up to 2,700,971 shares
of the Company&rsquo;s common stock at an initial per share exercise price of $0.78, subject to adjustment as set forth below
(anti-dilution). As of March 13, 2014, there were 787,378 warrants outstanding. These warrants have a cashless exercise provision.
The Company also has a right of first refusal on the holder&rsquo;s sale of the warrant shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">These
warrants have a cashless exercise provision. The Company also has a right of first refusal on the holder&rsquo;s sale of the warrant
shares. The exercise prices of the Stock Offering Warrants are subject to adjustment upon certain events. If the Company at any
time while the warrants remain outstanding and unexpired shall declare a dividend or make a distribution on the outstanding Common
Stock payable in shares of its capital stock, or split, subdivide or combine the securities as to which purchase rights under
this Warrant exist into a different number of securities of the same class, the exercise price for such securities shall be proportionately
decreased in the case of a dividend, split or subdivision or proportionately increased in the case of a combination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
addition, for so long as there are any warrants outstanding, if and whenever at any time and from time to time after the warrant
issue date, as applicable, the Company shall issue any shares of common stock for no consideration or a consideration per share
less than the exercise price, as applicable, then, forthwith upon such issue or sale, the warrants shall be subject to a proportional
adjustment determined by multiplying such warrant exercise price by the following fraction:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>N(0)
+ N(1)</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">N(0)
+ N(2)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">N(0)
= the number of shares of common stock outstanding (calculated on a Fully Diluted Basis) immediately prior to the issuance of
such additional shares of common stock or common stock Equivalents;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">N(1)
= the number of shares of common stock which the aggregate consideration, if any (including the aggregate Net Consideration Per
Share with respect to the issuance of common stock equivalents), received or receivable by the Company for the total number of
such additional shares of common stock so issued or deemed to be issued would purchase at the warrant exercise price, as applicable,
in effect immediately prior to such issuance; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">N(2)
= the number of such additional shares of common stock so issued or deemed to be issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Consulting
Firm Warrants</I></B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Consulting Firm Warrants have a term ending on December 17, 2019 and are exercisable for an aggregate of up to 3,755,562 shares
of the Company&rsquo;s common stock. As of March 13, 2014, there were 3,755,562 warrants outstanding. These warrants may not be
exercised by the Holder upon less than 90 days prior written notice of such exercise and provided further that that the Holder
may elect, in its sole discretion, to waive the Prior Notice Requirement, in whole or in part, upon 65 days prior written notice
of such waiver. These warrants have a cashless exercise provision and were issued at an initial per share exercise price of </FONT>$0.001,
subject to adjustment as if the Company at any time while the warrants remain outstanding and unexpired shall declare a dividend
or make a distribution on the outstanding Common Stock payable in shares of its capital stock, or split, subdivide or combine
the securities as to which purchase rights under this Warrant exist into a different number of securities of the same class, the
exercise price for such securities shall be proportionately decreased in the case of a dividend, split or subdivision or proportionately
increased in the case of a combination. The warrants are also subject to piggy-back registration rights. The holder has also agreed
that following the consummation of the pubco transaction (which occurred on December 28, 2012), the holder will not sell or otherwise
transfer any shares of common stock of the Company owned by holder, as a result of the exercise of the warrant until the date
that is the earlier of (i) twelve (12) months from the closing date of the pubco transaction; or (ii) six (6) months following
the effective date of the Registration Statement of which this prospectus is a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Placement
Agent Warrants</I></B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company issued three types of warrants to the Placement Agent, Placement Agent Stock Offering Warrants, Placement Agent Common
Stock Warrants, and Placement Agent December 2013 Offering Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Placement
Agent Stock Offering Warrants</I></B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Placement Agent Stock Offering Warrants have a term ending on January 31, 2019 and are exercisable for an aggregate of up to 1,245,210
shares of the Company&rsquo;s common stock at an initial per share exercise price of $0.78, subject to adjustment as set forth
below (anti dilution). As of March 13, 2014, there were 367,742 warrants outstanding. These warrants have a cashless exercise
provision. The exercise prices of the warrants are subject to adjustment upon certain events. If the Company at any time while
the warrants remain outstanding and unexpired shall declare a dividend or make a distribution on the outstanding Common Stock
payable in shares of its capital stock, or split, subdivide or combine the securities as to which purchase rights under this Warrant
exist into a different number of securities of the same class, the exercise price for such securities shall be proportionately
decreased in the case of a dividend, split or subdivision or proportionately increased in the case of a combination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
addition, for so long as there are any warrants outstanding, if and whenever at any time and from time to time after the warrant
issue date, as applicable, the Company shall issue any shares of common stock for no consideration or a consideration per share
less than the exercise price, as applicable, then, forthwith upon such issue or sale, the warrants shall be subject to a proportional
adjustment determined by multiplying such warrant exercise price by the following fraction:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>N(0)
+ N(1)</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">N(0) + N(2)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">N(0)
= the number of shares of common stock outstanding (calculated on a Fully Diluted Basis) immediately prior to the issuance of
such additional shares of common stock or common stock Equivalents;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">N(1)
= the number of shares of common stock which the aggregate consideration, if any (including the aggregate Net Consideration Per
Share with respect to the issuance of common stock equivalents), received or receivable by the Company for the total number of
such additional shares of common stock so issued or deemed to be issued would purchase at the warrant exercise price, as applicable,
in effect immediately prior to such issuance; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">N(2)
= the number of such additional shares of common stock so issued or deemed to be issued. Placement Agent Common Stock Warrants</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Placement Agent Common Stock Warrants have a five year term from January 28, 2013 and are exercisable for an aggregate of up to
467,845 shares of the Company&rsquo;s common stock at an initial per share exercise price of $2.48, subject to adjustment as set
forth below. As of March 20, 2014, there were 367,742 warrants outstanding.These warrants have a cashless exercise provision.
The Company may also call this warrant for redemption upon written notice to all warrant holders at any time the closing price
of the common stock exceeds $1.50 (as may be adjusted pursuant to warrant agreement) for 20 consecutive trading days, as reported
by Bloomberg, provided at such time there is an effective registration statement covering the resale of the shares underlying
the warrants. In the 60 business days following the date the redemption notice is deemed given in accordance with the agreement,
investors may choose to exercise this warrant or a portion of the warrant by paying the then applicable exercise price per share
for every share exercised. Any shares not exercised on the last day of the exercise period will be redeemed by the Company at
$0.001 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
exercise prices of the warrants are subject to adjustment upon certain events. If the Company at any time while the warrants remain
outstanding and unexpired shall declare a dividend or make a distribution on the outstanding Common Stock payable in shares of
its capital stock, or split, subdivide or combine the securities as to which purchase rights under this Warrant exist into a different
number of securities of the same class, the exercise price for such securities shall be proportionately decreased in the case
of a dividend, split or subdivision or proportionately increased in the case of a combination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
addition, for so long as there are any warrants outstanding, if and whenever at any time and from time to time after the warrant
issue date, as applicable, the Company shall issue any shares of common stock for no consideration or a consideration per share
less than the exercise price, as applicable, then, forthwith upon such issue or sale, the warrants shall be subject to a proportional
adjustment determined by multiplying such warrant exercise price by the following fraction:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>N(0)
+ N(1)</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">N(0)
+ N(2)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">N(0)
= the number of shares of common stock outstanding (calculated on a Fully Diluted Basis) immediately prior to the issuance of
such additional shares of common stock or common stock Equivalents;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">N(1)
= the number of shares of common stock which the aggregate consideration, if any (including the aggregate Net Consideration Per
Share with respect to the issuance of common stock equivalents), received or receivable by the Company for the total number of
such additional shares of common stock so issued or deemed to be issued would purchase at the warrant exercise price, as applicable,
in effect immediately prior to such issuance; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">N(2)
= the number of such additional shares of common stock so issued or deemed to be issued. Placement Agent December 2013 Offering
Warrants</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Placement Agent December 2013 Offering Warrants have a five year term from January 10, 2014 and are exercisable for an aggregate
of up to 138,265 shares of the Company&rsquo;s common stock at an initial per share exercise price of $9.00, subject to adjustment
as set forth below. As of March 13, 2014, there were 138,265 warrants outstanding. These warrants have a cashless exercise provision.
The Company may also call this warrant for redemption upon written notice to all warrant holders at any time the closing price
of the common stock exceeds $15.00 (as may be adjusted pursuant to warrant agreement) for 20 consecutive trading days, as reported
by Bloomberg, provided at such time there is an effective registration statement covering the resale of the shares underlying
the warrants. In the 60 business days following the date the redemption notice is deemed given in accordance with the agreement,
investors may choose to exercise this warrant or a portion of the warrant by paying the then applicable exercise price per share
for every share exercised. Any shares not exercised on the last day of the exercise period will be redeemed by the Company at
$0.001 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
exercise prices of the warrants are subject to adjustment upon certain events. If the Company at any time while the warrants remain
outstanding and unexpired shall declare a dividend or make a distribution on the outstanding Common Stock payable in shares of
its capital stock, or split, subdivide or combine the securities as to which purchase rights under this Warrant exist into a different
number of securities of the same class, the exercise price for such securities shall be proportionately decreased in the case
of a dividend, split or subdivision or proportionately increased in the case of a combination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Registration
Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>December
2013 Private Placement</I></B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
December 27, 2013 and January 10, 2014, in connection with our private placement of common stock and warrants, we entered into
a registration rights agreement with the purchasers pursuant to which we agreed to provide certain registration rights with respect
to the common stock and common stock issuable upon exercise of the warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A
registration statement was filed in satisfaction of the requirements of the registration rights agreement, was declared effective
on February 13, 2014 and remains in effect. Pursuant to the registration rights agreement, we must maintain the effectiveness
of these registration statement from the effective date until the date on which all securities registered under the applicable
registration statement have been sold, or are otherwise able to be sold pursuant to Rule 144 without volume or manner-of-sale
restrictions, subject to the our right to suspend or defer the use of the registration statement in certain events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>December
2012 Private Placement</I></B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
December 19, 2012, in connection with our private placement of common stock and warrants, we entered into a registration rights
agreement with the purchasers pursuant to which we agreed to provide certain registration rights with respect to the common stock
and common stock issuable upon exercise of the warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A
registration statement was filed in satisfaction of the requirements of the registration rights agreement, was declared effective
on November 8, 2013 and remains in effect. Pursuant to the registration rights agreement, we must maintain the effectiveness of
these registration statement from the effective date until the date on which all securities registered under the applicable registration
statement have been sold, or are otherwise able to be sold pursuant to Rule 144 without volume or manner-of-sale restrictions,
subject to the our right to suspend or defer the use of the registration statement in certain events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Delaware
Anti-Takeover Law, Provisions of our Certificate of Incorporation and Bylaws</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Delaware
Anti-Takeover Law</I></B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
are subject to Section 203 of the Delaware General Corporation Law. Section 203 generally prohibits a public Delaware corporation
from engaging in a &ldquo;business combination&rdquo; with an &ldquo;interested stockholder&rdquo; for a period of three years
after the date of the transaction in which the person became an interested stockholder, unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; color: #231F20"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">prior
                                         to the date of the transaction, the board of directors of the corporation approved either
                                         the business combination or the transaction which resulted in the stockholder becoming
                                         an interested stockholder;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         interested stockholder owned at least 85% of the voting stock of the corporation outstanding
                                         at the time the transaction commenced, excluding for purposes of determining the number
                                         of shares outstanding (i) shares owned by persons who are directors and also officers
                                         and (ii) shares owned by employee stock plans in which employee participants do not have
                                         the right to determine confidentially whether shares held subject to the plan will be
                                         tendered in a tender or exchange offer; or</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">on
                                         or subsequent to the date of the transaction, the business combination is approved by
                                         the board and authorized at an annual or special meeting of stockholders, and not by
                                         written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting
                                         stock which is not owned by the interested stockholder.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -9.55pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Section
203 defines a business combination to include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; color: #231F20"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">any
                                         merger or consolidation involving the corporation and the interested stockholder;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">any
                                         sale, transfer, pledge or other disposition involving the interested stockholder of 10%
                                         or more of the assets of the corporation;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">subject
                                         to exceptions, any transaction that results in the issuance or transfer by the corporation
                                         of any stock of the corporation to the interested stockholder; or</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         receipt by the interested stockholder of the benefit of any loans, advances, guarantees,
                                         pledges or other financial benefits provided by or through the corporation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding
voting stock of the corporation and any entity or person affiliated with, or controlling, or controlled by, the entity or person.
The term &ldquo;owner&rdquo; is broadly defined to include any person that, individually, with or through that person&rsquo;s
affiliates or associates, among other things, beneficially owns the stock, or has the right to acquire the stock, whether or not
the right is immediately exercisable, under any agreement or understanding or upon the exercise of warrants or options or otherwise
or has the right to vote the stock under any agreement or understanding, or has an agreement or understanding with the beneficial
owner of the stock for the purpose of acquiring, holding, voting or disposing of the stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
restrictions in Section 203 do not apply to corporations that have elected, in the manner provided in Section 203, not to be subject
to Section 203 of the Delaware General Corporation Law or, with certain exceptions, which do not have a class of voting stock
that is listed on a national securities exchange or authorized for quotation on the Nasdaq Stock Market or held of record by more
than 2,000 stockholders. Our certificate of incorporation and bylaws do not opt out of Section 203.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Section
203 could delay or prohibit mergers or other takeover or change in control attempts with respect to us and, accordingly, may discourage
attempts to acquire us even though such a transaction may offer our stockholders the opportunity to sell their stock at a price
above the prevailing market price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Certificate
of Incorporation and Bylaws</I></B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Provisions
of our certificate of incorporation and bylaws may delay or discourage transactions involving an actual or potential change in
our control or change in our management, including transactions in which stockholders might otherwise receive a premium for their
shares, or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions
could adversely affect the price of our common stock. Among other things, our certificate of incorporation and bylaws:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19.95pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; color: #231F20"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">permit
                                         our board of directors to issue up to 50,000,000 shares of preferred stock, without further
                                         action by the stockholders, with any rights, preferences and privileges as they may designate,
                                         including the right to approve an acquisition or other change in control;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">provide
                                         that the authorized number of directors may be changed only by the prior consent of the
                                         placement agent for the our 2012 common stock offering for a period ending on December
                                         28, 2014;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">provide
                                         that all vacancies, including newly created directorships, may, except as otherwise required
                                         by law, be filled by the affirmative vote of a majority of directors then in office;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">divide
                                         our board of directors into three classes, with each class serving staggered three-year
                                         terms, with such three year term commencing on the election of a director on and after
                                         the 2014 annual meeting;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">do
                                         not provide for cumulative voting rights (therefore allowing the holders of a majority
                                         of the shares of common stock entitled to vote in any election of directors to elect
                                         all of the directors standing for election, if they should so choose);</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">provide
                                         that special meetings of our stockholders may be called only by our Chairman of the Board,
                                         board of directors, president and chief executive officer; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="padding: 0; font: 10pt Times New Roman, Times, Serif; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">set
                                         forth an advance notice procedure with regard to business to be brought before a meeting
                                         of stockholders.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0; color: #231F20"><A NAME="a-21"></A>DESCRIPTION
OF<FONT STYLE="letter-spacing: 1.95pt"> </FONT>DEBT<FONT STYLE="letter-spacing: 1.95pt"> </FONT>SECURITIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>may<FONT STYLE="letter-spacing: 0.6pt"> </FONT>issue<FONT STYLE="letter-spacing: 0.6pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.6pt">
</FONT>securities<FONT STYLE="letter-spacing: 0.6pt"> </FONT>from<FONT STYLE="letter-spacing: 0.6pt"> </FONT>time<FONT STYLE="letter-spacing: 0.6pt">
</FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>time,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>in<FONT STYLE="letter-spacing: 0.6pt">
</FONT>one<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>more<FONT STYLE="letter-spacing: 0.6pt">
</FONT>series,<FONT STYLE="letter-spacing: 0.65pt"> </FONT>as<FONT STYLE="letter-spacing: 0.6pt"> </FONT>either<FONT STYLE="letter-spacing: 0.6pt">
</FONT>senior<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>subordinated<FONT STYLE="letter-spacing: 1pt">
</FONT>debt<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>as<FONT STYLE="letter-spacing: 0.55pt">
</FONT>senior<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>subordinated<FONT STYLE="letter-spacing: 0.6pt">
</FONT>convertible<FONT STYLE="letter-spacing: 0.55pt"> </FONT>debt.<FONT STYLE="letter-spacing: 0.35pt"> </FONT>While<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>terms<FONT STYLE="letter-spacing: 0.55pt"> </FONT>we<FONT STYLE="letter-spacing: 0.55pt">
</FONT>have<FONT STYLE="letter-spacing: 0.55pt"> </FONT>summarized<FONT STYLE="letter-spacing: 0.55pt"> </FONT>below<FONT STYLE="letter-spacing: 0.6pt">
</FONT>will<FONT STYLE="letter-spacing: 0.55pt"> </FONT>apply generally<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt">
</FONT>any<FONT STYLE="letter-spacing: 0.6pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.55pt">
</FONT>that<FONT STYLE="letter-spacing: 0.6pt"> </FONT>we<FONT STYLE="letter-spacing: 0.55pt"> </FONT>may<FONT STYLE="letter-spacing: 0.55pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">offer</FONT><FONT STYLE="letter-spacing: 0.6pt"> </FONT>under<FONT STYLE="letter-spacing: 0.55pt">
</FONT>this<FONT STYLE="letter-spacing: 0.6pt"> </FONT>prospectus,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>we<FONT STYLE="letter-spacing: 0.55pt">
</FONT>will<FONT STYLE="letter-spacing: 0.6pt"> </FONT>describe<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>particular<FONT STYLE="letter-spacing: 0.6pt"> </FONT>terms<FONT STYLE="letter-spacing: 1.05pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt">
</FONT>any<FONT STYLE="letter-spacing: 0.6pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.6pt">
</FONT>that<FONT STYLE="letter-spacing: 0.6pt"> </FONT>we<FONT STYLE="letter-spacing: 0.55pt"> </FONT>may<FONT STYLE="letter-spacing: 0.6pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">offer</FONT><FONT STYLE="letter-spacing: 0.6pt"> </FONT>in<FONT STYLE="letter-spacing: 0.55pt">
</FONT>more<FONT STYLE="letter-spacing: 0.6pt"> </FONT>detail<FONT STYLE="letter-spacing: 0.6pt"> </FONT>in<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>applicable<FONT STYLE="letter-spacing: 0.6pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt">
</FONT>supplement.<FONT STYLE="letter-spacing: 0.4pt"> </FONT>The<FONT STYLE="letter-spacing: 0.6pt"> </FONT>terms<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 1.05pt"> </FONT>any<FONT STYLE="letter-spacing: 0.5pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.55pt">
</FONT>securities<FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">offered</FONT><FONT STYLE="letter-spacing: 0.5pt">
</FONT>under<FONT STYLE="letter-spacing: 0.55pt"> </FONT>a<FONT STYLE="letter-spacing: 0.55pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.5pt">
</FONT>supplement may<FONT STYLE="letter-spacing: 0.5pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">differ</FONT><FONT STYLE="letter-spacing: 0.55pt">
</FONT>from<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.5pt"> </FONT>terms<FONT STYLE="letter-spacing: 0.55pt">
</FONT>described<FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.15pt">below.</FONT><FONT STYLE="letter-spacing: 0.5pt">
</FONT>Unless<FONT STYLE="letter-spacing: 1.05pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>context<FONT STYLE="letter-spacing: 0.55pt">
</FONT>requires<FONT STYLE="letter-spacing: 0.55pt"> </FONT>otherwise,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>whenever<FONT STYLE="letter-spacing: 0.55pt">
</FONT>we<FONT STYLE="letter-spacing: 0.55pt"> </FONT>refer<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>indenture,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>we<FONT STYLE="letter-spacing: 0.55pt">
</FONT>are<FONT STYLE="letter-spacing: 0.55pt"> </FONT>also<FONT STYLE="letter-spacing: 0.55pt"> </FONT>referring<FONT STYLE="letter-spacing: 0.55pt">
</FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>any<FONT STYLE="letter-spacing: 0.55pt"> </FONT>supplemental indentures
that<FONT STYLE="letter-spacing: 0.55pt"> </FONT>specify<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>terms<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>a<FONT STYLE="letter-spacing: 0.55pt">
</FONT>particular<FONT STYLE="letter-spacing: 0.6pt"> </FONT>series<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt">
</FONT>debt<FONT STYLE="letter-spacing: 0.6pt"> </FONT>securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>will<FONT STYLE="letter-spacing: 0.6pt"> </FONT>issue<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>debt<FONT STYLE="letter-spacing: 0.65pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.6pt"> </FONT>under<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>indenture<FONT STYLE="letter-spacing: 0.6pt"> </FONT>that<FONT STYLE="letter-spacing: 0.65pt">
</FONT>we<FONT STYLE="letter-spacing: 0.6pt"> </FONT>will<FONT STYLE="letter-spacing: 0.6pt"> </FONT>enter<FONT STYLE="letter-spacing: 0.6pt">
</FONT>into<FONT STYLE="letter-spacing: 0.6pt"> </FONT>with<FONT STYLE="letter-spacing: 0.65pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>trustee<FONT STYLE="letter-spacing: 0.6pt"> </FONT>named<FONT STYLE="letter-spacing: 0.6pt"> </FONT>in<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 1pt"> </FONT>indenture.<FONT STYLE="letter-spacing: 0.3pt"> </FONT>The<FONT STYLE="letter-spacing: 0.55pt">
</FONT>indenture<FONT STYLE="letter-spacing: 0.5pt"> </FONT>will<FONT STYLE="letter-spacing: 0.55pt"> </FONT>be<FONT STYLE="letter-spacing: 0.5pt">
</FONT>qualified<FONT STYLE="letter-spacing: 0.55pt"> </FONT>under<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.35pt">
</FONT><FONT STYLE="letter-spacing: -0.1pt">Trust</FONT><FONT STYLE="letter-spacing: 0.55pt"> </FONT>Indenture Act<FONT STYLE="letter-spacing: 0.5pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>1939,<FONT STYLE="letter-spacing: 0.5pt"> </FONT>as<FONT STYLE="letter-spacing: 0.55pt">
</FONT>amended<FONT STYLE="letter-spacing: 0.5pt"> </FONT><FONT STYLE="letter-spacing: -0.15pt">(&ldquo;<B>Trust</B></FONT><B><FONT STYLE="letter-spacing: 1.45pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">Indenture</FONT><FONT STYLE="letter-spacing: 0.55pt"> </FONT>Act</B>&rdquo;).<FONT STYLE="letter-spacing: 0.35pt">
</FONT><FONT STYLE="letter-spacing: -0.45pt">We</FONT><FONT STYLE="letter-spacing: 0.55pt"> </FONT>have<FONT STYLE="letter-spacing: 0.55pt">
</FONT>filed<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>form<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>indenture<FONT STYLE="letter-spacing: 0.55pt"> </FONT>as<FONT STYLE="letter-spacing: 0.55pt">
</FONT>an<FONT STYLE="letter-spacing: 0.55pt"> </FONT>exhibit<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>registration<FONT STYLE="letter-spacing: 0.55pt"> </FONT>statement<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>which<FONT STYLE="letter-spacing: 0.55pt"> </FONT>this<FONT STYLE="letter-spacing: 1.25pt">
</FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt"> </FONT>is<FONT STYLE="letter-spacing: 0.55pt"> </FONT>a<FONT STYLE="letter-spacing: 0.6pt">
</FONT>part,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>and<FONT STYLE="letter-spacing: 0.55pt"> </FONT>supplemental<FONT STYLE="letter-spacing: 0.6pt">
</FONT>indentures<FONT STYLE="letter-spacing: 0.55pt"> </FONT>and<FONT STYLE="letter-spacing: 0.55pt"> </FONT>forms<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.55pt">
</FONT>containing<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>terms<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>debt securities<FONT STYLE="letter-spacing: 0.55pt">
</FONT>being<FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">offered</FONT><FONT STYLE="letter-spacing: 0.55pt">
</FONT>will<FONT STYLE="letter-spacing: 0.55pt"> </FONT>be<FONT STYLE="letter-spacing: 0.55pt"> </FONT>filed<FONT STYLE="letter-spacing: 0.55pt">
</FONT>as<FONT STYLE="letter-spacing: 0.55pt"> </FONT>exhibits<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>registration<FONT STYLE="letter-spacing: 0.55pt"> </FONT>statement<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>which<FONT STYLE="letter-spacing: 0.55pt"> </FONT>this<FONT STYLE="letter-spacing: 0.55pt">
</FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt"> </FONT>is<FONT STYLE="letter-spacing: 0.55pt"> </FONT>a<FONT STYLE="letter-spacing: 0.55pt">
</FONT>part<FONT STYLE="letter-spacing: 1.15pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>will<FONT STYLE="letter-spacing: 0.55pt">
</FONT>be<FONT STYLE="letter-spacing: 0.55pt"> </FONT>incorporated<FONT STYLE="letter-spacing: 0.55pt"> </FONT>by<FONT STYLE="letter-spacing: 0.55pt">
</FONT>reference<FONT STYLE="letter-spacing: 0.55pt"> </FONT>from<FONT STYLE="letter-spacing: 0.55pt"> </FONT>reports<FONT STYLE="letter-spacing: 0.55pt">
</FONT>that<FONT STYLE="letter-spacing: 0.55pt"> </FONT>we<FONT STYLE="letter-spacing: 0.55pt"> </FONT>file<FONT STYLE="letter-spacing: 0.55pt">
</FONT>with<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">The<FONT STYLE="letter-spacing: 0.55pt">
</FONT>following<FONT STYLE="letter-spacing: 0.55pt"> </FONT>summary<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>material<FONT STYLE="letter-spacing: 0.55pt"> </FONT>provisions<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.6pt">
</FONT>and<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>indenture<FONT STYLE="letter-spacing: 0.6pt">
</FONT>is<FONT STYLE="letter-spacing: 0.55pt"> </FONT>subject<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to,<FONT STYLE="letter-spacing: 0.6pt">
</FONT>and qualified<FONT STYLE="letter-spacing: 0.55pt"> </FONT>in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>its<FONT STYLE="letter-spacing: 0.55pt">
</FONT>entirety<FONT STYLE="letter-spacing: 0.6pt"> </FONT>by<FONT STYLE="letter-spacing: 0.55pt"> </FONT>reference<FONT STYLE="letter-spacing: 0.55pt">
</FONT>to,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>all<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>provisions<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>indenture<FONT STYLE="letter-spacing: 0.55pt"> </FONT>applicable<FONT STYLE="letter-spacing: 0.55pt">
</FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>a<FONT STYLE="letter-spacing: 0.55pt"> </FONT>particular<FONT STYLE="letter-spacing: 0.55pt">
</FONT>series of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities.<FONT STYLE="letter-spacing: 0.4pt">
</FONT><FONT STYLE="letter-spacing: -0.45pt">We</FONT><FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">urge
</FONT>you<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>read<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>applicable<FONT STYLE="letter-spacing: 0.55pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt">
</FONT>supplements<FONT STYLE="letter-spacing: 0.55pt"> </FONT>and<FONT STYLE="letter-spacing: 0.6pt"> </FONT>any<FONT STYLE="letter-spacing: 0.55pt">
</FONT>related<FONT STYLE="letter-spacing: 0.55pt"> </FONT>free<FONT STYLE="letter-spacing: 0.6pt"> </FONT>writing<FONT STYLE="letter-spacing: 1pt">
</FONT>prospectuses<FONT STYLE="letter-spacing: 0.55pt"> </FONT>related<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.6pt">
</FONT>that<FONT STYLE="letter-spacing: 0.55pt"> </FONT>we<FONT STYLE="letter-spacing: 0.6pt"> </FONT>may<FONT STYLE="letter-spacing: 0.55pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">offer</FONT><FONT STYLE="letter-spacing: 0.6pt"> </FONT>under<FONT STYLE="letter-spacing: 0.55pt">
</FONT>this<FONT STYLE="letter-spacing: 0.6pt"> </FONT>prospectus,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>as<FONT STYLE="letter-spacing: 0.6pt">
</FONT>well<FONT STYLE="letter-spacing: 0.55pt"> </FONT>as<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>complete<FONT STYLE="letter-spacing: 1.05pt"> </FONT>indenture<FONT STYLE="letter-spacing: 0.55pt"> </FONT>that<FONT STYLE="letter-spacing: 0.55pt">
</FONT>contains<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>terms<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.55pt">
</FONT>securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0; color: #231F20"><B>General
<FONT STYLE="letter-spacing: -0.25pt">Terms</FONT><FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">Indenture</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">The<FONT STYLE="letter-spacing: 0.6pt">
</FONT>indenture<FONT STYLE="letter-spacing: 0.6pt"> </FONT>does<FONT STYLE="letter-spacing: 0.6pt"> </FONT>not<FONT STYLE="letter-spacing: 0.6pt">
</FONT>limit<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>amount<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.6pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.6pt">
</FONT>that<FONT STYLE="letter-spacing: 0.6pt"> </FONT>we<FONT STYLE="letter-spacing: 0.6pt"> </FONT>may<FONT STYLE="letter-spacing: 0.6pt">
</FONT>issue.<FONT STYLE="letter-spacing: 0.6pt"> </FONT>It<FONT STYLE="letter-spacing: 0.6pt"> </FONT>provides<FONT STYLE="letter-spacing: 0.6pt">
</FONT>that<FONT STYLE="letter-spacing: 0.6pt"> </FONT>we<FONT STYLE="letter-spacing: 0.6pt"> </FONT>may issue<FONT STYLE="letter-spacing: 0.6pt">
</FONT>debt<FONT STYLE="letter-spacing: 0.6pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.6pt"> </FONT>up<FONT STYLE="letter-spacing: 0.6pt">
</FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>principal<FONT STYLE="letter-spacing: 0.6pt">
</FONT>amount<FONT STYLE="letter-spacing: 0.6pt"> </FONT>that<FONT STYLE="letter-spacing: 0.6pt"> </FONT>we<FONT STYLE="letter-spacing: 0.6pt">
</FONT>may<FONT STYLE="letter-spacing: 0.6pt"> </FONT>authorize<FONT STYLE="letter-spacing: 0.6pt"> </FONT>and<FONT STYLE="letter-spacing: 0.6pt">
</FONT>may<FONT STYLE="letter-spacing: 0.6pt"> </FONT>be<FONT STYLE="letter-spacing: 0.6pt"> </FONT>in<FONT STYLE="letter-spacing: 0.6pt">
</FONT>any<FONT STYLE="letter-spacing: 0.6pt"> </FONT>currency<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or currency<FONT STYLE="letter-spacing: 0.55pt">
</FONT>unit<FONT STYLE="letter-spacing: 0.6pt"> </FONT>designated<FONT STYLE="letter-spacing: 0.55pt"> </FONT>by<FONT STYLE="letter-spacing: 0.55pt">
</FONT>us.<FONT STYLE="letter-spacing: 0.6pt"> </FONT>Except<FONT STYLE="letter-spacing: 0.55pt"> </FONT>for<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>limitations<FONT STYLE="letter-spacing: 0.6pt"> </FONT>on<FONT STYLE="letter-spacing: 0.55pt">
</FONT>consolidation,<FONT STYLE="letter-spacing: 0.6pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">merger</FONT><FONT STYLE="letter-spacing: 0.55pt">
</FONT>and<FONT STYLE="letter-spacing: 0.6pt"> </FONT>sale<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>all<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 1.1pt"> </FONT>substantially<FONT STYLE="letter-spacing: 0.55pt">
</FONT>all<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>our<FONT STYLE="letter-spacing: 0.55pt">
</FONT>assets<FONT STYLE="letter-spacing: 0.6pt"> </FONT>contained<FONT STYLE="letter-spacing: 0.6pt"> </FONT>in<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>indenture,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>terms<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>indenture<FONT STYLE="letter-spacing: 0.6pt"> </FONT>do<FONT STYLE="letter-spacing: 0.55pt"> </FONT>not<FONT STYLE="letter-spacing: 0.6pt">
</FONT>contain<FONT STYLE="letter-spacing: 0.6pt"> </FONT>any covenants<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt">
</FONT>other<FONT STYLE="letter-spacing: 0.55pt"> </FONT>provisions<FONT STYLE="letter-spacing: 0.55pt"> </FONT>designed<FONT STYLE="letter-spacing: 0.55pt">
</FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">afford</FONT><FONT STYLE="letter-spacing: 0.55pt">
</FONT>holders<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>any<FONT STYLE="letter-spacing: 0.55pt">
</FONT>debt<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.6pt"> </FONT>protection<FONT STYLE="letter-spacing: 0.55pt">
</FONT>with<FONT STYLE="letter-spacing: 0.55pt"> </FONT>respect<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt">
</FONT>our<FONT STYLE="letter-spacing: 1.1pt"> </FONT>operations,<FONT STYLE="letter-spacing: 0.35pt"> </FONT>financial<FONT STYLE="letter-spacing: 0.35pt">
</FONT>condition<FONT STYLE="letter-spacing: 0.4pt"> </FONT>or<FONT STYLE="letter-spacing: 0.35pt"> </FONT>transactions<FONT STYLE="letter-spacing: 0.4pt">
</FONT>involving<FONT STYLE="letter-spacing: 0.35pt"> </FONT>us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>may<FONT STYLE="letter-spacing: 0.55pt"> </FONT>issue<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>debt<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.55pt"> </FONT>issued<FONT STYLE="letter-spacing: 0.55pt">
</FONT>under<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>indenture<FONT STYLE="letter-spacing: 0.55pt">
</FONT>as<FONT STYLE="letter-spacing: 0.55pt"> </FONT>&ldquo;discount<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities,&rdquo;
which<FONT STYLE="letter-spacing: 0.55pt"> </FONT>means<FONT STYLE="letter-spacing: 0.6pt"> </FONT>they<FONT STYLE="letter-spacing: 1pt">
</FONT>may<FONT STYLE="letter-spacing: 0.55pt"> </FONT>be<FONT STYLE="letter-spacing: 0.6pt"> </FONT>sold<FONT STYLE="letter-spacing: 0.6pt">
</FONT>at<FONT STYLE="letter-spacing: 0.6pt"> </FONT>a<FONT STYLE="letter-spacing: 0.6pt"> </FONT>discount<FONT STYLE="letter-spacing: 0.55pt">
</FONT>below<FONT STYLE="letter-spacing: 0.6pt"> </FONT>their<FONT STYLE="letter-spacing: 0.6pt"> </FONT>stated<FONT STYLE="letter-spacing: 0.6pt">
</FONT>principal<FONT STYLE="letter-spacing: 0.6pt"> </FONT>amount.<FONT STYLE="letter-spacing: 0.4pt"> </FONT>These<FONT STYLE="letter-spacing: 0.55pt">
</FONT>debt<FONT STYLE="letter-spacing: 0.6pt"> </FONT>securities,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>as<FONT STYLE="letter-spacing: 0.6pt">
</FONT>well<FONT STYLE="letter-spacing: 0.6pt"> </FONT>as<FONT STYLE="letter-spacing: 0.6pt"> </FONT>other<FONT STYLE="letter-spacing: 0.55pt">
</FONT>debt securities<FONT STYLE="letter-spacing: 0.6pt"> </FONT>that<FONT STYLE="letter-spacing: 0.6pt"> </FONT>are<FONT STYLE="letter-spacing: 0.6pt">
</FONT>not<FONT STYLE="letter-spacing: 0.65pt"> </FONT>issued<FONT STYLE="letter-spacing: 0.6pt"> </FONT>at<FONT STYLE="letter-spacing: 0.6pt">
</FONT>a<FONT STYLE="letter-spacing: 0.6pt"> </FONT>discount,<FONT STYLE="letter-spacing: 0.65pt"> </FONT><FONT STYLE="letter-spacing: -0.25pt">may,
</FONT>for<FONT STYLE="letter-spacing: 0.6pt"> </FONT>U.S.<FONT STYLE="letter-spacing: 0.6pt"> </FONT>federal<FONT STYLE="letter-spacing: 0.65pt">
</FONT>income<FONT STYLE="letter-spacing: 0.6pt"> </FONT>tax<FONT STYLE="letter-spacing: 0.6pt"> </FONT>purposes,<FONT STYLE="letter-spacing: 0.6pt">
</FONT>be<FONT STYLE="letter-spacing: 0.65pt"> </FONT>treated<FONT STYLE="letter-spacing: 0.6pt"> </FONT>as<FONT STYLE="letter-spacing: 0.6pt">
</FONT>if<FONT STYLE="letter-spacing: 0.6pt"> </FONT>they<FONT STYLE="letter-spacing: 1.15pt"> </FONT>were<FONT STYLE="letter-spacing: 0.5pt">
</FONT>issued<FONT STYLE="letter-spacing: 0.5pt"> </FONT>with<FONT STYLE="letter-spacing: 0.55pt"> </FONT>&ldquo;original<FONT STYLE="letter-spacing: 0.5pt">
</FONT>issue<FONT STYLE="letter-spacing: 0.5pt"> </FONT>discount,&rdquo;<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.5pt">
</FONT>&ldquo;OID,&rdquo;<FONT STYLE="letter-spacing: 0.5pt"> </FONT>because<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.5pt">
</FONT>interest<FONT STYLE="letter-spacing: 0.55pt"> </FONT>payment<FONT STYLE="letter-spacing: 0.5pt"> </FONT>and<FONT STYLE="letter-spacing: 0.5pt">
</FONT>other<FONT STYLE="letter-spacing: 0.55pt"> </FONT>characteristics. Special<FONT STYLE="letter-spacing: 0.5pt"> </FONT>U.S.
federal<FONT STYLE="letter-spacing: 0.5pt"> </FONT>income<FONT STYLE="letter-spacing: 0.5pt"> </FONT>tax<FONT STYLE="letter-spacing: 0.55pt">
</FONT>considerations<FONT STYLE="letter-spacing: 0.5pt"> </FONT>applicable<FONT STYLE="letter-spacing: 0.5pt"> </FONT>to<FONT STYLE="letter-spacing: 0.5pt">
</FONT>debt<FONT STYLE="letter-spacing: 0.5pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.55pt"> </FONT>issued<FONT STYLE="letter-spacing: 0.5pt">
</FONT>with<FONT STYLE="letter-spacing: 0.5pt"> </FONT>original<FONT STYLE="letter-spacing: 0.5pt"> </FONT>issue<FONT STYLE="letter-spacing: 0.5pt">
</FONT>discount will<FONT STYLE="letter-spacing: 0.5pt"> </FONT>be<FONT STYLE="letter-spacing: 0.55pt"> </FONT>described<FONT STYLE="letter-spacing: 0.5pt">
</FONT>in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>more<FONT STYLE="letter-spacing: 0.55pt"> </FONT>detail<FONT STYLE="letter-spacing: 0.5pt">
</FONT>in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>any<FONT STYLE="letter-spacing: 0.55pt"> </FONT>applicable<FONT STYLE="letter-spacing: 0.5pt">
</FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt"> </FONT>supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>will<FONT STYLE="letter-spacing: 0.55pt"> </FONT>describe<FONT STYLE="letter-spacing: 0.6pt"> </FONT>in<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>applicable<FONT STYLE="letter-spacing: 0.55pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt">
</FONT>supplement<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>terms<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>series<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.6pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.55pt">
</FONT>being<FONT STYLE="letter-spacing: 1pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">offered,</FONT><FONT STYLE="letter-spacing: 0.05pt">
</FONT>including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">the
                                         title of the series of debt securities;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left"></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">any
                                         limit upon the aggregate principal amount that may be issued;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left"></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">the
                                         maturity date or dates;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left"></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">the
                                         form of the debt securities of the series;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left"></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">the
                                         applicability of any guarantees;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left"></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">whether
                                         or not the debt securities will be secured or unsecured, and the terms of any secured
                                         debt;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left"></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">whether
                                         the debt securities rank as senior debt, senior subordinated debt, subordinated debt
                                         or any combination thereof, and the terms of any subordination;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left"></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">if
                                         the price (expressed as a percentage of the aggregate principal amount thereof) at which
                                         such debt securities will be issued is a price other than the principal amount thereof,
                                         the portion of the principal amount thereof payable upon declaration of acceleration
                                         of the maturity thereof, or if applicable, the portion of the principal amount of such
                                         debt securities that is convertible into another security or the method by which any
                                         such portion shall be determined;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding: 0; text-indent: 0; text-align: left"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">the
                                         interest rate or rates, which may be fixed or variable, or the method for determining
                                         the rate and the date interest will begin to accrue, the dates interest will be payable
                                         and the regular record dates for interest payment dates or the method for determining
                                         such dates;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left"></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">our
                                         right, if any, to defer payment of interest and the maximum length of any such deferral
                                         period;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left"></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">if
                                         applicable, the date or dates after which, or the period or periods during which, and
                                         the price or prices at which, we may, at our option, redeem the series of debt securities
                                         pursuant to any optional or provisional redemption provisions and the terms of those
                                         redemption provisions;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left"></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">the
                                         date or dates, if any, on which, and the price or prices at which we are obligated, pursuant
                                         to any mandatory sinking fund or analogous fund provisions or otherwise, to redeem, or
                                         at the holder&rsquo;s option to purchase, the series of debt securities and the currency
                                         or currency unit in which the debt securities are payable;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left"></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">the
                                         denominations in which we will issue the series of debt securities, if other than denominations
                                         of $1,000, and any integral multiple thereof;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left"></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="text-align: left; padding: 0; text-indent: 0">any
                                         and all terms, if applicable, relating to any auction or remarketing of the debt securities
                                         of that series and any security for our obligations with respect to such debt securities
                                         and any other terms which may be advisable in connection with the marketing of debt securities
                                         of that series;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="text-align: left; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left"></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">whether
                                         the debt securities of the series shall be issued in whole or in part in the form of
                                         a global security or securities; the terms and conditions, if any, upon which such global
                                         security or securities may be exchanged in whole or in part for other individual securities;
                                         and the depositary for such global security or securities;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left"></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">if
                                         applicable, the provisions relating to conversion or exchange of any debt securities
                                         of the series and the terms and conditions upon which such debt securities will be so
                                         convertible or exchangeable, including the conversion or exchange price, as applicable,
                                         or how it will be calculated and may be adjusted, any mandatory or optional (at our option
                                         or the holders&rsquo; option) conversion or exchange features, the applicable conversion
                                         or exchange period and the manner of settlement for any conversion or exchange;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left"></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">if
                                         other than the full principal amount thereof, the portion of the principal amount of
                                         debt securities of the series which shall be payable upon declaration of acceleration
                                         of the maturity thereof;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left"></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">additions
                                         to or changes in the covenants applicable to the particular debt securities being issued,
                                         including, among others, the consolidation, merger or sale covenant;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left"></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="text-align: left; padding: 0; text-indent: 0">additions
                                         to or changes in the events of default with respect to the securities and any change
                                         in the right of the trustee or the holders to declare the principal, premium, if any,
                                         and interest, if any, with respect to such securities to be due and payable;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="text-align: left; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left"></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">additions
                                         to or changes in or deletions of the provisions relating to covenant defeasance and legal
                                         defeasance;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left"></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">additions
                                         to or changes in the provisions relating to satisfaction and discharge of the indenture;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left"></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">additions
                                         to or changes in the provisions relating to the modification of the indenture both with
                                         and without the consent of holders of debt securities issued under the indenture;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left"></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">the
                                         currency of payment of debt securities if other than U.S. dollars and the manner of determining
                                         the equivalent amount in U.S. dollars;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left"></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">whether
                                         interest will be payable in cash or additional debt securities at our or the holders&rsquo;
                                         option and the terms and conditions upon which the election may be made;</TD></TR></TABLE>



<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.3pt 0 0"></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.3pt 0 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0">the
                                         terms and conditions, if any, upon which we will pay amounts in addition to the stated
                                         interest, premium, if any, and principal amounts of the debt securities of the series
                                         to any holder that is not a &ldquo;United States person&rdquo; for federal tax purposes;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0"></TD><TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0">any
                                         restrictions on transfer, sale or assignment of the debt securities of the series; and</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0"></TD><TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="text-align: left; padding: 0; text-indent: 0">any
                                         other specific terms, preferences, rights or limitations of, or restrictions on, the
                                         debt securities, any other additions or changes in the provisions of the indenture, and
                                         any terms that may be required by us or advisable under applicable laws or regulations.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.3pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.3pt 0 0"><B>Conversion<FONT STYLE="letter-spacing: 0.35pt"> </FONT>or
Exchange<FONT STYLE="letter-spacing: 0.4pt"> </FONT>Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>will<FONT STYLE="letter-spacing: 0.6pt"> </FONT>set<FONT STYLE="letter-spacing: 0.6pt"> </FONT>forth<FONT STYLE="letter-spacing: 0.6pt">
</FONT>in<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.65pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.6pt">
</FONT>supplement<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>terms<FONT STYLE="letter-spacing: 0.6pt">
</FONT>on<FONT STYLE="letter-spacing: 0.6pt"> </FONT>which<FONT STYLE="letter-spacing: 0.65pt"> </FONT>a<FONT STYLE="letter-spacing: 0.6pt">
</FONT>series<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.6pt">
</FONT>securities<FONT STYLE="letter-spacing: 0.6pt"> </FONT>may<FONT STYLE="letter-spacing: 0.65pt"> </FONT>be<FONT STYLE="letter-spacing: 1pt">
</FONT>convertible<FONT STYLE="letter-spacing: 0.55pt"> </FONT>into<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt">
</FONT>exchangeable<FONT STYLE="letter-spacing: 0.55pt"> </FONT>for<FONT STYLE="letter-spacing: 0.55pt"> </FONT>our<FONT STYLE="letter-spacing: 0.55pt">
</FONT>common<FONT STYLE="letter-spacing: 0.6pt"> </FONT>stock<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt">
</FONT>our<FONT STYLE="letter-spacing: 0.55pt"> </FONT>other<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities.<FONT STYLE="letter-spacing: 0.4pt">
</FONT><FONT STYLE="letter-spacing: -0.45pt">We</FONT><FONT STYLE="letter-spacing: 0.55pt"> </FONT>will<FONT STYLE="letter-spacing: 0.55pt">
</FONT>include<FONT STYLE="letter-spacing: 0.55pt"> </FONT>provisions<FONT STYLE="letter-spacing: 0.55pt"> </FONT>as<FONT STYLE="letter-spacing: 1pt">
</FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>settlement<FONT STYLE="letter-spacing: 0.55pt"> </FONT>upon<FONT STYLE="letter-spacing: 0.5pt">
</FONT>conversion<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>exchange<FONT STYLE="letter-spacing: 0.55pt">
</FONT>and<FONT STYLE="letter-spacing: 0.55pt"> </FONT>whether<FONT STYLE="letter-spacing: 0.55pt"> </FONT>conversion<FONT STYLE="letter-spacing: 0.55pt">
</FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>exchange<FONT STYLE="letter-spacing: 0.55pt"> </FONT>is<FONT STYLE="letter-spacing: 0.55pt">
</FONT><FONT STYLE="letter-spacing: -0.1pt">mandatory,</FONT><FONT STYLE="letter-spacing: 0.55pt"> </FONT>at<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>option<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 1.35pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>holder<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt">
</FONT>at<FONT STYLE="letter-spacing: 0.6pt"> </FONT>our<FONT STYLE="letter-spacing: 0.6pt"> </FONT>option.<FONT STYLE="letter-spacing: 0.4pt">
</FONT><FONT STYLE="letter-spacing: -0.45pt">We</FONT><FONT STYLE="letter-spacing: 0.6pt"> </FONT>may<FONT STYLE="letter-spacing: 0.6pt">
</FONT>include<FONT STYLE="letter-spacing: 0.65pt"> </FONT>provisions<FONT STYLE="letter-spacing: 0.6pt"> </FONT>pursuant<FONT STYLE="letter-spacing: 0.6pt">
</FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>which<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>number<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>shares<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>our<FONT STYLE="letter-spacing: 1pt"> </FONT>common<FONT STYLE="letter-spacing: 0.55pt">
</FONT>stock<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>our<FONT STYLE="letter-spacing: 0.6pt">
</FONT>other<FONT STYLE="letter-spacing: 0.6pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.55pt"> </FONT>that<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>holders<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>series<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>debt<FONT STYLE="letter-spacing: 0.6pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.55pt"> </FONT>receive<FONT STYLE="letter-spacing: 0.6pt">
</FONT>would<FONT STYLE="letter-spacing: 0.6pt"> </FONT>be<FONT STYLE="letter-spacing: 0.55pt"> </FONT>subject to<FONT STYLE="letter-spacing: 0.25pt">
</FONT>adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; color: #231F20; text-align: left">Consolidation,
Merger<FONT STYLE="letter-spacing: 0.4pt"> </FONT>or<FONT STYLE="letter-spacing: 0.4pt"> </FONT>Sale</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Unless<FONT STYLE="letter-spacing: 0.5pt">
</FONT>we<FONT STYLE="letter-spacing: 0.55pt"> </FONT>provide<FONT STYLE="letter-spacing: 0.55pt"> </FONT>otherwise<FONT STYLE="letter-spacing: 0.55pt">
</FONT>in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt">
</FONT>supplement<FONT STYLE="letter-spacing: 0.55pt"> </FONT>applicable<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.5pt">
</FONT>a<FONT STYLE="letter-spacing: 0.55pt"> </FONT>particular<FONT STYLE="letter-spacing: 0.55pt"> </FONT>series<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>debt securities,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>indenture<FONT STYLE="letter-spacing: 0.55pt"> </FONT>will<FONT STYLE="letter-spacing: 0.6pt"> </FONT>not<FONT STYLE="letter-spacing: 0.55pt">
</FONT>contain<FONT STYLE="letter-spacing: 0.55pt"> </FONT>any<FONT STYLE="letter-spacing: 0.6pt"> </FONT>covenant<FONT STYLE="letter-spacing: 0.55pt">
</FONT>that<FONT STYLE="letter-spacing: 0.55pt"> </FONT>restricts<FONT STYLE="letter-spacing: 0.6pt"> </FONT>our<FONT STYLE="letter-spacing: 0.55pt">
</FONT>ability<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">merge
</FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>consolidate,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt">
</FONT>sell,<FONT STYLE="letter-spacing: 1.05pt"> </FONT><FONT STYLE="letter-spacing: -0.1pt">convey,</FONT><FONT STYLE="letter-spacing: 0.55pt">
</FONT>transfer<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>otherwise<FONT STYLE="letter-spacing: 0.55pt">
</FONT>dispose<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>our<FONT STYLE="letter-spacing: 0.55pt">
</FONT>assets<FONT STYLE="letter-spacing: 0.55pt"> </FONT>as<FONT STYLE="letter-spacing: 0.6pt"> </FONT>an<FONT STYLE="letter-spacing: 0.55pt">
</FONT>entirety<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>substantially<FONT STYLE="letter-spacing: 0.55pt">
</FONT>as<FONT STYLE="letter-spacing: 0.55pt"> </FONT>an<FONT STYLE="letter-spacing: 0.6pt"> </FONT><FONT STYLE="letter-spacing: -0.1pt">entirety.
</FONT><FONT STYLE="letter-spacing: -0.05pt">However,</FONT><FONT STYLE="letter-spacing: 0.55pt"> </FONT>any<FONT STYLE="letter-spacing: 1.35pt">
</FONT>successor<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt">
</FONT>acquirer<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>such<FONT STYLE="letter-spacing: 0.55pt">
</FONT>assets<FONT STYLE="letter-spacing: 0.6pt"> </FONT>(other<FONT STYLE="letter-spacing: 0.6pt"> </FONT>than<FONT STYLE="letter-spacing: 0.6pt">
</FONT>a<FONT STYLE="letter-spacing: 0.6pt"> </FONT>subsidiary<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>ours)<FONT STYLE="letter-spacing: 0.6pt"> </FONT>must<FONT STYLE="letter-spacing: 0.6pt"> </FONT>assume<FONT STYLE="letter-spacing: 0.6pt">
</FONT>all<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>our<FONT STYLE="letter-spacing: 0.6pt">
</FONT>obligations under<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>indenture
or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.5pt">
</FONT>securities,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>as<FONT STYLE="letter-spacing: 0.55pt"> </FONT>appropriate.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; color: #231F20; text-align: left">Events
of<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Default<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Under<FONT STYLE="letter-spacing: 0.5pt">
</FONT>the<FONT STYLE="letter-spacing: 0.5pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">Indenture</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Unless<FONT STYLE="letter-spacing: 0.5pt">
</FONT>we<FONT STYLE="letter-spacing: 0.55pt"> </FONT>provide<FONT STYLE="letter-spacing: 0.55pt"> </FONT>otherwise<FONT STYLE="letter-spacing: 0.55pt">
</FONT>in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt">
</FONT>supplement<FONT STYLE="letter-spacing: 0.55pt"> </FONT>applicable<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.5pt">
</FONT>a<FONT STYLE="letter-spacing: 0.55pt"> </FONT>particular<FONT STYLE="letter-spacing: 0.55pt"> </FONT>series<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>debt securities,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>following<FONT STYLE="letter-spacing: 0.6pt"> </FONT>are<FONT STYLE="letter-spacing: 0.55pt"> </FONT>events<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>default<FONT STYLE="letter-spacing: 0.55pt"> </FONT>under<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>indenture<FONT STYLE="letter-spacing: 0.55pt"> </FONT>with<FONT STYLE="letter-spacing: 0.6pt">
</FONT>respect<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>any<FONT STYLE="letter-spacing: 0.55pt">
</FONT>series<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.55pt">
</FONT>securities that<FONT STYLE="letter-spacing: 0.55pt"> </FONT>we<FONT STYLE="letter-spacing: 0.6pt"> </FONT>may<FONT STYLE="letter-spacing: 0.55pt">
</FONT>issue:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0">if
                                         we fail to pay any installment of interest on any debt securities of that series, as
                                         and when the same shall become due and payable, and such default continues for a period
                                         of 90 days; provided, however, that a valid extension of an interest payment period by
                                         us in accordance with the terms of any indenture supplemental thereto shall not constitute
                                         a default in the payment of interest for this purpose;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0"></TD><TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0">if
                                         we fail to pay the principal of (or premium, if any) on any debt securities of that series
                                         as and when the same shall become due and payable whether at maturity, upon redemption,
                                         by declaration or otherwise, or in any payment required by any sinking or analogous fund
                                         established with respect to that series; provided, however, that a valid extension of
                                         the maturity of such debt securities in accordance with the terms of any indenture supplemental
                                         thereto shall not constitute a default in the payment of principal or premium, if any;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0"></TD><TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0">if
                                         we fail to observe or perform any other covenant or agreement with respect to that series
                                         contained in the indenture or otherwise established with respect to that series pursuant
                                         to the indenture, other than a covenant or agreement specifically included solely for
                                         the benefit of one or more debt securities other than that series, and our failure continues
                                         for 90 days after we receive written notice of such failure, requiring the same to be
                                         remedied and stating that such is a notice of default thereunder, from the trustee or
                                         holders of at least 25% in aggregate principal amount of the outstanding debt securities
                                         of the applicable series; and</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0"></TD><TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0">if
                                         specified events of bankruptcy, insolvency or reorganization occur.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #231F20">If<FONT STYLE="letter-spacing: 0.6pt">
</FONT>an<FONT STYLE="letter-spacing: 0.6pt"> </FONT>event<FONT STYLE="letter-spacing: 0.65pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>default<FONT STYLE="letter-spacing: 0.65pt"> </FONT>with<FONT STYLE="letter-spacing: 0.6pt"> </FONT>respect<FONT STYLE="letter-spacing: 0.65pt">
</FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.65pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.65pt"> </FONT>any<FONT STYLE="letter-spacing: 0.6pt"> </FONT>series<FONT STYLE="letter-spacing: 0.65pt">
</FONT>occurs<FONT STYLE="letter-spacing: 0.6pt"> </FONT>and<FONT STYLE="letter-spacing: 0.65pt"> </FONT>is<FONT STYLE="letter-spacing: 0.6pt">
</FONT>continuing,<FONT STYLE="letter-spacing: 0.65pt"> </FONT>other<FONT STYLE="letter-spacing: 0.6pt"> </FONT>than<FONT STYLE="letter-spacing: 0.6pt">
</FONT>an event<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>default<FONT STYLE="letter-spacing: 0.6pt">
</FONT>described<FONT STYLE="letter-spacing: 0.65pt"> </FONT>in<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>last<FONT STYLE="letter-spacing: 0.65pt"> </FONT>bullet<FONT STYLE="letter-spacing: 0.6pt"> </FONT>point<FONT STYLE="letter-spacing: 0.6pt">
</FONT>above,<FONT STYLE="letter-spacing: 0.65pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>trustee<FONT STYLE="letter-spacing: 0.6pt">
</FONT>or<FONT STYLE="letter-spacing: 0.65pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>holders<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.65pt"> </FONT>at<FONT STYLE="letter-spacing: 0.6pt"> </FONT>least<FONT STYLE="letter-spacing: 0.6pt">
</FONT>25%<FONT STYLE="letter-spacing: 0.65pt"> </FONT>in<FONT STYLE="letter-spacing: 0.6pt"> </FONT>aggregate principal<FONT STYLE="letter-spacing: 0.55pt">
</FONT>amount<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>outstanding<FONT STYLE="letter-spacing: 0.6pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.6pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>that<FONT STYLE="letter-spacing: 0.6pt"> </FONT>series,<FONT STYLE="letter-spacing: 0.6pt">
</FONT>by<FONT STYLE="letter-spacing: 0.6pt"> </FONT>notice<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt">
</FONT>us<FONT STYLE="letter-spacing: 0.6pt"> </FONT>in<FONT STYLE="letter-spacing: 0.6pt"> </FONT>writing,<FONT STYLE="letter-spacing: 0.6pt">
</FONT>and<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>trustee if<FONT STYLE="letter-spacing: 0.55pt"> </FONT>notice<FONT STYLE="letter-spacing: 0.6pt"> </FONT>is<FONT STYLE="letter-spacing: 0.6pt">
</FONT>given<FONT STYLE="letter-spacing: 0.6pt"> </FONT>by<FONT STYLE="letter-spacing: 0.6pt"> </FONT>such<FONT STYLE="letter-spacing: 0.6pt">
</FONT>holders,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>may<FONT STYLE="letter-spacing: 0.6pt"> </FONT>declare<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>unpaid<FONT STYLE="letter-spacing: 0.6pt"> </FONT>principal<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>(premium,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>if<FONT STYLE="letter-spacing: 0.6pt">
</FONT>any)<FONT STYLE="letter-spacing: 0.6pt"> </FONT>and<FONT STYLE="letter-spacing: 0.6pt"> </FONT>accrued<FONT STYLE="letter-spacing: 0.6pt">
</FONT>and unpaid<FONT STYLE="letter-spacing: 0.55pt"> </FONT>interest,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>if<FONT STYLE="letter-spacing: 0.55pt">
</FONT><FONT STYLE="letter-spacing: -0.25pt">any,</FONT><FONT STYLE="letter-spacing: 0.6pt"> </FONT>due<FONT STYLE="letter-spacing: 0.55pt">
</FONT>and<FONT STYLE="letter-spacing: 0.6pt"> </FONT>payable<FONT STYLE="letter-spacing: 0.6pt"> </FONT><FONT STYLE="letter-spacing: -0.1pt">immediately.
</FONT>If<FONT STYLE="letter-spacing: 0.6pt"> </FONT>an<FONT STYLE="letter-spacing: 0.55pt"> </FONT>event<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>default<FONT STYLE="letter-spacing: 0.6pt"> </FONT>specified<FONT STYLE="letter-spacing: 0.6pt">
</FONT>in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>last<FONT STYLE="letter-spacing: 0.55pt">
</FONT>bullet<FONT STYLE="letter-spacing: 0.6pt"> </FONT>point<FONT STYLE="letter-spacing: 1.45pt"> </FONT>above<FONT STYLE="letter-spacing: 0.6pt">
</FONT>occurs<FONT STYLE="letter-spacing: 0.6pt"> </FONT>with<FONT STYLE="letter-spacing: 0.6pt"> </FONT>respect<FONT STYLE="letter-spacing: 0.65pt">
</FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>us,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>principal<FONT STYLE="letter-spacing: 0.65pt"> </FONT>amount<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>and<FONT STYLE="letter-spacing: 0.6pt"> </FONT>accrued<FONT STYLE="letter-spacing: 0.65pt"> </FONT>interest,<FONT STYLE="letter-spacing: 0.6pt">
</FONT>if<FONT STYLE="letter-spacing: 0.6pt"> </FONT><FONT STYLE="letter-spacing: -0.25pt">any,</FONT><FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.65pt"> </FONT>that<FONT STYLE="letter-spacing: 0.6pt"> </FONT>series<FONT STYLE="letter-spacing: 0.6pt">
</FONT>shall<FONT STYLE="letter-spacing: 0.6pt"> </FONT>be<FONT STYLE="letter-spacing: 1.15pt"> </FONT>automatically<FONT STYLE="letter-spacing: 0.55pt">
</FONT>due<FONT STYLE="letter-spacing: 0.6pt"> </FONT>and<FONT STYLE="letter-spacing: 0.55pt"> </FONT>payable<FONT STYLE="letter-spacing: 0.6pt">
</FONT>without<FONT STYLE="letter-spacing: 0.6pt"> </FONT>any<FONT STYLE="letter-spacing: 0.55pt"> </FONT>declaration<FONT STYLE="letter-spacing: 0.6pt">
</FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>other<FONT STYLE="letter-spacing: 0.55pt"> </FONT>action<FONT STYLE="letter-spacing: 0.6pt">
</FONT>on<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>part<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>trustee<FONT STYLE="letter-spacing: 0.6pt">
</FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>any<FONT STYLE="letter-spacing: 0.6pt"> </FONT><FONT STYLE="letter-spacing: -0.1pt">holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">The<FONT STYLE="letter-spacing: 0.55pt">
</FONT>holders<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>a<FONT STYLE="letter-spacing: 0.6pt">
</FONT>majority<FONT STYLE="letter-spacing: 0.55pt"> </FONT>in<FONT STYLE="letter-spacing: 0.6pt"> </FONT>principal<FONT STYLE="letter-spacing: 0.55pt">
</FONT>amount<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>outstanding<FONT STYLE="letter-spacing: 0.6pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>an<FONT STYLE="letter-spacing: 0.6pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">affected
</FONT>series<FONT STYLE="letter-spacing: 0.55pt"> </FONT>may<FONT STYLE="letter-spacing: 1.2pt"> </FONT>waive<FONT STYLE="letter-spacing: 0.55pt">
</FONT>any<FONT STYLE="letter-spacing: 0.6pt"> </FONT>default<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt">
</FONT>event<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>default<FONT STYLE="letter-spacing: 0.6pt">
</FONT>with<FONT STYLE="letter-spacing: 0.55pt"> </FONT>respect<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>series<FONT STYLE="letter-spacing: 0.6pt"> </FONT>and<FONT STYLE="letter-spacing: 0.6pt">
</FONT>its<FONT STYLE="letter-spacing: 0.55pt"> </FONT>consequences,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>except<FONT STYLE="letter-spacing: 0.55pt">
</FONT>defaults<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>events of<FONT STYLE="letter-spacing: 0.55pt">
</FONT>default<FONT STYLE="letter-spacing: 0.6pt"> </FONT>regarding<FONT STYLE="letter-spacing: 0.6pt"> </FONT>payment<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>principal,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>premium,<FONT STYLE="letter-spacing: 0.6pt">
</FONT>if<FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.25pt">any,</FONT><FONT STYLE="letter-spacing: 0.6pt">
</FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>interest,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>unless<FONT STYLE="letter-spacing: 0.55pt">
</FONT>we<FONT STYLE="letter-spacing: 0.6pt"> </FONT>have<FONT STYLE="letter-spacing: 0.6pt"> </FONT>cured<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>default<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 1.15pt">
</FONT>event<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>default<FONT STYLE="letter-spacing: 0.55pt">
</FONT>in<FONT STYLE="letter-spacing: 0.6pt"> </FONT>accordance<FONT STYLE="letter-spacing: 0.6pt"> </FONT>with<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>indenture.<FONT STYLE="letter-spacing: 0.05pt"> </FONT>Any<FONT STYLE="letter-spacing: 0.6pt">
</FONT>waiver<FONT STYLE="letter-spacing: 0.55pt"> </FONT>shall<FONT STYLE="letter-spacing: 0.6pt"> </FONT>cure<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>default<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt">
</FONT>event<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Subject<FONT STYLE="letter-spacing: 0.6pt">
</FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>terms<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.65pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>indenture,<FONT STYLE="letter-spacing: 0.6pt">
</FONT>if<FONT STYLE="letter-spacing: 0.6pt"> </FONT>an<FONT STYLE="letter-spacing: 0.6pt"> </FONT>event<FONT STYLE="letter-spacing: 0.65pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>default<FONT STYLE="letter-spacing: 0.6pt"> </FONT>under<FONT STYLE="letter-spacing: 0.6pt">
</FONT>an<FONT STYLE="letter-spacing: 0.6pt"> </FONT>indenture<FONT STYLE="letter-spacing: 0.65pt"> </FONT>shall<FONT STYLE="letter-spacing: 0.6pt">
</FONT>occur<FONT STYLE="letter-spacing: 0.6pt"> </FONT>and<FONT STYLE="letter-spacing: 0.6pt"> </FONT>be continuing,<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>trustee<FONT STYLE="letter-spacing: 0.55pt"> </FONT>will<FONT STYLE="letter-spacing: 0.6pt">
</FONT>be<FONT STYLE="letter-spacing: 0.6pt"> </FONT>under<FONT STYLE="letter-spacing: 0.55pt"> </FONT>no<FONT STYLE="letter-spacing: 0.6pt">
</FONT>obligation<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>exercise<FONT STYLE="letter-spacing: 0.6pt">
</FONT>any<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>its<FONT STYLE="letter-spacing: 0.6pt">
</FONT>rights<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>powers<FONT STYLE="letter-spacing: 0.55pt">
</FONT>under<FONT STYLE="letter-spacing: 0.6pt"> </FONT>such<FONT STYLE="letter-spacing: 0.6pt"> </FONT>indenture at<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>request<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt">
</FONT>direction<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>any<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>holders<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>applicable<FONT STYLE="letter-spacing: 0.55pt">
</FONT>series<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.6pt">
</FONT>securities,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>unless<FONT STYLE="letter-spacing: 0.6pt"> </FONT>such<FONT STYLE="letter-spacing: 0.6pt">
</FONT>holders have<FONT STYLE="letter-spacing: 0.5pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">offered</FONT><FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>trustee<FONT STYLE="letter-spacing: 0.55pt"> </FONT>reasonable<FONT STYLE="letter-spacing: 0.55pt">
</FONT><FONT STYLE="letter-spacing: -0.1pt">indemnity.</FONT><FONT STYLE="letter-spacing: 0.35pt"> </FONT>The<FONT STYLE="letter-spacing: 0.55pt">
</FONT>holders<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.5pt"> </FONT>a<FONT STYLE="letter-spacing: 0.55pt">
</FONT>majority<FONT STYLE="letter-spacing: 0.55pt"> </FONT>in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>principal<FONT STYLE="letter-spacing: 0.55pt">
</FONT>amount<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: -0.2pt">
</FONT>outstanding<FONT STYLE="letter-spacing: 1.85pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>any<FONT STYLE="letter-spacing: 0.6pt"> </FONT>series<FONT STYLE="letter-spacing: 0.6pt">
</FONT>will<FONT STYLE="letter-spacing: 0.6pt"> </FONT>have<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>right<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>direct<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>time,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>method<FONT STYLE="letter-spacing: 0.55pt">
</FONT>and<FONT STYLE="letter-spacing: 0.6pt"> </FONT>place<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>conducting<FONT STYLE="letter-spacing: -0.15pt"> </FONT>any<FONT STYLE="letter-spacing: 0.8pt"> </FONT>proceeding<FONT STYLE="letter-spacing: 0.55pt">
</FONT>for<FONT STYLE="letter-spacing: 0.55pt"> </FONT>any<FONT STYLE="letter-spacing: 0.6pt"> </FONT>remedy<FONT STYLE="letter-spacing: 0.55pt">
</FONT>available<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>trustee,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>exercising<FONT STYLE="letter-spacing: 0.55pt">
</FONT>any<FONT STYLE="letter-spacing: 0.55pt"> </FONT>trust<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt">
</FONT>power<FONT STYLE="letter-spacing: 0.55pt"> </FONT>conferred<FONT STYLE="letter-spacing: 0.6pt"> </FONT>on<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: -0.2pt"> </FONT>trustee,<FONT STYLE="letter-spacing: 0.8pt"> </FONT>with<FONT STYLE="letter-spacing: 0.55pt">
</FONT>respect<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>debt<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt">
</FONT>that<FONT STYLE="letter-spacing: 0.6pt"> </FONT>series,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>provided<FONT STYLE="letter-spacing: 0.6pt">
</FONT>that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0">the
                                         direction so given by the holder is not in conflict with any law or the applicable indenture;
                                         and</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0"></TD><TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0">subject
                                         to its duties under the Trust Indenture Act, the trustee need not take any action that
                                         might involve it in personal liability or might be unduly prejudicial to the holders
                                         not involved in the proceeding.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">A<FONT STYLE="letter-spacing: 0.05pt">
</FONT>holder<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.65pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>debt<FONT STYLE="letter-spacing: 0.6pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>any<FONT STYLE="letter-spacing: 0.6pt"> </FONT>series<FONT STYLE="letter-spacing: 0.65pt"> </FONT>will<FONT STYLE="letter-spacing: 0.6pt">
</FONT>have<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>right<FONT STYLE="letter-spacing: 0.6pt">
</FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>institute<FONT STYLE="letter-spacing: 0.6pt"> </FONT>a<FONT STYLE="letter-spacing: 0.65pt">
</FONT>proceeding<FONT STYLE="letter-spacing: 0.6pt"> </FONT>under<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the indenture<FONT STYLE="letter-spacing: 0.6pt">
</FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>appoint<FONT STYLE="letter-spacing: 0.6pt">
</FONT>a<FONT STYLE="letter-spacing: 0.6pt"> </FONT>receiver<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt">
</FONT>trustee,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.6pt">
</FONT>seek<FONT STYLE="letter-spacing: 0.6pt"> </FONT>other<FONT STYLE="letter-spacing: 0.6pt"> </FONT>remedies<FONT STYLE="letter-spacing: 0.6pt">
</FONT>only<FONT STYLE="letter-spacing: 0.6pt"> </FONT>if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding: 0; text-indent: 0; text-align: left"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">the
                                         holder has given written notice to the trustee of a continuing event of default with
                                         respect to that series;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left"></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">the
                                         holders of at least 25% in aggregate principal amount of the outstanding debt securities
                                         of that series have made written request;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left"></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">such
                                         holders have offered to the trustee indemnity satisfactory to it against the costs, expenses
                                         and liabilities to be incurred by the trustee in compliance with the request; and</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left"></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">the
                                         trustee does not institute the proceeding, and does not receive from the holders of a
                                         majority in aggregate principal amount of the outstanding debt securities of that series
                                         other inconsistent directions within 90 days after the notice, request and offer.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20; text-align: left">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">These<FONT STYLE="letter-spacing: 0.6pt">
</FONT>limitations<FONT STYLE="letter-spacing: 0.6pt"> </FONT>do<FONT STYLE="letter-spacing: 0.65pt"> </FONT>not<FONT STYLE="letter-spacing: 0.6pt">
</FONT>apply<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.65pt"> </FONT>a<FONT STYLE="letter-spacing: 0.6pt">
</FONT>suit<FONT STYLE="letter-spacing: 0.65pt"> </FONT>instituted<FONT STYLE="letter-spacing: 0.6pt"> </FONT>by<FONT STYLE="letter-spacing: 0.6pt">
</FONT>a<FONT STYLE="letter-spacing: 0.65pt"> </FONT>holder<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>debt<FONT STYLE="letter-spacing: 0.65pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.6pt"> </FONT>if<FONT STYLE="letter-spacing: 0.65pt">
</FONT>we<FONT STYLE="letter-spacing: 0.6pt"> </FONT>default<FONT STYLE="letter-spacing: 0.6pt"> </FONT>in<FONT STYLE="letter-spacing: 0.65pt">
</FONT>the payment<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>principal,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>premium,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>if<FONT STYLE="letter-spacing: 0.6pt">
</FONT><FONT STYLE="letter-spacing: -0.25pt">any,</FONT><FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt">
</FONT>interest<FONT STYLE="letter-spacing: 0.55pt"> </FONT>on,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>debt<FONT STYLE="letter-spacing: 0.6pt"> </FONT>securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>will<FONT STYLE="letter-spacing: 0.45pt"> </FONT>periodically<FONT STYLE="letter-spacing: 0.45pt"> </FONT>file<FONT STYLE="letter-spacing: 0.5pt">
</FONT>statements<FONT STYLE="letter-spacing: 0.45pt"> </FONT>with<FONT STYLE="letter-spacing: 0.45pt"> </FONT>the<FONT STYLE="letter-spacing: 0.5pt">
</FONT>trustee<FONT STYLE="letter-spacing: 0.45pt"> </FONT>regarding<FONT STYLE="letter-spacing: 0.45pt"> </FONT>our<FONT STYLE="letter-spacing: 0.5pt">
</FONT>compliance<FONT STYLE="letter-spacing: 0.45pt"> </FONT>with<FONT STYLE="letter-spacing: 0.45pt"> </FONT>specified<FONT STYLE="letter-spacing: 0.5pt">
</FONT>covenants<FONT STYLE="letter-spacing: 0.45pt"> </FONT>in<FONT STYLE="letter-spacing: 1pt"> </FONT>the<FONT STYLE="letter-spacing: 0.25pt">
</FONT>indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; color: #231F20; text-align: left">Modification
of<FONT STYLE="letter-spacing: 0.15pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">Indenture;</FONT><FONT STYLE="letter-spacing: 0.15pt">
</FONT><FONT STYLE="letter-spacing: -0.1pt">Waiver</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>and<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>trustee<FONT STYLE="letter-spacing: 0.55pt">
</FONT>may<FONT STYLE="letter-spacing: 0.55pt"> </FONT>change<FONT STYLE="letter-spacing: 0.6pt"> </FONT>an<FONT STYLE="letter-spacing: 0.55pt">
</FONT>indenture<FONT STYLE="letter-spacing: 0.6pt"> </FONT>without<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>consent<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>any<FONT STYLE="letter-spacing: 0.6pt">
</FONT>holders<FONT STYLE="letter-spacing: 0.55pt"> </FONT>with<FONT STYLE="letter-spacing: 0.55pt"> </FONT>respect<FONT STYLE="letter-spacing: 0.6pt">
</FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>specific<FONT STYLE="letter-spacing: 1pt"> </FONT>matters:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0">to
                                         cure any ambiguity, defect or inconsistency in the indenture or in the debt securities
                                         of any series;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0"></TD><TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0">to
                                         comply with the provisions described above under &ldquo;Description of Debt Securities&mdash;Consolidation,
                                         Merger or Sale;&rdquo;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0"></TD><TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0">to
                                         provide for uncertificated debt securities in addition to or in place of certificated
                                         debt securities;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0"></TD><TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0">to
                                         add to our covenants, restrictions, conditions or provisions such new covenants, restrictions,
                                         conditions or provisions for the benefit of the holders of all or any series of debt
                                         securities, to make the occurrence, or the occurrence and the continuance, of a default
                                         in any such additional covenants, restrictions, conditions or provisions an event of
                                         default or to surrender any right or power conferred upon us in the indenture;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">to
                                         add to, delete from or revise the conditions, limitations, and restrictions on the authorized
                                         amount, terms, or purposes of issue, authentication and delivery of debt securities,
                                         as set forth in the indenture;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left"></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">to
                                         make any change that does not adversely affect the interests of any holder of debt securities
                                         of any series in any material respect;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left"></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">to
                                         provide for the issuance of and establish the form and terms and conditions of the debt
                                         securities of any series as provided above under &ldquo;Description of Debt Securities&mdash;General&rdquo;
                                         to establish the form of any certifications required to be furnished pursuant to the
                                         terms of the indenture or any series of debt securities, or to add to the rights of the
                                         holders of any series of debt securities;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left"></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">to
                                         evidence and provide for the acceptance of appointment under any indenture by a successor
                                         trustee; or</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0; text-align: left"></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; text-align: left">to
                                         comply with any requirements of the SEC in connection with the qualification of any indenture
                                         under the Trust Indenture Act.</TD></TR></TABLE>



<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left"></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">In<FONT STYLE="letter-spacing: 0.6pt">
</FONT>addition,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>under<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>indenture,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>rights<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>holders<FONT STYLE="letter-spacing: 0.65pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>a<FONT STYLE="letter-spacing: 0.6pt"> </FONT>series<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>debt<FONT STYLE="letter-spacing: 0.6pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.6pt"> </FONT>may<FONT STYLE="letter-spacing: 0.6pt">
</FONT>be<FONT STYLE="letter-spacing: 0.6pt"> </FONT>changed<FONT STYLE="letter-spacing: 0.65pt"> </FONT>by<FONT STYLE="letter-spacing: 0.6pt">
</FONT>us and<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>trustee<FONT STYLE="letter-spacing: 0.6pt">
</FONT>with<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>written<FONT STYLE="letter-spacing: 0.6pt">
</FONT>consent<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>holders<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>at<FONT STYLE="letter-spacing: 0.6pt">
</FONT>least<FONT STYLE="letter-spacing: 0.6pt"> </FONT>a<FONT STYLE="letter-spacing: 0.6pt"> </FONT>majority<FONT STYLE="letter-spacing: 0.6pt">
</FONT>in<FONT STYLE="letter-spacing: 0.6pt"> </FONT>aggregate<FONT STYLE="letter-spacing: 0.6pt"> </FONT>principal<FONT STYLE="letter-spacing: 0.6pt">
</FONT>amount<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>outstanding<FONT STYLE="letter-spacing: 0.55pt">
</FONT>debt<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt">
</FONT>each<FONT STYLE="letter-spacing: 0.6pt"> </FONT>series<FONT STYLE="letter-spacing: 0.55pt"> </FONT>that<FONT STYLE="letter-spacing: 0.55pt">
</FONT>is<FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">affected.</FONT><FONT STYLE="letter-spacing: 0.55pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">However,</FONT><FONT STYLE="letter-spacing: 0.6pt"> </FONT>unless<FONT STYLE="letter-spacing: 0.55pt">
</FONT>we<FONT STYLE="letter-spacing: 0.55pt"> </FONT>provide<FONT STYLE="letter-spacing: 0.55pt"> </FONT>otherwise<FONT STYLE="letter-spacing: 0.55pt">
</FONT>in<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 1.3pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt">
</FONT>supplement<FONT STYLE="letter-spacing: 0.55pt"> </FONT>applicable<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt">
</FONT>a<FONT STYLE="letter-spacing: 0.55pt"> </FONT>particular<FONT STYLE="letter-spacing: 0.6pt"> </FONT>series<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities,<FONT STYLE="letter-spacing: 0.55pt">
</FONT>we<FONT STYLE="letter-spacing: 0.6pt"> </FONT>and<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>trustee<FONT STYLE="letter-spacing: 0.55pt"> </FONT>may<FONT STYLE="letter-spacing: 0.55pt"> </FONT>make<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the following<FONT STYLE="letter-spacing: 0.5pt"> </FONT>changes<FONT STYLE="letter-spacing: 0.55pt"> </FONT>only<FONT STYLE="letter-spacing: 0.55pt">
</FONT>with<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>consent<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.5pt"> </FONT>each<FONT STYLE="letter-spacing: 0.55pt"> </FONT>holder<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>any<FONT STYLE="letter-spacing: 0.55pt"> </FONT>outstanding<FONT STYLE="letter-spacing: 0.55pt">
</FONT>debt<FONT STYLE="letter-spacing: 0.5pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">affected:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="letter-spacing: -0.05pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0">extending
                                         the fixed maturity of any debt securities of any series;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0"></TD><TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0">reducing
                                         the principal amount, reducing the rate of or extending the time of payment of interest,
                                         or reducing any premium payable upon the redemption of any series of any debt securities;
                                         or</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0"></TD><TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding: 0; text-indent: 0">reducing
                                         the percentage of debt securities, the holders of which are required to consent to any
                                         amendment, supplement, modification or waiver.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="letter-spacing: -0.05pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; color: #231F20; text-align: left">Discharge</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Each<FONT STYLE="letter-spacing: 0.55pt">
</FONT>indenture<FONT STYLE="letter-spacing: 0.6pt"> </FONT>provides<FONT STYLE="letter-spacing: 0.6pt"> </FONT>that<FONT STYLE="letter-spacing: 0.55pt">
</FONT>we<FONT STYLE="letter-spacing: 0.6pt"> </FONT>can<FONT STYLE="letter-spacing: 0.6pt"> </FONT>elect<FONT STYLE="letter-spacing: 0.55pt">
</FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>be<FONT STYLE="letter-spacing: 0.6pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">discharged
</FONT>from<FONT STYLE="letter-spacing: 0.6pt"> </FONT>our<FONT STYLE="letter-spacing: 0.6pt"> </FONT>obligations<FONT STYLE="letter-spacing: 0.6pt">
</FONT>with<FONT STYLE="letter-spacing: 0.55pt"> </FONT>respect<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.6pt">
</FONT>one<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 1.3pt"> </FONT>more<FONT STYLE="letter-spacing: 0.45pt">
</FONT>series<FONT STYLE="letter-spacing: 0.45pt"> </FONT>of<FONT STYLE="letter-spacing: 0.5pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.45pt">
</FONT>securities,<FONT STYLE="letter-spacing: 0.5pt"> </FONT>except<FONT STYLE="letter-spacing: 0.45pt"> </FONT>for<FONT STYLE="letter-spacing: 0.5pt">
</FONT>specified<FONT STYLE="letter-spacing: 0.45pt"> </FONT>obligations,<FONT STYLE="letter-spacing: 0.5pt"> </FONT>including
obligations<FONT STYLE="letter-spacing: 0.5pt"> </FONT>to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD>provide
                                         for payment;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD>register the transfer or exchange of debt
                                         securities of the series;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD>replace stolen, lost or mutilated debt
                                         securities of the series;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD>pay principal of and premium and interest
                                         on any debt securities of the series;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD>maintain paying agencies;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD>hold monies for payment in trust;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD>recover excess money held by the trustee;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD>compensate and indemnify the trustee; and</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD>appoint any successor trustee.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">In<FONT STYLE="letter-spacing: 0.55pt">
</FONT>order<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>exercise<FONT STYLE="letter-spacing: 0.6pt">
</FONT>our<FONT STYLE="letter-spacing: 0.6pt"> </FONT>rights<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.6pt">
</FONT>be<FONT STYLE="letter-spacing: 0.6pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">discharged,</FONT><FONT STYLE="letter-spacing: 0.55pt">
</FONT>we<FONT STYLE="letter-spacing: 0.6pt"> </FONT>must<FONT STYLE="letter-spacing: 0.6pt"> </FONT>deposit<FONT STYLE="letter-spacing: 0.55pt">
</FONT>with<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>trustee<FONT STYLE="letter-spacing: 0.55pt">
</FONT>money<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>government<FONT STYLE="letter-spacing: 1.35pt">
</FONT>obligations<FONT STYLE="letter-spacing: 0.55pt"> </FONT>sufficient<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.6pt">
</FONT>pay<FONT STYLE="letter-spacing: 0.55pt"> </FONT>all<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>principal<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>any<FONT STYLE="letter-spacing: 0.6pt">
</FONT>premium,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>if<FONT STYLE="letter-spacing: 0.6pt"> </FONT><FONT STYLE="letter-spacing: -0.25pt">any,
</FONT>and<FONT STYLE="letter-spacing: 0.55pt"> </FONT>interest<FONT STYLE="letter-spacing: 0.6pt"> </FONT>on,<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.6pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 1.15pt"> </FONT>series<FONT STYLE="letter-spacing: 0.55pt">
</FONT>on<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>dates<FONT STYLE="letter-spacing: 0.6pt">
</FONT>payments<FONT STYLE="letter-spacing: 0.55pt"> </FONT>are<FONT STYLE="letter-spacing: 0.6pt"> </FONT>due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; color: #231F20; text-align: left">Form,
Exchange<FONT STYLE="letter-spacing: 0.4pt"> </FONT>and<FONT STYLE="letter-spacing: 0.4pt"> </FONT><FONT STYLE="letter-spacing: -0.1pt">Transfer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>will<FONT STYLE="letter-spacing: 0.6pt"> </FONT>issue<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>debt<FONT STYLE="letter-spacing: 0.6pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt">
</FONT>each<FONT STYLE="letter-spacing: 0.6pt"> </FONT>series<FONT STYLE="letter-spacing: 0.6pt"> </FONT>only<FONT STYLE="letter-spacing: 0.6pt">
</FONT>in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>fully<FONT STYLE="letter-spacing: 0.6pt"> </FONT>registered<FONT STYLE="letter-spacing: 0.6pt">
</FONT>form<FONT STYLE="letter-spacing: 0.55pt"> </FONT>without<FONT STYLE="letter-spacing: 0.6pt"> </FONT>coupons<FONT STYLE="letter-spacing: 0.6pt">
</FONT>and,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>unless<FONT STYLE="letter-spacing: 1pt"> </FONT>we<FONT STYLE="letter-spacing: 0.5pt">
</FONT>provide<FONT STYLE="letter-spacing: 0.5pt"> </FONT>otherwise<FONT STYLE="letter-spacing: 0.55pt"> </FONT>in<FONT STYLE="letter-spacing: 0.5pt">
</FONT>the<FONT STYLE="letter-spacing: 0.5pt"> </FONT>applicable<FONT STYLE="letter-spacing: 0.55pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.5pt">
</FONT>supplement,<FONT STYLE="letter-spacing: 0.5pt"> </FONT>in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>denominations<FONT STYLE="letter-spacing: 0.5pt">
</FONT>of<FONT STYLE="letter-spacing: 0.5pt"> </FONT>$1,000<FONT STYLE="letter-spacing: 0.55pt"> </FONT>and<FONT STYLE="letter-spacing: 0.5pt">
</FONT>any<FONT STYLE="letter-spacing: 0.5pt"> </FONT>integral multiple<FONT STYLE="letter-spacing: 0.55pt"> </FONT>thereof.<FONT STYLE="letter-spacing: 0.4pt">
</FONT>The<FONT STYLE="letter-spacing: 0.55pt"> </FONT>indenture<FONT STYLE="letter-spacing: 0.6pt"> </FONT>provides<FONT STYLE="letter-spacing: 0.55pt">
</FONT>that<FONT STYLE="letter-spacing: 0.55pt"> </FONT>we<FONT STYLE="letter-spacing: 0.6pt"> </FONT>may<FONT STYLE="letter-spacing: 0.55pt">
</FONT>issue<FONT STYLE="letter-spacing: 0.6pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>a<FONT STYLE="letter-spacing: 0.55pt"> </FONT>series<FONT STYLE="letter-spacing: 0.6pt">
</FONT>in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>temporary<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or permanent<FONT STYLE="letter-spacing: 0.55pt">
</FONT>global<FONT STYLE="letter-spacing: 0.6pt"> </FONT>form<FONT STYLE="letter-spacing: 0.55pt"> </FONT>and<FONT STYLE="letter-spacing: 0.55pt">
</FONT>as<FONT STYLE="letter-spacing: 0.6pt"> </FONT>book-entry<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.6pt">
</FONT>that<FONT STYLE="letter-spacing: 0.55pt"> </FONT>will<FONT STYLE="letter-spacing: 0.6pt"> </FONT>be<FONT STYLE="letter-spacing: 0.55pt">
</FONT>deposited<FONT STYLE="letter-spacing: 0.6pt"> </FONT>with,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt">
</FONT>on<FONT STYLE="letter-spacing: 0.55pt"> </FONT>behalf<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of,<FONT STYLE="letter-spacing: 0.4pt">
</FONT>The Depository<FONT STYLE="letter-spacing: 0.3pt"> </FONT><FONT STYLE="letter-spacing: -0.1pt">Trust</FONT><FONT STYLE="letter-spacing: 0.55pt">
</FONT><FONT STYLE="letter-spacing: -0.1pt">Company,</FONT><FONT STYLE="letter-spacing: 0.5pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt">
</FONT>DTC,<FONT STYLE="letter-spacing: 0.5pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>another<FONT STYLE="letter-spacing: 0.5pt">
</FONT>depositary<FONT STYLE="letter-spacing: 0.55pt"> </FONT>named<FONT STYLE="letter-spacing: 0.55pt"> </FONT>by<FONT STYLE="letter-spacing: 0.5pt">
</FONT>us<FONT STYLE="letter-spacing: 0.55pt"> </FONT>and<FONT STYLE="letter-spacing: 0.5pt"> </FONT>identified<FONT STYLE="letter-spacing: 0.55pt">
</FONT>in<FONT STYLE="letter-spacing: 0.5pt"> </FONT>a<FONT STYLE="letter-spacing: 0.55pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 1.3pt">
</FONT>supplement<FONT STYLE="letter-spacing: 0.6pt"> </FONT>with<FONT STYLE="letter-spacing: 0.6pt"> </FONT>respect<FONT STYLE="letter-spacing: 0.6pt">
</FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>that<FONT STYLE="letter-spacing: 0.6pt"> </FONT>series.<FONT STYLE="letter-spacing: 0.4pt">
</FONT><FONT STYLE="letter-spacing: -0.4pt">To</FONT><FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>extent<FONT STYLE="letter-spacing: 0.65pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.6pt">
</FONT>securities<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>a<FONT STYLE="letter-spacing: 0.6pt">
</FONT>series<FONT STYLE="letter-spacing: 0.6pt"> </FONT>are<FONT STYLE="letter-spacing: 0.6pt"> </FONT>issued<FONT STYLE="letter-spacing: 0.6pt">
</FONT>in<FONT STYLE="letter-spacing: 0.6pt"> </FONT>global<FONT STYLE="letter-spacing: 0.6pt"> </FONT>form<FONT STYLE="letter-spacing: 1pt">
</FONT>and<FONT STYLE="letter-spacing: 0.55pt"> </FONT>as<FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.1pt">book-entry,
</FONT>a<FONT STYLE="letter-spacing: 0.55pt"> </FONT>description<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt">
</FONT>terms<FONT STYLE="letter-spacing: 0.6pt"> </FONT>relating<FONT STYLE="letter-spacing: 0.55pt"> </FONT>will<FONT STYLE="letter-spacing: 0.55pt">
</FONT>be<FONT STYLE="letter-spacing: 0.55pt"> </FONT>set<FONT STYLE="letter-spacing: 0.55pt"> </FONT>forth<FONT STYLE="letter-spacing: 0.55pt">
</FONT>in<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>applicable<FONT STYLE="letter-spacing: 0.55pt">
</FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt"> </FONT>supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">At<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>option<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT><FONT STYLE="letter-spacing: -0.1pt">holder,</FONT><FONT STYLE="letter-spacing: 0.6pt">
</FONT>subject<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>terms<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>indenture<FONT STYLE="letter-spacing: 0.6pt"> </FONT>and<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>limitations<FONT STYLE="letter-spacing: 0.6pt"> </FONT>applicable<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.6pt">
</FONT>global<FONT STYLE="letter-spacing: 1.3pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.55pt"> </FONT>described<FONT STYLE="letter-spacing: 0.5pt">
</FONT>in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>applicable<FONT STYLE="letter-spacing: 0.55pt">
</FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt"> </FONT>supplement,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>holder<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>debt<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt">
</FONT>any<FONT STYLE="letter-spacing: 0.55pt"> </FONT>series<FONT STYLE="letter-spacing: 0.55pt"> </FONT>can exchange<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.55pt">
</FONT>for<FONT STYLE="letter-spacing: 0.6pt"> </FONT>other<FONT STYLE="letter-spacing: 0.55pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.55pt">
</FONT>securities<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>same<FONT STYLE="letter-spacing: 0.55pt"> </FONT>series,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>in<FONT STYLE="letter-spacing: 0.55pt">
</FONT>any<FONT STYLE="letter-spacing: 0.6pt"> </FONT>authorized<FONT STYLE="letter-spacing: 0.55pt"> </FONT>denomination<FONT STYLE="letter-spacing: 0.55pt">
</FONT>and<FONT STYLE="letter-spacing: -0.2pt"> </FONT>of<FONT STYLE="letter-spacing: 0.8pt"> </FONT>like<FONT STYLE="letter-spacing: 0.45pt">
</FONT>tenor<FONT STYLE="letter-spacing: 0.5pt"> </FONT>and<FONT STYLE="letter-spacing: 0.5pt"> </FONT>aggregate<FONT STYLE="letter-spacing: 0.45pt">
</FONT>principal<FONT STYLE="letter-spacing: 0.5pt"> </FONT>amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Subject<FONT STYLE="letter-spacing: 0.55pt">
</FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>terms<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>indenture<FONT STYLE="letter-spacing: 0.6pt">
</FONT>and<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>limitations<FONT STYLE="letter-spacing: 0.6pt">
</FONT>applicable<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>global<FONT STYLE="letter-spacing: 0.6pt">
</FONT>securities<FONT STYLE="letter-spacing: 0.6pt"> </FONT>set<FONT STYLE="letter-spacing: 0.6pt"> </FONT>forth<FONT STYLE="letter-spacing: 0.55pt">
</FONT>in<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the applicable<FONT STYLE="letter-spacing: 0.5pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.5pt">
</FONT>supplement,<FONT STYLE="letter-spacing: 0.5pt"> </FONT>holders<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.5pt">
</FONT>the<FONT STYLE="letter-spacing: 0.5pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.5pt">
</FONT>may<FONT STYLE="letter-spacing: 0.5pt"> </FONT>present<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>debt<FONT STYLE="letter-spacing: 0.5pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.5pt"> </FONT>for<FONT STYLE="letter-spacing: 0.5pt">
</FONT>exchange or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>for<FONT STYLE="letter-spacing: 0.6pt"> </FONT>registration<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">transfer,</FONT><FONT STYLE="letter-spacing: 0.6pt">
</FONT>duly<FONT STYLE="letter-spacing: 0.55pt"> </FONT>endorsed<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt">
</FONT>with<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>form<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>transfer<FONT STYLE="letter-spacing: 0.6pt"> </FONT>endorsed<FONT STYLE="letter-spacing: 0.6pt">
</FONT>thereon<FONT STYLE="letter-spacing: 0.55pt"> </FONT>duly<FONT STYLE="letter-spacing: 0.6pt"> </FONT>executed<FONT STYLE="letter-spacing: 0.6pt">
</FONT>if<FONT STYLE="letter-spacing: 0.55pt"> </FONT>so<FONT STYLE="letter-spacing: 1.05pt"> </FONT>required<FONT STYLE="letter-spacing: 0.55pt">
</FONT>by<FONT STYLE="letter-spacing: 0.55pt"> </FONT>us<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>security<FONT STYLE="letter-spacing: 0.6pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">registrar,
</FONT>at<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>office<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>security<FONT STYLE="letter-spacing: 0.55pt">
</FONT>registrar<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>at<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>office<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt">
</FONT>any<FONT STYLE="letter-spacing: 0.55pt"> </FONT>transfer<FONT STYLE="letter-spacing: 1.1pt"> </FONT>agent<FONT STYLE="letter-spacing: 0.55pt">
</FONT>designated<FONT STYLE="letter-spacing: 0.55pt"> </FONT>by<FONT STYLE="letter-spacing: 0.6pt"> </FONT>us<FONT STYLE="letter-spacing: 0.55pt">
</FONT>for<FONT STYLE="letter-spacing: 0.55pt"> </FONT>this<FONT STYLE="letter-spacing: 0.6pt"> </FONT>purpose.<FONT STYLE="letter-spacing: 0.55pt">
</FONT>Unless<FONT STYLE="letter-spacing: 0.55pt"> </FONT>otherwise<FONT STYLE="letter-spacing: 0.6pt"> </FONT>provided<FONT STYLE="letter-spacing: 0.55pt">
</FONT>in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.55pt">
</FONT>securities<FONT STYLE="letter-spacing: 0.55pt"> </FONT>that<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>holder presents<FONT STYLE="letter-spacing: 0.55pt"> </FONT>for<FONT STYLE="letter-spacing: 0.55pt"> </FONT>transfer<FONT STYLE="letter-spacing: 0.6pt">
</FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>exchange,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>we<FONT STYLE="letter-spacing: 0.55pt">
</FONT>will<FONT STYLE="letter-spacing: 0.6pt"> </FONT>impose<FONT STYLE="letter-spacing: 0.55pt"> </FONT>no<FONT STYLE="letter-spacing: 0.6pt">
</FONT>service<FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">charge</FONT><FONT STYLE="letter-spacing: 0.6pt">
</FONT>for<FONT STYLE="letter-spacing: 0.55pt"> </FONT>any<FONT STYLE="letter-spacing: 0.55pt"> </FONT>registration<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>transfer<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 1.1pt">
</FONT>exchange,<FONT STYLE="letter-spacing: 0.5pt"> </FONT>but<FONT STYLE="letter-spacing: 0.55pt"> </FONT>we<FONT STYLE="letter-spacing: 0.55pt">
</FONT>may<FONT STYLE="letter-spacing: 0.55pt"> </FONT>require<FONT STYLE="letter-spacing: 0.55pt"> </FONT>payment<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>any<FONT STYLE="letter-spacing: 0.55pt"> </FONT>taxes<FONT STYLE="letter-spacing: 0.55pt">
</FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>other<FONT STYLE="letter-spacing: 0.55pt"> </FONT>governmental<FONT STYLE="letter-spacing: 0.55pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">charges.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>will<FONT STYLE="letter-spacing: 0.55pt"> </FONT>name<FONT STYLE="letter-spacing: 0.55pt"> </FONT>in<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>applicable<FONT STYLE="letter-spacing: 0.55pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt">
</FONT>supplement<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>security<FONT STYLE="letter-spacing: 0.6pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">registrar,</FONT><FONT STYLE="letter-spacing: 0.55pt"> </FONT>and<FONT STYLE="letter-spacing: 0.55pt">
</FONT>any<FONT STYLE="letter-spacing: 0.55pt"> </FONT>transfer<FONT STYLE="letter-spacing: 0.55pt"> </FONT>agent<FONT STYLE="letter-spacing: 0.6pt">
</FONT>in<FONT STYLE="letter-spacing: 1.1pt"> </FONT>addition<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>security<FONT STYLE="letter-spacing: 0.6pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">registrar,
</FONT>that<FONT STYLE="letter-spacing: 0.6pt"> </FONT>we<FONT STYLE="letter-spacing: 0.6pt"> </FONT>initially<FONT STYLE="letter-spacing: 0.6pt">
</FONT>designate<FONT STYLE="letter-spacing: 0.55pt"> </FONT>for<FONT STYLE="letter-spacing: 0.6pt"> </FONT>any<FONT STYLE="letter-spacing: 0.6pt">
</FONT>debt<FONT STYLE="letter-spacing: 0.6pt"> </FONT>securities.<FONT STYLE="letter-spacing: 0.4pt"> </FONT><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>may<FONT STYLE="letter-spacing: 0.6pt"> </FONT>at<FONT STYLE="letter-spacing: 0.6pt"> </FONT>any<FONT STYLE="letter-spacing: 0.6pt">
</FONT>time<FONT STYLE="letter-spacing: 1.1pt"> </FONT>designate<FONT STYLE="letter-spacing: 0.55pt"> </FONT>additional<FONT STYLE="letter-spacing: 0.55pt">
</FONT>transfer<FONT STYLE="letter-spacing: 0.55pt"> </FONT>agents<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt">
</FONT>rescind<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>designation<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>any<FONT STYLE="letter-spacing: 0.6pt"> </FONT>transfer<FONT STYLE="letter-spacing: 0.55pt">
</FONT>agent<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>approve<FONT STYLE="letter-spacing: 0.55pt">
</FONT>a<FONT STYLE="letter-spacing: 0.55pt"> </FONT>change<FONT STYLE="letter-spacing: 0.6pt"> </FONT>in<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the office<FONT STYLE="letter-spacing: 0.55pt"> </FONT>through<FONT STYLE="letter-spacing: 0.55pt"> </FONT>which<FONT STYLE="letter-spacing: 0.55pt">
</FONT>any<FONT STYLE="letter-spacing: 0.55pt"> </FONT>transfer<FONT STYLE="letter-spacing: 0.6pt"> </FONT>agent<FONT STYLE="letter-spacing: 0.55pt">
</FONT>acts,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>except<FONT STYLE="letter-spacing: 0.55pt"> </FONT>that<FONT STYLE="letter-spacing: 0.6pt">
</FONT>we<FONT STYLE="letter-spacing: 0.55pt"> </FONT>will<FONT STYLE="letter-spacing: 0.55pt"> </FONT>be<FONT STYLE="letter-spacing: 0.55pt">
</FONT>required<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>maintain<FONT STYLE="letter-spacing: 0.55pt">
</FONT>a<FONT STYLE="letter-spacing: 0.55pt"> </FONT>transfer<FONT STYLE="letter-spacing: 0.6pt"> </FONT>agent<FONT STYLE="letter-spacing: 0.55pt">
</FONT>in each<FONT STYLE="letter-spacing: 0.55pt"> </FONT>place<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>payment<FONT STYLE="letter-spacing: 0.55pt"> </FONT>for<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>debt<FONT STYLE="letter-spacing: 0.6pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>each<FONT STYLE="letter-spacing: 0.6pt"> </FONT>series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0.5in">If<FONT STYLE="letter-spacing: 0.6pt">
</FONT>we<FONT STYLE="letter-spacing: 0.6pt"> </FONT>elect<FONT STYLE="letter-spacing: 0.65pt"> </FONT>to<FONT STYLE="letter-spacing: 0.6pt">
</FONT>redeem<FONT STYLE="letter-spacing: 0.65pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.65pt">
</FONT>securities<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.65pt"> </FONT>any<FONT STYLE="letter-spacing: 0.6pt">
</FONT>series,<FONT STYLE="letter-spacing: 0.65pt"> </FONT>we<FONT STYLE="letter-spacing: 0.6pt"> </FONT>will<FONT STYLE="letter-spacing: 0.65pt">
</FONT>not<FONT STYLE="letter-spacing: 0.6pt"> </FONT>be<FONT STYLE="letter-spacing: 0.6pt"> </FONT>required<FONT STYLE="letter-spacing: 0.65pt">
</FONT>to:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 5.25pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding-right: 14.6pt">issue,
                                         register the transfer of, or exchange any debt securities of that series during a period
                                         beginning at the opening of business 15 days before the day of mailing of a notice of
                                         redemption of any debt securities that may be selected for redemption and ending at the
                                         close of business on the day of the mailing; or</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="padding-right: 14.6pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding-right: 11.5pt">register
                                         the transfer of or exchange any debt securities so selected for redemption, in whole
                                         or in part, except the unredeemed portion of any debt securities we are redeeming in
                                         part.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0">Information<FONT STYLE="letter-spacing: 0.3pt">
</FONT>Concerning<FONT STYLE="letter-spacing: 0.3pt"> </FONT>the<FONT STYLE="letter-spacing: 0.3pt"> </FONT><FONT STYLE="letter-spacing: -0.15pt">Trustee</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">The<FONT STYLE="letter-spacing: 0.55pt">
</FONT>trustee,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>other<FONT STYLE="letter-spacing: 0.55pt"> </FONT>than<FONT STYLE="letter-spacing: 0.6pt">
</FONT>during<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>occurrence<FONT STYLE="letter-spacing: 0.6pt">
</FONT>and<FONT STYLE="letter-spacing: 0.55pt"> </FONT>continuance<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>an<FONT STYLE="letter-spacing: 0.55pt"> </FONT>event<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>default<FONT STYLE="letter-spacing: 0.55pt"> </FONT>under<FONT STYLE="letter-spacing: 0.55pt"> </FONT>an<FONT STYLE="letter-spacing: 0.55pt">
</FONT>indenture, undertakes<FONT STYLE="letter-spacing: 0.5pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>perform
only<FONT STYLE="letter-spacing: 0.55pt"> </FONT>those<FONT STYLE="letter-spacing: 0.5pt"> </FONT>duties<FONT STYLE="letter-spacing: 0.55pt">
</FONT>as<FONT STYLE="letter-spacing: 0.55pt"> </FONT>are<FONT STYLE="letter-spacing: 0.55pt"> </FONT>specifically<FONT STYLE="letter-spacing: 0.55pt">
</FONT>set<FONT STYLE="letter-spacing: 0.5pt"> </FONT>forth<FONT STYLE="letter-spacing: 0.55pt"> </FONT>in<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>applicable<FONT STYLE="letter-spacing: 0.5pt"> </FONT>indenture.<FONT STYLE="letter-spacing: 0.55pt">
</FONT>Upon<FONT STYLE="letter-spacing: 0.55pt"> </FONT>an<FONT STYLE="letter-spacing: 0.55pt"> </FONT>event of<FONT STYLE="letter-spacing: 0.55pt">
</FONT>default<FONT STYLE="letter-spacing: 0.6pt"> </FONT>under<FONT STYLE="letter-spacing: 0.6pt"> </FONT>an<FONT STYLE="letter-spacing: 0.6pt">
</FONT>indenture,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>trustee<FONT STYLE="letter-spacing: 0.6pt">
</FONT>must<FONT STYLE="letter-spacing: 0.55pt"> </FONT>use<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>same<FONT STYLE="letter-spacing: 0.6pt"> </FONT>degree<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>care<FONT STYLE="letter-spacing: 0.6pt"> </FONT>as<FONT STYLE="letter-spacing: 0.6pt"> </FONT>a<FONT STYLE="letter-spacing: 0.55pt">
</FONT>prudent<FONT STYLE="letter-spacing: 0.6pt"> </FONT>person<FONT STYLE="letter-spacing: 0.6pt"> </FONT>would<FONT STYLE="letter-spacing: 0.6pt">
</FONT>exercise or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>use<FONT STYLE="letter-spacing: 0.6pt"> </FONT>in<FONT STYLE="letter-spacing: 0.65pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>conduct<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.65pt">
</FONT>his<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.65pt"> </FONT>her<FONT STYLE="letter-spacing: 0.6pt">
</FONT>own<FONT STYLE="letter-spacing: 0.6pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">affairs.</FONT><FONT STYLE="letter-spacing: 0.65pt">
</FONT>Subject<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.65pt"> </FONT>this<FONT STYLE="letter-spacing: 0.6pt">
</FONT>provision,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.65pt"> </FONT>trustee<FONT STYLE="letter-spacing: 0.6pt">
</FONT>is<FONT STYLE="letter-spacing: 0.65pt"> </FONT>under<FONT STYLE="letter-spacing: 0.6pt"> </FONT>no<FONT STYLE="letter-spacing: 0.6pt">
</FONT>obligation<FONT STYLE="letter-spacing: 0.65pt"> </FONT>to<FONT STYLE="letter-spacing: 1.2pt"> </FONT>exercise<FONT STYLE="letter-spacing: 0.6pt">
</FONT>any<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.65pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>powers<FONT STYLE="letter-spacing: 0.6pt"> </FONT>given<FONT STYLE="letter-spacing: 0.65pt"> </FONT>it<FONT STYLE="letter-spacing: 0.6pt">
</FONT>by<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.65pt"> </FONT>indenture<FONT STYLE="letter-spacing: 0.6pt">
</FONT>at<FONT STYLE="letter-spacing: 0.65pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>request<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.65pt"> </FONT>any<FONT STYLE="letter-spacing: 0.6pt"> </FONT>holder<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.65pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.6pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.6pt">
</FONT>unless<FONT STYLE="letter-spacing: 0.65pt"> </FONT>it<FONT STYLE="letter-spacing: 0.6pt"> </FONT>is <FONT STYLE="letter-spacing: -0.05pt">offered
</FONT>reasonable<FONT STYLE="letter-spacing: 0.55pt"> </FONT>security<FONT STYLE="letter-spacing: 0.5pt"> </FONT>and<FONT STYLE="letter-spacing: 0.55pt">
</FONT>indemnity<FONT STYLE="letter-spacing: 0.55pt"> </FONT>against<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>costs,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>expenses<FONT STYLE="letter-spacing: 0.5pt"> </FONT>and<FONT STYLE="letter-spacing: 0.55pt">
</FONT>liabilities<FONT STYLE="letter-spacing: 0.5pt"> </FONT>that<FONT STYLE="letter-spacing: 0.55pt"> </FONT>it<FONT STYLE="letter-spacing: 0.55pt">
</FONT>might<FONT STYLE="letter-spacing: 0.5pt"> </FONT><FONT STYLE="letter-spacing: -0.1pt">incur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="letter-spacing: -0.1pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0">Payment<FONT STYLE="letter-spacing: 0.4pt">
</FONT>and<FONT STYLE="letter-spacing: 0.4pt"> </FONT>Paying<FONT STYLE="letter-spacing: 0.45pt"> </FONT>Agents</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Unless<FONT STYLE="letter-spacing: 0.5pt">
</FONT>we<FONT STYLE="letter-spacing: 0.55pt"> </FONT>otherwise<FONT STYLE="letter-spacing: 0.55pt"> </FONT>indicate<FONT STYLE="letter-spacing: 0.55pt">
</FONT>in<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>applicable<FONT STYLE="letter-spacing: 0.55pt">
</FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt"> </FONT>supplement,<FONT STYLE="letter-spacing: 0.5pt"> </FONT>we<FONT STYLE="letter-spacing: 0.55pt">
</FONT>will<FONT STYLE="letter-spacing: 0.55pt"> </FONT>make<FONT STYLE="letter-spacing: 0.55pt"> </FONT>payment<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the interest<FONT STYLE="letter-spacing: 0.55pt"> </FONT>on<FONT STYLE="letter-spacing: 0.6pt">
</FONT>any<FONT STYLE="letter-spacing: 0.6pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.6pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.6pt">
</FONT>on<FONT STYLE="letter-spacing: 0.55pt"> </FONT>any<FONT STYLE="letter-spacing: 0.6pt"> </FONT>interest<FONT STYLE="letter-spacing: 0.6pt">
</FONT>payment<FONT STYLE="letter-spacing: 0.6pt"> </FONT>date<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>person<FONT STYLE="letter-spacing: 0.6pt"> </FONT>in<FONT STYLE="letter-spacing: 0.6pt">
</FONT>whose<FONT STYLE="letter-spacing: 0.6pt"> </FONT>name<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>debt<FONT STYLE="letter-spacing: 0.6pt"> </FONT>securities,<FONT STYLE="letter-spacing: -0.2pt"> </FONT>or<FONT STYLE="letter-spacing: 0.8pt">
</FONT>one<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>more<FONT STYLE="letter-spacing: 0.6pt">
</FONT>predecessor<FONT STYLE="letter-spacing: 0.6pt"> </FONT>securities,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>are<FONT STYLE="letter-spacing: 0.6pt">
</FONT>registered<FONT STYLE="letter-spacing: 0.6pt"> </FONT>at<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>close<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>business<FONT STYLE="letter-spacing: 0.6pt">
</FONT>on<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>regular<FONT STYLE="letter-spacing: 0.6pt">
</FONT>record<FONT STYLE="letter-spacing: 0.6pt"> </FONT>date<FONT STYLE="letter-spacing: 0.6pt"> </FONT>for<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>will<FONT STYLE="letter-spacing: 0.6pt"> </FONT>pay<FONT STYLE="letter-spacing: 0.6pt"> </FONT>principal<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.65pt"> </FONT>and<FONT STYLE="letter-spacing: 0.6pt"> </FONT>any<FONT STYLE="letter-spacing: 0.6pt">
</FONT>premium<FONT STYLE="letter-spacing: 0.6pt"> </FONT>and<FONT STYLE="letter-spacing: 0.65pt"> </FONT>interest<FONT STYLE="letter-spacing: 0.6pt">
</FONT>on<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.65pt">
</FONT>securities<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>a<FONT STYLE="letter-spacing: 0.6pt">
</FONT>particular<FONT STYLE="letter-spacing: 0.65pt"> </FONT>series<FONT STYLE="letter-spacing: 0.6pt"> </FONT>at<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 1pt"> </FONT>office<FONT STYLE="letter-spacing: 0.5pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>paying<FONT STYLE="letter-spacing: 0.55pt"> </FONT>agents<FONT STYLE="letter-spacing: 0.5pt">
</FONT>designated<FONT STYLE="letter-spacing: 0.55pt"> </FONT>by<FONT STYLE="letter-spacing: 0.55pt"> </FONT>us,<FONT STYLE="letter-spacing: 0.55pt">
</FONT>except<FONT STYLE="letter-spacing: 0.55pt"> </FONT>that<FONT STYLE="letter-spacing: 0.5pt"> </FONT>unless<FONT STYLE="letter-spacing: 0.55pt">
</FONT>we<FONT STYLE="letter-spacing: 0.55pt"> </FONT>otherwise<FONT STYLE="letter-spacing: 0.55pt"> </FONT>indicate<FONT STYLE="letter-spacing: 0.55pt">
</FONT>in<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>applicable prospectus<FONT STYLE="letter-spacing: 0.55pt">
</FONT>supplement,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>we<FONT STYLE="letter-spacing: 0.6pt"> </FONT>will<FONT STYLE="letter-spacing: 0.55pt">
</FONT>make<FONT STYLE="letter-spacing: 0.6pt"> </FONT>interest<FONT STYLE="letter-spacing: 0.6pt"> </FONT>payments<FONT STYLE="letter-spacing: 0.6pt">
</FONT>by<FONT STYLE="letter-spacing: 0.55pt"> </FONT>check<FONT STYLE="letter-spacing: 0.6pt"> </FONT>that<FONT STYLE="letter-spacing: 0.6pt">
</FONT>we<FONT STYLE="letter-spacing: 0.6pt"> </FONT>will<FONT STYLE="letter-spacing: 0.55pt"> </FONT>mail<FONT STYLE="letter-spacing: 0.6pt">
</FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>holder<FONT STYLE="letter-spacing: 0.55pt">
</FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>by<FONT STYLE="letter-spacing: 0.6pt"> </FONT>wire transfer<FONT STYLE="letter-spacing: 0.5pt">
</FONT>to<FONT STYLE="letter-spacing: 0.5pt"> </FONT>certain<FONT STYLE="letter-spacing: 0.55pt"> </FONT>holders.<FONT STYLE="letter-spacing: 0.5pt">
</FONT>Unless<FONT STYLE="letter-spacing: 0.55pt"> </FONT>we<FONT STYLE="letter-spacing: 0.5pt"> </FONT>otherwise<FONT STYLE="letter-spacing: 0.55pt">
</FONT>indicate<FONT STYLE="letter-spacing: 0.5pt"> </FONT>in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.5pt">
</FONT>applicable<FONT STYLE="letter-spacing: 0.55pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.5pt"> </FONT>supplement,
we<FONT STYLE="letter-spacing: 0.5pt"> </FONT>will designate<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>corporate<FONT STYLE="letter-spacing: 0.55pt"> </FONT>trust<FONT STYLE="letter-spacing: 0.55pt"> </FONT>office<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>trustee<FONT STYLE="letter-spacing: 0.55pt">
</FONT>as<FONT STYLE="letter-spacing: 0.55pt"> </FONT>our<FONT STYLE="letter-spacing: 0.6pt"> </FONT>sole<FONT STYLE="letter-spacing: 0.55pt">
</FONT>paying<FONT STYLE="letter-spacing: 0.55pt"> </FONT>agent<FONT STYLE="letter-spacing: 0.55pt"> </FONT>for<FONT STYLE="letter-spacing: 0.6pt">
</FONT>payments<FONT STYLE="letter-spacing: 0.55pt"> </FONT>with<FONT STYLE="letter-spacing: 0.55pt"> </FONT>respect<FONT STYLE="letter-spacing: 0.55pt">
</FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>debt securities<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt">
</FONT>each<FONT STYLE="letter-spacing: 0.55pt"> </FONT>series.<FONT STYLE="letter-spacing: 0.4pt"> </FONT><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>will<FONT STYLE="letter-spacing: 0.55pt"> </FONT>name<FONT STYLE="letter-spacing: 0.55pt"> </FONT>in<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>applicable<FONT STYLE="letter-spacing: 0.55pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt">
</FONT>supplement<FONT STYLE="letter-spacing: 0.55pt"> </FONT>any<FONT STYLE="letter-spacing: 0.55pt"> </FONT>other<FONT STYLE="letter-spacing: 0.55pt">
</FONT>paying<FONT STYLE="letter-spacing: 0.6pt"> </FONT>agents<FONT STYLE="letter-spacing: 0.55pt"> </FONT>that<FONT STYLE="letter-spacing: 1pt">
</FONT>we<FONT STYLE="letter-spacing: 0.55pt"> </FONT>initially<FONT STYLE="letter-spacing: 0.6pt"> </FONT>designate<FONT STYLE="letter-spacing: 0.6pt">
</FONT>for<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.6pt">
</FONT>securities<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>a<FONT STYLE="letter-spacing: 0.55pt">
</FONT>particular<FONT STYLE="letter-spacing: 0.6pt"> </FONT>series.<FONT STYLE="letter-spacing: 0.4pt"> </FONT><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>will<FONT STYLE="letter-spacing: 0.6pt"> </FONT>maintain<FONT STYLE="letter-spacing: 0.6pt"> </FONT>a<FONT STYLE="letter-spacing: 0.6pt">
</FONT>paying<FONT STYLE="letter-spacing: 0.6pt"> </FONT>agent<FONT STYLE="letter-spacing: 0.6pt"> </FONT>in<FONT STYLE="letter-spacing: 0.6pt">
</FONT>each<FONT STYLE="letter-spacing: 1pt"> </FONT>place<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>payment<FONT STYLE="letter-spacing: 0.55pt"> </FONT>for<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>debt<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt">
</FONT>a<FONT STYLE="letter-spacing: 0.6pt"> </FONT>particular<FONT STYLE="letter-spacing: 0.6pt"> </FONT>series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">All<FONT STYLE="letter-spacing: 0.6pt">
</FONT>money<FONT STYLE="letter-spacing: 0.65pt"> </FONT>we<FONT STYLE="letter-spacing: 0.6pt"> </FONT>pay<FONT STYLE="letter-spacing: 0.65pt">
</FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>a<FONT STYLE="letter-spacing: 0.65pt"> </FONT>paying<FONT STYLE="letter-spacing: 0.6pt">
</FONT>agent<FONT STYLE="letter-spacing: 0.65pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.65pt">
</FONT>trustee<FONT STYLE="letter-spacing: 0.6pt"> </FONT>for<FONT STYLE="letter-spacing: 0.65pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>payment<FONT STYLE="letter-spacing: 0.65pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.65pt">
</FONT>principal<FONT STYLE="letter-spacing: 0.65pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.65pt">
</FONT>any<FONT STYLE="letter-spacing: 0.6pt"> </FONT>premium<FONT STYLE="letter-spacing: 0.65pt"> </FONT>or interest<FONT STYLE="letter-spacing: 0.55pt">
</FONT>on<FONT STYLE="letter-spacing: 0.6pt"> </FONT>any<FONT STYLE="letter-spacing: 0.55pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.6pt">
</FONT>securities<FONT STYLE="letter-spacing: 0.6pt"> </FONT>that<FONT STYLE="letter-spacing: 0.55pt"> </FONT>remains<FONT STYLE="letter-spacing: 0.6pt">
</FONT>unclaimed<FONT STYLE="letter-spacing: 0.55pt"> </FONT>at<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>end<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>two<FONT STYLE="letter-spacing: 0.6pt">
</FONT>years<FONT STYLE="letter-spacing: 0.55pt"> </FONT>after<FONT STYLE="letter-spacing: 0.6pt"> </FONT>such<FONT STYLE="letter-spacing: 0.55pt">
</FONT>principal,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>premium<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or interest<FONT STYLE="letter-spacing: 0.55pt">
</FONT>has<FONT STYLE="letter-spacing: 0.55pt"> </FONT>become<FONT STYLE="letter-spacing: 0.55pt"> </FONT>due<FONT STYLE="letter-spacing: 0.6pt">
</FONT>and<FONT STYLE="letter-spacing: 0.55pt"> </FONT>payable<FONT STYLE="letter-spacing: 0.55pt"> </FONT>(or<FONT STYLE="letter-spacing: 0.55pt">
</FONT>such<FONT STYLE="letter-spacing: 0.6pt"> </FONT>shorter<FONT STYLE="letter-spacing: 0.55pt"> </FONT>period<FONT STYLE="letter-spacing: 0.55pt">
</FONT>set<FONT STYLE="letter-spacing: 0.55pt"> </FONT>forth<FONT STYLE="letter-spacing: 0.55pt"> </FONT>in<FONT STYLE="letter-spacing: 0.6pt">
</FONT>applicable<FONT STYLE="letter-spacing: 0.55pt"> </FONT>escheat,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>abandoned<FONT STYLE="letter-spacing: 0.55pt">
</FONT>or unclaimed<FONT STYLE="letter-spacing: 0.6pt"> </FONT>property<FONT STYLE="letter-spacing: 0.6pt"> </FONT>law)<FONT STYLE="letter-spacing: 0.6pt">
</FONT>will<FONT STYLE="letter-spacing: 0.6pt"> </FONT>be<FONT STYLE="letter-spacing: 0.6pt"> </FONT>repaid<FONT STYLE="letter-spacing: 0.6pt">
</FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>us,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>and<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>holder<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.6pt"> </FONT>security<FONT STYLE="letter-spacing: 0.6pt">
</FONT>thereafter<FONT STYLE="letter-spacing: 0.6pt"> </FONT>may<FONT STYLE="letter-spacing: 0.6pt"> </FONT>look<FONT STYLE="letter-spacing: 0.6pt">
</FONT>only<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: -0.15pt"> </FONT>us<FONT STYLE="letter-spacing: 0.8pt">
</FONT>for<FONT STYLE="letter-spacing: 0.4pt"> </FONT>payment<FONT STYLE="letter-spacing: 0.4pt"> </FONT>thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0">Governing<FONT STYLE="letter-spacing: 0.15pt">
</FONT>Law</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">The<FONT STYLE="letter-spacing: 0.55pt">
</FONT>indenture<FONT STYLE="letter-spacing: 0.6pt"> </FONT>and<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>debt<FONT STYLE="letter-spacing: 0.6pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.55pt"> </FONT>will<FONT STYLE="letter-spacing: 0.6pt">
</FONT>be<FONT STYLE="letter-spacing: 0.6pt"> </FONT>governed<FONT STYLE="letter-spacing: 0.55pt"> </FONT>by<FONT STYLE="letter-spacing: 0.6pt">
</FONT>and<FONT STYLE="letter-spacing: 0.6pt"> </FONT>construed<FONT STYLE="letter-spacing: 0.55pt"> </FONT>in<FONT STYLE="letter-spacing: 0.6pt">
</FONT>accordance<FONT STYLE="letter-spacing: 0.6pt"> </FONT>with<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>laws<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>State<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>New<FONT STYLE="letter-spacing: 0.3pt"> </FONT><FONT STYLE="letter-spacing: -0.25pt">York,
</FONT>except<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>extent<FONT STYLE="letter-spacing: 0.65pt"> </FONT>that<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.4pt">
</FONT><FONT STYLE="letter-spacing: -0.1pt">Trust</FONT><FONT STYLE="letter-spacing: 0.6pt"> </FONT>Indenture<FONT STYLE="letter-spacing: 0.1pt">
</FONT>Act<FONT STYLE="letter-spacing: 0.6pt"> </FONT>is<FONT STYLE="letter-spacing: 0.65pt"> </FONT>applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #231F20; text-indent: 0.5in"><A NAME="a-22"></A>DESCRIPTION
OF<FONT STYLE="letter-spacing: 0.95pt"> </FONT>WARRANTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">As<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>March<FONT STYLE="letter-spacing: 0.6pt"> </FONT>13,<FONT STYLE="letter-spacing: 0.55pt">
</FONT>2014,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>there<FONT STYLE="letter-spacing: 0.55pt"> </FONT>were<FONT STYLE="letter-spacing: 0.6pt">
</FONT>9,391,044<FONT STYLE="letter-spacing: 0.6pt"> </FONT>shares<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>common<FONT STYLE="letter-spacing: 0.6pt"> </FONT>stock<FONT STYLE="letter-spacing: 0.55pt"> </FONT>that<FONT STYLE="letter-spacing: 0.6pt">
</FONT>may<FONT STYLE="letter-spacing: 0.6pt"> </FONT>be<FONT STYLE="letter-spacing: 0.55pt"> </FONT>issued<FONT STYLE="letter-spacing: 0.6pt">
</FONT>upon<FONT STYLE="letter-spacing: 0.6pt"> </FONT>exercise of<FONT STYLE="letter-spacing: 0.3pt"> </FONT>outstanding<FONT STYLE="letter-spacing: 0.35pt">
</FONT>warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>may<FONT STYLE="letter-spacing: 0.6pt"> </FONT>issue<FONT STYLE="letter-spacing: 0.6pt"> </FONT>warrants<FONT STYLE="letter-spacing: 0.6pt">
</FONT>for<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>purchase<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.6pt"> </FONT>securities,<FONT STYLE="letter-spacing: 0.6pt">
</FONT>common<FONT STYLE="letter-spacing: 0.6pt"> </FONT>stock<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt">
</FONT>preferred<FONT STYLE="letter-spacing: 0.6pt"> </FONT>stock<FONT STYLE="letter-spacing: 0.6pt"> </FONT>in<FONT STYLE="letter-spacing: 0.6pt">
</FONT>one<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 1pt"> </FONT>more<FONT STYLE="letter-spacing: 0.5pt">
</FONT>series.<FONT STYLE="letter-spacing: 0.35pt"> </FONT><FONT STYLE="letter-spacing: -0.45pt">We</FONT><FONT STYLE="letter-spacing: 0.55pt">
</FONT>may<FONT STYLE="letter-spacing: 0.55pt"> </FONT>issue<FONT STYLE="letter-spacing: 0.5pt"> </FONT>warrants<FONT STYLE="letter-spacing: 0.55pt">
</FONT>independently<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.5pt"> </FONT>together<FONT STYLE="letter-spacing: 0.55pt">
</FONT>with<FONT STYLE="letter-spacing: 0.55pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities,<FONT STYLE="letter-spacing: 0.5pt">
</FONT>common<FONT STYLE="letter-spacing: 0.55pt"> </FONT>stock<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.5pt">
</FONT>preferred<FONT STYLE="letter-spacing: 1pt"> </FONT>stock,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>and<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>warrants<FONT STYLE="letter-spacing: 0.55pt"> </FONT>may<FONT STYLE="letter-spacing: 0.6pt">
</FONT>be<FONT STYLE="letter-spacing: 0.55pt"> </FONT>attached<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt">
</FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>separate<FONT STYLE="letter-spacing: 0.6pt"> </FONT>from<FONT STYLE="letter-spacing: 0.55pt">
</FONT>these<FONT STYLE="letter-spacing: 0.6pt"> </FONT>securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>will<FONT STYLE="letter-spacing: 0.55pt"> </FONT>evidence<FONT STYLE="letter-spacing: 0.55pt"> </FONT>each<FONT STYLE="letter-spacing: 0.55pt">
</FONT>series<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>warrants<FONT STYLE="letter-spacing: 0.55pt">
</FONT>by<FONT STYLE="letter-spacing: 0.55pt"> </FONT>warrant<FONT STYLE="letter-spacing: 0.6pt"> </FONT>certificates<FONT STYLE="letter-spacing: 0.55pt">
</FONT>that<FONT STYLE="letter-spacing: 0.55pt"> </FONT>we<FONT STYLE="letter-spacing: 0.55pt"> </FONT>may<FONT STYLE="letter-spacing: 0.55pt">
</FONT>issue<FONT STYLE="letter-spacing: 0.55pt"> </FONT>under<FONT STYLE="letter-spacing: 0.55pt"> </FONT>a<FONT STYLE="letter-spacing: 0.55pt">
</FONT>separate<FONT STYLE="letter-spacing: 1pt"> </FONT>agreement.<FONT STYLE="letter-spacing: 0.4pt"> </FONT><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>may<FONT STYLE="letter-spacing: 0.6pt"> </FONT>enter<FONT STYLE="letter-spacing: 0.6pt"> </FONT>into<FONT STYLE="letter-spacing: 0.6pt">
</FONT>a<FONT STYLE="letter-spacing: 0.6pt"> </FONT>warrant<FONT STYLE="letter-spacing: 0.55pt"> </FONT>agreement<FONT STYLE="letter-spacing: 0.6pt">
</FONT>with<FONT STYLE="letter-spacing: 0.6pt"> </FONT>a<FONT STYLE="letter-spacing: 0.6pt"> </FONT>warrant<FONT STYLE="letter-spacing: 0.6pt">
</FONT>agent.<FONT STYLE="letter-spacing: 0.55pt"> </FONT>Each<FONT STYLE="letter-spacing: 0.6pt"> </FONT>warrant<FONT STYLE="letter-spacing: 0.6pt">
</FONT>agent<FONT STYLE="letter-spacing: 0.6pt"> </FONT>may<FONT STYLE="letter-spacing: 0.6pt"> </FONT>be<FONT STYLE="letter-spacing: 0.55pt">
</FONT>a<FONT STYLE="letter-spacing: 0.6pt"> </FONT>bank<FONT STYLE="letter-spacing: 1pt"> </FONT>that<FONT STYLE="letter-spacing: 0.6pt">
</FONT>we<FONT STYLE="letter-spacing: 0.6pt"> </FONT>select<FONT STYLE="letter-spacing: 0.6pt"> </FONT>which<FONT STYLE="letter-spacing: 0.6pt">
</FONT>has<FONT STYLE="letter-spacing: 0.6pt"> </FONT>its<FONT STYLE="letter-spacing: 0.6pt"> </FONT>principal<FONT STYLE="letter-spacing: 0.6pt">
</FONT>office<FONT STYLE="letter-spacing: 0.55pt"> </FONT>in<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>United<FONT STYLE="letter-spacing: 0.6pt"> </FONT>States.<FONT STYLE="letter-spacing: 0.45pt"> </FONT><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>may<FONT STYLE="letter-spacing: 0.6pt"> </FONT>also<FONT STYLE="letter-spacing: 0.6pt"> </FONT>choose<FONT STYLE="letter-spacing: 0.6pt">
</FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>act<FONT STYLE="letter-spacing: 0.6pt"> </FONT>as<FONT STYLE="letter-spacing: 0.6pt">
</FONT>our<FONT STYLE="letter-spacing: 0.6pt"> </FONT>own<FONT STYLE="letter-spacing: 1pt"> </FONT>warrant<FONT STYLE="letter-spacing: 0.55pt">
</FONT>agent.<FONT STYLE="letter-spacing: 0.4pt"> </FONT><FONT STYLE="letter-spacing: -0.45pt">We</FONT><FONT STYLE="letter-spacing: 0.55pt">
</FONT>will<FONT STYLE="letter-spacing: 0.6pt"> </FONT>indicate<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>name<FONT STYLE="letter-spacing: 0.55pt"> </FONT>and<FONT STYLE="letter-spacing: 0.6pt"> </FONT>address<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>any<FONT STYLE="letter-spacing: 0.55pt"> </FONT>such<FONT STYLE="letter-spacing: 0.6pt">
</FONT>warrant<FONT STYLE="letter-spacing: 0.55pt"> </FONT>agent<FONT STYLE="letter-spacing: 0.6pt"> </FONT>in<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>applicable<FONT STYLE="letter-spacing: 0.55pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 1pt">
</FONT>supplement<FONT STYLE="letter-spacing: 0.5pt"> </FONT>relating<FONT STYLE="letter-spacing: 0.5pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt">
</FONT>a<FONT STYLE="letter-spacing: 0.5pt"> </FONT>particular<FONT STYLE="letter-spacing: 0.55pt"> </FONT>series of<FONT STYLE="letter-spacing: 0.5pt">
</FONT>warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0.5in"><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>will<FONT STYLE="letter-spacing: 0.55pt"> </FONT>describe<FONT STYLE="letter-spacing: 0.55pt"> </FONT>in<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>applicable<FONT STYLE="letter-spacing: 0.55pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt">
</FONT>supplement<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>terms<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>series<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>warrants,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; font-size: 10pt; width: 0.5in; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; font-size: 10pt; width: 0.25in; text-align: left; vertical-align: top; text-indent: 0"><FONT STYLE="font: 10pt Symbol; color: #231F20">&middot;</FONT></TD>
    <TD STYLE="padding: 0; line-height: 115%; font-size: 10pt; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    offering price and aggregate number of warrants offered;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; font-size: 10pt; text-align: left; vertical-align: top; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; font-size: 10pt; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt/102% Symbol; color: #231F20">&middot;</FONT></TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0"><FONT STYLE="font: 10pt/102% Times New Roman, Times, Serif">if applicable,
    the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each
    such security or each principal amount of such security;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt/102% Symbol; color: #231F20">&middot;</FONT></TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0"><FONT STYLE="font: 10pt/102% Times New Roman, Times, Serif">if applicable,
    the date on and after which the warrants and the related securities will be separately transferable;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt/102% Symbol; color: #231F20">&middot;</FONT></TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0"><FONT STYLE="font: 10pt/102% Times New Roman, Times, Serif">in the
    case of warrants to debt securities, purchase common stock or preferred stock, the number or amount of shares of common stock
    or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which and currency in
    which these shares may be purchased upon such exercise;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Symbol; color: #231F20">&middot;</FONT></TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the manner
    of exercise of the warrants, including any cashless exercise rights;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Symbol; color: #231F20">&middot;</FONT></TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the warrant
    agreement under which the warrants will be issued;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt/102% Symbol; color: #231F20">&middot;</FONT></TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0"><FONT STYLE="font: 10pt/102% Times New Roman, Times, Serif">the
    effect of any merger, consolidation, sale or other disposition of our business on the warrant agreement and the warrants;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Symbol; color: #231F20">&middot;</FONT></TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">anti-dilution
    provisions of the warrants, if any;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Symbol; color: #231F20">&middot;</FONT></TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the terms
    of any rights to redeem or call the warrants;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt/102% Symbol; color: #231F20">&middot;</FONT></TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0"><FONT STYLE="font: 10pt/102% Times New Roman, Times, Serif">any
    provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt/102% Symbol; color: #231F20">&middot;</FONT></TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0"><FONT STYLE="font: 10pt/102% Times New Roman, Times, Serif">the
    dates on which the right to exercise the warrants will commence and expire or, if the warrants are not continuously exercisable
    during that period, the specific date or dates on which the warrants will be exercisable;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Symbol; color: #231F20">&middot;</FONT></TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the manner
    in which the warrant agreement and warrants may be modified;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Symbol; color: #231F20">&middot;</FONT></TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the identities
    of the warrant agent and any calculation or other agent for the warrants;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Symbol; color: #231F20">&middot;</FONT></TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">federal income
    tax consequences of holding or exercising the warrants;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Symbol; color: #231F20">&middot;</FONT></TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the terms
    of the securities issuable upon exercise of the warrants;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt/102% Symbol; color: #231F20">&middot;</FONT></TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0"><FONT STYLE="font: 10pt/102% Times New Roman, Times, Serif">any
    securities exchange or quotation system on which the warrants or any securities deliverable upon exercise of the warrants
    may be listed or quoted; and</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Symbol; color: #231F20">&middot;</FONT></TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">any other
    specific terms, preferences, rights or limitations of or restrictions on the warrants.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Before<FONT STYLE="letter-spacing: 0.55pt">
</FONT>exercising<FONT STYLE="letter-spacing: 0.6pt"> </FONT>their<FONT STYLE="letter-spacing: 0.6pt"> </FONT>warrants,<FONT STYLE="letter-spacing: 0.6pt">
</FONT>holders<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>warrants<FONT STYLE="letter-spacing: 0.6pt">
</FONT>will<FONT STYLE="letter-spacing: 0.6pt"> </FONT>not<FONT STYLE="letter-spacing: 0.55pt"> </FONT>have<FONT STYLE="letter-spacing: 0.6pt">
</FONT>any<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>rights<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>holders<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the securities<FONT STYLE="letter-spacing: 0.5pt"> </FONT>purchasable<FONT STYLE="letter-spacing: 0.55pt">
</FONT>upon<FONT STYLE="letter-spacing: 0.55pt"> </FONT>such<FONT STYLE="letter-spacing: 0.55pt"> </FONT>exercise,<FONT STYLE="letter-spacing: 0.55pt">
</FONT>including,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>in<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>case<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>warrants<FONT STYLE="letter-spacing: 0.55pt">
</FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>purchase<FONT STYLE="letter-spacing: 0.5pt"> </FONT>common<FONT STYLE="letter-spacing: 0.55pt">
</FONT>stock<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or preferred<FONT STYLE="letter-spacing: 0.55pt"> </FONT>stock,<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>right<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt">
</FONT>receive<FONT STYLE="letter-spacing: 0.55pt"> </FONT>dividends,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>if<FONT STYLE="letter-spacing: 0.55pt">
</FONT><FONT STYLE="letter-spacing: -0.25pt">any,</FONT><FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.15pt">or,
</FONT>payments<FONT STYLE="letter-spacing: 0.6pt"> </FONT>upon<FONT STYLE="letter-spacing: 0.55pt"> </FONT>our<FONT STYLE="letter-spacing: 0.55pt">
</FONT>liquidation,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>dissolution<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 1.25pt">
</FONT>winding<FONT STYLE="letter-spacing: 0.6pt"> </FONT>up<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.65pt">
</FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>exercise<FONT STYLE="letter-spacing: 0.6pt"> </FONT>voting<FONT STYLE="letter-spacing: 0.65pt">
</FONT>rights,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>if<FONT STYLE="letter-spacing: 0.6pt"> </FONT><FONT STYLE="letter-spacing: -0.25pt">any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="letter-spacing: -0.25pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0"><FONT STYLE="letter-spacing: -0.05pt">Exercise
</FONT>of<FONT STYLE="letter-spacing: 0.35pt"> </FONT><FONT STYLE="letter-spacing: -0.1pt">Warrants</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Each<FONT STYLE="letter-spacing: 0.55pt">
</FONT>warrant<FONT STYLE="letter-spacing: 0.55pt"> </FONT>will<FONT STYLE="letter-spacing: 0.55pt"> </FONT>entitle<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>holder<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt">
</FONT>purchase<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.55pt">
</FONT>that<FONT STYLE="letter-spacing: 0.55pt"> </FONT>we<FONT STYLE="letter-spacing: 0.55pt"> </FONT>specify<FONT STYLE="letter-spacing: 0.6pt">
</FONT>in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>applicable<FONT STYLE="letter-spacing: 0.55pt">
</FONT>prospectus supplement<FONT STYLE="letter-spacing: 0.5pt"> </FONT>at<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>exercise<FONT STYLE="letter-spacing: 0.5pt"> </FONT>price<FONT STYLE="letter-spacing: 0.55pt"> </FONT>that<FONT STYLE="letter-spacing: 0.5pt">
</FONT>we<FONT STYLE="letter-spacing: 0.55pt"> </FONT>describe<FONT STYLE="letter-spacing: 0.5pt"> </FONT>in<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.5pt"> </FONT>applicable<FONT STYLE="letter-spacing: 0.55pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.5pt">
</FONT>supplement.<FONT STYLE="letter-spacing: 0.55pt"> </FONT>Unless<FONT STYLE="letter-spacing: 0.5pt"> </FONT>we<FONT STYLE="letter-spacing: -0.25pt">
</FONT>otherwise<FONT STYLE="letter-spacing: 0.8pt"> </FONT>specify<FONT STYLE="letter-spacing: 0.5pt"> </FONT>in<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.5pt"> </FONT>applicable<FONT STYLE="letter-spacing: 0.55pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt">
</FONT>supplement,<FONT STYLE="letter-spacing: 0.5pt"> </FONT>holders<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.5pt"> </FONT>warrants<FONT STYLE="letter-spacing: 0.55pt"> </FONT>may<FONT STYLE="letter-spacing: 0.5pt">
</FONT>exercise<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>warrants<FONT STYLE="letter-spacing: -0.25pt">
</FONT>at<FONT STYLE="letter-spacing: 0.8pt"> </FONT>any<FONT STYLE="letter-spacing: 0.6pt"> </FONT>time<FONT STYLE="letter-spacing: 0.65pt">
</FONT>up<FONT STYLE="letter-spacing: 0.65pt"> </FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>5:00<FONT STYLE="letter-spacing: 0.65pt">
</FONT><FONT STYLE="letter-spacing: -0.35pt">P.M.</FONT><FONT STYLE="letter-spacing: 0.65pt"> </FONT>eastern<FONT STYLE="letter-spacing: 0.6pt">
</FONT>time,<FONT STYLE="letter-spacing: 0.65pt"> </FONT>the<FONT STYLE="letter-spacing: 0.65pt"> </FONT>close<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.65pt"> </FONT>business,<FONT STYLE="letter-spacing: 0.65pt"> </FONT>on<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 0.65pt"> </FONT>expiration<FONT STYLE="letter-spacing: 0.65pt"> </FONT>date<FONT STYLE="letter-spacing: 0.6pt">
</FONT>that<FONT STYLE="letter-spacing: 0.65pt"> </FONT>we<FONT STYLE="letter-spacing: 0.65pt"> </FONT>set<FONT STYLE="letter-spacing: 0.6pt">
</FONT>forth<FONT STYLE="letter-spacing: 0.65pt"> </FONT>in<FONT STYLE="letter-spacing: 0.65pt"> </FONT>the<FONT STYLE="letter-spacing: 1.05pt">
</FONT>applicable<FONT STYLE="letter-spacing: 0.5pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.5pt"> </FONT>supplement.
After<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.5pt"> </FONT>close<FONT STYLE="letter-spacing: 0.5pt">
</FONT>of<FONT STYLE="letter-spacing: 0.5pt"> </FONT>business<FONT STYLE="letter-spacing: 0.5pt"> </FONT>on<FONT STYLE="letter-spacing: 0.5pt">
</FONT>the<FONT STYLE="letter-spacing: 0.5pt"> </FONT>expiration<FONT STYLE="letter-spacing: 0.55pt"> </FONT>date,<FONT STYLE="letter-spacing: 0.5pt">
</FONT>unexercised<FONT STYLE="letter-spacing: 0.5pt"> </FONT>warrants<FONT STYLE="letter-spacing: 0.5pt"> </FONT>will become
void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Holders<FONT STYLE="letter-spacing: 0.5pt">
</FONT>of<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.5pt"> </FONT>warrants<FONT STYLE="letter-spacing: 0.5pt">
</FONT>may<FONT STYLE="letter-spacing: 0.5pt"> </FONT>exercise<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.5pt">
</FONT>warrants<FONT STYLE="letter-spacing: 0.5pt"> </FONT>by<FONT STYLE="letter-spacing: 0.5pt"> </FONT>delivering<FONT STYLE="letter-spacing: 0.5pt">
</FONT>the<FONT STYLE="letter-spacing: 0.5pt"> </FONT>warrant<FONT STYLE="letter-spacing: 0.5pt"> </FONT>certificate<FONT STYLE="letter-spacing: 0.5pt">
</FONT>representing<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the warrants<FONT STYLE="letter-spacing: 0.5pt"> </FONT>to<FONT STYLE="letter-spacing: 0.5pt">
</FONT>be<FONT STYLE="letter-spacing: 0.55pt"> </FONT>exercised<FONT STYLE="letter-spacing: 0.5pt"> </FONT>together<FONT STYLE="letter-spacing: 0.5pt">
</FONT>with<FONT STYLE="letter-spacing: 0.55pt"> </FONT>specified<FONT STYLE="letter-spacing: 0.5pt"> </FONT>information,<FONT STYLE="letter-spacing: 0.5pt">
</FONT>and<FONT STYLE="letter-spacing: 0.55pt"> </FONT>paying<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.5pt">
</FONT>required<FONT STYLE="letter-spacing: 0.55pt"> </FONT>exercise<FONT STYLE="letter-spacing: 0.5pt"> </FONT>price<FONT STYLE="letter-spacing: 0.5pt">
</FONT>by<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the methods<FONT STYLE="letter-spacing: 0.55pt"> </FONT>provided<FONT STYLE="letter-spacing: 0.55pt">
</FONT>in<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>applicable<FONT STYLE="letter-spacing: 0.55pt">
</FONT>prospectus<FONT STYLE="letter-spacing: 0.6pt"> </FONT>supplement.<FONT STYLE="letter-spacing: 0.4pt"> </FONT><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>will<FONT STYLE="letter-spacing: 0.55pt"> </FONT>set<FONT STYLE="letter-spacing: 0.6pt"> </FONT>forth<FONT STYLE="letter-spacing: 0.55pt">
</FONT>on<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>reverse<FONT STYLE="letter-spacing: 0.55pt">
</FONT>side<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>warrant<FONT STYLE="letter-spacing: 1pt"> </FONT>certificate,<FONT STYLE="letter-spacing: 0.5pt"> </FONT>and<FONT STYLE="letter-spacing: 0.55pt">
</FONT>in<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>applicable<FONT STYLE="letter-spacing: 0.5pt">
</FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt"> </FONT>supplement,<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>information<FONT STYLE="letter-spacing: 0.5pt"> </FONT>that<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>holder<FONT STYLE="letter-spacing: 0.5pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.5pt">
</FONT>warrant<FONT STYLE="letter-spacing: 0.55pt"> </FONT>will<FONT STYLE="letter-spacing: 0.5pt"> </FONT>be required<FONT STYLE="letter-spacing: 0.55pt">
</FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>deliver<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>warrant<FONT STYLE="letter-spacing: 0.55pt"> </FONT>agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Upon<FONT STYLE="letter-spacing: 0.5pt">
</FONT>receipt<FONT STYLE="letter-spacing: 0.5pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.5pt">
</FONT>required<FONT STYLE="letter-spacing: 0.5pt"> </FONT>payment<FONT STYLE="letter-spacing: 0.5pt"> </FONT>and<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.5pt"> </FONT>warrant<FONT STYLE="letter-spacing: 0.5pt"> </FONT>certificate<FONT STYLE="letter-spacing: 0.55pt">
</FONT>properly<FONT STYLE="letter-spacing: 0.5pt"> </FONT>completed<FONT STYLE="letter-spacing: 0.5pt"> </FONT>and<FONT STYLE="letter-spacing: 0.55pt">
</FONT>duly<FONT STYLE="letter-spacing: 0.5pt"> </FONT>executed<FONT STYLE="letter-spacing: 0.5pt"> </FONT>at the<FONT STYLE="letter-spacing: 0.5pt">
</FONT>corporate<FONT STYLE="letter-spacing: 0.5pt"> </FONT>trust<FONT STYLE="letter-spacing: 0.5pt"> </FONT>office<FONT STYLE="letter-spacing: 0.5pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.5pt"> </FONT>warrant<FONT STYLE="letter-spacing: 0.5pt">
</FONT>agent<FONT STYLE="letter-spacing: 0.5pt"> </FONT>or<FONT STYLE="letter-spacing: 0.5pt"> </FONT>any<FONT STYLE="letter-spacing: 0.5pt">
</FONT>other<FONT STYLE="letter-spacing: 0.55pt"> </FONT>office<FONT STYLE="letter-spacing: 0.5pt"> </FONT>indicated<FONT STYLE="letter-spacing: 0.5pt">
</FONT>in<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.5pt"> </FONT>applicable<FONT STYLE="letter-spacing: 0.55pt">
</FONT>prospectus supplement,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>we<FONT STYLE="letter-spacing: 0.55pt"> </FONT>will
issue<FONT STYLE="letter-spacing: 0.55pt"> </FONT>and<FONT STYLE="letter-spacing: 0.6pt"> </FONT>deliver<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.55pt"> </FONT>purchasable<FONT STYLE="letter-spacing: 0.6pt">
</FONT>upon<FONT STYLE="letter-spacing: 0.55pt"> </FONT>such<FONT STYLE="letter-spacing: 0.55pt"> </FONT>exercise.<FONT STYLE="letter-spacing: 0.6pt">
</FONT>If<FONT STYLE="letter-spacing: 0.55pt"> </FONT>fewer<FONT STYLE="letter-spacing: 0.6pt"> </FONT>than<FONT STYLE="letter-spacing: 0.55pt">
</FONT>all<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the warrants<FONT STYLE="letter-spacing: 0.5pt">
</FONT>represented<FONT STYLE="letter-spacing: 0.5pt"> </FONT>by<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.5pt">
</FONT>warrant<FONT STYLE="letter-spacing: 0.5pt"> </FONT>certificate<FONT STYLE="letter-spacing: 0.5pt"> </FONT>are<FONT STYLE="letter-spacing: 0.5pt">
</FONT>exercised,<FONT STYLE="letter-spacing: 0.5pt"> </FONT>then<FONT STYLE="letter-spacing: 0.5pt"> </FONT>we<FONT STYLE="letter-spacing: 0.5pt">
</FONT>will<FONT STYLE="letter-spacing: 0.5pt"> </FONT>issue<FONT STYLE="letter-spacing: 0.55pt"> </FONT>a<FONT STYLE="letter-spacing: 0.5pt">
</FONT>new<FONT STYLE="letter-spacing: 0.5pt"> </FONT>warrant<FONT STYLE="letter-spacing: 0.5pt"> </FONT>certificate<FONT STYLE="letter-spacing: 0.5pt">
</FONT>for the<FONT STYLE="letter-spacing: 0.45pt"> </FONT>remaining<FONT STYLE="letter-spacing: 0.5pt"> </FONT>amount<FONT STYLE="letter-spacing: 0.45pt">
</FONT>of<FONT STYLE="letter-spacing: 0.5pt"> </FONT>warrants.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0"><FONT STYLE="letter-spacing: -0.05pt">Enforceability
</FONT>of<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Rights<FONT STYLE="letter-spacing: 0.45pt"> </FONT>By<FONT STYLE="letter-spacing: 0.5pt">
</FONT>Holders<FONT STYLE="letter-spacing: 0.45pt"> </FONT>of<FONT STYLE="letter-spacing: 0.5pt"> </FONT><FONT STYLE="letter-spacing: -0.1pt">Warrants</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Any<FONT STYLE="letter-spacing: 0.55pt">
</FONT>warrant<FONT STYLE="letter-spacing: 0.6pt"> </FONT>agent<FONT STYLE="letter-spacing: 0.55pt"> </FONT>will<FONT STYLE="letter-spacing: 0.6pt">
</FONT>act<FONT STYLE="letter-spacing: 0.55pt"> </FONT>solely<FONT STYLE="letter-spacing: 0.6pt"> </FONT>as<FONT STYLE="letter-spacing: 0.55pt">
</FONT>our<FONT STYLE="letter-spacing: 0.6pt"> </FONT>agent<FONT STYLE="letter-spacing: 0.6pt"> </FONT>under<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>applicable<FONT STYLE="letter-spacing: 0.55pt"> </FONT>warrant<FONT STYLE="letter-spacing: 0.6pt">
</FONT>agreement<FONT STYLE="letter-spacing: 0.55pt"> </FONT>and<FONT STYLE="letter-spacing: 0.6pt"> </FONT>will<FONT STYLE="letter-spacing: 0.6pt">
</FONT>not assume<FONT STYLE="letter-spacing: 0.55pt"> </FONT>any<FONT STYLE="letter-spacing: 0.6pt"> </FONT>obligation<FONT STYLE="letter-spacing: 0.6pt">
</FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>relationship<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>agency<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>trust<FONT STYLE="letter-spacing: 0.6pt">
</FONT>with<FONT STYLE="letter-spacing: 0.55pt"> </FONT>any<FONT STYLE="letter-spacing: 0.6pt"> </FONT>holder<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>any<FONT STYLE="letter-spacing: 0.6pt"> </FONT>warrant.<FONT STYLE="letter-spacing: 0.05pt">
</FONT>A<FONT STYLE="letter-spacing: 0.1pt"> </FONT>single<FONT STYLE="letter-spacing: 0.55pt"> </FONT>bank<FONT STYLE="letter-spacing: 0.6pt">
</FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>trust company<FONT STYLE="letter-spacing: 0.6pt"> </FONT>may<FONT STYLE="letter-spacing: 0.6pt">
</FONT>act<FONT STYLE="letter-spacing: 0.6pt"> </FONT>as<FONT STYLE="letter-spacing: 0.6pt"> </FONT>warrant<FONT STYLE="letter-spacing: 0.6pt">
</FONT>agent<FONT STYLE="letter-spacing: 0.6pt"> </FONT>for<FONT STYLE="letter-spacing: 0.6pt"> </FONT>more<FONT STYLE="letter-spacing: 0.6pt">
</FONT>than<FONT STYLE="letter-spacing: 0.6pt"> </FONT>one<FONT STYLE="letter-spacing: 0.6pt"> </FONT>issue<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.65pt"> </FONT>warrants.<FONT STYLE="letter-spacing: 0.05pt"> </FONT>A<FONT STYLE="letter-spacing: 0.1pt">
</FONT>warrant<FONT STYLE="letter-spacing: 0.6pt"> </FONT>agent<FONT STYLE="letter-spacing: 0.6pt"> </FONT>will<FONT STYLE="letter-spacing: 0.6pt">
</FONT>have<FONT STYLE="letter-spacing: 0.6pt"> </FONT>no<FONT STYLE="letter-spacing: 0.6pt"> </FONT>duty<FONT STYLE="letter-spacing: 0.6pt">
</FONT>or responsibility<FONT STYLE="letter-spacing: 0.55pt"> </FONT>in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>case<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>any<FONT STYLE="letter-spacing: 0.55pt"> </FONT>default<FONT STYLE="letter-spacing: 0.55pt">
</FONT>by<FONT STYLE="letter-spacing: 0.55pt"> </FONT>us<FONT STYLE="letter-spacing: 0.55pt"> </FONT>under<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>applicable<FONT STYLE="letter-spacing: 0.55pt"> </FONT>warrant<FONT STYLE="letter-spacing: 0.55pt">
</FONT>agreement<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>warrant,<FONT STYLE="letter-spacing: 0.55pt">
</FONT>including<FONT STYLE="letter-spacing: 0.55pt"> </FONT>any duty<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt">
</FONT>responsibility<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>initiate<FONT STYLE="letter-spacing: 0.6pt">
</FONT>any<FONT STYLE="letter-spacing: 0.6pt"> </FONT>proceedings<FONT STYLE="letter-spacing: 0.55pt"> </FONT>at<FONT STYLE="letter-spacing: 0.6pt">
</FONT>law<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>otherwise,<FONT STYLE="letter-spacing: 0.55pt">
</FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>make<FONT STYLE="letter-spacing: 0.55pt">
</FONT>any<FONT STYLE="letter-spacing: 0.6pt"> </FONT>demand<FONT STYLE="letter-spacing: 0.6pt"> </FONT>upon<FONT STYLE="letter-spacing: 0.6pt">
</FONT>us.<FONT STYLE="letter-spacing: 0.05pt"> </FONT>Any holder<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>a<FONT STYLE="letter-spacing: 0.6pt"> </FONT>warrant<FONT STYLE="letter-spacing: 0.6pt"> </FONT><FONT STYLE="letter-spacing: -0.25pt">may,
</FONT>without<FONT STYLE="letter-spacing: 0.65pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>consent<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>related<FONT STYLE="letter-spacing: 0.6pt">
</FONT>warrant<FONT STYLE="letter-spacing: 0.6pt"> </FONT>agent<FONT STYLE="letter-spacing: 0.65pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>holder<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>any<FONT STYLE="letter-spacing: 0.6pt"> </FONT>other<FONT STYLE="letter-spacing: 0.65pt"> </FONT>warrant,<FONT STYLE="letter-spacing: 1.15pt">
</FONT>enforce<FONT STYLE="letter-spacing: 0.5pt"> </FONT>by<FONT STYLE="letter-spacing: 0.55pt"> </FONT>appropriate<FONT STYLE="letter-spacing: 0.55pt">
</FONT>legal<FONT STYLE="letter-spacing: 0.5pt"> </FONT>action<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT><FONT STYLE="letter-spacing: -0.1pt">holder&rsquo;s</FONT><FONT STYLE="letter-spacing: 0.5pt"> </FONT>right<FONT STYLE="letter-spacing: 0.55pt">
</FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>exercise,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>and<FONT STYLE="letter-spacing: 0.5pt">
</FONT>receive<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.5pt">
</FONT>purchasable<FONT STYLE="letter-spacing: 0.55pt"> </FONT>upon<FONT STYLE="letter-spacing: 1.3pt"> </FONT>exercise<FONT STYLE="letter-spacing: 0.5pt">
</FONT>of,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>its<FONT STYLE="letter-spacing: 0.55pt"> </FONT>warrants<FONT STYLE="letter-spacing: 0.55pt">
</FONT>in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>accordance<FONT STYLE="letter-spacing: 0.55pt"> </FONT>with<FONT STYLE="letter-spacing: 0.55pt">
</FONT>their<FONT STYLE="letter-spacing: 0.55pt"> </FONT>terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0"><FONT STYLE="letter-spacing: -0.1pt">Warrant
</FONT><FONT STYLE="letter-spacing: -0.05pt">Agreement</FONT><FONT STYLE="letter-spacing: 0.45pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">Will
</FONT>Not<FONT STYLE="letter-spacing: 0.45pt"> </FONT>Be<FONT STYLE="letter-spacing: 0.45pt"> </FONT>Qualified<FONT STYLE="letter-spacing: 0.45pt">
</FONT>Under<FONT STYLE="letter-spacing: 0.45pt"> </FONT><FONT STYLE="letter-spacing: -0.15pt">Trust</FONT><FONT STYLE="letter-spacing: 0.45pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">Indenture</FONT><FONT STYLE="letter-spacing: 0.45pt"> </FONT>Act</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">No<FONT STYLE="letter-spacing: 0.55pt">
</FONT>warrant<FONT STYLE="letter-spacing: 0.55pt"> </FONT>agreement<FONT STYLE="letter-spacing: 0.55pt"> </FONT>will<FONT STYLE="letter-spacing: 0.55pt">
</FONT>be<FONT STYLE="letter-spacing: 0.55pt"> </FONT>qualified<FONT STYLE="letter-spacing: 0.6pt"> </FONT>as<FONT STYLE="letter-spacing: 0.55pt">
</FONT>an<FONT STYLE="letter-spacing: 0.55pt"> </FONT>indenture,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>and<FONT STYLE="letter-spacing: 0.55pt">
</FONT>no<FONT STYLE="letter-spacing: 0.6pt"> </FONT>warrant<FONT STYLE="letter-spacing: 0.55pt"> </FONT>agent<FONT STYLE="letter-spacing: 0.55pt">
</FONT>will<FONT STYLE="letter-spacing: 0.55pt"> </FONT>be<FONT STYLE="letter-spacing: 0.55pt"> </FONT>required<FONT STYLE="letter-spacing: 0.55pt">
</FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>qualify as<FONT STYLE="letter-spacing: 0.55pt"> </FONT>a<FONT STYLE="letter-spacing: 0.55pt">
</FONT>trustee,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>under<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.35pt">
</FONT><FONT STYLE="letter-spacing: -0.1pt">Trust</FONT><FONT STYLE="letter-spacing: 0.55pt"> </FONT>Indenture<FONT STYLE="letter-spacing: 0.05pt">
</FONT>Act.<FONT STYLE="letter-spacing: 0.35pt"> </FONT>Therefore,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>holders<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>warrants<FONT STYLE="letter-spacing: 0.55pt"> </FONT>issued<FONT STYLE="letter-spacing: 0.55pt">
</FONT>under<FONT STYLE="letter-spacing: 0.55pt"> </FONT>a<FONT STYLE="letter-spacing: 0.55pt"> </FONT>warrant<FONT STYLE="letter-spacing: 0.55pt">
</FONT>agreement<FONT STYLE="letter-spacing: 1.15pt"> </FONT>will<FONT STYLE="letter-spacing: 0.55pt"> </FONT>not<FONT STYLE="letter-spacing: 0.6pt">
</FONT>have<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>protection<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.4pt"> </FONT><FONT STYLE="letter-spacing: -0.1pt">Trust
</FONT>Indenture<FONT STYLE="letter-spacing: 0.05pt"> </FONT>Act<FONT STYLE="letter-spacing: 0.55pt"> </FONT>with<FONT STYLE="letter-spacing: 0.6pt">
</FONT>respect<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>their<FONT STYLE="letter-spacing: 0.6pt">
</FONT>warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0">Governing<FONT STYLE="letter-spacing: 0.15pt">
</FONT>Law</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Each<FONT STYLE="letter-spacing: 0.5pt">
</FONT>warrant<FONT STYLE="letter-spacing: 0.55pt"> </FONT>agreement<FONT STYLE="letter-spacing: 0.55pt"> </FONT>and<FONT STYLE="letter-spacing: 0.55pt">
</FONT>any<FONT STYLE="letter-spacing: 0.55pt"> </FONT>warrants<FONT STYLE="letter-spacing: 0.55pt"> </FONT>issued<FONT STYLE="letter-spacing: 0.55pt">
</FONT>under<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>warrant<FONT STYLE="letter-spacing: 0.55pt">
</FONT>agreements<FONT STYLE="letter-spacing: 0.5pt"> </FONT>will<FONT STYLE="letter-spacing: 0.55pt"> </FONT>be<FONT STYLE="letter-spacing: 0.55pt">
</FONT>governed<FONT STYLE="letter-spacing: 0.55pt"> </FONT>by<FONT STYLE="letter-spacing: 0.55pt"> </FONT>New <FONT STYLE="letter-spacing: -0.3pt">York
</FONT><FONT STYLE="letter-spacing: -0.25pt">law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="letter-spacing: -0.25pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="letter-spacing: -0.25pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: #231F20"><A NAME="a-23"></A>DESCRIPTION
OF<FONT STYLE="letter-spacing: 1.75pt"> </FONT>RIGHTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>may<FONT STYLE="letter-spacing: 0.6pt"> </FONT>issue<FONT STYLE="letter-spacing: 0.6pt"> </FONT>rights<FONT STYLE="letter-spacing: 0.6pt">
</FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>our<FONT STYLE="letter-spacing: 0.55pt"> </FONT>stockholders<FONT STYLE="letter-spacing: 0.6pt">
</FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>purchase<FONT STYLE="letter-spacing: 0.6pt"> </FONT>shares<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>our<FONT STYLE="letter-spacing: 0.55pt"> </FONT>common<FONT STYLE="letter-spacing: 0.6pt">
</FONT>stock<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>preferred<FONT STYLE="letter-spacing: 0.6pt">
</FONT>stock.<FONT STYLE="letter-spacing: 0.4pt"> </FONT><FONT STYLE="letter-spacing: -0.45pt">We</FONT><FONT STYLE="letter-spacing: 1pt">
</FONT>may<FONT STYLE="letter-spacing: 0.5pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">offer</FONT><FONT STYLE="letter-spacing: 0.55pt">
</FONT>rights<FONT STYLE="letter-spacing: 0.55pt"> </FONT>separately<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt">
</FONT>together<FONT STYLE="letter-spacing: 0.55pt"> </FONT>with<FONT STYLE="letter-spacing: 0.55pt"> </FONT>one<FONT STYLE="letter-spacing: 0.5pt">
</FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>more<FONT STYLE="letter-spacing: 0.55pt"> </FONT>additional<FONT STYLE="letter-spacing: 0.55pt">
</FONT>rights,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities,<FONT STYLE="letter-spacing: 0.55pt">
</FONT>preferred<FONT STYLE="letter-spacing: 0.5pt"> </FONT>stock,<FONT STYLE="letter-spacing: 1.05pt"> </FONT>common<FONT STYLE="letter-spacing: 0.55pt">
</FONT>stock<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>warrants,<FONT STYLE="letter-spacing: 0.6pt">
</FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>any<FONT STYLE="letter-spacing: 0.55pt"> </FONT>combination<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>those<FONT STYLE="letter-spacing: 0.6pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.6pt">
</FONT>in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>form<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>units,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>as<FONT STYLE="letter-spacing: 0.55pt">
</FONT>described<FONT STYLE="letter-spacing: 0.6pt"> </FONT>in<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the applicable<FONT STYLE="letter-spacing: 0.55pt">
</FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt"> </FONT>supplement.<FONT STYLE="letter-spacing: 0.55pt"> </FONT>Each<FONT STYLE="letter-spacing: 0.55pt">
</FONT>series<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>rights<FONT STYLE="letter-spacing: 0.55pt">
</FONT>will<FONT STYLE="letter-spacing: 0.55pt"> </FONT>be<FONT STYLE="letter-spacing: 0.55pt"> </FONT>issued<FONT STYLE="letter-spacing: 0.55pt">
</FONT>under<FONT STYLE="letter-spacing: 0.55pt"> </FONT>a<FONT STYLE="letter-spacing: 0.55pt"> </FONT>separate<FONT STYLE="letter-spacing: 0.55pt">
</FONT>rights<FONT STYLE="letter-spacing: 0.55pt"> </FONT>agreement<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt">
</FONT>be entered<FONT STYLE="letter-spacing: 0.6pt"> </FONT>into<FONT STYLE="letter-spacing: 0.6pt"> </FONT>between<FONT STYLE="letter-spacing: 0.6pt">
</FONT>us<FONT STYLE="letter-spacing: 0.6pt"> </FONT>and<FONT STYLE="letter-spacing: 0.65pt"> </FONT>a<FONT STYLE="letter-spacing: 0.6pt">
</FONT>bank<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>trust<FONT STYLE="letter-spacing: 0.6pt">
</FONT><FONT STYLE="letter-spacing: -0.1pt">company,</FONT><FONT STYLE="letter-spacing: 0.65pt"> </FONT>as<FONT STYLE="letter-spacing: 0.6pt">
</FONT>rights agent.<FONT STYLE="letter-spacing: 0.4pt"> </FONT>The<FONT STYLE="letter-spacing: 0.65pt"> </FONT>rights<FONT STYLE="letter-spacing: 0.6pt">
</FONT>agent<FONT STYLE="letter-spacing: 0.6pt"> </FONT>will<FONT STYLE="letter-spacing: 0.6pt"> </FONT>act<FONT STYLE="letter-spacing: 0.6pt">
</FONT>solely<FONT STYLE="letter-spacing: 0.65pt"> </FONT>as<FONT STYLE="letter-spacing: 0.6pt"> </FONT>our<FONT STYLE="letter-spacing: 1.15pt">
</FONT>agent<FONT STYLE="letter-spacing: 0.5pt"> </FONT>in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>connection<FONT STYLE="letter-spacing: 0.55pt">
</FONT>with<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>certificates<FONT STYLE="letter-spacing: 0.55pt">
</FONT>relating<FONT STYLE="letter-spacing: 0.5pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>rights<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>series<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.5pt"> </FONT>certificates<FONT STYLE="letter-spacing: 0.55pt">
</FONT>and<FONT STYLE="letter-spacing: 0.55pt"> </FONT>will<FONT STYLE="letter-spacing: 0.55pt"> </FONT>not<FONT STYLE="letter-spacing: 0.5pt">
</FONT>assume any<FONT STYLE="letter-spacing: 0.5pt"> </FONT>obligation<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.5pt">
</FONT>relationship<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.5pt"> </FONT>agency<FONT STYLE="letter-spacing: 0.55pt">
</FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>trust<FONT STYLE="letter-spacing: 0.5pt"> </FONT>for<FONT STYLE="letter-spacing: 0.55pt">
</FONT>or<FONT STYLE="letter-spacing: 0.5pt"> </FONT>with<FONT STYLE="letter-spacing: 0.55pt"> </FONT>any<FONT STYLE="letter-spacing: 0.5pt">
</FONT>holders<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>rights<FONT STYLE="letter-spacing: 0.5pt">
</FONT>certificates<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.5pt"> </FONT>beneficial owners
of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>rights.<FONT STYLE="letter-spacing: 0.35pt"> </FONT>The<FONT STYLE="letter-spacing: 0.6pt">
</FONT>following<FONT STYLE="letter-spacing: 0.55pt"> </FONT>description<FONT STYLE="letter-spacing: 0.55pt"> </FONT>sets<FONT STYLE="letter-spacing: 0.55pt">
</FONT>forth<FONT STYLE="letter-spacing: 0.55pt"> </FONT>certain<FONT STYLE="letter-spacing: 0.6pt"> </FONT>general<FONT STYLE="letter-spacing: 0.55pt">
</FONT>terms<FONT STYLE="letter-spacing: 0.55pt"> </FONT>and<FONT STYLE="letter-spacing: 0.55pt"> </FONT>provisions<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>rights<FONT STYLE="letter-spacing: 0.55pt">
</FONT>to which<FONT STYLE="letter-spacing: 0.5pt"> </FONT>any<FONT STYLE="letter-spacing: 0.55pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt">
</FONT>supplement<FONT STYLE="letter-spacing: 0.55pt"> </FONT>may<FONT STYLE="letter-spacing: 0.55pt"> </FONT>relate.<FONT STYLE="letter-spacing: 0.35pt">
</FONT>The<FONT STYLE="letter-spacing: 0.55pt"> </FONT>particular<FONT STYLE="letter-spacing: 0.55pt"> </FONT>terms<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>rights<FONT STYLE="letter-spacing: 0.55pt">
</FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>which<FONT STYLE="letter-spacing: 0.55pt"> </FONT>any<FONT STYLE="letter-spacing: 0.55pt">
</FONT>prospectus supplement<FONT STYLE="letter-spacing: 0.6pt"> </FONT>may<FONT STYLE="letter-spacing: 0.6pt"> </FONT>relate
and<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>extent,<FONT STYLE="letter-spacing: 0.6pt">
</FONT>if<FONT STYLE="letter-spacing: 0.6pt"> </FONT><FONT STYLE="letter-spacing: -0.25pt">any, </FONT>to<FONT STYLE="letter-spacing: 0.6pt">
</FONT>which<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>general<FONT STYLE="letter-spacing: 0.6pt">
</FONT>provisions<FONT STYLE="letter-spacing: 0.6pt"> </FONT>may<FONT STYLE="letter-spacing: 0.6pt"> </FONT>apply<FONT STYLE="letter-spacing: 0.6pt">
</FONT>to<FONT STYLE="letter-spacing: 0.65pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>rights<FONT STYLE="letter-spacing: 0.6pt">
</FONT>so<FONT STYLE="letter-spacing: 1.15pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">offered</FONT><FONT STYLE="letter-spacing: 0.55pt">
</FONT>will<FONT STYLE="letter-spacing: 0.55pt"> </FONT>be<FONT STYLE="letter-spacing: 0.55pt"> </FONT>described<FONT STYLE="letter-spacing: 0.55pt">
</FONT>in<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>applicable<FONT STYLE="letter-spacing: 0.55pt">
</FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt"> </FONT>supplement.<FONT STYLE="letter-spacing: 0.4pt"> </FONT><FONT STYLE="letter-spacing: -0.4pt">To
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>extent<FONT STYLE="letter-spacing: 0.55pt"> </FONT>that<FONT STYLE="letter-spacing: 0.6pt">
</FONT>any<FONT STYLE="letter-spacing: 0.55pt"> </FONT>particular<FONT STYLE="letter-spacing: 0.55pt"> </FONT>terms<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 1.2pt"> </FONT>the<FONT STYLE="letter-spacing: 0.5pt"> </FONT>rights,<FONT STYLE="letter-spacing: 0.55pt">
</FONT>rights<FONT STYLE="letter-spacing: 0.5pt"> </FONT>agreement<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.5pt">
</FONT>rights<FONT STYLE="letter-spacing: 0.55pt"> </FONT>certificates<FONT STYLE="letter-spacing: 0.5pt"> </FONT>described<FONT STYLE="letter-spacing: 0.55pt">
</FONT>in<FONT STYLE="letter-spacing: 0.5pt"> </FONT>a<FONT STYLE="letter-spacing: 0.55pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.5pt">
</FONT>supplement<FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">differ</FONT><FONT STYLE="letter-spacing: 0.55pt">
</FONT>from<FONT STYLE="letter-spacing: 0.5pt"> </FONT>any<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.5pt">
</FONT>the terms<FONT STYLE="letter-spacing: 0.55pt"> </FONT>described<FONT STYLE="letter-spacing: 0.55pt"> </FONT>below,<FONT STYLE="letter-spacing: 0.6pt">
</FONT>then<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>terms<FONT STYLE="letter-spacing: 0.6pt">
</FONT>described<FONT STYLE="letter-spacing: 0.55pt"> </FONT>below<FONT STYLE="letter-spacing: 0.55pt"> </FONT>will<FONT STYLE="letter-spacing: 0.6pt">
</FONT>be<FONT STYLE="letter-spacing: 0.55pt"> </FONT>deemed<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.6pt">
</FONT>have<FONT STYLE="letter-spacing: 0.55pt"> </FONT>been<FONT STYLE="letter-spacing: 0.55pt"> </FONT>superseded<FONT STYLE="letter-spacing: 0.6pt">
</FONT>by<FONT STYLE="letter-spacing: 0.55pt"> </FONT>that prospectus supplement.<FONT STYLE="letter-spacing: 0.35pt"> </FONT><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>encourage<FONT STYLE="letter-spacing: 0.5pt"> </FONT>you<FONT STYLE="letter-spacing: 0.5pt"> </FONT>to read<FONT STYLE="letter-spacing: 0.5pt">
</FONT>the<FONT STYLE="letter-spacing: 0.5pt"> </FONT>applicable<FONT STYLE="letter-spacing: 0.5pt"> </FONT>rights<FONT STYLE="letter-spacing: 0.5pt">
</FONT>agreement<FONT STYLE="letter-spacing: 0.5pt"> </FONT>and<FONT STYLE="letter-spacing: 0.5pt"> </FONT>rights<FONT STYLE="letter-spacing: 0.5pt">
</FONT>certificate<FONT STYLE="letter-spacing: 0.5pt"> </FONT>for<FONT STYLE="letter-spacing: 1pt"> </FONT>additional<FONT STYLE="letter-spacing: 0.5pt">
</FONT>information<FONT STYLE="letter-spacing: 0.55pt"> </FONT>before<FONT STYLE="letter-spacing: 0.55pt"> </FONT>you<FONT STYLE="letter-spacing: 0.5pt">
</FONT>decide<FONT STYLE="letter-spacing: 0.55pt"> </FONT>whether<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt">
</FONT>purchase<FONT STYLE="letter-spacing: 0.5pt"> </FONT>any<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt">
</FONT>our<FONT STYLE="letter-spacing: 0.5pt"> </FONT>rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0.5in"><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>will<FONT STYLE="letter-spacing: 0.55pt"> </FONT>provide<FONT STYLE="letter-spacing: 0.6pt"> </FONT>in<FONT STYLE="letter-spacing: 0.55pt">
</FONT>a<FONT STYLE="letter-spacing: 0.6pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt"> </FONT>supplement<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>following<FONT STYLE="letter-spacing: 0.6pt"> </FONT>terms<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>rights<FONT STYLE="letter-spacing: 0.6pt">
</FONT>being<FONT STYLE="letter-spacing: 0.55pt"> </FONT>issued:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; padding-right: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding-right: 0; text-align: left">the
                                         date on which stockholders entitled to the rights distribution will be determined;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0; text-align: left"></TD><TD STYLE="padding-right: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding-right: 0; text-align: left">the
                                         aggregate number of shares of common stock or preferred stock purchasable upon exercise
                                         of the rights;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0; text-align: left"></TD><TD STYLE="padding-right: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding-right: 0; text-align: left">the
                                         exercise price;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0; text-align: left"></TD><TD STYLE="padding-right: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding-right: 0; text-align: left">the
                                         aggregate number of rights issued;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0; text-align: left"></TD><TD STYLE="padding-right: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding-right: 0; text-align: left">the
                                         date, if any, on and after which the rights will be separately transferable;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0; text-align: left"></TD><TD STYLE="padding-right: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding-right: 0; text-align: left">the
                                         date on which the ability to exercise the rights will commence, and the date on which
                                         such ability will expire;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0; text-align: left"></TD><TD STYLE="padding-right: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding-right: 0; text-align: left">the
                                         conditions to the completion of the offering, if any;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0; text-align: left"></TD><TD STYLE="padding-right: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding-right: 0; text-align: left">the
                                         withdrawal, termination and cancellation rights, if any;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0; text-align: left"></TD><TD STYLE="padding-right: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding-right: 0; text-align: left">any
                                         applicable material U.S. federal income tax considerations; and</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0; text-align: left"></TD><TD STYLE="padding-right: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding-right: 0; text-align: left">any
                                         other terms of the rights, including terms, procedures and limitations relating to the
                                         distribution, exchange and exercise of the rights.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Each<FONT STYLE="letter-spacing: 0.55pt">
</FONT>right<FONT STYLE="letter-spacing: 0.6pt"> </FONT>will<FONT STYLE="letter-spacing: 0.6pt"> </FONT>entitle<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>holder<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>rights<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>purchase,<FONT STYLE="letter-spacing: 0.6pt">
</FONT>for<FONT STYLE="letter-spacing: 0.6pt"> </FONT>cash,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>number<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>shares<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>common<FONT STYLE="letter-spacing: 0.6pt"> </FONT>stock or<FONT STYLE="letter-spacing: 0.5pt">
</FONT>preferred<FONT STYLE="letter-spacing: 0.55pt"> </FONT>stock<FONT STYLE="letter-spacing: 0.55pt"> </FONT>at<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>exercise<FONT STYLE="letter-spacing: 0.55pt"> </FONT>price<FONT STYLE="letter-spacing: 0.55pt">
</FONT>provided<FONT STYLE="letter-spacing: 0.55pt"> </FONT>in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>applicable<FONT STYLE="letter-spacing: 0.55pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt"> </FONT>supplement.
Rights<FONT STYLE="letter-spacing: 0.55pt"> </FONT>may<FONT STYLE="letter-spacing: 0.55pt"> </FONT>be exercised<FONT STYLE="letter-spacing: 0.6pt">
</FONT>at<FONT STYLE="letter-spacing: 0.6pt"> </FONT>any<FONT STYLE="letter-spacing: 0.6pt"> </FONT>time<FONT STYLE="letter-spacing: 0.65pt">
</FONT>up<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.65pt">
</FONT>close<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>business<FONT STYLE="letter-spacing: 0.65pt">
</FONT>on<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>expiration<FONT STYLE="letter-spacing: 0.6pt">
</FONT>date<FONT STYLE="letter-spacing: 0.65pt"> </FONT>for<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>rights<FONT STYLE="letter-spacing: 0.65pt"> </FONT>provided<FONT STYLE="letter-spacing: 0.6pt"> </FONT>in<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the applicable<FONT STYLE="letter-spacing: 0.1pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.15pt"> </FONT>supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Holders<FONT STYLE="letter-spacing: 0.5pt">
</FONT>may<FONT STYLE="letter-spacing: 0.5pt"> </FONT>exercise<FONT STYLE="letter-spacing: 0.55pt"> </FONT>rights<FONT STYLE="letter-spacing: 0.5pt">
</FONT>as<FONT STYLE="letter-spacing: 0.55pt"> </FONT>described<FONT STYLE="letter-spacing: 0.5pt"> </FONT>in<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.5pt"> </FONT>applicable<FONT STYLE="letter-spacing: 0.5pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt">
</FONT>supplement.<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Upon<FONT STYLE="letter-spacing: 0.55pt"> </FONT>receipt<FONT STYLE="letter-spacing: 0.5pt">
</FONT>of payment<FONT STYLE="letter-spacing: 0.5pt"> </FONT>and<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.5pt">
</FONT>rights<FONT STYLE="letter-spacing: 0.5pt"> </FONT>certificate<FONT STYLE="letter-spacing: 0.5pt"> </FONT>properly<FONT STYLE="letter-spacing: 0.5pt">
</FONT>completed<FONT STYLE="letter-spacing: 0.5pt"> </FONT>and<FONT STYLE="letter-spacing: 0.5pt"> </FONT>duly<FONT STYLE="letter-spacing: 0.5pt">
</FONT>executed<FONT STYLE="letter-spacing: 0.5pt"> </FONT>at<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.5pt">
</FONT>corporate<FONT STYLE="letter-spacing: 0.5pt"> </FONT>trust<FONT STYLE="letter-spacing: 0.5pt"> </FONT>office<FONT STYLE="letter-spacing: 0.5pt">
</FONT>of<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the rights<FONT STYLE="letter-spacing: 0.5pt"> </FONT>agent<FONT STYLE="letter-spacing: 0.55pt">
</FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>any<FONT STYLE="letter-spacing: 0.55pt"> </FONT>other<FONT STYLE="letter-spacing: 0.5pt">
</FONT>office<FONT STYLE="letter-spacing: 0.55pt"> </FONT>indicated<FONT STYLE="letter-spacing: 0.55pt"> </FONT>in<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.5pt"> </FONT>supplement,<FONT STYLE="letter-spacing: 0.55pt">
</FONT>we<FONT STYLE="letter-spacing: 0.55pt"> </FONT>will,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>as<FONT STYLE="letter-spacing: 0.5pt">
</FONT>soon<FONT STYLE="letter-spacing: 0.55pt"> </FONT>as<FONT STYLE="letter-spacing: 0.55pt"> </FONT>practicable, forward<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>shares<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt">
</FONT>common<FONT STYLE="letter-spacing: 0.55pt"> </FONT>stock<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt">
</FONT>preferred<FONT STYLE="letter-spacing: 0.55pt"> </FONT>stock,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>as<FONT STYLE="letter-spacing: 0.55pt">
</FONT>applicable,<FONT STYLE="letter-spacing: 0.5pt"> </FONT>purchasable<FONT STYLE="letter-spacing: 0.55pt"> </FONT>upon<FONT STYLE="letter-spacing: 0.55pt">
</FONT>exercise<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>rights. If<FONT STYLE="letter-spacing: 0.55pt"> </FONT>less<FONT STYLE="letter-spacing: 0.6pt"> </FONT>than<FONT STYLE="letter-spacing: 0.6pt">
</FONT>all<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>rights<FONT STYLE="letter-spacing: 0.6pt"> </FONT>issued<FONT STYLE="letter-spacing: 0.6pt"> </FONT>in<FONT STYLE="letter-spacing: 0.6pt">
</FONT>any<FONT STYLE="letter-spacing: 0.6pt"> </FONT>rights<FONT STYLE="letter-spacing: 0.6pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">offering
</FONT>are<FONT STYLE="letter-spacing: 0.6pt"> </FONT>exercised,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>we<FONT STYLE="letter-spacing: 0.6pt">
</FONT>may<FONT STYLE="letter-spacing: 0.6pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">offer</FONT><FONT STYLE="letter-spacing: 0.6pt">
</FONT>any<FONT STYLE="letter-spacing: 0.6pt"> </FONT>unsubscribed<FONT STYLE="letter-spacing: 1.3pt"> </FONT>securities directly
to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>persons<FONT STYLE="letter-spacing: 0.55pt"> </FONT>other<FONT STYLE="letter-spacing: 0.55pt">
</FONT>than<FONT STYLE="letter-spacing: 0.55pt"> </FONT>stockholders,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.5pt">
</FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>through<FONT STYLE="letter-spacing: 0.55pt"> </FONT>agents,<FONT STYLE="letter-spacing: 0.55pt">
</FONT>underwriters<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>dealers<FONT STYLE="letter-spacing: 0.55pt">
</FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>through<FONT STYLE="letter-spacing: -0.25pt"> </FONT>a<FONT STYLE="letter-spacing: 0.8pt">
</FONT>combination<FONT STYLE="letter-spacing: 0.5pt"> </FONT>of<FONT STYLE="letter-spacing: 0.5pt"> </FONT>such<FONT STYLE="letter-spacing: 0.5pt">
</FONT>methods,<FONT STYLE="letter-spacing: 0.5pt"> </FONT>including<FONT STYLE="letter-spacing: 0.5pt"> </FONT>pursuant<FONT STYLE="letter-spacing: 0.5pt">
</FONT>to<FONT STYLE="letter-spacing: 0.5pt"> </FONT>standby<FONT STYLE="letter-spacing: 0.5pt"> </FONT>arrangements,<FONT STYLE="letter-spacing: 0.5pt">
</FONT>as<FONT STYLE="letter-spacing: 0.5pt"> </FONT>described<FONT STYLE="letter-spacing: 0.5pt"> </FONT>in<FONT STYLE="letter-spacing: 0.5pt">
</FONT>the<FONT STYLE="letter-spacing: 0.5pt"> </FONT>applicable prospectus<FONT STYLE="letter-spacing: -0.15pt"> </FONT>supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0; color: #231F20"><A NAME="a-24"></A>DESCRIPTION
OF<FONT STYLE="letter-spacing: 1.45pt"> </FONT>PURCHASE<FONT STYLE="letter-spacing: 1.45pt"> </FONT>CONTRACTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>may<FONT STYLE="letter-spacing: 0.55pt"> </FONT>issue<FONT STYLE="letter-spacing: 0.55pt"> </FONT>purchase<FONT STYLE="letter-spacing: 0.55pt">
</FONT>contracts,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>including<FONT STYLE="letter-spacing: 0.55pt"> </FONT>contracts<FONT STYLE="letter-spacing: 0.55pt">
</FONT>obligating<FONT STYLE="letter-spacing: 0.55pt"> </FONT>holders<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt">
</FONT>purchase<FONT STYLE="letter-spacing: 0.55pt"> </FONT>from<FONT STYLE="letter-spacing: 0.55pt"> </FONT>us,<FONT STYLE="letter-spacing: 0.55pt">
</FONT>and<FONT STYLE="letter-spacing: 0.6pt"> </FONT>for<FONT STYLE="letter-spacing: 0.55pt"> </FONT>us<FONT STYLE="letter-spacing: -0.2pt">
</FONT>to<FONT STYLE="letter-spacing: 1.8pt"> </FONT>sell<FONT STYLE="letter-spacing: 0.5pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt">
</FONT>holders,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>a<FONT STYLE="letter-spacing: 0.55pt"> </FONT>specific<FONT STYLE="letter-spacing: 0.55pt">
</FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>variable<FONT STYLE="letter-spacing: 0.55pt"> </FONT>number<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>our<FONT STYLE="letter-spacing: 0.55pt"> </FONT>debt<FONT STYLE="letter-spacing: 0.55pt">
</FONT>securities,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>shares<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt">
</FONT>common<FONT STYLE="letter-spacing: 0.55pt"> </FONT>stock,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>preferred<FONT STYLE="letter-spacing: -0.25pt">
</FONT>stock,<FONT STYLE="letter-spacing: 0.8pt"> </FONT>warrants<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt">
</FONT>rights,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>an<FONT STYLE="letter-spacing: 0.55pt"> </FONT>entity<FONT STYLE="letter-spacing: 0.6pt">
</FONT>unaffiliated<FONT STYLE="letter-spacing: 0.55pt"> </FONT>with<FONT STYLE="letter-spacing: 0.6pt"> </FONT>us,<FONT STYLE="letter-spacing: 0.55pt">
</FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>any<FONT STYLE="letter-spacing: 0.6pt"> </FONT>combination<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>above,<FONT STYLE="letter-spacing: 0.55pt">
</FONT>at<FONT STYLE="letter-spacing: 0.6pt"> </FONT>a<FONT STYLE="letter-spacing: -0.2pt"> </FONT>future<FONT STYLE="letter-spacing: 0.8pt">
</FONT>date<FONT STYLE="letter-spacing: 0.5pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>dates. <FONT STYLE="letter-spacing: -0.05pt">Alternatively,
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>purchase<FONT STYLE="letter-spacing: 0.55pt"> </FONT>contracts<FONT STYLE="letter-spacing: 0.5pt">
</FONT>may<FONT STYLE="letter-spacing: 0.55pt"> </FONT>obligate<FONT STYLE="letter-spacing: 0.55pt"> </FONT>us<FONT STYLE="letter-spacing: 0.5pt">
</FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>purchase<FONT STYLE="letter-spacing: 0.55pt"> </FONT>from<FONT STYLE="letter-spacing: 0.5pt">
</FONT>holders,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>and<FONT STYLE="letter-spacing: -0.2pt"> </FONT>obligate<FONT STYLE="letter-spacing: 1.85pt">
</FONT>holders<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>sell<FONT STYLE="letter-spacing: 0.55pt">
</FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>us,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>a<FONT STYLE="letter-spacing: 0.55pt">
</FONT>specific<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>variable<FONT STYLE="letter-spacing: 0.55pt">
</FONT>number<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>our<FONT STYLE="letter-spacing: 0.55pt">
</FONT>debt<FONT STYLE="letter-spacing: 0.6pt"> </FONT>securities,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>shares<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>common<FONT STYLE="letter-spacing: 0.55pt"> </FONT>stock,<FONT STYLE="letter-spacing: -0.2pt">
</FONT>preferred<FONT STYLE="letter-spacing: 0.8pt"> </FONT>stock,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>warrants,<FONT STYLE="letter-spacing: 0.6pt">
</FONT>rights<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>other<FONT STYLE="letter-spacing: 0.55pt">
</FONT><FONT STYLE="letter-spacing: -0.1pt">property,</FONT><FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt">
</FONT>any<FONT STYLE="letter-spacing: 0.6pt"> </FONT>combination<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>above.<FONT STYLE="letter-spacing: 0.4pt"> </FONT>The<FONT STYLE="letter-spacing: 0.55pt">
</FONT>price<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>securities<FONT STYLE="letter-spacing: -0.2pt"> </FONT>or<FONT STYLE="letter-spacing: 0.8pt"> </FONT><FONT STYLE="letter-spacing: 0.7pt">
</FONT>other<FONT STYLE="letter-spacing: 0.55pt"> </FONT>property<FONT STYLE="letter-spacing: 0.55pt"> </FONT>subject<FONT STYLE="letter-spacing: 0.55pt">
</FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>purchase<FONT STYLE="letter-spacing: 0.55pt">
</FONT>contracts<FONT STYLE="letter-spacing: 0.6pt"> </FONT>may<FONT STYLE="letter-spacing: 0.55pt"> </FONT>be<FONT STYLE="letter-spacing: 0.55pt">
</FONT>fixed<FONT STYLE="letter-spacing: 0.55pt"> </FONT>at<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>time<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>purchase<FONT STYLE="letter-spacing: 0.55pt">
</FONT>contracts<FONT STYLE="letter-spacing: 0.55pt"> </FONT>are<FONT STYLE="letter-spacing: 0.55pt"> </FONT>issued<FONT STYLE="letter-spacing: -0.2pt">
</FONT>or<FONT STYLE="letter-spacing: 0.8pt"> </FONT>may<FONT STYLE="letter-spacing: 0.55pt"> </FONT>be<FONT STYLE="letter-spacing: 0.55pt">
</FONT>determined<FONT STYLE="letter-spacing: 0.55pt"> </FONT>by<FONT STYLE="letter-spacing: 0.55pt"> </FONT>reference<FONT STYLE="letter-spacing: 0.55pt">
</FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>a<FONT STYLE="letter-spacing: 0.55pt"> </FONT>specific<FONT STYLE="letter-spacing: 0.55pt">
</FONT>formula<FONT STYLE="letter-spacing: 0.55pt"> </FONT>described<FONT STYLE="letter-spacing: 0.55pt"> </FONT>in<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>purchase<FONT STYLE="letter-spacing: 0.55pt"> </FONT>contracts.<FONT STYLE="letter-spacing: 0.35pt">
</FONT><FONT STYLE="letter-spacing: -0.45pt">We</FONT><FONT STYLE="letter-spacing: 0.55pt"> </FONT>may<FONT STYLE="letter-spacing: 0.55pt">
</FONT>issue<FONT STYLE="letter-spacing: 1pt"> </FONT>purchase<FONT STYLE="letter-spacing: 0.55pt"> </FONT>contracts<FONT STYLE="letter-spacing: 0.6pt">
</FONT>separately<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>as<FONT STYLE="letter-spacing: 0.6pt">
</FONT>a<FONT STYLE="letter-spacing: 0.6pt"> </FONT>part<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>units<FONT STYLE="letter-spacing: 0.6pt"> </FONT>each<FONT STYLE="letter-spacing: 0.6pt"> </FONT>consisting<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>a<FONT STYLE="letter-spacing: 0.6pt"> </FONT>purchase<FONT STYLE="letter-spacing: 0.6pt">
</FONT>contract<FONT STYLE="letter-spacing: 0.6pt"> </FONT>and<FONT STYLE="letter-spacing: 0.6pt"> </FONT>one<FONT STYLE="letter-spacing: 0.6pt">
</FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>more of our<FONT STYLE="letter-spacing: 0.5pt"> </FONT>other<FONT STYLE="letter-spacing: 0.5pt">
</FONT>securities<FONT STYLE="letter-spacing: 0.55pt"> </FONT>described<FONT STYLE="letter-spacing: 0.5pt"> </FONT>in<FONT STYLE="letter-spacing: 0.55pt">
</FONT>this<FONT STYLE="letter-spacing: 0.5pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.5pt">
</FONT>securities<FONT STYLE="letter-spacing: 0.5pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>third<FONT STYLE="letter-spacing: 0.5pt">
</FONT>parties,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>including<FONT STYLE="letter-spacing: 0.5pt"> </FONT>U.S.<FONT STYLE="letter-spacing: 0.35pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">Treasury</FONT><FONT STYLE="letter-spacing: -0.25pt"> </FONT>securities,<FONT STYLE="letter-spacing: 1.85pt">
</FONT>securing<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the <FONT STYLE="letter-spacing: -0.1pt">holder&rsquo;s</FONT> obligations
under the purchase<FONT STYLE="letter-spacing: 0.6pt"> </FONT>contract. The purchase<FONT STYLE="letter-spacing: 0.6pt"> </FONT>contracts
may require us to<FONT STYLE="letter-spacing: 0.8pt"> </FONT>make<FONT STYLE="letter-spacing: 0.55pt"> </FONT>periodic<FONT STYLE="letter-spacing: 0.55pt">
</FONT>payments<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>holders<FONT STYLE="letter-spacing: 0.55pt">
</FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>vice<FONT STYLE="letter-spacing: 0.6pt"> </FONT>versa<FONT STYLE="letter-spacing: 0.55pt">
</FONT>and<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>payments<FONT STYLE="letter-spacing: 0.55pt">
</FONT>may<FONT STYLE="letter-spacing: 0.55pt"> </FONT>be<FONT STYLE="letter-spacing: 0.6pt"> </FONT>unsecured<FONT STYLE="letter-spacing: 0.55pt">
</FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>pre-funded<FONT STYLE="letter-spacing: 0.6pt"> </FONT>on<FONT STYLE="letter-spacing: -0.2pt">
</FONT>some<FONT STYLE="letter-spacing: 0.8pt"> </FONT>basis.<FONT STYLE="letter-spacing: 0.35pt"> </FONT>The<FONT STYLE="letter-spacing: 0.5pt">
</FONT>purchase<FONT STYLE="letter-spacing: 0.55pt"> </FONT>contracts<FONT STYLE="letter-spacing: 0.5pt"> </FONT>may<FONT STYLE="letter-spacing: 0.55pt">
</FONT>require<FONT STYLE="letter-spacing: 0.55pt"> </FONT>holders<FONT STYLE="letter-spacing: 0.5pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt">
</FONT>secure<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.5pt"> </FONT><FONT STYLE="letter-spacing: -0.1pt">holder&rsquo;s
</FONT>obligations<FONT STYLE="letter-spacing: 0.55pt"> </FONT>in<FONT STYLE="letter-spacing: 0.5pt"> </FONT>a<FONT STYLE="letter-spacing: 0.55pt">
</FONT>manner specified<FONT STYLE="letter-spacing: 0.55pt"> </FONT>in<FONT STYLE="letter-spacing: 0.8pt"> </FONT>the applicable
prospectus<FONT STYLE="letter-spacing: 0.35pt"> </FONT>supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">The<FONT STYLE="letter-spacing: 0.5pt">
</FONT>applicable<FONT STYLE="letter-spacing: 0.55pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt"> </FONT>supplement
will<FONT STYLE="letter-spacing: 0.5pt"> </FONT>describe<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>terms<FONT STYLE="letter-spacing: 0.5pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>any<FONT STYLE="letter-spacing: 0.55pt">
</FONT>purchase<FONT STYLE="letter-spacing: 0.55pt"> </FONT>contracts<FONT STYLE="letter-spacing: 0.5pt"> </FONT>in<FONT STYLE="letter-spacing: 0.55pt">
</FONT>respect<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of which<FONT STYLE="letter-spacing: 0.5pt"> </FONT>this<FONT STYLE="letter-spacing: 0.5pt">
</FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt"> </FONT>is<FONT STYLE="letter-spacing: 0.5pt"> </FONT>being<FONT STYLE="letter-spacing: 0.55pt">
</FONT>delivered,<FONT STYLE="letter-spacing: 0.5pt"> </FONT>including,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.5pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>extent<FONT STYLE="letter-spacing: 0.5pt"> </FONT>applicable,<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.5pt"> </FONT>following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding-right: 0; text-align: left"></TD><TD STYLE="width: 0.25in; padding-right: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding-right: 0; text-align: left">whether
                                         the purchase contracts obligate the holder or us to purchase or sell, or both purchase
                                         and sell, the securities subject to purchase under the purchase contract, and the nature
                                         and amount of each of those securities, or the method of determining those amounts;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0; text-align: left"></TD><TD STYLE="padding-right: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding-right: 0; text-align: left">whether
                                         the purchase contracts are to be prepaid;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0; text-align: left"></TD><TD STYLE="padding-right: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding-right: 0; text-align: left">whether
                                         the purchase contracts are to be settled by delivery, or by reference or linkage to the
                                         value, performance or level of the securities subject to purchase under the purchase
                                         contract;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0; text-align: left"></TD><TD STYLE="padding-right: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding-right: 0; text-align: left">any
                                         acceleration, cancellation, termination or other provisions relating to the settlement
                                         of the purchase contracts;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0; text-align: left"></TD><TD STYLE="padding-right: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding-right: 0; text-align: left">any
                                         applicable federal income tax considerations; and</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD><TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0; text-align: left"></TD><TD STYLE="padding-right: 0; text-align: left"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding-right: 0; text-align: left">whether
                                         the purchase contracts will be issued in fully registered or global form.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20; text-align: left">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">The<FONT STYLE="letter-spacing: 0.5pt">
</FONT>preceding<FONT STYLE="letter-spacing: 0.55pt"> </FONT>description<FONT STYLE="letter-spacing: 0.55pt"> </FONT>sets<FONT STYLE="letter-spacing: 0.5pt">
</FONT>forth<FONT STYLE="letter-spacing: 0.55pt"> </FONT>certain<FONT STYLE="letter-spacing: 0.55pt"> </FONT>general<FONT STYLE="letter-spacing: 0.55pt">
</FONT>terms<FONT STYLE="letter-spacing: 0.5pt"> </FONT>and<FONT STYLE="letter-spacing: 0.55pt"> </FONT>provisions<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.5pt"> </FONT>purchase<FONT STYLE="letter-spacing: 0.55pt">
</FONT>contracts<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to which<FONT STYLE="letter-spacing: 0.5pt"> </FONT>any<FONT STYLE="letter-spacing: 0.55pt">
</FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt"> </FONT>supplement<FONT STYLE="letter-spacing: 0.55pt"> </FONT>may<FONT STYLE="letter-spacing: 0.55pt">
</FONT>relate.<FONT STYLE="letter-spacing: 0.35pt"> </FONT>The<FONT STYLE="letter-spacing: 0.55pt"> </FONT>particular<FONT STYLE="letter-spacing: 0.55pt">
</FONT>terms<FONT STYLE="letter-spacing: 0.5pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>purchase<FONT STYLE="letter-spacing: 0.55pt"> </FONT>contracts<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt">
</FONT>which<FONT STYLE="letter-spacing: 0.55pt"> </FONT>any prospectus<FONT STYLE="letter-spacing: 0.55pt"> </FONT>supplement
may<FONT STYLE="letter-spacing: 0.6pt"> </FONT>relate<FONT STYLE="letter-spacing: 0.6pt"> </FONT>and<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>extent,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>if<FONT STYLE="letter-spacing: 0.6pt">
</FONT><FONT STYLE="letter-spacing: -0.25pt">any,</FONT><FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.6pt">
</FONT>which<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>general<FONT STYLE="letter-spacing: 0.55pt">
</FONT>provisions<FONT STYLE="letter-spacing: 0.6pt"> </FONT>may<FONT STYLE="letter-spacing: 0.6pt"> </FONT>apply<FONT STYLE="letter-spacing: 0.6pt">
</FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 1.15pt"> </FONT>purchase<FONT STYLE="letter-spacing: 0.55pt">
</FONT>contracts<FONT STYLE="letter-spacing: 0.55pt"> </FONT>so<FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">offered
</FONT>will<FONT STYLE="letter-spacing: 0.55pt"> </FONT>be<FONT STYLE="letter-spacing: 0.55pt"> </FONT>described<FONT STYLE="letter-spacing: 0.55pt">
</FONT>in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>applicable<FONT STYLE="letter-spacing: 0.55pt">
</FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt"> </FONT>supplement.<FONT STYLE="letter-spacing: 0.4pt"> </FONT><FONT STYLE="letter-spacing: -0.4pt">To
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>extent<FONT STYLE="letter-spacing: 0.55pt"> </FONT>that<FONT STYLE="letter-spacing: 0.55pt">
</FONT>any<FONT STYLE="letter-spacing: 1.2pt"> </FONT>particular<FONT STYLE="letter-spacing: 0.55pt"> </FONT>terms<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>purchase<FONT STYLE="letter-spacing: 0.55pt">
</FONT>contracts<FONT STYLE="letter-spacing: 0.55pt"> </FONT>described<FONT STYLE="letter-spacing: 0.55pt"> </FONT>in<FONT STYLE="letter-spacing: 0.55pt">
</FONT>a<FONT STYLE="letter-spacing: 0.6pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt"> </FONT>supplement<FONT STYLE="letter-spacing: 0.55pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">differ</FONT><FONT STYLE="letter-spacing: 0.55pt"> </FONT>from<FONT STYLE="letter-spacing: 0.55pt">
</FONT>any<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>terms<FONT STYLE="letter-spacing: 1.1pt"> </FONT>described<FONT STYLE="letter-spacing: 0.55pt"> </FONT>above,<FONT STYLE="letter-spacing: 0.55pt">
</FONT>then<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>terms<FONT STYLE="letter-spacing: 0.55pt">
</FONT>described<FONT STYLE="letter-spacing: 0.55pt"> </FONT>above<FONT STYLE="letter-spacing: 0.55pt"> </FONT>will<FONT STYLE="letter-spacing: 0.55pt">
</FONT>be<FONT STYLE="letter-spacing: 0.55pt"> </FONT>deemed<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.6pt">
</FONT>have<FONT STYLE="letter-spacing: 0.55pt"> </FONT>been<FONT STYLE="letter-spacing: 0.55pt"> </FONT>superseded<FONT STYLE="letter-spacing: 0.55pt">
</FONT>by<FONT STYLE="letter-spacing: 0.55pt"> </FONT>that<FONT STYLE="letter-spacing: 0.55pt"> </FONT>prospectus supplement.
<FONT STYLE="letter-spacing: -0.45pt">We</FONT><FONT STYLE="letter-spacing: 0.55pt"> </FONT>encourage<FONT STYLE="letter-spacing: 0.5pt">
</FONT>you<FONT STYLE="letter-spacing: 0.5pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>read<FONT STYLE="letter-spacing: 0.5pt">
</FONT>the<FONT STYLE="letter-spacing: 0.5pt"> </FONT>applicable<FONT STYLE="letter-spacing: 0.55pt"> </FONT>purchase<FONT STYLE="letter-spacing: 0.5pt">
</FONT>contract<FONT STYLE="letter-spacing: 0.5pt"> </FONT>for<FONT STYLE="letter-spacing: 0.55pt"> </FONT>additional<FONT STYLE="letter-spacing: 0.5pt">
</FONT>information<FONT STYLE="letter-spacing: 0.5pt"> </FONT>before<FONT STYLE="letter-spacing: 0.55pt"> </FONT>you<FONT STYLE="letter-spacing: 1pt">
</FONT>decide<FONT STYLE="letter-spacing: 0.5pt"> </FONT>whether<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt">
</FONT>purchase<FONT STYLE="letter-spacing: 0.5pt"> </FONT>any<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt">
</FONT>our<FONT STYLE="letter-spacing: 0.5pt"> </FONT>purchase<FONT STYLE="letter-spacing: 0.55pt"> </FONT>contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #231F20; text-indent: 0.5in"><A NAME="a-25"></A>DESCRIPTION
OF<FONT STYLE="letter-spacing: 1.55pt"> </FONT>UNITS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>may<FONT STYLE="letter-spacing: 0.6pt"> </FONT>issue<FONT STYLE="letter-spacing: 0.6pt"> </FONT>units<FONT STYLE="letter-spacing: 0.6pt">
</FONT>comprised<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>one<FONT STYLE="letter-spacing: 0.6pt">
</FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>more<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>other<FONT STYLE="letter-spacing: 0.6pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.6pt">
</FONT>described<FONT STYLE="letter-spacing: 0.6pt"> </FONT>in<FONT STYLE="letter-spacing: 0.6pt"> </FONT>this<FONT STYLE="letter-spacing: 0.6pt">
</FONT>prospectus<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>any<FONT STYLE="letter-spacing: 1pt">
</FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt"> </FONT>supplement<FONT STYLE="letter-spacing: 0.6pt"> </FONT>in<FONT STYLE="letter-spacing: 0.6pt">
</FONT>any<FONT STYLE="letter-spacing: 0.6pt"> </FONT>combination.<FONT STYLE="letter-spacing: 0.6pt"> </FONT>Each<FONT STYLE="letter-spacing: 0.6pt">
</FONT>unit<FONT STYLE="letter-spacing: 0.6pt"> </FONT>will<FONT STYLE="letter-spacing: 0.6pt"> </FONT>be<FONT STYLE="letter-spacing: 0.6pt">
</FONT>issued<FONT STYLE="letter-spacing: 0.6pt"> </FONT>so<FONT STYLE="letter-spacing: 0.6pt"> </FONT>that<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>holder<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>unit<FONT STYLE="letter-spacing: 0.6pt"> </FONT>is<FONT STYLE="letter-spacing: 0.6pt">
</FONT>also<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the <FONT STYLE="letter-spacing: -0.1pt">holder,</FONT><FONT STYLE="letter-spacing: 0.55pt">
</FONT>with<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>rights<FONT STYLE="letter-spacing: 0.55pt">
</FONT>and<FONT STYLE="letter-spacing: 0.6pt"> </FONT>obligations<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>a<FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.1pt">holder,</FONT><FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>each<FONT STYLE="letter-spacing: 0.55pt"> </FONT>security<FONT STYLE="letter-spacing: 0.6pt">
</FONT>included<FONT STYLE="letter-spacing: 0.6pt"> </FONT>in<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>unit.<FONT STYLE="letter-spacing: 0.4pt"> </FONT>The<FONT STYLE="letter-spacing: 0.6pt"> </FONT>unit<FONT STYLE="letter-spacing: 0.6pt">
</FONT>agreement<FONT STYLE="letter-spacing: 1.25pt"> </FONT>under<FONT STYLE="letter-spacing: 0.6pt"> </FONT>which<FONT STYLE="letter-spacing: 0.6pt">
</FONT>a<FONT STYLE="letter-spacing: 0.6pt"> </FONT>unit<FONT STYLE="letter-spacing: 0.6pt"> </FONT>is<FONT STYLE="letter-spacing: 0.6pt">
</FONT>issued<FONT STYLE="letter-spacing: 0.6pt"> </FONT>may<FONT STYLE="letter-spacing: 0.6pt"> </FONT>provide<FONT STYLE="letter-spacing: 0.6pt">
</FONT>that<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.6pt">
</FONT>included<FONT STYLE="letter-spacing: 0.6pt"> </FONT>in<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>unit<FONT STYLE="letter-spacing: 0.6pt"> </FONT>may<FONT STYLE="letter-spacing: 0.6pt"> </FONT>not<FONT STYLE="letter-spacing: 0.6pt">
</FONT>be<FONT STYLE="letter-spacing: 0.6pt"> </FONT>held<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: -0.15pt">
</FONT>transferred<FONT STYLE="letter-spacing: 0.8pt"> </FONT><FONT STYLE="letter-spacing: -0.1pt">separately,</FONT><FONT STYLE="letter-spacing: 0.55pt">
</FONT>at<FONT STYLE="letter-spacing: 0.55pt"> </FONT>any<FONT STYLE="letter-spacing: 0.55pt"> </FONT>time<FONT STYLE="letter-spacing: 0.6pt">
</FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>at<FONT STYLE="letter-spacing: 0.55pt"> </FONT>any<FONT STYLE="letter-spacing: 0.6pt">
</FONT>times<FONT STYLE="letter-spacing: 0.55pt"> </FONT>before<FONT STYLE="letter-spacing: 0.55pt"> </FONT>a<FONT STYLE="letter-spacing: 0.6pt">
</FONT>specified<FONT STYLE="letter-spacing: 0.55pt"> </FONT>date<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt">
</FONT>upon<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>occurrence<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>a<FONT STYLE="letter-spacing: 0.55pt"> </FONT>specified <FONT STYLE="letter-spacing: 0.15pt">
</FONT>event<FONT STYLE="letter-spacing: 0.4pt"> </FONT>or<FONT STYLE="letter-spacing: 0.4pt"> </FONT>occurrence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0.5in">The<FONT STYLE="letter-spacing: 0.4pt">
</FONT>applicable<FONT STYLE="letter-spacing: 0.4pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.4pt"> </FONT>supplement
will<FONT STYLE="letter-spacing: 0.4pt"> </FONT>describe:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding-right: 0"></TD><TD STYLE="width: 0.25in; padding-right: 0"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding-right: 0">the
                                         designation and the terms of the units and of the securities comprising the units, including
                                         whether and under what circumstances those securities may be held or transferred separately;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0">&nbsp;</TD><TD STYLE="padding-right: 0">&nbsp;</TD><TD STYLE="padding-right: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0"></TD><TD STYLE="padding-right: 0"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding-right: 0">any
                                         unit agreement under which the units will be issued;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0">&nbsp;</TD><TD STYLE="padding-right: 0">&nbsp;</TD><TD STYLE="padding-right: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0"></TD><TD STYLE="padding-right: 0"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding-right: 0">any
                                         provisions for the issuance, payment, settlement, transfer or exchange of the units or
                                         of the securities comprising the units; and</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0">&nbsp;</TD><TD STYLE="padding-right: 0">&nbsp;</TD><TD STYLE="padding-right: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0"></TD><TD STYLE="padding-right: 0"><FONT STYLE="font-family: Symbol; color: #231F20">&middot;</FONT></TD><TD STYLE="padding-right: 0">whether
                                         the units will be issued in fully registered or global form.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #231F20; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: #231F20"><A NAME="a-26"></A>PLAN
OF<FONT STYLE="letter-spacing: 1.2pt"> </FONT>DISTRIBUTION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>may<FONT STYLE="letter-spacing: 0.55pt"> </FONT>sell<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>securities<FONT STYLE="letter-spacing: 0.55pt"> </FONT>being<FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">offered
</FONT>pursuant<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>this<FONT STYLE="letter-spacing: 0.6pt">
</FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt">
</FONT>through<FONT STYLE="letter-spacing: 0.55pt"> </FONT>underwriters,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>through<FONT STYLE="letter-spacing: 1.15pt">
</FONT>dealers,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>through<FONT STYLE="letter-spacing: 0.55pt"> </FONT>agents,<FONT STYLE="letter-spacing: 0.55pt">
</FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>directly<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt">
</FONT>one<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>more<FONT STYLE="letter-spacing: 0.55pt">
</FONT>purchasers<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>through<FONT STYLE="letter-spacing: 0.55pt">
</FONT>a<FONT STYLE="letter-spacing: 0.6pt"> </FONT>combination<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt">
</FONT>these<FONT STYLE="letter-spacing: 0.55pt"> </FONT>methods.<FONT STYLE="letter-spacing: 0.4pt"> </FONT>The applicable<FONT STYLE="letter-spacing: 0.5pt">
</FONT>prospectus<FONT STYLE="letter-spacing: 0.5pt"> </FONT>supplement<FONT STYLE="letter-spacing: 0.55pt"> </FONT>will<FONT STYLE="letter-spacing: 0.5pt">
</FONT>describe<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>terms<FONT STYLE="letter-spacing: 0.5pt">
</FONT>of<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">offering
</FONT>of<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities,<FONT STYLE="letter-spacing: 0.5pt">
</FONT>including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding-right: 0"></TD><TD STYLE="width: 0.25in; padding-right: 0"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 0">the
                                         name<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt">
                                         </FONT>names<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.65pt">
                                         </FONT>any<FONT STYLE="letter-spacing: 0.6pt"> </FONT>underwriters,<FONT STYLE="letter-spacing: 0.6pt">
                                         </FONT>if<FONT STYLE="letter-spacing: 0.6pt"> </FONT><FONT STYLE="letter-spacing: -0.25pt">any,
                                         </FONT>and<FONT STYLE="letter-spacing: 0.6pt"> </FONT>if<FONT STYLE="letter-spacing: 0.6pt">
                                         </FONT>required,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>any<FONT STYLE="letter-spacing: 0.65pt">
                                         </FONT>dealers<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt">
                                         </FONT>agents;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0">&nbsp;</TD><TD STYLE="padding-right: 0">&nbsp;</TD><TD STYLE="padding-right: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0"></TD><TD STYLE="padding-right: 0"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 0">the
                                         purchase<FONT STYLE="letter-spacing: 0.6pt"> </FONT>price<FONT STYLE="letter-spacing: 0.6pt">
                                         </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
                                         </FONT>securities<FONT STYLE="letter-spacing: 0.6pt"> </FONT>and<FONT STYLE="letter-spacing: 0.6pt">
                                         </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>proceeds<FONT STYLE="letter-spacing: 0.6pt">
                                         </FONT>we<FONT STYLE="letter-spacing: 0.55pt"> </FONT>will<FONT STYLE="letter-spacing: 0.6pt">
                                         </FONT>receive<FONT STYLE="letter-spacing: 0.6pt"> </FONT>from<FONT STYLE="letter-spacing: 0.6pt">
                                         </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>sale;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0">&nbsp;</TD><TD STYLE="padding-right: 0">&nbsp;</TD><TD STYLE="padding-right: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0"></TD><TD STYLE="padding-right: 0"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 0">any
                                         underwriting<FONT STYLE="letter-spacing: 0.4pt"> </FONT>discounts<FONT STYLE="letter-spacing: 0.4pt">
                                         </FONT>and<FONT STYLE="letter-spacing: 0.4pt"> </FONT>other<FONT STYLE="letter-spacing: 0.35pt">
                                         </FONT>items<FONT STYLE="letter-spacing: 0.4pt"> </FONT>constituting<FONT STYLE="letter-spacing: 0.4pt">
                                         </FONT>underwriters&rsquo;<FONT STYLE="letter-spacing: -0.25pt"> </FONT>compensation;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0">&nbsp;</TD><TD STYLE="padding-right: 0">&nbsp;</TD><TD STYLE="padding-right: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0"></TD><TD STYLE="padding-right: 0"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 0">any
                                         discounts<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt">
                                         </FONT>concessions<FONT STYLE="letter-spacing: 0.55pt"> </FONT>allowed<FONT STYLE="letter-spacing: 0.55pt">
                                         </FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>re-allowed<FONT STYLE="letter-spacing: 0.55pt">
                                         </FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>paid<FONT STYLE="letter-spacing: 0.55pt">
                                         </FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>dealers;<FONT STYLE="letter-spacing: 0.6pt">
                                         </FONT>and</TD></TR>                                                                                                                                                                                                                                                                                                                                                                     <TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0">&nbsp;</TD><TD STYLE="padding-right: 0">&nbsp;</TD><TD STYLE="padding-right: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0">&nbsp;</TD><TD STYLE="padding-right: 0">&#9679;</TD><TD STYLE="padding-right: 0">any<FONT STYLE="letter-spacing: 0.55pt">
                                         </FONT>securities<FONT STYLE="letter-spacing: 0.55pt"> </FONT>exchange<FONT STYLE="letter-spacing: 0.6pt">
                                         </FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>market<FONT STYLE="letter-spacing: 0.6pt">
                                         </FONT>on<FONT STYLE="letter-spacing: 0.55pt"> </FONT>which<FONT STYLE="letter-spacing: 0.6pt">
                                         </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.6pt">
                                         </FONT>may<FONT STYLE="letter-spacing: 0.55pt"> </FONT>be<FONT STYLE="letter-spacing: 0.6pt">
                                         </FONT>listed<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt">
                                         </FONT>traded.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">We<FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20; letter-spacing: 0.6pt">
</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">may<FONT STYLE="letter-spacing: 0.6pt"> </FONT>distribute
the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.6pt"> </FONT>from<FONT STYLE="letter-spacing: 0.6pt">
</FONT>time<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>time<FONT STYLE="letter-spacing: 0.6pt">
</FONT>in<FONT STYLE="letter-spacing: 0.6pt"> </FONT>one<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt">
</FONT>more<FONT STYLE="letter-spacing: 0.6pt"> </FONT>transactions<FONT STYLE="letter-spacing: 0.6pt"> </FONT>at:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; padding-right: 0"></TD><TD STYLE="width: 0.25in; padding-right: 0"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 0">a
                                         fixed<FONT STYLE="letter-spacing: 0.55pt"> </FONT>price<FONT STYLE="letter-spacing: 0.55pt">
                                         </FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>prices,<FONT STYLE="letter-spacing: 0.55pt">
                                         </FONT>which<FONT STYLE="letter-spacing: 0.5pt"> </FONT>may<FONT STYLE="letter-spacing: 0.55pt">
                                         </FONT>be<FONT STYLE="letter-spacing: 0.55pt"> </FONT>changed;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0">&nbsp;</TD><TD STYLE="padding-right: 0">&nbsp;</TD><TD STYLE="padding-right: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0"></TD><TD STYLE="padding-right: 0"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 0">market
                                         prices<FONT STYLE="letter-spacing: 0.6pt"> </FONT>prevailing<FONT STYLE="letter-spacing: 0.6pt">
                                         </FONT>at<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
                                         </FONT>time<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
                                         </FONT>sale,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>directly<FONT STYLE="letter-spacing: 0.6pt">
                                         </FONT>by<FONT STYLE="letter-spacing: 0.55pt"> </FONT>us<FONT STYLE="letter-spacing: 0.6pt">
                                         </FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>through<FONT STYLE="letter-spacing: 0.6pt">
                                         </FONT>a<FONT STYLE="letter-spacing: 0.55pt"> </FONT>designated<FONT STYLE="letter-spacing: 0.6pt">
                                         </FONT>agent;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0">&nbsp;</TD><TD STYLE="padding-right: 0">&nbsp;</TD><TD STYLE="padding-right: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0"></TD><TD STYLE="padding-right: 0"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 0">prices
                                         related<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt">
                                         </FONT>such<FONT STYLE="letter-spacing: 0.55pt"> </FONT>prevailing<FONT STYLE="letter-spacing: 0.55pt">
                                         </FONT>market<FONT STYLE="letter-spacing: 0.55pt"> </FONT>prices;<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>or</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0">&nbsp;</TD><TD STYLE="padding-right: 0">&nbsp;</TD><TD STYLE="padding-right: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding-right: 0"></TD><TD STYLE="padding-right: 0"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 0">negotiated
                                         prices.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #231F20">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Only<FONT STYLE="letter-spacing: 0.5pt">
</FONT>underwriters<FONT STYLE="letter-spacing: 0.55pt"> </FONT>named<FONT STYLE="letter-spacing: 0.5pt"> </FONT>in<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.5pt"> </FONT>supplement<FONT STYLE="letter-spacing: 0.55pt">
</FONT>are<FONT STYLE="letter-spacing: 0.5pt"> </FONT>underwriters<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.5pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">offered
</FONT>by<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 1.15pt"> </FONT>prospectus<FONT STYLE="letter-spacing: -0.15pt">
</FONT>supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">If<FONT STYLE="letter-spacing: 0.5pt">
</FONT>underwriters<FONT STYLE="letter-spacing: 0.55pt"> </FONT>are<FONT STYLE="letter-spacing: 0.55pt"> </FONT>used<FONT STYLE="letter-spacing: 0.55pt">
</FONT>in<FONT STYLE="letter-spacing: 0.5pt"> </FONT>an<FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">offering,
</FONT>we<FONT STYLE="letter-spacing: 0.55pt"> </FONT>will<FONT STYLE="letter-spacing: 0.5pt"> </FONT>execute<FONT STYLE="letter-spacing: 0.55pt">
</FONT>an<FONT STYLE="letter-spacing: 0.55pt"> </FONT>underwriting<FONT STYLE="letter-spacing: 0.55pt"> </FONT>agreement<FONT STYLE="letter-spacing: 0.5pt">
</FONT>with<FONT STYLE="letter-spacing: 0.55pt"> </FONT>such<FONT STYLE="letter-spacing: -0.2pt"> </FONT>underwriters<FONT STYLE="letter-spacing: 2.05pt">
</FONT>and<FONT STYLE="letter-spacing: 0.55pt"> </FONT>will<FONT STYLE="letter-spacing: 0.55pt"> </FONT>specify<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>name<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt">
</FONT>each<FONT STYLE="letter-spacing: 0.55pt"> </FONT>underwriter<FONT STYLE="letter-spacing: 0.55pt"> </FONT>and<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>terms<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>transaction<FONT STYLE="letter-spacing: 0.55pt"> </FONT>(including<FONT STYLE="letter-spacing: 0.55pt">
</FONT>any<FONT STYLE="letter-spacing: -0.2pt"> </FONT>underwriting<FONT STYLE="letter-spacing: 0.8pt"> </FONT>discounts<FONT STYLE="letter-spacing: 0.5pt">
</FONT>and<FONT STYLE="letter-spacing: 0.5pt"> </FONT>other<FONT STYLE="letter-spacing: 0.55pt"> </FONT>terms<FONT STYLE="letter-spacing: 0.5pt">
</FONT>constituting<FONT STYLE="letter-spacing: 0.55pt"> </FONT>compensation<FONT STYLE="letter-spacing: 0.5pt"> </FONT>of<FONT STYLE="letter-spacing: 0.5pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>underwriters<FONT STYLE="letter-spacing: 0.5pt"> </FONT>and<FONT STYLE="letter-spacing: 0.55pt">
</FONT>any<FONT STYLE="letter-spacing: 0.5pt"> </FONT>dealers)<FONT STYLE="letter-spacing: 0.5pt"> </FONT>in<FONT STYLE="letter-spacing: 0.55pt">
</FONT>a<FONT STYLE="letter-spacing: -0.25pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.8pt"> </FONT>supplement.<FONT STYLE="letter-spacing: 0.3pt">
</FONT>The<FONT STYLE="letter-spacing: 0.45pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.5pt"> </FONT>may<FONT STYLE="letter-spacing: 0.5pt">
</FONT>be<FONT STYLE="letter-spacing: 0.5pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">offered</FONT><FONT STYLE="letter-spacing: 0.45pt">
</FONT>to<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.5pt"> </FONT>public<FONT STYLE="letter-spacing: 0.5pt">
</FONT>either<FONT STYLE="letter-spacing: 0.5pt"> </FONT>through<FONT STYLE="letter-spacing: 0.45pt"> </FONT>underwriting<FONT STYLE="letter-spacing: 0.5pt">
</FONT>syndicates<FONT STYLE="letter-spacing: -0.25pt"> </FONT>represented<FONT STYLE="letter-spacing: 0.8pt"> </FONT><FONT STYLE="letter-spacing: 0.65pt">
</FONT>by<FONT STYLE="letter-spacing: 0.5pt"> </FONT>managing<FONT STYLE="letter-spacing: 0.5pt"> </FONT>underwriters<FONT STYLE="letter-spacing: 0.5pt">
</FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>directly<FONT STYLE="letter-spacing: 0.5pt"> </FONT>by<FONT STYLE="letter-spacing: 0.5pt">
</FONT>one<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.5pt"> </FONT>more<FONT STYLE="letter-spacing: 0.5pt">
</FONT>investment<FONT STYLE="letter-spacing: 0.55pt"> </FONT>banking<FONT STYLE="letter-spacing: 0.5pt"> </FONT>firms<FONT STYLE="letter-spacing: 0.5pt">
</FONT>or<FONT STYLE="letter-spacing: 0.5pt"> </FONT>others,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>as<FONT STYLE="letter-spacing: -0.25pt">
</FONT>designated.<FONT STYLE="letter-spacing: 0.8pt"> </FONT>If<FONT STYLE="letter-spacing: 0.5pt"> </FONT>an<FONT STYLE="letter-spacing: 0.55pt">
</FONT>underwriting<FONT STYLE="letter-spacing: 0.55pt"> </FONT>syndicate<FONT STYLE="letter-spacing: 0.55pt"> </FONT>is<FONT STYLE="letter-spacing: 0.55pt">
</FONT>used,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>managing<FONT STYLE="letter-spacing: 0.5pt">
</FONT>underwriter(s)<FONT STYLE="letter-spacing: 0.55pt"> </FONT>will<FONT STYLE="letter-spacing: 0.55pt"> </FONT>be<FONT STYLE="letter-spacing: 0.55pt">
</FONT>specified<FONT STYLE="letter-spacing: 0.55pt"> </FONT>on<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>cover<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: -0.25pt"> </FONT>the<FONT STYLE="letter-spacing: 0.8pt">
</FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt"> </FONT>supplement.<FONT STYLE="letter-spacing: 0.55pt"> </FONT>If<FONT STYLE="letter-spacing: 0.55pt">
</FONT>underwriters<FONT STYLE="letter-spacing: 0.6pt"> </FONT>are<FONT STYLE="letter-spacing: 0.55pt"> </FONT>used<FONT STYLE="letter-spacing: 0.55pt">
</FONT>in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>sale,<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">offered</FONT><FONT STYLE="letter-spacing: 0.6pt">
</FONT>securities<FONT STYLE="letter-spacing: 0.55pt"> </FONT>will<FONT STYLE="letter-spacing: 0.55pt"> </FONT>be<FONT STYLE="letter-spacing: 0.55pt">
</FONT>acquired<FONT STYLE="letter-spacing: 0.6pt"> </FONT>by<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 1.15pt">
</FONT>underwriters<FONT STYLE="letter-spacing: 0.55pt"> </FONT>for<FONT STYLE="letter-spacing: 0.6pt"> </FONT>their<FONT STYLE="letter-spacing: 0.6pt">
</FONT>own<FONT STYLE="letter-spacing: 0.55pt"> </FONT>accounts<FONT STYLE="letter-spacing: 0.6pt"> </FONT>and<FONT STYLE="letter-spacing: 0.6pt">
</FONT>may<FONT STYLE="letter-spacing: 0.6pt"> </FONT>be<FONT STYLE="letter-spacing: 0.55pt"> </FONT>resold<FONT STYLE="letter-spacing: 0.6pt">
</FONT>from<FONT STYLE="letter-spacing: 0.6pt"> </FONT>time<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt">
</FONT>time<FONT STYLE="letter-spacing: 0.6pt"> </FONT>in<FONT STYLE="letter-spacing: 0.6pt"> </FONT>one<FONT STYLE="letter-spacing: 0.6pt">
</FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>more<FONT STYLE="letter-spacing: 0.6pt"> </FONT>transactions, including
negotiated<FONT STYLE="letter-spacing: 0.55pt"> </FONT>transactions,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>at<FONT STYLE="letter-spacing: 0.55pt">
</FONT>a<FONT STYLE="letter-spacing: 0.55pt"> </FONT>fixed<FONT STYLE="letter-spacing: 0.5pt"> </FONT>public<FONT STYLE="letter-spacing: 0.55pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">offering</FONT><FONT STYLE="letter-spacing: 0.55pt"> </FONT>price<FONT STYLE="letter-spacing: 0.55pt">
</FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>at<FONT STYLE="letter-spacing: 0.5pt"> </FONT>varying<FONT STYLE="letter-spacing: 0.55pt">
</FONT>prices<FONT STYLE="letter-spacing: 0.55pt"> </FONT>determined<FONT STYLE="letter-spacing: 0.55pt"> </FONT>at<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>time<FONT STYLE="letter-spacing: 0.5pt"> </FONT>of<FONT STYLE="letter-spacing: 1.2pt">
</FONT>sale.<FONT STYLE="letter-spacing: 0.05pt"> </FONT>Any<FONT STYLE="letter-spacing: 0.55pt"> </FONT>public<FONT STYLE="letter-spacing: 0.55pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">offering</FONT><FONT STYLE="letter-spacing: 0.6pt"> </FONT>price<FONT STYLE="letter-spacing: 0.55pt">
</FONT>and<FONT STYLE="letter-spacing: 0.55pt"> </FONT>any<FONT STYLE="letter-spacing: 0.6pt"> </FONT>discounts<FONT STYLE="letter-spacing: 0.55pt">
</FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>concessions<FONT STYLE="letter-spacing: 0.6pt"> </FONT>allowed<FONT STYLE="letter-spacing: 0.55pt">
</FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>reallowed<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt">
</FONT>paid<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>dealers<FONT STYLE="letter-spacing: 0.6pt">
</FONT>may<FONT STYLE="letter-spacing: 1.2pt"> </FONT>be<FONT STYLE="letter-spacing: 0.55pt"> </FONT>changed<FONT STYLE="letter-spacing: 0.55pt">
</FONT>from<FONT STYLE="letter-spacing: 0.6pt"> </FONT>time<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt">
</FONT>time.<FONT STYLE="letter-spacing: 0.6pt"> </FONT>Unless<FONT STYLE="letter-spacing: 0.55pt"> </FONT>otherwise<FONT STYLE="letter-spacing: 0.6pt">
</FONT>set<FONT STYLE="letter-spacing: 0.55pt"> </FONT>forth<FONT STYLE="letter-spacing: 0.55pt"> </FONT>in<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt"> </FONT>supplement,<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>obligations<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the underwriters<FONT STYLE="letter-spacing: 0.5pt"> </FONT>to<FONT STYLE="letter-spacing: 0.5pt"> </FONT>purchase<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.5pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">offered</FONT><FONT STYLE="letter-spacing: 0.55pt">
</FONT>securities<FONT STYLE="letter-spacing: 0.5pt"> </FONT>will<FONT STYLE="letter-spacing: 0.55pt"> </FONT>be<FONT STYLE="letter-spacing: 0.5pt">
</FONT>subject<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.5pt"> </FONT>conditions<FONT STYLE="letter-spacing: 0.5pt">
</FONT>precedent,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>and<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>underwriters<FONT STYLE="letter-spacing: -0.25pt"> </FONT>will<FONT STYLE="letter-spacing: 1.95pt"> </FONT>be<FONT STYLE="letter-spacing: 0.55pt">
</FONT>obligated<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>purchase<FONT STYLE="letter-spacing: 0.6pt">
</FONT>all<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">offered</FONT><FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities,<FONT STYLE="letter-spacing: 0.6pt">
</FONT>if<FONT STYLE="letter-spacing: 0.55pt"> </FONT>any<FONT STYLE="letter-spacing: 0.6pt"> </FONT>are<FONT STYLE="letter-spacing: 0.55pt">
</FONT>purchased.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>may<FONT STYLE="letter-spacing: 0.55pt"> </FONT>grant<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>underwriters<FONT STYLE="letter-spacing: 0.55pt"> </FONT>options<FONT STYLE="letter-spacing: 0.55pt">
</FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>purchase<FONT STYLE="letter-spacing: 0.55pt"> </FONT>additional<FONT STYLE="letter-spacing: 0.6pt">
</FONT>securities<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>cover<FONT STYLE="letter-spacing: 0.55pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">over-allotments,</FONT><FONT STYLE="letter-spacing: 0.55pt"> </FONT>if<FONT STYLE="letter-spacing: -0.2pt">
</FONT><FONT STYLE="letter-spacing: -0.25pt">any,</FONT><FONT STYLE="letter-spacing: 2.35pt"> </FONT>at<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>public<FONT STYLE="letter-spacing: 0.6pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">offering
</FONT>price,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>with<FONT STYLE="letter-spacing: 0.6pt"> </FONT>additional<FONT STYLE="letter-spacing: 0.55pt">
</FONT>underwriting<FONT STYLE="letter-spacing: 0.6pt"> </FONT>commissions<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt">
</FONT>discounts,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>as<FONT STYLE="letter-spacing: 0.55pt"> </FONT>may<FONT STYLE="letter-spacing: 0.55pt">
</FONT>be<FONT STYLE="letter-spacing: 0.6pt"> </FONT>set<FONT STYLE="letter-spacing: 0.55pt"> </FONT>forth<FONT STYLE="letter-spacing: 0.6pt">
</FONT>in<FONT STYLE="letter-spacing: -0.2pt"> </FONT>a<FONT STYLE="letter-spacing: 2pt"> </FONT>related<FONT STYLE="letter-spacing: 0.5pt">
</FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt"> </FONT>supplement.<FONT STYLE="letter-spacing: 0.35pt"> </FONT>The<FONT STYLE="letter-spacing: 0.55pt">
</FONT>terms<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>any<FONT STYLE="letter-spacing: 0.55pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">over-allotment</FONT><FONT STYLE="letter-spacing: 0.55pt"> </FONT>option<FONT STYLE="letter-spacing: 0.55pt">
</FONT>will<FONT STYLE="letter-spacing: 0.55pt"> </FONT>be<FONT STYLE="letter-spacing: 0.55pt"> </FONT>set<FONT STYLE="letter-spacing: 0.5pt">
</FONT>forth<FONT STYLE="letter-spacing: 0.55pt"> </FONT>in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>prospectus<FONT STYLE="letter-spacing: 1.05pt"> </FONT>supplement<FONT STYLE="letter-spacing: 0.4pt"> </FONT>for<FONT STYLE="letter-spacing: 0.4pt">
</FONT>those<FONT STYLE="letter-spacing: 0.4pt"> </FONT>securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">If<FONT STYLE="letter-spacing: 0.6pt">
</FONT>we<FONT STYLE="letter-spacing: 0.6pt"> </FONT>use<FONT STYLE="letter-spacing: 0.6pt"> </FONT>a<FONT STYLE="letter-spacing: 0.6pt">
</FONT>dealer<FONT STYLE="letter-spacing: 0.6pt"> </FONT>in<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>sale<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.65pt">
</FONT>securities<FONT STYLE="letter-spacing: 0.6pt"> </FONT>being<FONT STYLE="letter-spacing: 0.6pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">offered
</FONT>pursuant<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>this<FONT STYLE="letter-spacing: 0.6pt">
</FONT>prospectus<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>any<FONT STYLE="letter-spacing: 0.6pt">
</FONT>prospectus<FONT STYLE="letter-spacing: 1.15pt"> </FONT>supplement,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>we<FONT STYLE="letter-spacing: 0.6pt">
</FONT>will<FONT STYLE="letter-spacing: 0.6pt"> </FONT>sell<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>securities<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT><FONT STYLE="letter-spacing: -0.1pt">dealer,</FONT><FONT STYLE="letter-spacing: 0.6pt"> </FONT>as<FONT STYLE="letter-spacing: 0.55pt">
</FONT>principal.<FONT STYLE="letter-spacing: 0.4pt"> </FONT>The<FONT STYLE="letter-spacing: 0.6pt"> </FONT>dealer<FONT STYLE="letter-spacing: 0.6pt">
</FONT>may<FONT STYLE="letter-spacing: 0.55pt"> </FONT>then<FONT STYLE="letter-spacing: 0.6pt"> </FONT>resell<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 1.3pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>public<FONT STYLE="letter-spacing: 0.6pt"> </FONT>at<FONT STYLE="letter-spacing: 0.65pt">
</FONT>varying<FONT STYLE="letter-spacing: 0.6pt"> </FONT>prices<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.65pt">
</FONT>be<FONT STYLE="letter-spacing: 0.6pt"> </FONT>determined<FONT STYLE="letter-spacing: 0.6pt"> </FONT>by<FONT STYLE="letter-spacing: 0.65pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>dealer<FONT STYLE="letter-spacing: 0.6pt"> </FONT>at<FONT STYLE="letter-spacing: 0.65pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>time<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.65pt">
</FONT>resale.<FONT STYLE="letter-spacing: 0.4pt"> </FONT>The<FONT STYLE="letter-spacing: 0.6pt"> </FONT>names<FONT STYLE="letter-spacing: 0.65pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>dealers<FONT STYLE="letter-spacing: 0.65pt">
</FONT>and the<FONT STYLE="letter-spacing: 0.5pt"> </FONT>terms<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.5pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>transaction<FONT STYLE="letter-spacing: 0.5pt"> </FONT>will<FONT STYLE="letter-spacing: 0.55pt">
</FONT>be<FONT STYLE="letter-spacing: 0.5pt"> </FONT>specified<FONT STYLE="letter-spacing: 0.55pt"> </FONT>in<FONT STYLE="letter-spacing: 0.5pt">
</FONT>a<FONT STYLE="letter-spacing: 0.55pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt"> </FONT>supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>may<FONT STYLE="letter-spacing: 0.6pt"> </FONT>sell<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>securities<FONT STYLE="letter-spacing: 0.6pt"> </FONT>directly<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt">
</FONT>through<FONT STYLE="letter-spacing: 0.6pt"> </FONT>agents<FONT STYLE="letter-spacing: 0.6pt"> </FONT>we<FONT STYLE="letter-spacing: 0.6pt">
</FONT>designate<FONT STYLE="letter-spacing: 0.65pt"> </FONT>from<FONT STYLE="letter-spacing: 0.6pt"> </FONT>time<FONT STYLE="letter-spacing: 0.6pt">
</FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>time.<FONT STYLE="letter-spacing: 0.4pt"> </FONT><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>will<FONT STYLE="letter-spacing: 0.6pt"> </FONT>name<FONT STYLE="letter-spacing: 0.6pt"> </FONT>any<FONT STYLE="letter-spacing: 1pt">
</FONT>agent<FONT STYLE="letter-spacing: 0.55pt"> </FONT>involved<FONT STYLE="letter-spacing: 0.6pt"> </FONT>in<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">offering</FONT><FONT STYLE="letter-spacing: 0.55pt">
</FONT>and<FONT STYLE="letter-spacing: 0.6pt"> </FONT>sale<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>securities<FONT STYLE="letter-spacing: 0.55pt"> </FONT>and<FONT STYLE="letter-spacing: 0.6pt"> </FONT>we<FONT STYLE="letter-spacing: 0.6pt">
</FONT>will<FONT STYLE="letter-spacing: 0.6pt"> </FONT>describe<FONT STYLE="letter-spacing: 0.6pt"> </FONT>any<FONT STYLE="letter-spacing: 0.55pt">
</FONT>commissions<FONT STYLE="letter-spacing: 0.6pt"> </FONT>we<FONT STYLE="letter-spacing: 0.6pt"> </FONT>will<FONT STYLE="letter-spacing: 0.6pt">
</FONT>pay<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 1.2pt"> </FONT>agent<FONT STYLE="letter-spacing: 0.5pt">
</FONT>in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt">
</FONT>supplement.<FONT STYLE="letter-spacing: 0.55pt"> </FONT>Unless<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt"> </FONT>supplement<FONT STYLE="letter-spacing: 0.55pt"> </FONT>states<FONT STYLE="letter-spacing: 0.55pt">
</FONT>otherwise,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>any<FONT STYLE="letter-spacing: 0.55pt"> </FONT>agent<FONT STYLE="letter-spacing: 0.55pt">
</FONT>will<FONT STYLE="letter-spacing: 0.55pt"> </FONT>act<FONT STYLE="letter-spacing: 0.55pt"> </FONT>on<FONT STYLE="letter-spacing: 0.55pt">
</FONT>a <FONT STYLE="letter-spacing: -0.05pt">best-efforts</FONT><FONT STYLE="letter-spacing: 0.5pt"> </FONT>basis<FONT STYLE="letter-spacing: 0.55pt">
</FONT>for<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.5pt"> </FONT>period<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>its<FONT STYLE="letter-spacing: 0.5pt"> </FONT>appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>may<FONT STYLE="letter-spacing: 0.55pt"> </FONT>authorize<FONT STYLE="letter-spacing: 0.55pt"> </FONT>agents<FONT STYLE="letter-spacing: 0.5pt">
</FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>underwriters<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.5pt">
</FONT>solicit<FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">offers</FONT><FONT STYLE="letter-spacing: 0.55pt">
</FONT>by<FONT STYLE="letter-spacing: 0.5pt"> </FONT>institutional<FONT STYLE="letter-spacing: 0.55pt"> </FONT>investors<FONT STYLE="letter-spacing: 0.55pt">
</FONT>to<FONT STYLE="letter-spacing: 0.5pt"> </FONT>purchase<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities<FONT STYLE="letter-spacing: 1.1pt">
</FONT>from<FONT STYLE="letter-spacing: 0.55pt"> </FONT>us<FONT STYLE="letter-spacing: 0.55pt"> </FONT>at<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>public<FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">offering
</FONT>price<FONT STYLE="letter-spacing: 0.55pt"> </FONT>set<FONT STYLE="letter-spacing: 0.55pt"> </FONT>forth<FONT STYLE="letter-spacing: 0.6pt">
</FONT>in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt">
</FONT>supplement<FONT STYLE="letter-spacing: 0.55pt"> </FONT>pursuant<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt">
</FONT>delayed<FONT STYLE="letter-spacing: 0.55pt"> </FONT>delivery<FONT STYLE="letter-spacing: 1.2pt"> </FONT>contracts<FONT STYLE="letter-spacing: 0.55pt">
</FONT>providing<FONT STYLE="letter-spacing: 0.5pt"> </FONT>for<FONT STYLE="letter-spacing: 0.55pt"> </FONT>payment<FONT STYLE="letter-spacing: 0.55pt">
</FONT>and<FONT STYLE="letter-spacing: 0.55pt"> </FONT>delivery<FONT STYLE="letter-spacing: 0.55pt"> </FONT>on<FONT STYLE="letter-spacing: 0.55pt">
</FONT>a<FONT STYLE="letter-spacing: 0.55pt"> </FONT>specified<FONT STYLE="letter-spacing: 0.55pt"> </FONT>date<FONT STYLE="letter-spacing: 0.55pt">
</FONT>in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>future.<FONT STYLE="letter-spacing: 0.4pt">
</FONT><FONT STYLE="letter-spacing: -0.45pt">We</FONT><FONT STYLE="letter-spacing: 0.55pt"> </FONT>will<FONT STYLE="letter-spacing: 0.55pt">
</FONT>describe<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>conditions to<FONT STYLE="letter-spacing: 0.55pt">
</FONT>these<FONT STYLE="letter-spacing: 0.55pt"> </FONT>contracts<FONT STYLE="letter-spacing: 0.6pt"> </FONT>and<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>commissions<FONT STYLE="letter-spacing: 0.6pt"> </FONT>we<FONT STYLE="letter-spacing: 0.55pt">
</FONT>must<FONT STYLE="letter-spacing: 0.55pt"> </FONT>pay<FONT STYLE="letter-spacing: 0.6pt"> </FONT>for<FONT STYLE="letter-spacing: 0.55pt">
</FONT>solicitation<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>these<FONT STYLE="letter-spacing: 0.55pt">
</FONT>contracts<FONT STYLE="letter-spacing: 0.55pt"> </FONT>in<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">In<FONT STYLE="letter-spacing: 0.5pt">
</FONT>connection<FONT STYLE="letter-spacing: 0.55pt"> </FONT>with<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>sale<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>securities,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>underwriters,<FONT STYLE="letter-spacing: 0.5pt"> </FONT>dealers
or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>agents<FONT STYLE="letter-spacing: 0.5pt"> </FONT>may<FONT STYLE="letter-spacing: 0.55pt">
</FONT>receive<FONT STYLE="letter-spacing: 0.5pt"> </FONT>compensation from<FONT STYLE="letter-spacing: 0.55pt"> </FONT>us<FONT STYLE="letter-spacing: 0.6pt">
</FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>from<FONT STYLE="letter-spacing: 0.6pt"> </FONT>purchasers<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.6pt">
</FONT>for<FONT STYLE="letter-spacing: 0.6pt"> </FONT>whom<FONT STYLE="letter-spacing: 0.55pt"> </FONT>they<FONT STYLE="letter-spacing: 0.6pt">
</FONT>act<FONT STYLE="letter-spacing: 0.6pt"> </FONT>as<FONT STYLE="letter-spacing: 0.6pt"> </FONT>agents,<FONT STYLE="letter-spacing: 0.6pt">
</FONT>in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>form<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>discounts,<FONT STYLE="letter-spacing: -0.2pt"> </FONT>concessions<FONT STYLE="letter-spacing: 0.8pt">
</FONT>or<FONT STYLE="letter-spacing: 0.5pt"> </FONT>commissions.<FONT STYLE="letter-spacing: 0.55pt"> </FONT>Underwriters<FONT STYLE="letter-spacing: 0.55pt">
</FONT>may<FONT STYLE="letter-spacing: 0.55pt"> </FONT>sell<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>securities<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt">
</FONT>through<FONT STYLE="letter-spacing: 0.5pt"> </FONT>dealers,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>and<FONT STYLE="letter-spacing: 0.55pt">
</FONT>those<FONT STYLE="letter-spacing: 0.55pt"> </FONT>dealers<FONT STYLE="letter-spacing: 0.5pt"> </FONT>may<FONT STYLE="letter-spacing: -0.2pt">
</FONT>receive<FONT STYLE="letter-spacing: 0.8pt"> </FONT>compensation<FONT STYLE="letter-spacing: 0.45pt"> </FONT>in<FONT STYLE="letter-spacing: 0.5pt">
</FONT>the<FONT STYLE="letter-spacing: 0.5pt"> </FONT>form<FONT STYLE="letter-spacing: 0.5pt"> </FONT>of<FONT STYLE="letter-spacing: 0.5pt">
</FONT>discounts,<FONT STYLE="letter-spacing: 0.45pt"> </FONT>concessions<FONT STYLE="letter-spacing: 0.5pt"> </FONT>or<FONT STYLE="letter-spacing: 0.5pt">
</FONT>commissions<FONT STYLE="letter-spacing: 0.5pt"> </FONT>from<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.45pt">
</FONT>underwriters<FONT STYLE="letter-spacing: 0.5pt"> </FONT>or<FONT STYLE="letter-spacing: -0.25pt"> </FONT>commissions<FONT STYLE="letter-spacing: 0.8pt">
</FONT>from<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>purchasers<FONT STYLE="letter-spacing: 0.55pt">
</FONT>for<FONT STYLE="letter-spacing: 0.55pt"> </FONT>whom<FONT STYLE="letter-spacing: 0.55pt"> </FONT>they<FONT STYLE="letter-spacing: 0.55pt">
</FONT>may<FONT STYLE="letter-spacing: 0.55pt"> </FONT>act<FONT STYLE="letter-spacing: 0.55pt"> </FONT>as<FONT STYLE="letter-spacing: 0.55pt">
</FONT>agents.<FONT STYLE="letter-spacing: 0.55pt"> </FONT>Underwriters,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>dealers<FONT STYLE="letter-spacing: 0.55pt">
</FONT>and<FONT STYLE="letter-spacing: 0.55pt"> </FONT>agents<FONT STYLE="letter-spacing: 0.5pt"> </FONT>that<FONT STYLE="letter-spacing: -0.2pt">
</FONT>participate<FONT STYLE="letter-spacing: 0.8pt"> </FONT>in<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>distribution<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>securities,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>and<FONT STYLE="letter-spacing: 0.5pt"> </FONT>any<FONT STYLE="letter-spacing: 0.55pt">
</FONT>institutional<FONT STYLE="letter-spacing: 0.55pt"> </FONT>investors<FONT STYLE="letter-spacing: 0.5pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt">
</FONT>others<FONT STYLE="letter-spacing: 0.55pt"> </FONT>that<FONT STYLE="letter-spacing: 0.55pt"> </FONT>purchase<FONT STYLE="letter-spacing: 0.5pt">
</FONT>securities<FONT STYLE="letter-spacing: -0.2pt"> </FONT>directly<FONT STYLE="letter-spacing: 0.8pt"> </FONT>for<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>purpose<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt">
</FONT>resale<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>distribution,<FONT STYLE="letter-spacing: 0.55pt">
</FONT>may<FONT STYLE="letter-spacing: 0.55pt"> </FONT>be<FONT STYLE="letter-spacing: 0.6pt"> </FONT>deemed<FONT STYLE="letter-spacing: 0.55pt">
</FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>be<FONT STYLE="letter-spacing: 0.55pt"> </FONT>underwriters,<FONT STYLE="letter-spacing: 0.6pt">
</FONT>and<FONT STYLE="letter-spacing: 0.55pt"> </FONT>any<FONT STYLE="letter-spacing: 0.55pt"> </FONT>discounts<FONT STYLE="letter-spacing: 0.55pt">
</FONT>or<FONT STYLE="letter-spacing: -0.2pt"> </FONT>commissions<FONT STYLE="letter-spacing: 0.8pt"> </FONT>received<FONT STYLE="letter-spacing: 0.55pt">
</FONT>by<FONT STYLE="letter-spacing: 0.6pt"> </FONT>them<FONT STYLE="letter-spacing: 0.6pt"> </FONT>from<FONT STYLE="letter-spacing: 0.6pt">
</FONT>us<FONT STYLE="letter-spacing: 0.55pt"> </FONT>and<FONT STYLE="letter-spacing: 0.6pt"> </FONT>any<FONT STYLE="letter-spacing: 0.6pt">
</FONT>profit<FONT STYLE="letter-spacing: 0.6pt"> </FONT>on<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>resale<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>common<FONT STYLE="letter-spacing: 0.6pt"> </FONT>stock<FONT STYLE="letter-spacing: 0.6pt"> </FONT>by<FONT STYLE="letter-spacing: 0.6pt">
</FONT>them<FONT STYLE="letter-spacing: 0.55pt"> </FONT>may<FONT STYLE="letter-spacing: 0.6pt"> </FONT>be<FONT STYLE="letter-spacing: -0.2pt">
</FONT>deemed<FONT STYLE="letter-spacing: 0.8pt"> </FONT>to<FONT STYLE="letter-spacing: 0.5pt"> </FONT>be<FONT STYLE="letter-spacing: 0.55pt">
</FONT>underwriting<FONT STYLE="letter-spacing: 0.55pt"> </FONT>discounts<FONT STYLE="letter-spacing: 0.5pt"> </FONT>and<FONT STYLE="letter-spacing: 0.55pt">
</FONT>commissions<FONT STYLE="letter-spacing: 0.55pt"> </FONT>under<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>Securities<FONT STYLE="letter-spacing: 0.05pt"> </FONT>Act<FONT STYLE="letter-spacing: 0.5pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt">
</FONT>1933,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>as<FONT STYLE="letter-spacing: 0.55pt"> </FONT>amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>may<FONT STYLE="letter-spacing: 0.45pt"> </FONT>provide<FONT STYLE="letter-spacing: 0.45pt"> </FONT>agents,<FONT STYLE="letter-spacing: 0.4pt">
</FONT>underwriters<FONT STYLE="letter-spacing: 0.45pt"> </FONT>and<FONT STYLE="letter-spacing: 0.45pt"> </FONT>other<FONT STYLE="letter-spacing: 0.45pt">
</FONT>purchasers<FONT STYLE="letter-spacing: 0.4pt"> </FONT>with<FONT STYLE="letter-spacing: 0.45pt"> </FONT>indemnification
against<FONT STYLE="letter-spacing: 0.4pt"> </FONT>particular<FONT STYLE="letter-spacing: 0.45pt"> </FONT>civil<FONT STYLE="letter-spacing: 1pt">
</FONT>liabilities,<FONT STYLE="letter-spacing: 0.5pt"> </FONT>including<FONT STYLE="letter-spacing: 0.55pt"> </FONT>liabilities
under<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>Securities<FONT STYLE="letter-spacing: 0.05pt">
</FONT>Act<FONT STYLE="letter-spacing: 0.5pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>1933,<FONT STYLE="letter-spacing: 0.55pt">
</FONT>as<FONT STYLE="letter-spacing: 0.5pt"> </FONT>amended,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt">
</FONT>contribution<FONT STYLE="letter-spacing: 0.55pt"> </FONT>with<FONT STYLE="letter-spacing: 0.5pt"> </FONT>respect<FONT STYLE="letter-spacing: 0.55pt">
</FONT>to payments<FONT STYLE="letter-spacing: 0.5pt"> </FONT>that<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>agents,<FONT STYLE="letter-spacing: 0.5pt"> </FONT>underwriters<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt">
</FONT>other<FONT STYLE="letter-spacing: 0.5pt"> </FONT>purchasers<FONT STYLE="letter-spacing: 0.55pt"> </FONT>may<FONT STYLE="letter-spacing: 0.55pt">
</FONT>make<FONT STYLE="letter-spacing: 0.5pt"> </FONT>with<FONT STYLE="letter-spacing: 0.55pt"> </FONT>respect<FONT STYLE="letter-spacing: 0.55pt">
</FONT>to<FONT STYLE="letter-spacing: 0.5pt"> </FONT>such<FONT STYLE="letter-spacing: 0.55pt"> </FONT>liabilities.<FONT STYLE="letter-spacing: 0.05pt">
</FONT>Agents and<FONT STYLE="letter-spacing: 0.55pt"> </FONT>underwriters<FONT STYLE="letter-spacing: 0.55pt"> </FONT>may<FONT STYLE="letter-spacing: 0.6pt">
</FONT>engage<FONT STYLE="letter-spacing: 0.55pt"> </FONT>in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>transactions<FONT STYLE="letter-spacing: 0.6pt">
</FONT>with,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>perform<FONT STYLE="letter-spacing: 0.6pt">
</FONT>services<FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.1pt">for,</FONT><FONT STYLE="letter-spacing: 0.6pt">
</FONT>us<FONT STYLE="letter-spacing: 0.55pt"> </FONT>in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>ordinary<FONT STYLE="letter-spacing: 0.55pt"> </FONT>course<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 1pt">
</FONT>business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="letter-spacing: -0.4pt">To
</FONT>facilitate<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>public<FONT STYLE="letter-spacing: 0.55pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">offering</FONT><FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>a<FONT STYLE="letter-spacing: 0.55pt"> </FONT>series<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt">
</FONT>securities,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>persons<FONT STYLE="letter-spacing: 0.6pt"> </FONT>participating
in<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">offering
</FONT>may<FONT STYLE="letter-spacing: 0.6pt"> </FONT>engage<FONT STYLE="letter-spacing: 1.45pt"> </FONT>in<FONT STYLE="letter-spacing: 0.55pt">
</FONT>transactions<FONT STYLE="letter-spacing: 0.55pt"> </FONT>that<FONT STYLE="letter-spacing: 0.5pt"> </FONT>stabilize,<FONT STYLE="letter-spacing: 0.55pt">
</FONT>maintain,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>otherwise<FONT STYLE="letter-spacing: 0.55pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">affect</FONT><FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>market<FONT STYLE="letter-spacing: 0.55pt"> </FONT>price<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities.<FONT STYLE="letter-spacing: 0.4pt"> </FONT>This<FONT STYLE="letter-spacing: 0.55pt">
</FONT>may<FONT STYLE="letter-spacing: 0.55pt"> </FONT>include<FONT STYLE="letter-spacing: 1.1pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">over-allotments
</FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>short<FONT STYLE="letter-spacing: 0.5pt"> </FONT>sales<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities,<FONT STYLE="letter-spacing: 0.55pt">
</FONT>which<FONT STYLE="letter-spacing: 0.55pt"> </FONT>involves<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>sale<FONT STYLE="letter-spacing: 0.55pt"> </FONT>by<FONT STYLE="letter-spacing: 0.55pt"> </FONT>persons<FONT STYLE="letter-spacing: 0.55pt">
</FONT>participating<FONT STYLE="letter-spacing: 0.55pt"> </FONT>in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">offering</FONT><FONT STYLE="letter-spacing: 1.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt">
</FONT>more<FONT STYLE="letter-spacing: 0.6pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.6pt"> </FONT>than<FONT STYLE="letter-spacing: 0.6pt">
</FONT>have<FONT STYLE="letter-spacing: 0.6pt"> </FONT>been<FONT STYLE="letter-spacing: 0.6pt"> </FONT>sold<FONT STYLE="letter-spacing: 0.6pt">
</FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>them<FONT STYLE="letter-spacing: 0.6pt"> </FONT>by<FONT STYLE="letter-spacing: 0.6pt">
</FONT>us.<FONT STYLE="letter-spacing: 0.55pt"> </FONT>In<FONT STYLE="letter-spacing: 0.6pt"> </FONT>addition,<FONT STYLE="letter-spacing: 0.6pt">
</FONT>those<FONT STYLE="letter-spacing: 0.6pt"> </FONT>persons<FONT STYLE="letter-spacing: 0.6pt"> </FONT>may<FONT STYLE="letter-spacing: 0.6pt">
</FONT>stabilize<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>maintain<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the price<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>securities<FONT STYLE="letter-spacing: 0.6pt"> </FONT>by<FONT STYLE="letter-spacing: 0.6pt"> </FONT>bidding<FONT STYLE="letter-spacing: 0.55pt">
</FONT>for<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>purchasing<FONT STYLE="letter-spacing: 0.55pt">
</FONT>securities<FONT STYLE="letter-spacing: 0.6pt"> </FONT>in<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>open<FONT STYLE="letter-spacing: 0.6pt"> </FONT>market<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt">
</FONT>by<FONT STYLE="letter-spacing: 0.6pt"> </FONT>imposing<FONT STYLE="letter-spacing: 0.55pt"> </FONT>penalty<FONT STYLE="letter-spacing: 0.6pt">
</FONT>bids, whereby<FONT STYLE="letter-spacing: 0.5pt"> </FONT>selling<FONT STYLE="letter-spacing: 0.55pt"> </FONT>concessions
allowed<FONT STYLE="letter-spacing: 0.5pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>underwriters<FONT STYLE="letter-spacing: 0.5pt">
</FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>dealers<FONT STYLE="letter-spacing: 0.5pt"> </FONT>participating<FONT STYLE="letter-spacing: 0.55pt">
</FONT>in<FONT STYLE="letter-spacing: 0.5pt"> </FONT>any<FONT STYLE="letter-spacing: 0.55pt"> </FONT>such<FONT STYLE="letter-spacing: 0.5pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">offering</FONT><FONT STYLE="letter-spacing: 0.55pt"> </FONT>may<FONT STYLE="letter-spacing: 0.5pt">
</FONT>be<FONT STYLE="letter-spacing: 1.2pt"> </FONT>reclaimed<FONT STYLE="letter-spacing: 0.5pt"> </FONT>if<FONT STYLE="letter-spacing: 0.55pt">
</FONT>securities<FONT STYLE="letter-spacing: 0.5pt"> </FONT>sold<FONT STYLE="letter-spacing: 0.55pt"> </FONT>by<FONT STYLE="letter-spacing: 0.5pt">
</FONT>them<FONT STYLE="letter-spacing: 0.55pt"> </FONT>are<FONT STYLE="letter-spacing: 0.5pt"> </FONT>repurchased<FONT STYLE="letter-spacing: 0.55pt">
</FONT>in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>connection<FONT STYLE="letter-spacing: 0.5pt"> </FONT>with<FONT STYLE="letter-spacing: 0.55pt">
</FONT>stabilization<FONT STYLE="letter-spacing: 0.5pt"> </FONT>transactions.<FONT STYLE="letter-spacing: 0.35pt"> </FONT>The
<FONT STYLE="letter-spacing: -0.05pt">effect</FONT><FONT STYLE="letter-spacing: 0.5pt"> </FONT>of<FONT STYLE="letter-spacing: 1.1pt">
</FONT>these<FONT STYLE="letter-spacing: 0.55pt"> </FONT>transactions<FONT STYLE="letter-spacing: 0.6pt"> </FONT>may<FONT STYLE="letter-spacing: 0.6pt">
</FONT>be<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>stabilize<FONT STYLE="letter-spacing: 0.6pt">
</FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>maintain<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>market<FONT STYLE="letter-spacing: 0.6pt"> </FONT>price<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.6pt"> </FONT>at<FONT STYLE="letter-spacing: 0.6pt">
</FONT>a<FONT STYLE="letter-spacing: 0.55pt"> </FONT>level<FONT STYLE="letter-spacing: 0.6pt"> </FONT>above<FONT STYLE="letter-spacing: 0.6pt">
</FONT>that<FONT STYLE="letter-spacing: 0.6pt"> </FONT>which might<FONT STYLE="letter-spacing: 0.5pt"> </FONT>otherwise<FONT STYLE="letter-spacing: 0.55pt">
</FONT>prevail<FONT STYLE="letter-spacing: 0.55pt"> </FONT>in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>open<FONT STYLE="letter-spacing: 0.55pt"> </FONT>market.<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Such<FONT STYLE="letter-spacing: 0.55pt">
</FONT>transactions,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>if<FONT STYLE="letter-spacing: 0.55pt"> </FONT>commenced,<FONT STYLE="letter-spacing: 0.55pt">
</FONT>may<FONT STYLE="letter-spacing: 0.55pt"> </FONT>be<FONT STYLE="letter-spacing: 0.55pt"> </FONT>discontinued<FONT STYLE="letter-spacing: 0.5pt">
</FONT>at<FONT STYLE="letter-spacing: 0.55pt"> </FONT>any time.<FONT STYLE="letter-spacing: 0.4pt"> </FONT><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>make<FONT STYLE="letter-spacing: 0.55pt"> </FONT>no representation<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt">
</FONT>prediction<FONT STYLE="letter-spacing: 0.6pt"> </FONT>as<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>direction<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt">
</FONT>magnitude<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>any<FONT STYLE="letter-spacing: 0.6pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">effect</FONT><FONT STYLE="letter-spacing: 0.6pt"> </FONT>that<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 1.1pt"> </FONT>transactions<FONT STYLE="letter-spacing: 0.5pt"> </FONT>described<FONT STYLE="letter-spacing: 0.55pt">
</FONT>above,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>if<FONT STYLE="letter-spacing: 0.55pt"> </FONT>implemented,<FONT STYLE="letter-spacing: 0.5pt">
</FONT>may<FONT STYLE="letter-spacing: 0.55pt"> </FONT>have<FONT STYLE="letter-spacing: 0.55pt"> </FONT>on<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.5pt"> </FONT>price<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt">
</FONT>our<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">Unless<FONT STYLE="letter-spacing: 0.45pt">
</FONT>otherwise<FONT STYLE="letter-spacing: 0.5pt"> </FONT>specified<FONT STYLE="letter-spacing: 0.5pt"> </FONT>in<FONT STYLE="letter-spacing: 0.5pt">
</FONT>the<FONT STYLE="letter-spacing: 0.5pt"> </FONT>applicable<FONT STYLE="letter-spacing: 0.5pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.5pt">
</FONT>supplement,<FONT STYLE="letter-spacing: 0.5pt"> </FONT>any<FONT STYLE="letter-spacing: 0.5pt"> </FONT>common<FONT STYLE="letter-spacing: 0.5pt">
</FONT>stock<FONT STYLE="letter-spacing: 0.5pt"> </FONT>sold<FONT STYLE="letter-spacing: 0.5pt"> </FONT>pursuant<FONT STYLE="letter-spacing: 0.5pt">
</FONT>to<FONT STYLE="letter-spacing: 0.5pt"> </FONT>a prospectus<FONT STYLE="letter-spacing: 0.55pt"> </FONT>supplement<FONT STYLE="letter-spacing: 0.55pt">
</FONT>will<FONT STYLE="letter-spacing: 0.55pt"> </FONT>be<FONT STYLE="letter-spacing: 0.55pt"> </FONT>eligible<FONT STYLE="letter-spacing: 0.6pt">
</FONT>for<FONT STYLE="letter-spacing: 0.55pt"> </FONT>listing<FONT STYLE="letter-spacing: 0.55pt"> </FONT>on<FONT STYLE="letter-spacing: 0.55pt">
</FONT>a<FONT STYLE="letter-spacing: 0.55pt"> </FONT>national<FONT STYLE="letter-spacing: 0.6pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.55pt">
</FONT>exchange,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>such<FONT STYLE="letter-spacing: 0.55pt"> </FONT>as<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>NYSE<FONT STYLE="letter-spacing: 0.55pt"> </FONT>MKT<FONT STYLE="letter-spacing: -0.2pt">
</FONT>or<FONT STYLE="letter-spacing: 0.8pt"> </FONT>NASDAQ,<FONT STYLE="letter-spacing: 0.5pt"> </FONT>subject<FONT STYLE="letter-spacing: 0.5pt">
</FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>official<FONT STYLE="letter-spacing: 0.5pt"> </FONT>notice<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.5pt"> </FONT>issuance.<FONT STYLE="letter-spacing: 0.05pt"> </FONT>Any<FONT STYLE="letter-spacing: 0.5pt">
</FONT>underwriters<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.5pt"> </FONT>whom<FONT STYLE="letter-spacing: 0.55pt">
</FONT>securities<FONT STYLE="letter-spacing: 0.5pt"> </FONT>are<FONT STYLE="letter-spacing: 0.55pt"> </FONT>sold<FONT STYLE="letter-spacing: 0.5pt">
</FONT>by<FONT STYLE="letter-spacing: 0.5pt"> </FONT>us<FONT STYLE="letter-spacing: 0.55pt"> </FONT>for<FONT STYLE="letter-spacing: -0.25pt">
</FONT>public<FONT STYLE="letter-spacing: 0.8pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">offering</FONT><FONT STYLE="letter-spacing: 0.6pt">
</FONT>and<FONT STYLE="letter-spacing: 0.65pt"> </FONT>sale<FONT STYLE="letter-spacing: 0.65pt"> </FONT>may<FONT STYLE="letter-spacing: 0.65pt">
</FONT>make<FONT STYLE="letter-spacing: 0.65pt"> </FONT>a<FONT STYLE="letter-spacing: 0.65pt"> </FONT>market<FONT STYLE="letter-spacing: 0.6pt">
</FONT>in<FONT STYLE="letter-spacing: 0.65pt"> </FONT>the<FONT STYLE="letter-spacing: 0.65pt"> </FONT>securities,<FONT STYLE="letter-spacing: 0.65pt">
</FONT>but<FONT STYLE="letter-spacing: 0.65pt"> </FONT>such<FONT STYLE="letter-spacing: 0.65pt"> </FONT>underwriters<FONT STYLE="letter-spacing: 0.65pt">
</FONT>will<FONT STYLE="letter-spacing: 0.6pt"> </FONT>not<FONT STYLE="letter-spacing: 0.65pt"> </FONT>be<FONT STYLE="letter-spacing: 0.65pt">
</FONT>obligated<FONT STYLE="letter-spacing: 0.65pt"> </FONT>to<FONT STYLE="letter-spacing: -0.15pt"> </FONT>do <FONT STYLE="letter-spacing: 1.95pt">
</FONT>so<FONT STYLE="letter-spacing: 0.8pt"> </FONT>and<FONT STYLE="letter-spacing: 0.55pt"> </FONT>may<FONT STYLE="letter-spacing: 0.55pt">
</FONT>discontinue<FONT STYLE="letter-spacing: 0.55pt"> </FONT>any<FONT STYLE="letter-spacing: 0.55pt"> </FONT>market<FONT STYLE="letter-spacing: 0.55pt">
</FONT>making<FONT STYLE="letter-spacing: 0.55pt"> </FONT>at<FONT STYLE="letter-spacing: 0.55pt"> </FONT>any<FONT STYLE="letter-spacing: 0.55pt">
</FONT>time<FONT STYLE="letter-spacing: 0.55pt"> </FONT>without<FONT STYLE="letter-spacing: 0.55pt"> </FONT>notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">In<FONT STYLE="letter-spacing: 0.55pt">
</FONT>order<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt"> </FONT>comply<FONT STYLE="letter-spacing: 0.6pt">
</FONT>with<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.55pt">
</FONT>laws<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>some<FONT STYLE="letter-spacing: 0.6pt">
</FONT>states,<FONT STYLE="letter-spacing: 0.6pt"> </FONT>if<FONT STYLE="letter-spacing: 0.55pt"> </FONT>applicable,<FONT STYLE="letter-spacing: 0.6pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.6pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">offered
</FONT>pursuant<FONT STYLE="letter-spacing: 0.6pt"> </FONT>to<FONT STYLE="letter-spacing: 1.15pt"> </FONT>this<FONT STYLE="letter-spacing: 0.55pt">
</FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt"> </FONT>will<FONT STYLE="letter-spacing: 0.6pt"> </FONT>be<FONT STYLE="letter-spacing: 0.55pt">
</FONT>sold<FONT STYLE="letter-spacing: 0.55pt"> </FONT>in<FONT STYLE="letter-spacing: 0.6pt"> </FONT>those<FONT STYLE="letter-spacing: 0.55pt">
</FONT>states<FONT STYLE="letter-spacing: 0.6pt"> </FONT>only<FONT STYLE="letter-spacing: 0.55pt"> </FONT>through<FONT STYLE="letter-spacing: 0.55pt">
</FONT>registered<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>licensed<FONT STYLE="letter-spacing: 0.6pt">
</FONT>brokers<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>dealers.<FONT STYLE="letter-spacing: 0.6pt">
</FONT>In<FONT STYLE="letter-spacing: 0.55pt"> </FONT>addition, in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>some<FONT STYLE="letter-spacing: 0.6pt">
</FONT>states<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities<FONT STYLE="letter-spacing: 0.6pt"> </FONT>may<FONT STYLE="letter-spacing: 0.6pt">
</FONT>not<FONT STYLE="letter-spacing: 0.55pt"> </FONT>be<FONT STYLE="letter-spacing: 0.6pt"> </FONT>sold<FONT STYLE="letter-spacing: 0.6pt">
</FONT>unless<FONT STYLE="letter-spacing: 0.55pt"> </FONT>they<FONT STYLE="letter-spacing: 0.6pt"> </FONT>have<FONT STYLE="letter-spacing: 0.6pt">
</FONT>been<FONT STYLE="letter-spacing: 0.55pt"> </FONT>registered<FONT STYLE="letter-spacing: 0.6pt"> </FONT>or<FONT STYLE="letter-spacing: 0.6pt">
</FONT>qualified<FONT STYLE="letter-spacing: 0.55pt"> </FONT>for<FONT STYLE="letter-spacing: 0.6pt"> </FONT>sale<FONT STYLE="letter-spacing: 0.6pt">
</FONT>in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the applicable<FONT STYLE="letter-spacing: 0.45pt"> </FONT>state<FONT STYLE="letter-spacing: 0.5pt">
</FONT>or<FONT STYLE="letter-spacing: 0.45pt"> </FONT>an<FONT STYLE="letter-spacing: 0.5pt"> </FONT>exemption<FONT STYLE="letter-spacing: 0.45pt">
</FONT>from<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.5pt"> </FONT>registration<FONT STYLE="letter-spacing: 0.45pt">
</FONT>or<FONT STYLE="letter-spacing: 0.5pt"> </FONT>qualification<FONT STYLE="letter-spacing: 0.45pt"> </FONT>requirement<FONT STYLE="letter-spacing: 0.5pt">
</FONT>is<FONT STYLE="letter-spacing: 0.5pt"> </FONT>available<FONT STYLE="letter-spacing: 0.45pt"> </FONT>and<FONT STYLE="letter-spacing: 0.5pt">
</FONT>complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0; color: #231F20"><A NAME="a-27"></A><B>LEGAL
MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">The<FONT STYLE="letter-spacing: 0.55pt">
</FONT>validity<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>securities<FONT STYLE="letter-spacing: 0.6pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">offered</FONT><FONT STYLE="letter-spacing: 0.55pt">
</FONT>by<FONT STYLE="letter-spacing: 0.6pt"> </FONT>this<FONT STYLE="letter-spacing: 0.6pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.6pt">
</FONT>will<FONT STYLE="letter-spacing: 0.6pt"> </FONT>be<FONT STYLE="letter-spacing: 0.55pt"> </FONT>passed<FONT STYLE="letter-spacing: 0.6pt">
</FONT>upon<FONT STYLE="letter-spacing: 0.6pt"> </FONT>by<FONT STYLE="letter-spacing: 0.6pt"> </FONT>Hiscock<FONT STYLE="letter-spacing: 0.6pt">
</FONT>&amp;<FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.1pt">Barclay,</FONT><FONT STYLE="letter-spacing: 0.6pt">
</FONT><FONT STYLE="letter-spacing: -0.35pt">LLP,</FONT><FONT STYLE="letter-spacing: 1.4pt"> </FONT>Syracuse,<FONT STYLE="letter-spacing: 0.5pt">
</FONT>New<FONT STYLE="letter-spacing: 0.5pt"> </FONT><FONT STYLE="letter-spacing: -0.25pt">York.&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0; color: #231F20"><A NAME="a-28"></A><B>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">The<FONT STYLE="letter-spacing: 0.5pt">
</FONT>financial<FONT STYLE="letter-spacing: 0.5pt"> </FONT>statements<FONT STYLE="letter-spacing: 0.55pt"> </FONT>incorporated
in<FONT STYLE="letter-spacing: 0.5pt"> </FONT>this<FONT STYLE="letter-spacing: 0.55pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.5pt">
</FONT>by<FONT STYLE="letter-spacing: 0.5pt"> </FONT>reference<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.5pt">
</FONT>the Annual<FONT STYLE="letter-spacing: 0.55pt"> </FONT>Report<FONT STYLE="letter-spacing: 0.5pt"> </FONT>on<FONT STYLE="letter-spacing: 0.5pt">
</FONT>Form<FONT STYLE="letter-spacing: 0.55pt"> </FONT>10-K for<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>fiscal<FONT STYLE="letter-spacing: 0.6pt"> </FONT>year<FONT STYLE="letter-spacing: 0.55pt"> </FONT>ended<FONT STYLE="letter-spacing: 0.55pt">
</FONT>December<FONT STYLE="letter-spacing: 0.6pt"> </FONT>31,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>2013<FONT STYLE="letter-spacing: 0.6pt">
</FONT>have<FONT STYLE="letter-spacing: 0.55pt"> </FONT>been<FONT STYLE="letter-spacing: 0.55pt"> </FONT>so<FONT STYLE="letter-spacing: 0.6pt">
</FONT>incorporated<FONT STYLE="letter-spacing: 0.55pt"> </FONT>in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>reliance<FONT STYLE="letter-spacing: 0.6pt">
</FONT>on<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>report<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>GBH <FONT STYLE="letter-spacing: -0.25pt">CPAs,</FONT><FONT STYLE="letter-spacing: 0.5pt">
</FONT>PC,<FONT STYLE="letter-spacing: 0.5pt"> </FONT>an<FONT STYLE="letter-spacing: 0.55pt"> </FONT>independent<FONT STYLE="letter-spacing: 0.5pt">
</FONT>registered<FONT STYLE="letter-spacing: 0.5pt"> </FONT>public<FONT STYLE="letter-spacing: 0.55pt"> </FONT>accounting<FONT STYLE="letter-spacing: 0.5pt">
</FONT>firm,<FONT STYLE="letter-spacing: 0.5pt"> </FONT>given<FONT STYLE="letter-spacing: 0.55pt"> </FONT>on<FONT STYLE="letter-spacing: 0.5pt">
</FONT>the<FONT STYLE="letter-spacing: 0.5pt"> </FONT>authority<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.5pt">
</FONT>said<FONT STYLE="letter-spacing: 0.5pt"> </FONT>firm<FONT STYLE="letter-spacing: 0.55pt"> </FONT>as<FONT STYLE="letter-spacing: 0.5pt">
</FONT>experts<FONT STYLE="letter-spacing: 0.55pt"> </FONT>in<FONT STYLE="letter-spacing: 1.05pt"> </FONT>auditing<FONT STYLE="letter-spacing: 0.3pt">
</FONT>and<FONT STYLE="letter-spacing: 0.35pt"> </FONT>accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: #231F20"><A NAME="a-29"></A>WHERE
YOU<FONT STYLE="letter-spacing: -0.05pt"> </FONT>CAN<FONT STYLE="letter-spacing: -0.05pt"> </FONT>FIND<FONT STYLE="letter-spacing: -0.1pt">
</FONT>MORE<FONT STYLE="letter-spacing: -0.05pt"> </FONT>INFORMATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>are<FONT STYLE="letter-spacing: 0.55pt"> </FONT>subject<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>informational<FONT STYLE="letter-spacing: 0.55pt"> </FONT>requirements
of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>Securities<FONT STYLE="letter-spacing: 0.55pt">
</FONT>Exchange<FONT STYLE="letter-spacing: 0.05pt"> </FONT>Act<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt">
</FONT>1934,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>as<FONT STYLE="letter-spacing: 0.55pt"> </FONT>amended,<FONT STYLE="letter-spacing: 1pt">
</FONT>and<FONT STYLE="letter-spacing: 0.45pt"> </FONT>in<FONT STYLE="letter-spacing: 0.45pt"> </FONT>accordance<FONT STYLE="letter-spacing: 0.5pt">
</FONT>therewith<FONT STYLE="letter-spacing: 0.45pt"> </FONT>file<FONT STYLE="letter-spacing: 0.5pt"> </FONT>annual,<FONT STYLE="letter-spacing: 0.45pt">
</FONT>quarterly<FONT STYLE="letter-spacing: 0.5pt"> </FONT>and<FONT STYLE="letter-spacing: 0.45pt"> </FONT>current<FONT STYLE="letter-spacing: 0.5pt">
</FONT>reports,<FONT STYLE="letter-spacing: 0.45pt"> </FONT>proxy<FONT STYLE="letter-spacing: 0.5pt"> </FONT>statements<FONT STYLE="letter-spacing: 0.45pt">
</FONT>and<FONT STYLE="letter-spacing: 0.5pt"> </FONT>other<FONT STYLE="letter-spacing: 0.45pt"> </FONT>information with<FONT STYLE="letter-spacing: 0.5pt">
</FONT>the<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Securities<FONT STYLE="letter-spacing: 0.5pt"> </FONT>and<FONT STYLE="letter-spacing: 0.55pt">
</FONT>Exchange<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Commission.<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Such<FONT STYLE="letter-spacing: 0.55pt">
</FONT>reports,<FONT STYLE="letter-spacing: 0.5pt"> </FONT>proxy<FONT STYLE="letter-spacing: 0.5pt"> </FONT>statements<FONT STYLE="letter-spacing: 0.55pt">
</FONT>and<FONT STYLE="letter-spacing: 0.5pt"> </FONT>other<FONT STYLE="letter-spacing: 0.5pt"> </FONT>information<FONT STYLE="letter-spacing: 0.55pt">
</FONT>can<FONT STYLE="letter-spacing: 0.5pt"> </FONT>be read<FONT STYLE="letter-spacing: 0.55pt"> </FONT>and<FONT STYLE="letter-spacing: 0.55pt">
</FONT>copied<FONT STYLE="letter-spacing: 0.55pt"> </FONT>at<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.55pt">
</FONT>Securities<FONT STYLE="letter-spacing: 0.55pt"> </FONT>and<FONT STYLE="letter-spacing: 0.55pt"> </FONT>Exchange<FONT STYLE="letter-spacing: 0.55pt">
</FONT><FONT STYLE="letter-spacing: -0.1pt">Commission&rsquo;s</FONT><FONT STYLE="letter-spacing: 0.55pt"> </FONT>public<FONT STYLE="letter-spacing: 0.55pt">
</FONT>reference<FONT STYLE="letter-spacing: 0.55pt"> </FONT>facilities<FONT STYLE="letter-spacing: 0.55pt"> </FONT>at<FONT STYLE="letter-spacing: 0.55pt">
</FONT>100<FONT STYLE="letter-spacing: 0.55pt"> </FONT>F<FONT STYLE="letter-spacing: 0.55pt"> </FONT>Street,<FONT STYLE="letter-spacing: 0.55pt">
</FONT>N.E.,<FONT STYLE="letter-spacing: 1.35pt"> </FONT><FONT STYLE="letter-spacing: -0.1pt">Washington,</FONT><FONT STYLE="letter-spacing: 0.5pt">
</FONT>D.C.<FONT STYLE="letter-spacing: 0.5pt"> </FONT>20549,<FONT STYLE="letter-spacing: 0.5pt"> </FONT>at<FONT STYLE="letter-spacing: 0.55pt">
</FONT>prescribed<FONT STYLE="letter-spacing: 0.5pt"> </FONT>rates.<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Please<FONT STYLE="letter-spacing: 0.55pt">
</FONT>call<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Securities<FONT STYLE="letter-spacing: 0.55pt">
</FONT>and<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Exchange<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Commission<FONT STYLE="letter-spacing: 0.55pt">
</FONT>at<FONT STYLE="letter-spacing: 0.5pt"> </FONT>1-800-732-0330<FONT STYLE="letter-spacing: 0.5pt"> </FONT>for<FONT STYLE="letter-spacing: 0.55pt">
</FONT>further<FONT STYLE="letter-spacing: 0.55pt"> </FONT>information<FONT STYLE="letter-spacing: 0.5pt"> </FONT>on<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>operation<FONT STYLE="letter-spacing: 0.5pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>public<FONT STYLE="letter-spacing: 0.5pt"> </FONT>reference<FONT STYLE="letter-spacing: 0.55pt">
</FONT>facilities.<FONT STYLE="letter-spacing: 0.55pt"> </FONT>In<FONT STYLE="letter-spacing: 0.5pt"> </FONT>addition,<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>Securities and<FONT STYLE="letter-spacing: 0.45pt"> </FONT>Exchange<FONT STYLE="letter-spacing: 0.5pt">
</FONT>Commission<FONT STYLE="letter-spacing: 0.5pt"> </FONT>maintains<FONT STYLE="letter-spacing: 0.5pt"> </FONT>a<FONT STYLE="letter-spacing: 0.5pt">
</FONT>website<FONT STYLE="letter-spacing: 0.5pt"> </FONT>that<FONT STYLE="letter-spacing: 0.5pt"> </FONT>contains<FONT STYLE="letter-spacing: 0.45pt">
</FONT>reports,<FONT STYLE="letter-spacing: 0.5pt"> </FONT>proxy<FONT STYLE="letter-spacing: 0.5pt"> </FONT>and<FONT STYLE="letter-spacing: 0.5pt">
</FONT>information<FONT STYLE="letter-spacing: 0.5pt"> </FONT>statements<FONT STYLE="letter-spacing: 0.5pt"> </FONT>and other
information<FONT STYLE="letter-spacing: 0.4pt"> </FONT>regarding<FONT STYLE="letter-spacing: 0.45pt"> </FONT>registrants<FONT STYLE="letter-spacing: 0.4pt">
</FONT>that<FONT STYLE="letter-spacing: 0.4pt"> </FONT>file<FONT STYLE="letter-spacing: 0.4pt"> </FONT>electronically<FONT STYLE="letter-spacing: 0.45pt">
</FONT>with<FONT STYLE="letter-spacing: 0.4pt"> </FONT>the<FONT STYLE="letter-spacing: 0.4pt"> </FONT>Securities<FONT STYLE="letter-spacing: 0.45pt">
</FONT>and<FONT STYLE="letter-spacing: 0.4pt"> </FONT>Exchange<FONT STYLE="letter-spacing: 0.4pt"> </FONT>Commission. The<FONT STYLE="letter-spacing: 0.45pt">
</FONT>address<FONT STYLE="letter-spacing: 0.5pt"> </FONT>of<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.5pt">
</FONT>Securities<FONT STYLE="letter-spacing: 0.45pt"> </FONT>and<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Exchange<FONT STYLE="letter-spacing: 0.5pt">
</FONT><FONT STYLE="letter-spacing: -0.1pt">Commission&rsquo;s</FONT><FONT STYLE="letter-spacing: 0.5pt"> </FONT>website<FONT STYLE="letter-spacing: 0.45pt">
</FONT>is<FONT STYLE="letter-spacing: 0.5pt"> </FONT><FONT STYLE="letter-spacing: -0.15pt">www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>make<FONT STYLE="letter-spacing: 0.5pt"> </FONT>available<FONT STYLE="letter-spacing: 0.5pt"> </FONT>free<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.5pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">charge</FONT><FONT STYLE="letter-spacing: 0.5pt">
</FONT>on<FONT STYLE="letter-spacing: 0.5pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt"> </FONT>through<FONT STYLE="letter-spacing: 0.5pt">
</FONT>our<FONT STYLE="letter-spacing: 0.5pt"> </FONT>website<FONT STYLE="letter-spacing: 0.55pt"> </FONT>at<FONT STYLE="letter-spacing: 0.5pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">www.actiniumpharmaceuticals.com,</FONT><FONT STYLE="letter-spacing: 0.5pt"> </FONT>our
Annual<FONT STYLE="letter-spacing: 0.55pt"> </FONT>Reports<FONT STYLE="letter-spacing: 0.55pt"> </FONT>on<FONT STYLE="letter-spacing: 0.55pt">
</FONT>Form<FONT STYLE="letter-spacing: 0.55pt"> </FONT>10-K,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>Quarterly<FONT STYLE="letter-spacing: 0.6pt">
</FONT>Reports<FONT STYLE="letter-spacing: 0.55pt"> </FONT>on<FONT STYLE="letter-spacing: 0.55pt"> </FONT>Form<FONT STYLE="letter-spacing: 0.55pt">
</FONT>10-Q,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>Current<FONT STYLE="letter-spacing: 0.55pt"> </FONT>Reports<FONT STYLE="letter-spacing: 0.55pt">
</FONT>on<FONT STYLE="letter-spacing: 0.6pt"> </FONT>Form<FONT STYLE="letter-spacing: 0.55pt"> </FONT>8-K<FONT STYLE="letter-spacing: 0.55pt">
</FONT>and amendments<FONT STYLE="letter-spacing: 0.5pt"> </FONT>to<FONT STYLE="letter-spacing: 0.5pt"> </FONT>those<FONT STYLE="letter-spacing: 0.55pt">
</FONT>reports<FONT STYLE="letter-spacing: 0.5pt"> </FONT>filed<FONT STYLE="letter-spacing: 0.5pt"> </FONT>or<FONT STYLE="letter-spacing: 0.55pt">
</FONT>furnished<FONT STYLE="letter-spacing: 0.5pt"> </FONT>pursuant<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.5pt">
</FONT>Section<FONT STYLE="letter-spacing: 0.5pt"> </FONT>13(a)<FONT STYLE="letter-spacing: 0.55pt"> </FONT>or<FONT STYLE="letter-spacing: 0.5pt">
</FONT>15(d)<FONT STYLE="letter-spacing: 0.5pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.5pt">
</FONT>Securities<FONT STYLE="letter-spacing: 0.55pt"> </FONT>Exchange Act<FONT STYLE="letter-spacing: 0.5pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt">
</FONT>1934,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>as<FONT STYLE="letter-spacing: 0.55pt"> </FONT>amended,<FONT STYLE="letter-spacing: 0.5pt">
</FONT>as<FONT STYLE="letter-spacing: 0.55pt"> </FONT>soon<FONT STYLE="letter-spacing: 0.55pt"> </FONT>as<FONT STYLE="letter-spacing: 0.55pt">
</FONT>reasonably<FONT STYLE="letter-spacing: 0.55pt"> </FONT>practicable<FONT STYLE="letter-spacing: 0.5pt"> </FONT>after<FONT STYLE="letter-spacing: 0.55pt">
</FONT>we<FONT STYLE="letter-spacing: 0.55pt"> </FONT>electronically<FONT STYLE="letter-spacing: 0.55pt"> </FONT>file<FONT STYLE="letter-spacing: 0.55pt">
</FONT>such<FONT STYLE="letter-spacing: 0.5pt"> </FONT>material<FONT STYLE="letter-spacing: 0.55pt"> </FONT>with<FONT STYLE="letter-spacing: 0.55pt">
</FONT>or otherwise<FONT STYLE="letter-spacing: 0.5pt"> </FONT>furnish<FONT STYLE="letter-spacing: 0.5pt"> </FONT>it<FONT STYLE="letter-spacing: 0.5pt">
</FONT>to<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Securities<FONT STYLE="letter-spacing: 0.5pt">
</FONT>and<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Exchange<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>have<FONT STYLE="letter-spacing: 0.5pt"> </FONT>filed<FONT STYLE="letter-spacing: 0.5pt"> </FONT>with<FONT STYLE="letter-spacing: 0.5pt">
</FONT>the<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Securities<FONT STYLE="letter-spacing: 0.45pt"> </FONT>and<FONT STYLE="letter-spacing: 0.5pt">
</FONT>Exchange<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Commission<FONT STYLE="letter-spacing: 0.5pt"> </FONT>a<FONT STYLE="letter-spacing: 0.5pt">
</FONT>registration<FONT STYLE="letter-spacing: 0.5pt"> </FONT>statement<FONT STYLE="letter-spacing: 0.45pt"> </FONT>under<FONT STYLE="letter-spacing: 0.5pt">
</FONT>the<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Securities<FONT STYLE="letter-spacing: 1pt"> </FONT>Act<FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>1933,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>as<FONT STYLE="letter-spacing: 0.55pt">
</FONT>amended,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>relating<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">offering</FONT><FONT STYLE="letter-spacing: 0.55pt">
</FONT>of<FONT STYLE="letter-spacing: 0.55pt"> </FONT>these<FONT STYLE="letter-spacing: 0.55pt"> </FONT>securities.<FONT STYLE="letter-spacing: 0.35pt">
</FONT>The<FONT STYLE="letter-spacing: 0.55pt"> </FONT>registration<FONT STYLE="letter-spacing: 0.55pt"> </FONT>statement,<FONT STYLE="letter-spacing: 0.55pt">
</FONT>including<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 1.2pt"> </FONT>attached<FONT STYLE="letter-spacing: 0.5pt">
</FONT>exhibits,<FONT STYLE="letter-spacing: 0.5pt"> </FONT>contains<FONT STYLE="letter-spacing: 0.5pt"> </FONT>additional<FONT STYLE="letter-spacing: 0.5pt">
</FONT>relevant<FONT STYLE="letter-spacing: 0.5pt"> </FONT>information<FONT STYLE="letter-spacing: 0.5pt"> </FONT>about<FONT STYLE="letter-spacing: 0.5pt">
</FONT>us<FONT STYLE="letter-spacing: 0.5pt"> </FONT>and<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.5pt">
</FONT>securities.<FONT STYLE="letter-spacing: 0.3pt"> </FONT>This<FONT STYLE="letter-spacing: 0.5pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.5pt">
</FONT>does<FONT STYLE="letter-spacing: -0.25pt"> </FONT>not<FONT STYLE="letter-spacing: 0.8pt"> </FONT>contain<FONT STYLE="letter-spacing: 0.55pt">
</FONT>all<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>information<FONT STYLE="letter-spacing: 0.55pt"> </FONT>set<FONT STYLE="letter-spacing: 0.6pt"> </FONT>forth<FONT STYLE="letter-spacing: 0.6pt">
</FONT>in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>registration<FONT STYLE="letter-spacing: 0.6pt">
</FONT>statement.<FONT STYLE="letter-spacing: 0.25pt"> </FONT><FONT STYLE="letter-spacing: -0.4pt">You</FONT><FONT STYLE="letter-spacing: 0.6pt">
</FONT>can<FONT STYLE="letter-spacing: 0.6pt"> </FONT>obtain<FONT STYLE="letter-spacing: 0.55pt"> </FONT>a<FONT STYLE="letter-spacing: 0.6pt">
</FONT>copy<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: -0.2pt">
</FONT>registration statement,<FONT STYLE="letter-spacing: 0.5pt"> </FONT>at<FONT STYLE="letter-spacing: 0.5pt"> </FONT>prescribed
rates,<FONT STYLE="letter-spacing: 0.5pt"> </FONT>from<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.5pt">
</FONT>Securities<FONT STYLE="letter-spacing: 0.5pt"> </FONT>and<FONT STYLE="letter-spacing: 0.55pt"> </FONT>Exchange<FONT STYLE="letter-spacing: 0.5pt">
</FONT>Commission<FONT STYLE="letter-spacing: 0.55pt"> </FONT>at<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.5pt">
</FONT>address<FONT STYLE="letter-spacing: 0.55pt"> </FONT>listed<FONT STYLE="letter-spacing: -0.25pt"> </FONT>above,<FONT STYLE="letter-spacing: 0.8pt">
</FONT>or<FONT STYLE="letter-spacing: 0.5pt"> </FONT>for<FONT STYLE="letter-spacing: 0.55pt"> </FONT>free<FONT STYLE="letter-spacing: 0.55pt">
</FONT>at<FONT STYLE="letter-spacing: 0.55pt"> </FONT>www.sec.gov.<FONT STYLE="letter-spacing: 0.35pt"> </FONT>The<FONT STYLE="letter-spacing: 0.55pt">
</FONT>registration<FONT STYLE="letter-spacing: 0.55pt"> </FONT>statement<FONT STYLE="letter-spacing: 0.55pt"> </FONT>and<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>documents<FONT STYLE="letter-spacing: 0.55pt"> </FONT>referred<FONT STYLE="letter-spacing: 0.55pt">
</FONT>to<FONT STYLE="letter-spacing: 0.5pt"> </FONT>below<FONT STYLE="letter-spacing: 0.55pt"> </FONT>under &ldquo;Incorporation
of<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Certain<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Information<FONT STYLE="letter-spacing: 0.5pt">
</FONT>By<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Reference&rdquo;<FONT STYLE="letter-spacing: 0.5pt"> </FONT>are<FONT STYLE="letter-spacing: 0.55pt">
</FONT>also<FONT STYLE="letter-spacing: 0.5pt"> </FONT>available<FONT STYLE="letter-spacing: 0.5pt"> </FONT>on<FONT STYLE="letter-spacing: 0.5pt">
</FONT>our<FONT STYLE="letter-spacing: 0.5pt"> </FONT>website, <FONT STYLE="letter-spacing: -0.05pt">www.actiniumpharmaceuticals.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>have<FONT STYLE="letter-spacing: 0.55pt"> </FONT>not<FONT STYLE="letter-spacing: 0.55pt"> </FONT>incorporated<FONT STYLE="letter-spacing: 0.6pt">
</FONT>by<FONT STYLE="letter-spacing: 0.55pt"> </FONT>reference<FONT STYLE="letter-spacing: 0.55pt"> </FONT>into<FONT STYLE="letter-spacing: 0.6pt">
</FONT>this<FONT STYLE="letter-spacing: 0.55pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt">
</FONT>information<FONT STYLE="letter-spacing: 0.55pt"> </FONT>on<FONT STYLE="letter-spacing: 0.55pt"> </FONT>our<FONT STYLE="letter-spacing: 0.6pt">
</FONT>website,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>and<FONT STYLE="letter-spacing: 0.55pt"> </FONT>you<FONT STYLE="letter-spacing: 1pt">
</FONT>should<FONT STYLE="letter-spacing: 0.6pt"> </FONT>not<FONT STYLE="letter-spacing: 0.6pt"> </FONT>consider<FONT STYLE="letter-spacing: 0.6pt">
</FONT>it<FONT STYLE="letter-spacing: 0.65pt"> </FONT>to<FONT STYLE="letter-spacing: 0.6pt"> </FONT>be<FONT STYLE="letter-spacing: 0.6pt">
</FONT>a<FONT STYLE="letter-spacing: 0.65pt"> </FONT>part<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>this<FONT STYLE="letter-spacing: 0.65pt"> </FONT>prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0; color: #231F20"><A NAME="a-30"></A>INCORPORATION
OF<FONT STYLE="letter-spacing: 0.4pt"> </FONT>CERTAIN<FONT STYLE="letter-spacing: 0.35pt"> </FONT>INFORMATION<FONT STYLE="letter-spacing: 0.4pt">
</FONT>BY<FONT STYLE="letter-spacing: 0.35pt"> </FONT>REFERENCE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">The Securities and Exchange
Commission allows us to &ldquo;incorporate by reference&rdquo; the information we have filed with it, which means that we can
disclose important information to you by referring you to those documents. The information we incorporate by reference is an important
part of this prospectus, and later information that we file with the Securities and Exchange Commission will automatically update
and supersede this information. We incorporate by reference the documents listed below and any future documents (excluding information
furnished pursuant to Items 2.02 and 7.01 of Form&nbsp;8-K) we file with the Securities and Exchange Commission pursuant to Sections
l3(a), l3(c), 14 or l5(d) of the Securities Exchange Act of 1934, as amended, subsequent to the date of this prospectus and prior
to the termination of the offering:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20; text-align: left"><FONT STYLE="letter-spacing: -0.05pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; text-align: left; padding-right: 0"></TD><TD STYLE="width: 0.25in; text-align: left; padding-right: 0"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 0; text-align: left">Our
                                         Annual<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Report<FONT STYLE="letter-spacing: 0.55pt">
                                         </FONT>on<FONT STYLE="letter-spacing: 0.55pt"> </FONT>Form<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>10-K<FONT STYLE="letter-spacing: 0.55pt"> </FONT>for<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>fiscal<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>year<FONT STYLE="letter-spacing: 0.55pt"> </FONT>ended<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>December<FONT STYLE="letter-spacing: 0.55pt"> </FONT>31,<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>2013,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>filed<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>with<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the Securities<FONT STYLE="letter-spacing: 0.45pt">
                                         </FONT>and<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Exchange<FONT STYLE="letter-spacing: 0.45pt">
                                         </FONT>Commission<FONT STYLE="letter-spacing: 0.5pt"> </FONT>on<FONT STYLE="letter-spacing: 0.45pt">
                                         </FONT>February<FONT STYLE="letter-spacing: 0.5pt"> </FONT>28,<FONT STYLE="letter-spacing: 0.45pt">
                                         </FONT>2014;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; padding-right: 0">&nbsp;</TD><TD STYLE="text-align: left; padding-right: 0">&nbsp;</TD><TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; padding-right: 0"></TD><TD STYLE="text-align: left; padding-right: 0"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 0; text-align: left">Our
                                         Current<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Report<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>on<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Form<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>8-K,<FONT STYLE="letter-spacing: 0.5pt"> </FONT>filed<FONT STYLE="letter-spacing: 0.55pt">
                                         </FONT>with<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>Securities<FONT STYLE="letter-spacing: 0.5pt"> </FONT>and<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>Exchange<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Commission<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>on January<FONT STYLE="letter-spacing: 0.45pt"> </FONT>3,<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>2014;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; padding-right: 0">&nbsp;</TD><TD STYLE="text-align: left; padding-right: 0">&nbsp;</TD><TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; padding-right: 0"></TD><TD STYLE="text-align: left; padding-right: 0"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 0; text-align: left">Our
                                         Current<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Report<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>on<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Form<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>8-K,<FONT STYLE="letter-spacing: 0.5pt"> </FONT>filed<FONT STYLE="letter-spacing: 0.55pt">
                                         </FONT>with<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>Securities<FONT STYLE="letter-spacing: 0.5pt"> </FONT>and<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>Exchange<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Commission<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>on January<FONT STYLE="letter-spacing: 0.5pt"> </FONT>13,<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>2014;<FONT STYLE="letter-spacing: 0.55pt"> </FONT>and;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; padding-right: 0">&nbsp;</TD><TD STYLE="text-align: left; padding-right: 0">&nbsp;</TD><TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; padding-right: 0"></TD><TD STYLE="text-align: left; padding-right: 0"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 0; text-align: left">Our
                                         Current<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Report<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>on<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Form<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>8-K,<FONT STYLE="letter-spacing: 0.5pt"> </FONT>filed<FONT STYLE="letter-spacing: 0.55pt">
                                         </FONT>with<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>Securities<FONT STYLE="letter-spacing: 0.5pt"> </FONT>and<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>Exchange<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Commission<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>on February<FONT STYLE="letter-spacing: 0.45pt"> </FONT>7,<FONT STYLE="letter-spacing: 0.45pt">
                                         </FONT>2014;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; padding-right: 0">&nbsp;</TD><TD STYLE="text-align: left; padding-right: 0">&nbsp;</TD><TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; padding-right: 0"></TD><TD STYLE="text-align: left; padding-right: 0"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 0; text-align: left">Our
                                         Current<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Report<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>on<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Form<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>8-K,<FONT STYLE="letter-spacing: 0.5pt"> </FONT>filed<FONT STYLE="letter-spacing: 0.55pt">
                                         </FONT>with<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>Securities<FONT STYLE="letter-spacing: 0.5pt"> </FONT>and<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>Exchange<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Commission<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>on March<FONT STYLE="letter-spacing: 0.45pt"> </FONT>24,<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>2014;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; padding-right: 0">&nbsp;</TD><TD STYLE="text-align: left; padding-right: 0">&nbsp;</TD><TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; padding-right: 0"></TD><TD STYLE="text-align: left; padding-right: 0"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 0; text-align: left">Our
                                         Current<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Report<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>on<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Form<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>8-K,<FONT STYLE="letter-spacing: 0.5pt"> </FONT>filed<FONT STYLE="letter-spacing: 0.55pt">
                                         </FONT>with<FONT STYLE="letter-spacing: 0.5pt"> </FONT>the<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>Securities<FONT STYLE="letter-spacing: 0.5pt"> </FONT>and<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>Exchange<FONT STYLE="letter-spacing: 0.5pt"> </FONT>Commission<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>on March<FONT STYLE="letter-spacing: 0.45pt"> </FONT>24,<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>2014;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; padding-right: 0">&nbsp;</TD><TD STYLE="text-align: left; padding-right: 0">&nbsp;</TD><TD STYLE="padding-right: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; padding-right: 0"></TD><TD STYLE="text-align: left; padding-right: 0"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 0; text-align: left">The
                                         description<FONT STYLE="letter-spacing: 0.55pt"> </FONT>of<FONT STYLE="letter-spacing: 0.55pt">
                                         </FONT>our<FONT STYLE="letter-spacing: 0.5pt"> </FONT>common<FONT STYLE="letter-spacing: 0.55pt">
                                         </FONT>stock,<FONT STYLE="letter-spacing: 0.55pt"> </FONT>which<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>is<FONT STYLE="letter-spacing: 0.55pt"> </FONT>contained<FONT STYLE="letter-spacing: 0.55pt">
                                         </FONT>in<FONT STYLE="letter-spacing: 0.55pt"> </FONT>our<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>Form<FONT STYLE="letter-spacing: 0.55pt"> </FONT>8-K/A,<FONT STYLE="letter-spacing: 0.55pt">
                                         </FONT>filed<FONT STYLE="letter-spacing: 0.5pt"> </FONT>with<FONT STYLE="letter-spacing: 0.55pt">
                                         </FONT>the<FONT STYLE="letter-spacing: 0.55pt"> </FONT>Securities and<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>Exchange<FONT STYLE="letter-spacing: 0.45pt"> </FONT>Commission<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>on<FONT STYLE="letter-spacing: 0.5pt"> </FONT>January<FONT STYLE="letter-spacing: 0.5pt">
                                         </FONT>28,<FONT STYLE="letter-spacing: 0.5pt"> </FONT>2013.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20; text-align: left"><FONT STYLE="letter-spacing: -0.05pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20; text-align: left"><FONT STYLE="letter-spacing: -0.05pt">All
filings</FONT><FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">filed</FONT><FONT STYLE="letter-spacing: 0.55pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">by</FONT><FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">us
pursuant</FONT><FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">to</FONT><FONT STYLE="letter-spacing: 0.55pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">the</FONT><FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">Securities
Exchange</FONT><FONT STYLE="letter-spacing: 0.05pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">Act</FONT><FONT STYLE="letter-spacing: 0.55pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">of</FONT><FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">1934,
as</FONT><FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">amended,</FONT><FONT STYLE="letter-spacing: 0.55pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">after</FONT><FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">the
date</FONT><FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">of</FONT><FONT STYLE="letter-spacing: 0.55pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">the initial</FONT><FONT STYLE="letter-spacing: 0.5pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">filing
of</FONT><FONT STYLE="letter-spacing: 0.5pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">this</FONT><FONT STYLE="letter-spacing: 0.5pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">registration</FONT><FONT STYLE="letter-spacing: 0.5pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">statement
and</FONT><FONT STYLE="letter-spacing: 0.5pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">prior</FONT><FONT STYLE="letter-spacing: 0.5pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">to</FONT><FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">the
effectiveness</FONT><FONT STYLE="letter-spacing: 0.5pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">of</FONT><FONT STYLE="letter-spacing: 0.5pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">such</FONT><FONT STYLE="letter-spacing: 0.5pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">registration
statement</FONT><FONT STYLE="letter-spacing: 1.45pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">(excluding</FONT><FONT STYLE="letter-spacing: 0.55pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">information furnished</FONT><FONT STYLE="letter-spacing: 0.55pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">pursuant
to</FONT><FONT STYLE="letter-spacing: 0.6pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">Items</FONT><FONT STYLE="letter-spacing: 0.55pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">2.02</FONT><FONT STYLE="letter-spacing: 0.6pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">and
7.01</FONT><FONT STYLE="letter-spacing: 0.6pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">of</FONT><FONT STYLE="letter-spacing: 0.55pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">Form</FONT><FONT STYLE="letter-spacing: 0.6pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">8-K)
shall</FONT><FONT STYLE="letter-spacing: 0.6pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">also</FONT><FONT STYLE="letter-spacing: 0.55pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">be</FONT><FONT STYLE="letter-spacing: 0.6pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">deemed
to</FONT><FONT STYLE="letter-spacing: 0.6pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">be incorporated</FONT><FONT STYLE="letter-spacing: 0.45pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">by</FONT><FONT STYLE="letter-spacing: 0.45pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">reference
into</FONT><FONT STYLE="letter-spacing: 0.45pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">the</FONT><FONT STYLE="letter-spacing: 0.45pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"><FONT STYLE="letter-spacing: -0.4pt">You
</FONT>should<FONT STYLE="letter-spacing: 0.55pt"> </FONT>rely<FONT STYLE="letter-spacing: 0.6pt"> </FONT>only<FONT STYLE="letter-spacing: 0.55pt">
</FONT>on<FONT STYLE="letter-spacing: 0.55pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>information<FONT STYLE="letter-spacing: 0.55pt">
</FONT>incorporated<FONT STYLE="letter-spacing: 0.6pt"> </FONT>by<FONT STYLE="letter-spacing: 0.55pt"> </FONT>reference<FONT STYLE="letter-spacing: 0.55pt">
</FONT>or<FONT STYLE="letter-spacing: 0.6pt"> </FONT>provided<FONT STYLE="letter-spacing: 0.55pt"> </FONT>in<FONT STYLE="letter-spacing: 0.6pt">
</FONT>this<FONT STYLE="letter-spacing: 0.55pt"> </FONT>prospectus.<FONT STYLE="letter-spacing: 0.4pt"> </FONT><FONT STYLE="letter-spacing: -0.45pt">We
</FONT>have<FONT STYLE="letter-spacing: 0.55pt"> </FONT>not<FONT STYLE="letter-spacing: 0.55pt"> </FONT>authorized<FONT STYLE="letter-spacing: 0.55pt">
</FONT>anyone<FONT STYLE="letter-spacing: 0.6pt"> </FONT>else<FONT STYLE="letter-spacing: 0.55pt"> </FONT>to<FONT STYLE="letter-spacing: 0.55pt">
</FONT>provide<FONT STYLE="letter-spacing: 0.6pt"> </FONT>you<FONT STYLE="letter-spacing: 0.55pt"> </FONT>with<FONT STYLE="letter-spacing: 0.55pt">
</FONT><FONT STYLE="letter-spacing: -0.05pt">different</FONT><FONT STYLE="letter-spacing: 0.6pt"> </FONT>information.<FONT STYLE="letter-spacing: 0.25pt">
</FONT><FONT STYLE="letter-spacing: -0.4pt">You</FONT><FONT STYLE="letter-spacing: 0.55pt"> </FONT>should<FONT STYLE="letter-spacing: 0.55pt">
</FONT>not<FONT STYLE="letter-spacing: 0.6pt"> </FONT>assume<FONT STYLE="letter-spacing: 0.55pt"> </FONT>that<FONT STYLE="letter-spacing: 0.55pt">
</FONT>the<FONT STYLE="letter-spacing: 1.3pt"> </FONT>information<FONT STYLE="letter-spacing: 0.6pt"> </FONT>in<FONT STYLE="letter-spacing: 0.6pt">
</FONT>this<FONT STYLE="letter-spacing: 0.6pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.6pt"> </FONT>is<FONT STYLE="letter-spacing: 0.65pt">
</FONT>accurate<FONT STYLE="letter-spacing: 0.6pt"> </FONT>as<FONT STYLE="letter-spacing: 0.6pt"> </FONT>of<FONT STYLE="letter-spacing: 0.6pt">
</FONT>any<FONT STYLE="letter-spacing: 0.65pt"> </FONT>date<FONT STYLE="letter-spacing: 0.6pt"> </FONT>other<FONT STYLE="letter-spacing: 0.6pt">
</FONT>than<FONT STYLE="letter-spacing: 0.6pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>date<FONT STYLE="letter-spacing: 0.65pt">
</FONT>of<FONT STYLE="letter-spacing: 0.6pt"> </FONT>this<FONT STYLE="letter-spacing: 0.6pt"> </FONT>prospectus<FONT STYLE="letter-spacing: 0.6pt">
</FONT>or<FONT STYLE="letter-spacing: 0.65pt"> </FONT>the<FONT STYLE="letter-spacing: 0.6pt"> </FONT>date<FONT STYLE="letter-spacing: 0.6pt">
</FONT>of the<FONT STYLE="letter-spacing: 0.45pt"> </FONT>documents<FONT STYLE="letter-spacing: 0.5pt"> </FONT>incorporated<FONT STYLE="letter-spacing: 0.5pt">
</FONT>by<FONT STYLE="letter-spacing: 0.45pt"> </FONT>reference<FONT STYLE="letter-spacing: 0.5pt"> </FONT>in<FONT STYLE="letter-spacing: 0.5pt">
</FONT>this<FONT STYLE="letter-spacing: 0.45pt"> </FONT>prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">We will provide without charge
to each person to whom a copy of this prospectus is delivered, upon written or oral request, a copy of any or all of the information
that has been incorporated by reference in this prospectus but not delivered with this prospectus (other than an exhibit to these
filings, unless we have specifically incorporated that exhibit by reference in this prospectus). Any such request should be addressed
to us at: 501 5 th Avenue, 3rd Floor, New York, New York 10017, Attention: Corey Sohmer, Vice President of Finance and Business
Development, or made by phone at (646)&nbsp;459-4201. You may also access the documents incorporated by reference in this prospectus
through our website at www.actiniumpharmceuticals.com. Except for the specific incorporated documents listed above, no information
available on or through our website shall be deemed to be incorporated in this prospectus or the registration statement of which
it forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20"></P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">Table of Contents</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #231F20">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0; color: #231F20"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; color: #231F20"><B>1,923,078</B> <B>Shares
of Common Stock</B><BR> </P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; color: #231F20"></P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; color: #231F20"></P>





<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: #231F20">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: #231F20">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: #231F20">_______________________</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: #231F20"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: #231F20">PROSPECTUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: #231F20">SUPPLEMENT&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: #231F20">_______________________&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; color: #231F20"></P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; color: #231F20"><FONT STYLE="font-size: 16pt"><B>LAIDLAW
&amp; COMPANY (UK) LTD.</B></FONT></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"> June 4,
2015</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->















</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`"E`;(#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`***JQ:C93W]Q8Q74+W=N%::%7!>,-T)';
M-`%JBBB@`HHI"0H))P!U)H`6BHK>Y@NX5FMIHYHF^[)&P93]"*EH`***BM[J
MWNT+VT\4R*Q4M&X8!AU''<4`2T444`%%%%`!1139)$AB>65U2-`69F.`H'4D
M]A0`ZBLG_A*?#VW/]O:7CU^V1_XU=L]0LM0C,EE>6]R@ZM#*K@?B#0!9HJ*2
MY@ADCCEFC1Y3MC5F`+GK@#O4M`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`445%%=6\\LL44\4DD1VR(C@E#Z$=OQH`EHHHH`***9+-%;Q-+-(D<:C+
M.[``#W)H`?12*RNH92"I&00>"*6@`HHI&944LQ"J!DDG``H`6BLG_A*?#VW=
M_;VE[?7[9'C^=:B.DB*Z,&1AE64Y!'J*`'4444`%%%%`!1110`4444`%%%%`
M$=Q/':V\MQ,P2*)"[L>@4#)-?/>@:YJ.A?%VSUK508K;Q*@EY/`AE.(L^ZE5
M_`UZW\09);C08M"M9/+NM;N%L5;&=B')D;'<!`WYUYY\6_!^L1^&+;5KC58;
MP:8P15AL1`8XVP,Y#'(!"\4`>X5BZAXMT'2Y9HKO4X4>#'G`9?R<_P!\J#M_
M'%<[%XNNM0^#<WB*R)-^FGN6QU25058_@035#X/0:?J7PO-O(J3FXEG2^#'+
M2,Q.=QZDE2.:`.H\0>.-"\/:"NK7%]%+%-&7M4A<,UP>P3'7Z]!5?1O%6A^*
MO"^ZZO[)6GM%%["LX`A\Q3E23T[C\*XKXI:+IGA_X/QZ9I*XM;:]15S)O(.Y
MBP)]<YK4U*RM;GX`(9[:&4QZ,DJ%T!VN(QAAZ$>M`'0>";7PQH'A,0Z#J"2Z
M4DTF;F68$%\X;YN!U&..*N3^./"]M8M>S:[8K;+,8/,\T$-(`"57'WL9'3/6
MO/?`MC:ZA\`;Z&\MXYXU2[D"R+D!EW%2/<$`UG?"_2-.O/@_KUS<V4$TY^TI
MYDB!B`(@0!GISSQ0![-#JFFWNEK?17MO)8RKQ.)!L(/'6N7\&VO@_P`*:%JD
MFB:G&^G1W3-=7$D^](WP/EW=,`%?\:XKX600:A\%M;M[R&.XA66X98Y4#`$1
MJP.#WSS5WX$@-\.]2#`$&[DR".O[M*`/1K;Q5H%YI]S?VVKV<MI:X\^9)05C
M_P!X]JDT[Q'HNK6\\^GZI:7,,!`EDCE!5,],GM7E/P"`/A_Q""`1]H7@C_8J
M+X%V=MJ'A_Q/:7D$<]M+,BR12+N5AM/!%`'I\_C;PS;074\NNV*Q6KK',_F@
MA689"Y'4X!X&34DOC#P[!HL>L2ZU9+ITAVI.91M9O0=R?;K7D_P)TK3[ZT\1
M"[LK><+,D:B6,-A2&R!GI2_`S2[#4(_$27EI#<)#,L<:S+O"*P;=@'IG:,GO
M@4`>S:7JVGZU8I>Z9>0W5LY($D39&1U'L?:K;HLB,CJ&5A@@C((KQGX`LR+X
MFM@2(8[F,JG8'YQ_)1^5>ST`>!Z!I^GK^T7J=F;&W-O^]"0^4NQ3Y:G.,8]?
MSIM\4T#]H>U@\.HD,=Q)$ES!!PAW+^\!`XZ8;V-%E90:E^T5K%C<JS03K,CA
M7*G!A7H001]17JOAOX>>'/"U])?:?:.UXX(^T7$K2N`>H!/3Z]:`/--5LK;3
M?VC],\K<D;C[0^^0L%9DDW$9/`XSCI7K6D^+_#VNWLMGI>L6=W<19+1Q2`G`
MZD>H]Q7E7BBV@O/VC-(M[F))87ACW1N,JV$D/([]*768(=/_`&CM$2RACMUD
MB3<L2A0<I(#P/8#\J`/8[[4[+350W=PD1<D(IY9R.N%')_"H-'\0:3X@ADET
MJ_ANEB;9)Y9Y1O1@>1^-<IJ%[I>F?$G_`$8W.J>)[VV$4-H9`L-I`,$DG'R@
MD9/4GTKD/A(96^(_C2&8J"SL9!$2%W><PX[]SB@#U/4O%F@Z1//!J&JVMO+;
MQI)*LCX**QPI/U/:IM1\1:-I,`GO]4M+="`PWRC+`],#J<^U>)>`/#&DZW\0
MO&&D:K;&]M8BRKY\C,_RS$`[\YS@8SFK_P`>=,L;8>')X+2&.8NT!D1<,8U"
M[5SZ#)Q0!ZNGB_P[)KG]BIK-DVI9V_9Q*-V[^[Z9]NM-7QEX;;6_[&76K(ZC
MNV?9Q*-V[^[Z;O;K7E/QRTVRTRR\-S6%I#:RB=U#P($;`"D<CG@\TGQOTRQT
MG2O#<^GV<%K*DS*'A0*<!0PR1UY&>:`/<)IHK>%YII$CB0%F=V`51ZDGI61;
M^+=!NM5CTR+4X?MLB[XX6RID'JN0-W0]*Q?'[Z&GANSO?$E]<PZ?!,DS00'F
MZD`RJ$=6&><<=.:\[\<WU_=_%#P3>W5F+%I'B:*'S-\BJ91]\C@'GH,X]:`/
M;[_4;/2[5KJ_NHK:!2`9)7"C)Z#GO[52T_Q-HVJ7TEC:7\;WD:[VMV!20+Z[
M6`./>O-/$FIF?]H'0-/U)L:?:QAK9'/R&5T;#X]=P`'TKT:[\.:/-XHLO$,\
M0&JP1M!`_F;=P(/&.YQN_,T`3:EXET?2)S!>W\44P3S&C`+,J?WF"@E5]SQ3
MYO$.CV^DQZM-J=JFGR8V7)E'EMGIANE>0?">74=<UKQ7*^JBUU&:X#SH\"RL
MZY88^;H%/&.E=6G@F+P5\-_$]C#J$]Y;SVLTRI,J@1-Y9SM`]>#^%`'7CQ5H
M#:0VK#5[,Z>LGEFY\T;`WIGUI!XJT%M&EUA=6M&TZ)BKW*R`H&';([\CBO,/
MAP`?@-KF0"-MX>?^N=+\,5!^!FN9`/\`Q^'G_KD*`.R\)?$C1O%!N0+J"VD%
MS(EM!+)B22)5!\P@],_,?8"G^%=)\*67BG7[O0[U;C4;IEDO42?S%BW$D`8X
M&3D]2?I7-?`NUM[KX;W$5Q!'+')>RHZ2(&#*53((/45C_`]1!K?C!88AMCD4
M)&O`P'DP!0!ZWJ/B#2M*F$%Y>QI.5+B%07DVC^+:H)Q[XJ;2]7T_6K);W3+R
M&[MF)`DB<,,CJ#Z'VKRWX(ZC_:MUXGOKYP^KSW2O*7^^$P<`?[(.1CM757GA
M;PSH7AG7[:*\DTJRNG-SJ$L,WSH#C(&<[00,``=^*`-B?QEX=M;F&WGU>VC>
M=_+B9B0CMZ!\;<_C7G7[05E!_P`(W87^UOM'V@0;@[8*;7;!7..HZXS7/_$_
M4TU/X:Z'-IM@;30X[@1V+3-^]E58V4-M'W5X/4Y/7`K<^-K,_P`,M#=R2S3Q
M$D]SY+4`>EVFK6.E^&]*EO[I(O,MXE0-DM(VP<*!RQ]A5G2]?TK67GCT^^BG
ME@($T0R'C)Z;E."/Q%>;>*=/\0M=^%-9\+2P7&I:=IN382,NXQNJJ7"DC(_A
M/(/3%7/`/B;^V_&>I+K6B/I/B1+-5G`)"31*W!*GD,-W7)X/7B@#T^D(#*5(
M!!X(/>J>G:OINKQR2:;?VUVD3E':"0.%;T.*NT`>`W>FV!_:3BLS96WV7*'R
M?*79_P`>^?NXQUYKVW4M;TC0[<R:CJ%K9QHN<2R!>/8=3^%>.77_`"<]#]5_
M])JM_M"6=L-,T>^$$8NS.T1F"C<4VD[<^F>:`/3)?&?AN'5H]+EUNR2^DP%@
M,H#9/0'T)ST/-;,]Q#:P//<2I%#&-SR2,%51ZDGI7A_QHTG3].\%>'Y;*SA@
MD68#?&@#',9)R>IY`/-7/BWJTP;P;8WC$:5<21SWA/W9=I3(;U`!)Q[^U`'I
MMMXP\/W=_!90ZI`;BX&8$;*^</\`8)`#?AFMNL+7?#NB:X=-N]3C0C3IUGMI
M!)L"MQCD=03MX]A6M]LMA=BT-Q"+HKO$.\;ROKMZX]Z`)Z***`"BBB@`HHHH
M`Y75/!":KK46K2:]K$-U`S&V\F5`D`888*I0]1USDU=\1^&5\2Z:-/N-3OK>
MV9"DR6S(OG`_WB5/Z8ZUNT4`<CX8^'UCX3#PV.IZE+8R;O,LKAT>%RPP21MS
M^M9</PDTW3M2EN=%UK6=(@G.9;:SN`JL/0$@D#\Z]"HH`YW4/!.BZAX1;PT\
M#QV!`*E'^=6!W;]QSEL\DG.<G-95M\-;:'PU+H<FO:U+!*JQ.[7`XB&?W:J0
M0J\\X&>!S7;T4`<=IOP\M-)\,W?A^SUC54L;GJ/,0M&#G<%.S@-GG],5'I/P
MUL=$T&^T:PUC5HK.\^^OFH2N?O;?DXW``'V]*[6B@#BM(^&MCH>A7VC:?K&K
M16=YRZB2/*DX#%3LXR!@^U7/"'@:Q\%13P:;?7TMM,=Q@N'5D#<#<,*#G``Z
MUU-%`'!Z9\*=(TC5;NYL]0U.*SNCNET];C;"QYX;'++R>"?SJUX>^'&F>%]/
MNK?2[_4H);I<23K/SG^\%QM!'0''&:[*B@#BO#OPVL?"J7JZ3J^JQ"\0K)F2
M,X;LXRGWASCMSTH\.?#:Q\*F].E:OJL7VQ"LH:2-OF[./D^\,G';GI7:T4`<
MAX3^'FG^#;VXN--U#476Y'[Z*>1&1SSACA0<C)[]ZZR9#+!)&LC1LRE0Z8RI
M/<9XR*?10!Y_!\)M.MM<;6XM>UQ=4<DM=>?&7.1@_P`&.G%=^HVJ`23@=3WI
M:*`.+O?AM8WWBQ?$SZMJB:DC9B9'CVQCD!0"G3!(Y]:2_P#AM8ZAXK7Q))J^
MJ+J4;`Q.CQ[8@,X4`ITY/7/6NUHH`XC6/AGI^J^+1XDCU34["]90LILY0A<!
M=O!QE<C@XJ32_AKI&B>)+C6=,N+RU::+8;=),QAL8W\@ECWYR,DFNSHH`XSP
M_P##>P\-^()M:M-5U22ZN"QN?.D1EGR<G<`H[G/&*D\7?#S3_&=W!-J>H:BB
M6X_=0PR(J(W=AE2<GCOVKKZ*`.*\1?#:Q\4PV,6K:OJLRV:;8\21C+=W/R<L
M>/;CI1XA^&UCXIMK&WU;5]5F2S3:G[R,%F[NWR<MCC\*[6B@#DO$O@"Q\5>'
M+32-1OKQVM&WQ799?,)P1\W&#P?2LR\^$FDWT%D9]4U9[^TD5EOWN-TQ4=$R
M1A0,<8'!YKT"B@#E/%7P^T3Q;;6R7R313VJA(+J!\2(/3)SD=^>]/T'P3#H]
MU%>7FJZEK%Y"I2"6_FWB$'@[%Z`D<9ZXKJ**`.$U;X6:9>^(GUW3=1U'1M0D
M),KV,@4.3U.".">_;VKH]-\-6.G:7<V)>XNQ=@BZFNYC))/D;3N8^W&!@"MB
MB@#S[3/A)I6EV=_8Q:KJKV%TK!;1Y_W4988W;0!N(XQGT'!K=\-^!])\+Z3-
MIED;J2UG4B5+B<N&R,$XZ`D=<"NDHH`X;P_\,;+PV;A=/UO6$@<NT,`N`$A9
MEV[P,89@.A;/TJQX6^'.G^$=4GO]/U+4G:XR9XYI$9)3S@MA0<@DG@]Z[&B@
M#@]2^%>E7&OOK>E:CJ.BWTK$RO82A0^>O!'&>_;VK4F\!Z1/X7O="E:ZD2^.
M^YNY)=T\K@@AV<]2,#`Z8&,5U%%`'G0^#NC2>'#H]YJ.IW:J,6TLTP/V7G/[
MM<;1GOP<U>UCX8Z;KNC:?I5]JFJO:62X5?.4F1^?G8E22>2/0#M7;T4`<HW@
M:)3I4\.L:E'?Z7&\4%V71F:-L91QMVLO`[=JN67ABSLKZ_U6^G>]OKR`03W$
MP"@1*#\BJN`J\DGO[UOT=:`/*?A;X=L].\5^(-0T%ISX<D2."U>4G$S@Y8H3
M]Y5/`;W/6O56!9&4,5)&`PZBA55%"J`%`P`!P*6@#S]OA/I[Z]_;K:]KG]JY
MS]J\Z/>#C;_<QTXQBM'Q7\/;'QBEK'JFI:CY5LH"QQ.BJS8P7/R_>(_#VKKZ
M*`.)UWX:6/B33K&QU36-6F@LUP@\U`6;GYF^3DX./H*T=4\$:7KGAF'1-7:X
MO8X/]7<R,!,A[$,H`Z<=.1US72T4`<3HGPVM-*>W6[UK5M4M;5P]M:7<^88B
M/NG:!R1VSP/2KLG@/3)?'\?C!I;G[<D7EB(/^[SMVY]>AZ9QWKJ:*`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`**#P*RM<\1:;X=M$NM3G\J-Y!&N!DDGV]!U
M--)R=EN!JT5'%,D\22Q,KQN`RLIR&![@U)2`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"B@]*\C^)7Q;_L.>71?#[))J*_+
M/<D;E@/H!W;]!0!Z;J>MZ7HL'G:G?V]I'V,T@7/T'4UQMY\:/!=HY5+V>Y([
MP0,1^9Q7S5?W]YJEV]U?W4UU<.<M)*Y8FJI('4@4#L?2T/QR\'R2;7:_B']Y
M[?C]#77Z'XOT#Q&O_$IU2WN7[QAL./\`@)YKXZW#U%20S2V\R3P2/%*ARLB,
M58'V(H"Q]N4$XKQ+X;?%^2XGAT7Q/,&=R$M[YN,GLLG_`,5^=>UD\4"*]_?V
MVG6$]Y=RB*"%"\CGL!7SIXK\3W'BC6'OI<QVZ?);0'^!/?\`VCW_`"KH?B3X
MR_MR^_LJPDSIUL_SNIXFD'?_`'1V]^:;X$\/6D5M+XN\0%8]*L@7BW])7'\6
M.X!X'J:]7#TXX>G[:IN83;F^5'9^$IU\#>"8;CQ/J/V:*>8>3#+_`,L0W1?7
MW/I7H*.LB*Z,&1@"K*<@CU%?)7CKQI>>-=<:[EW1V41*VMN3PB^I_P!H]S^%
M>S_!%]?D\).=2;=I@;%AOSOV_P`6/]C/3\:\R<W.3D^INE96/4****D`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`#-&:X_QQXSE\()9-%8
MK=?:6<'=)MV[0/;WKC?^%TW?;0X?_`@_X5O3PM6I'FBM"'.*=F=3\4_&#>$_
M"CFU?;J%Z3!;GNO'S/\`@/U(KY:+%F+,Q8DY))R2?4UWWCS7KOQQJ=M=2QI:
MQV\7EI"K%ADG).??C\JP='LHM.U>UO;J!+V&"0.;=CM$A'0$^F:T^I5^P_:1
M[G;>`O@Y/KMO%JFOO+:6,@#16Z<2RKZDG[H_7Z5[3I7@KPSHT02QT6R3'\;1
MAV/_``)LFO.1\:;T#`T.W'_;<_X4O_"Z+_\`Z`MM_P!_V_PH^HU^WXB]K$]3
MN-"T>\B,=QI=E*AZAX%/]*\V\8_!32M1MY+KPX!87J@D09S#)[?[)]^E5?\`
MA<VH]M%M?^_S?X5Z?X=U1];T&RU*2)8FN(@YC4Y"^V:RJX>I25YH<9J6Q\=W
M5K/974UK=0O#/"Y22-Q@JPZ@U[#X"\<W/B3P]-X+O]2-KJ,D7EV-ZW)D'_/-
MCZXXSUQ[UU7Q3^&J>)[9M7TF-5UB%?F0<?:5'8_[0['\*^<?WMM<?QQ31/\`
M[K(P/Z$&LD[.Z+W/6]#^'^IW?B1]-U.W>SM+3Y[J8_<,?8*W0Y]>PS6%\3/'
M,?B"ZCT31\1:#8'9$J<+,PXW8_NCM^=/USXN:OK?@J#0W!CNFREY=J<&9!T`
M]"?XO_KURWA3PQ?>+M=ATNP7!;YI92/EB3NQ_H.YK:OB)UFN;H1""B;7PW\"
MS>,]=!G5ETJU8-=2#C=Z1@^I[^@KZF@@BM;>.""-8XHU"(BC`4#@`5G>'M`L
M?#>BV^EZ='L@A'4]7;NS>I-:M8%!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`'(>-_"EGXFCLQ>:I]@%NS;6PN'W`<<D>E<?\`\*IT
M7_H;%_[YC_\`BJT_C!8W-[IVE"VM9KC9<.6$2%MOR]\5Y(=#U,?\PJ\_\!V_
MPKU<+";I)JI;RT,)M<VQ6\80_P#"->)[G2K6=+R")4*SX'S;E![<<9K<^'GA
MVU\91:@U_JJZ<;5D"*`OSA@<GYCVQ6!=VSV#*MY`]L7&5$T93=],U'`JW<RP
MVRB:5ONI&NYC^`KH]G4_Y^_D3=?RGK7_``J?1/\`H:L_A'_C2CX3Z'_T-#'_
M`+]_XUYC_8]^.NEW?_@.W^%']D7_`/T#+L?]N[?X4>RJ?\_?R"Z_E/4?^%4:
M'C_D9G_`Q_XUZ-H&GP:5HMII]M/Y\-O&$64D$MCOQQ7S4NDWPZZ;=X_ZX-_A
M7N_PQ@DM_`UG%+$\3!Y#L=2I'SGL:Y,93DH)RG?7R+IM7T1V!&17@GQUT31+
M.]M=3MY5AU:Z;$UL@XE0?\M#Z'/'O^%>N^+_`!78^$-!EU*\.YA\L$(/S2OV
M4?U/85\H:YK=]XBUBXU349?,N)VR?11V4>@`KS3=&=7TY\'['0[;P5!<:0XE
MN)SF]D88<2CJI'8#M[<]Z\"U#P=K>F>&;+Q!=6I6PNSA3_$G]TL.P;M5SP#X
MUN?!6O+<C=)83X2[@'\2_P!X?[0_^M0!]:457L+VVU&QAO;.99K>=`\<BG(8
M&K%`@HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@!,"E
MQ110!YS\9/"SZ_X/-Y;1E[O36,Z@#):/'SC\N?PKYQTO4KK1]3MM1L9/+N;=
MQ)&P]?0^QZ5]IL,J01D'L:^=OBA\+Y]$NIM;T2W:32Y"7FA09-L>Y`_N?RH&
MCV+P3XVT_P`::0MS;L([R,`7-J3\T;?U4]C73U\6:9JE]H]]'?:;=26URGW9
M(VP?H?4>QKU32OC[JMO`(]4TFWNW`_UL+F(M]1@C\J`L?0%9'B'Q%I?AC3'U
M#5+A88EX5?XI#_=4=S7C6I?M`:A+"R:;HL%O(1Q)/*9-OX`"O+M:U[5?$5\;
MW5;V6ZG/0L>%'HHZ`?2@+&GXV\97OC37&O;@&*WCREM;YR(E_JQ[FM+P+X5M
MKM)/$NO*R:!8,-PVY-S)GB-?49QG\JB\`_#Z_P#&NH*VUX-*C;]_=$=?]E/5
MOY5]-1Z%ID.@+HJ6<?\`9ZQ>4(,<;?\`'OGUIQM=<VPGY'F>E?$2WU_4;K1_
M$-I!'H]^/)A3'$(Z!6/OZ]C7EGC[P/=>"=:,)W2Z=.2UK<$=1_=/^T/UZUTW
MC'PE/X6U/R3F2PFR;:8CJ/[I_P!H?KUKH_#&K67C+06\&>)6W%EQ97)/S`CH
M,G^(=O4<5Z&(PT'!5:.W]?TS&$VGRR.8^$WQ$/AR^71=4E/]DW+_`+N1C_Q[
MN>_^Z>_IU]:^CU8,`0<@]"*^./$OAR^\+:Y/I.H)^\C.4D`^65#T8>QKW[X+
MZGKFH>$-FIQ,;2!A'97+GYI$[CW`Z`_X5YQN>E4444""BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"D*A@01D'M2T4`>;>*_@WH&OR
M/=6!.EWK98M"N8G/NG;\,5YG??`[Q=;2D6WV*\0'ADFV9_!J^E:*`/F>T^"'
MC"X<"=+*U7NSS[OT4&N\\._`C2;)UFUR\DU"0<^3&/+B_'N?TKURB@"&UM+>
MRMH[:UA2&"-=J1QJ`JCV%3$9HHH`S-<T2SU[29]/O4W12#@CJC=F'N*^>->T
M*^\,ZP]C=;@Z'?#,G`=<\,OO_(U],GD5C>(O"^G>)[..WU!&/EN'22,X=?4`
M^A'!KJPN)=%V?PLSJ0YEYG%:/IEG\4?#-I)XCLI#-83A5ND^7SP.HSZ'HP]>
ME>EP016L$<$$:QQ1J%1$&`H'0`4RUM(+*UBMK:)8H(E"I&@P%`[5/7/.2E)N
M*LBTK(****D84444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
<%`!1110`4444`%%%%`!1110`4444`%%%%`'_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
